Uday R Popat, M.D.

Peer-Reviewed Articles

1. Mehta RS, Aljawai YM, Kebriaei P, Cao K, Zou J, Carmazzi Y, Rondon G, Oran B, Popat U, Rezvani K, Champlin RE, Shpall EJ. Development and explainable AI-driven characterization of a prognostic model for haploidentical transplantation outcomes. NPJ Digit Med, 2026. e-Pub 2026. PMID: 41772139.
2. Smallbone P, Mendt M, Sackstein R, Tanner MR, Kaur I, Basar R, Rafei H, Daher M, Overman B, Al-Atrash G, Alousi AM, Bashir Q, Hosing CM, Im JS, Kebriaei P, Banerjee P, Patel KP, Zou J, Cao K, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat UR, Qazilbash MH, Rondon G, Saini N, Srour S, Champlin RE, Rezvani K, Shpall EJ, Olson A. Ex vivo mesenchymal progenitor cell-based cord blood cell expansion and exofucosylation to enhance transplant engraftment. Cytotherapy 28(3):102010, 2026. e-Pub 2026. PMID: 41396090.
3. Senapati, J, Croden, J, Garcia-Manero, G, Takahashi, K, Daver, N, Kadia, TM, Borthakur, G, Short, NJ, Jabbour, EJ, Haddad, FG, Marvin-Peek, J, Abbas, HA, Bose, P, Tang, G, Loghavi, S, Shpall, E, Ramdial, JL, Popat, UR, Champlin, RE, Ravandi-Kashani, F, Kantarjian, HM, DiNardo, C. Outcomes of therapy-related non-core binding factor acute myeloid leukemia with venetoclax-based therapies. HemaSphere 10(2), 2026. e-Pub 2026. PMID: 41694734.
4. Senapati J, Croden J, Garcia-Manero G, Takahashi K, Daver NG, Kadia TM, Borthakur G, Short NJ, Jabbour E, Haddad F, Marvin-Peek J, Abbas HA, Bose P, Tang G, Loghavi S, Shpall EJ, Ramdial J, Popat UR, Champlin RE, Ravandi F, Kantarjian HM, Dinardo CD. Outcomes of therapy-related non-core binding factor acute myeloid leukemia with venetoclax-based therapies. Hemasphere 10(2):e70317, 2026. e-Pub 2026. PMID: 41694734.
5. Nieto Y, Ward JF, Hofstetter W, Rice D, Karam JA, Pisters L, Vauthey JN, Shah A, Lin JK, Johns AC, Araujo J, Tu SM, Wang J, Li J, Abudayyeh A, Thall PF, Bassett R, Barnett M, Gulbis A, Shigle TL, Ramdial J, Popat U, Qazilbash M, Jones RB, Andersson BS, Shpall EJ, Sheikh I, Pagliaro L, Campbell MT. High-Dose Chemotherapy for Multiply or Poor-Risk Relapsed Germ Cell Tumors. Clin Cancer Res 32(2):300-311, 2026. e-Pub 2026. PMID: 40853903.
6. Mehta RS, Aljawai YM, Kebriaei P, Hosing C, Olson A, Oran B, Popat U, Rondon G, Rezvani K, Champlin RE, Shpall EJ. Re-Evaluating Donor Selection Priorities for Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide. JCO Oncol Pract:OP2500675, 2026. e-Pub 2026. PMID: 41529219.
7. Oran B, Thall P, Alousi A, Al-Atrash G, Mehta R, Marin D, Kebriaei P, Popat U, Bassett R, Bashir Q, Im J, Olson A, Jewell J, Smallbone P, Shpall E, Champlin R. Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center. Haematologica 111(1):149-157, 2026. e-Pub 2026. PMID: 40702903.
8. Jen WY, Tang G, Kugler E, Croden J, Sasaki K, Bazinet A, Bataller A, Montalban-Bravo G, Borthakur G, Toruner GA, Loghavi S, Short NJ, Issa GC, Bouligny IM, Pierce S, Popat U, Pemmaraju N, Jabbour E, Garcia-Manero G, Bhalla K, Ravandi F, Daver NG, DiNardo CD, Kantarjian HM, Kadia TM. MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia. Br J Haematol 207(6):2451-2461, 2025. e-Pub 2025. PMID: 40983567.
9. Short NJ, Loghavi S, Yilmaz M, Karrar O, Kim K, Dinardo CD, Kadia TM, Maroun M, Borthakur G, Issa GC, Jabbour J, Oran B, Shpall EJ, Popat U, Patel KP, Routbort M, Konopleva M, Ravandi F, Kantarjian H, Daver N. Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor. Haematologica, 2025. e-Pub 2025. PMID: 41035402.
10. Bazinet A, Montalban-Bravo G, Bataller A, Hammond D, Loghavi S, Chien K, Sasaki K, Bouligny I, Swaminathan M, Jen WY, Popat U, Kadia T, DiNardo C, Jabbour E, Short N, Daver N, Ravandi F, Garcia-Manero G. Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome. Leukemia 39(11):2820-2824, 2025. e-Pub 2025. PMID: 40913105.
11. Schoettler ML, Gavriilaki E, Carreras E, Bo-Kyoung C, Dandoy CE, Ho VT, Jodele S, Moiseev I, Sanchez-Ortega I, Srivastava A, Atsuta Y, Carpenter PA, Koreth J, Kroger N, Ljungman P, Page K, Popat U, Shaw BE, Sureda AM, Soiffer R, Vasu S. An ASTCT, CIBMTR, EBMT, and APBMT Consensus Statement Defining Response Criteria for Hematopoietic Cell Transplantation Associated Thrombotic Microangiopathy (TA-TMA) Directed Therapy. Transplant Cell Ther 31(9):610-623, 2025. e-Pub 2025. PMID: 40514012.
12. Kawedia JD, Handy VW, Myers AL, Gulbis AM, Mehta R, Champlin RE, Shpall EJ, Nieto Y, Andersson BS, Popat UR. Seizure Prophylaxis and its Impact on Busulfan Pharmacokinetics and Dosing in a Novel Timed Sequential Protocol: MD Anderson Experience. Transplant Cell Ther 31(9):709.e1-709.e10, 2025. e-Pub 2025. PMID: 40514011.
13. Senapati, J, Kantarjian, HM, Kadia, TM, Kekedjian, J, Borthakur, G, Daver, N, DiNardo, C, Jabbour, EJ, Bose, P, Short, NJ, Yilmaz, M, Jain, N, Pemmaraju, N, Abbas, HA, Issa, GC, Maiti, A, Bravo, GM, Deshmukh, I, Shpall, E, Kebriaei, P, Popat, UR, Loghavi, S, Thakral, B, Tang, G, Haddad, FG, Alvarado, Y, Manero, GG, Ravandi-Kashani, F. Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia. Cancer 131(16), 2025. e-Pub 2025. PMID: 40772501.
14. Arora S, Jen WY, Yilmaz M, Deshmukh I, Senapati J, Loghavi S, Issa GC, Short NJ, Kadia TM, DiNardo CD, Borthakur G, Jabbour J, Pemmaraju N, Andreeff M, Takahashi K, Bhalla K, Popat U, Shpall EJ, Oran B, Abbas HA, Garcia-Manero G, Ravandi F, Kantarjian H, Daver N. Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation. Cancer 131(16):e70032, 2025. e-Pub 2025. PMID: 40782343.
15. Aljawai YM, Ramdial JL, Smallbone P, Chen GL, Kebriaei P, Pasvolsky O, Popat UR, Oran B, Rezvani K, Champlin RE, Shpall EJ, Mehta RS. Comparative Outcomes of HCT with Post-Transplant Cyclophosphamide in Older Adults: The Impact of Donor Type. Blood Adv 9(20):5201-5206, 2025. e-Pub 2025. PMID: 40795211.
16. Kadia TM, Jen WY, Bataller A, Bazinet A, Borthakur G, Jabbour E, Qiao W, Short NJ, Takahashi K, Issa GC, DiNardo CD, Montalban-Bravo G, Pemmaraju N, Tran A, Bharathi V, Loghavi S, Alousi AM, Popat U, Daver NG, Ravandi F, Kantarjian HM. A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia. Am J Hematol 100(8):1365-1373, 2025. e-Pub 2025. PMID: 40401707.
17. Smallbone P, Shigle TL, Paslovsky O, Hosing C, Alousi A, Bashir Q, Aljawai Y, Ramdial J, Popat U, Champlin R, Shpall EJ, Oran B. Maintenance therapy with oral decitabine plus cedazuridine after allogeneic stem cell transplantation for myelodysplastic syndrome. Haematologica 110(8):1798-1807, 2025. e-Pub 2025. PMID: 40013380.
18. Aljawai YM, Ramdial JL, Rondon G, Smallbone P, Kebriaei P, Popat UR, Oran B, Rezvani K, Champlin RE, Shpall EJ, Mehta RS. Outcomes of Haploidentical vs Mismatched Unrelated Donor HCT with Post-Transplant Cyclophosphamide Prophylaxis. Blood Adv 9(15):4023-4036, 2025. e-Pub 2025. PMID: 40517414.
19. Nieto Y, Banerjee P, Kaur I, Basar R, Li Y, Daher M, Rafei H, Kerbauy LN, Kaplan M, Marin D, Griffin L, Barnett M, Bassett R, Uprety N, Shrestha R, Silva FR, Islam S, Ganesh C, Borneo Z, Ramdial J, Ramirez A, Hosing C, Alousi A, Popat U, Qazilbash M, Ahmed S, Iyer S, Sainz TP, Vega F, Fowlkes NW, Alexis K, Emig M, Harstrick A, Overesch A, Shpall EJ, Rezvani K. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Nat Med 31(6):1987-1993, 2025. e-Pub 2025. PMID: 40186077.
20. Senapati J, Loghavi S, Marvin-Peek J, Garcia-Manero G, Kadia TM, Borthakur G, Daver N, Short NJ, Jain N, Issa GC, Haddad F, Hammond D, Chien K, Tang G, Thakral B, Montalban-Bravo G, Pemmaraju N, Bazinet A, Swaminathan M, Pierce S, Abbas HA, Reville P, Popat U, Shpall E, Champlin R, Jabbour E, Ravandi F, Kantarjian HM, DiNardo CD. Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies. Am J Hematol 100(5):758-769, 2025. e-Pub 2025. PMID: 39921561.
21. Alkhunaizi M, Soto F, Leung CH, Bhan N, Bashoura L, Dickey BF, Sharifi H, Cheng GS, Yanik G, Rondon G, Saliba R, Chen G, Al-Atrash G, Hosing C, Kebriaei P, Popat UR, Shpall EJ, Champlin RE, Li L, Alousi AM, Sheshadri A. Restrictive Ventilatory Defect Following Hematopoietic Stem Cell Transplant Is Associated With Increased Mortality. Transplant Cell Ther 31(4):255.e1-255.e10, 2025. e-Pub 2025. PMID: 39921208.
22. Nieto, Y, Ramdial, JL, Valdez, B, Thall, PF, Bassett Jr, R, Barnett, M, Srour, S, Hosing, C, Alousi, AM, Qazilbash, MH, Popat, UR, Gulbis, A, Shigle, TL, Ahmed, S, Pacheco, MG, Champlin, RE, Shpall, E, Andersson, BS. Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma. Clinical Cancer Research 31(6):975-982, 2025. e-Pub 2025. PMID: 39804167.
23. Walters MC, Eapen M, Liu Y, El Rassi F, Waller EK, Levine JE, Strouse JJ, Antin JH, Parikh SH, Bakshi N, Dampier CD, Jaroscak JJ, Bergmann S, Wong TE, Kota VK, Pace BS, Lekakis LJ, Lulla PD, Nickel R, Kasow KA, Popat UR, Smith WR, Yu LC, DiFronzo NL, Geller NL, Kamani N, Klings ES, Hassell K, Mendizabal AM, Sullivan K, Neuberg DS, Krishnamurti L. Hematopoietic Cell Transplant compared with Standard Care in Adolescents and Young Adults with Sickle Cell Disease. Blood Adv 9(5):955-965, 2025. e-Pub 2025. PMID: 39471440.
24. Arthur, JA, Reddy, AS, Popat, UR, Halm, J, Vaughan-Adams, N, Myers, AL, Yang, P, De Moraes, AR, Laureano, R, Lopez-Quinones, I, Urbauer, D, Hui, D, Bruera, E. Abuse potential and analgesic efficacy of intravenous hydromorphone bolus administration among hospitalized patients with cancer pain. Cancer 131(3), 2025. e-Pub 2025. PMID: 39865340.
25. Senapati, J, Kantarjian, HM, Haddad, FG, Short, NJ, Borthakur, G, Kanagal Shamanna, R, Tang, G, Jabbour, EJ, DiNardo, C, Daver, N, Montalban Bravo, G, Shah, V, Alousi, AM, Shpall, E, Popat, UR, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia. American journal of hematology 100(2):249-259, 2025. e-Pub 2025. PMID: 39718824.
26. Alkhunaizi M, Soto-Lanza F, Leung CH, Bhan N, Bashoura L, Dickey BF, Sharifi H, Cheng G, Yanik GA, Rondon G, Saliba R, Chen G, Al-Atrash G, Hosing C, Kebriaei P, Popat UR, Shpall EJ, Champlin RE, Li L, Alousi AM, Sheshadri A. Restrictive Ventilatory Defects Following Hematopoietic Stem Cell Transplant Are Associated With Increased Mortality. Transplant Cell Ther. e-Pub 2025.
27. Lontos K, Saliba RM, Kanagal-Shamanna R, Ozcan G, Ramdial JL, Chen GL, Kadia TM, Short NJ, Daver NG, Kantarjian HM, Marin D, Kebriaei P, Popat UR, Champlin RE, Shpall EJ, Oran B. TP53 Mutant Variant Allele Frequency and Cytogenetics Determine Prognostic Groups in MDS/AML for Transplantation. Blood Adv 9(11):2845-2854, 2025. e-Pub 2025. PMID: 39853269.
28. Bashir Q, Konopleva M, Abueg G, Ramdial J, Hosing C, Srour SA, Alousi A, Popat UR, Nieto Y, Alatrash G, Champlin RE, Shpall EJ, Qazilbash M, Pemmaraju N. Tagraxofusp maintenance post-hematopoietic stem cell transplantation provides long-term survival and manageable safety for a patient with blastic plasmacytoid dendritic cell neoplasm. Leuk Res Rep 24:100518, 2025. e-Pub 2025. PMID: 40612021.
29. Senapati J, Loghavi S, Garcia-Manero G, Tang G, Kadia T, Short NJ, Abbas HA, Arani N, DiNardo CD, Borthakur G, Pemmaraju N, Oran B, Shpall E, Popat U, Champlin R, Pierce S, Arora S, Issa G, Yilmaz M, Patel K, Takahashi K, Montalban-Bravo G, Hammond D, Haddad FG, Ravandi F, Kantarjian HM, Daver NG. Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms. Haematologica 110(6):1304-1315, 2024. e-Pub 2024. PMID: 39665206.
30. Ramdial J, Lin R, Thall PF, Valdez BC, Hosing C, Srour S, Popat U, Qazilbash M, Alousi A, Barnett M, Gulbis A, Shigle TL, Shpall EJ, Andersson BS, Nieto Y. High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas. Bone Marrow Transplant 59(12):1754-1762, 2024. e-Pub 2024. PMID: 39341929.
31. Yeh J, Pasvolsky O, Saliba RM, Figgins B, Wang C, Fang Z, Ahmed S, Yilmaz M, Daver N, Ravandi F, DiNardo C, Short NJ, Kadia T, Al-Atrash G, Daher M, Costa DM, Popat U, Champlin R, Shpall E, Oran B. Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 24(11):e819-e826, 2024. e-Pub 2024. PMID: 39183099.
32. Marcoux CM, Alousi AM, Im J, Hill LC, Smallbone P, Popat U, Hosing C, Kebriaei P, Olson A, Mehta R, Chen G, Qazilbash M, Shpall E, Champlin RC, Saliba RM. Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host disease. Bone Marrow Transplant 59(11):1594-1600, 2024. e-Pub 2024. PMID: 39187601.
33. Mehta RS, Ramdial JL, Kebriaei P, Champlin RE, Popat UR, Rezvani K, Shpall EJ. Haploidentical versus HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations. Blood Adv 8(20):5306-5314, 2024. e-Pub 2024. PMID: 39167765.
34. Senapati J, Kantarjian HM, Bazinet A, Reville P, Short NJ, Daver N, Borthakur G, Bataller A, Jabbour E, DiNardo C, Haddad F, Sasaki K, Popat U, Oran B, Alousi AM, Loghavi S, Shpall E, Garcia-Manero G, Ravandi F, Kadia TM. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer 130(19):3333-3343, 2024. e-Pub 2024. PMID: 38809547.
35. Cheng JT, Obaisi O, Yadav R, Gupta E, Fu JB, Bruera E, Collaco A, Szewcyzk N, Popat U, Ngo-Huang A. The Role of Outpatient Physical Medicine and Rehabilitation in a Multidisciplinary Prehabilitation Program for Older Adults before Allogeneic Hematopoietic Stem Cell Transplant. Am J Phys Med Rehabil 103(8):710-715, 2024. e-Pub 2024. PMID: 38207179.
36. Saengboon S, Ciurea S, Popat U, Ramdial J, Bashir Q, Alousi A, Chen J, Rondon G, Olson A, Im J, Hosing C, Shpall E, Champlin R, Srour SA. Long-term outcomes after haploidentical stem cell transplantation for hematologic malignancies. Blood Adv 8(12):3237-3245, 2024. e-Pub 2024. PMID: 38607399.
37. Sureda A, Carpenter PA, Bacigalupo A, Bhatt VR, de la Fuente J, Ho A, Kean L, Lee JW, Sánchez-Ortega I, Savani BN, Schetelig J, Stadtmauer EA, Takahashi Y, Atsuta Y, Koreth J, Kröger N, Ljungman P, Okamoto S, Popat U, Soiffer R, Stefanski HE, Kharfan-Dabaja MA. Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT. Bone Marrow Transplant 59(6):832-837, 2024. e-Pub 2024. PMID: 38443706.
38. Ramdial J, Kebriaei P, Champlin RE, Popat U, Rezvani K, Shpall EJ, Mehta RS. Improved survival with younger HLA-matched unrelated donors versus older matched sibling donor HCT with PTCy-prophylaxis. Leukemia 38(6):1432-1434, 2024. e-Pub 2024. PMID: 38698071.
39. Malek AE, Al-Juhaishi T, Milton DR, Ramdial JL, Daher M, Olson AL, Srour SA, Alatrash G, Oran B, Mehta RS, Khouri IF, Bashir Q, Shah N, Ciurea SO, Rondon G, Maadani F, Hosing C, Marin D, Kebriaei P, Rezvani K, Nieto Y, Anderlini P, Alousi AM, Faisal MS, Qazilbash MH, Popat UR, Champlin RE, Shpall EJ, Mulanovich VE, Ahmed S. Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis. Bone marrow transplantation 59(5):699-704, 2024. e-Pub 2024. PMID: 38355908.
40. Khouri IF, Alzahrani K, Kantarjian H, Milton DR, Gulbis AM, Sasaki K, Jain N, Short NJ, Kadia T, Daher M, Rafei H, Im JS, Marin D, Olson AL, Popat U, Qazilbash M, Ramdial J, Rondon G, Srour S, Kebriaei P, Shpall E, Champlin R, Jabbour EJ. Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial. American journal of hematology 99(5):836-843, 2024. e-Pub 2024. PMID: 38400519.
41. Pasvolsky O, Saliba RM, Popat UR, Alousi A, Mehta R, Yeh J, Al-Atrash G, Adeel M, Ramdial J, Marin D, Rondon G, Kebriaei P, Champlin R, Daver N, Dinardo C, Short NJ, Shpall EJ, Oran B. Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 24(5):e196-e204, 2024. e-Pub 2024. PMID: 38403505.
42. Ahmed S, Bashir Q, Bassett RL, Ullah F, Aung F, Valdez BC, Alousi AM, Hosing C, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Rezvani K, Mehta R, Shpall EJ, Ciurea S, Andersson BS, Champlin RE, Popat UR. Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study. American journal of hematology 99(4):562-569, 2024. e-Pub 2024. PMID: 38314663.
43. Valdez BC, Yuan B, Murray D, Ramdial JL, Popat U, Nieto Y, Andersson BS. ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells. Oncotarget 15:220-231, 2024. e-Pub 2024. PMID: 38484153.
44. Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, Mohanty V, Dede M, Nieto Y, Uprety N, Acharya S, Liu E, Wilson J, Banerjee P, Macapinlac HA, Ganesh C, Thall PF, Bassett R, Ammari M, Rao S, Cao K, Shanley M, Kaplan M, Hosing C, Kebriaei P, Nastoupil LJ, Flowers CR, Moseley SM, Lin P, Ang S, Popat UR, Qazilbash MH, Champlin RE, Chen K, Shpall EJ, Rezvani K. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. Nature medicine 30(3):772-784, 2024. e-Pub 2024. PMID: 38238616.
45. Marcoux C, Saliba RM, Wallis W, Khazal SJ, Ragoonanan D, Rondon G, Tewari P, Popat UR, Oran B, Olson AL, Bashir Q, Qazilbash MH, Alousi A, Hosing C, Nieto Y, Alatrash G, Marin DC, Rezvani K, Khouri IF, Srour SA, Champlin RE, Shpall EJ, Kebriaei P. Incidence and Risk Factors of Early Onset VOD/SOS Differ in Younger vs Older Adults After Stem Cell Transplantation. Blood Advances 8(5):1128-1136, 2024. e-Pub 2024. PMID: 38266155.
46. Yalniz FF, Greenbaum U, Pasvolsky O, Milton DR, Kanagal-Shamanna R, Ramdial J, Srour S, Mehta R, Alousi A, Popat UR, Nieto Y, Kebriaei P, Al-Atrash G, Oran B, Hosing C, Ahmed S, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation. Transplantation and Cellular Therapy 30(2):205.e1-205.e12, 2024. e-Pub 2024. PMID: 37437764.
47. Pasvolsky, O, Bassett Jr, R, Ghanem, S, Cuglievan, B, Tewari, P, Hosing, C, Srour, S, Ramdial, JL, Mahadeo, KM, Khazal, SJ, Petropoulos, D, Popat, UR, Qazilbash, MH, Kebriaei, P, Champlin, RE, Shpall, E, Nieto, Y. Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant. BMC cancer 23(1), 2023. e-Pub 2023. PMID: 38124057.
48. Joseph J, Srour SA, Milton DR, Ramdial JL, Saini NY, Olson AL, Bashir Q, Oran B, Alousi AM, Hosing C, Qazilbash MH, Kebriaei P, Shpall EJ, Champlin RE, Popat UR. Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning. Transplant Cell Ther 29(12):770.e1-770.e6, 2023. e-Pub 2023. PMID: 37742746.
49. Wall, S, Olin, R, Bhatt, VR, Chhabra, S, Munshi, P, Hacker, E, Hashmi, SK, Hassel, H, Howard, DS, Jayani, R, Lin, RJ, McCurdy, SR, Mishra, A, Murthy, H, Popat, UR, Wood, WA, Rosko, A, Artz, AS. The Transplantation Ecosystem. Transplantation and Cellular Therapy 29(10):632.e1-632.e10, 2023. e-Pub 2023. PMID: 37137442.
50. Popat UR, Pasvolsky O, Bassett R, Mehta RS, Olson AL, Chen J, Alousi AM, Al-Atrash G, Bashir Q, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin DC, Nieto Y, Oran B, Saini NY, Shigle TL, Srour SA, Ramdial JL, Rezvani K, Qazilbash MH, Andersson BS, Champlin RE, Shpall EJ. Myeloablative Fractionated Busulfan for Allogeneic Stem Cell Transplant in Older Patients or Patients with Comorbidities. Blood Adv 7(20):6196-6205, 2023. e-Pub 2023. PMID: 37611156.
51. Bazinet A, Kantarjian H, Arani N, Popat U, Bataller A, Sasaki K, DiNardo CD, Daver N, Yilmaz M, Abbas HA, Short NJ, Issa G, Jabbour E, Pierce SA, Chen J, Garcia R, Konopleva M, Garcia-Manero G, Alousi A, Shpall EJ, Champlin RE, Borthakur G, Ravandi F, Kadia T. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. Am J Hematol 98(9):1383-1393, 2023. e-Pub 2023. PMID: 37334870.
52. Al-Juhaishi T, Wang Y, Milton DR, Xu-Monette ZY, Jabbour E, Daher M, Im JS, Bashir Q, Iyer SP, Marin D, Olson AL, Popat U, Qazilbash M, Rondon G, Gulbis AM, Champlin RE, Young KH, Khouri IF. Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant. Bone Marrow Transplant 58(9):1000-1007, 2023. e-Pub 2023. PMID: 37198234.
53. Short NJ, Ong F, Ravandi F, Nogueras-Gonzalez G, Kadia TM, Daver N, DiNardo CD, Konopleva M, Borthakur G, Oran B, Al-Atrash G, Mehta R, Jabbour EJ, Yilmaz M, Issa GC, Maiti A, Champlin RE, Kantarjian H, Shpall EJ, Popat U. Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. Blood Adv 7(14):3573-3581, 2023. e-Pub 2023. PMID: 37104058.
54. Ostrin EJ, Rider NL, Alousi AM, Irajizad E, Li L, Peng Q, Kim ST, Bashoura L, Arain MH, Noor LZ, Patel N, Mehta R, Popat UR, Hosing C, Jenq RR, Rondon G, Hanash SM, Paczesny S, Shpall EJ, Champlin RE, Dickey BF, Sheshadri A. A Nasal Inflammatory Cytokine Signature Is Associated with Early Graft-versus-Host Disease of the Lung after Allogeneic Hematopoietic Cell Transplantation: Proof of Concept. Immunohorizons 7(6):421-430, 2023. e-Pub 2023. PMID: 37289498.
55. Marcoux C, Marin D, Ramdial J, AlAtrash G, Alousi AM, Oran B, Kebriaei P, Popat UR, Rezvani K, Champlin RE, Shpall EJ, Mehta RS. Younger Haploidentical Donor Versus Older Matched Unrelated Donor for Patients With AML/MDS. Am J Hematol 98(5):712-719, 2023. e-Pub 2023. PMID: 36734029.
56. Afrough A, Alsfeld LC, Milton DR, Delgado R, Popat UR, Nieto Y, Kebriaei P, Oran B, Saini N, Srour S, Hosing C, Cheema FH, Ahmed S, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Weber DM, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Long-term outcomes of allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma. Transplant Cell Ther 29(4):264.e1-264.e9, 2023. e-Pub 2023. PMID: 35605883.
57. Ngo-Huang A, Ombres R, Saliba RM, Szewczyk N, Adekoya L, Soones TN, Ferguson J, Fontillas R, Gulbis A, Hosing C, Kebriaei P, Lindsay R, Marin DC, Mehta RS, Alousi AM, Srour S, Oran B, Olson A, Qazilbash MH, Rivera Z, Champlin RE, Shpall EJ, Popat UR. Enhanced Recovery Stem-Cell Transplantation: Multidisciplinary Efforts to Improve Outcomes in Older Adults Undergoing Hematopoietic Stem-Cell Transplant. JCO Oncol Pract 19(3):e417-e427, 2023. e-Pub 2023. PMID: 36626702.
58. Alkhunaizi M, Patel B, Bueno L, Bhan N, Ahmed T, Arain MH, Saliba R, Rondon G, Dickey BF, Bashoura L, Ost DE, Li L, Wang S, Shpall E, Champlin RE, Mehta R, Popat UR, Hosing C, Alousi AM, Sheshadri A. Risk factors for bronchiolitis obliterans syndrome after initial detection of pulmonary impairment. Transplant Cell Ther 29(3):204.e1-204.e7, 2023. e-Pub 2023. PMID: 36503180.
59. Mehta RS, Cao K, Saliba RM, Al-Atrash G, Alousi AM, Lontos K, Marcoux C, Carmazzi Y, Rondon G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rezvani K, Champlin RE, Shpall EJ. HLA Factors Versus Non-HLA Factors for Haploidentical Donor Selection. Transplant Cell Ther 29(3):189-198, 2023. e-Pub 2023. PMID: 36470579.
60. Schoettler M, Carreras E, Cho B, Dandoy CE, Ho VT, Jodele S, Moissev I, Sanchez-Ortega I, Srivastava A, Atsuta Y, Carpenter P, Koreth J, Kroger N, Ljungman P, Page K, Popat U, Shaw BE, Sureda A, Soiffer R, Vasu S. Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplant Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation (EBMT), American Society for Transplantation and Cellular Therapy (ASTCT), Asia-Pacific Blood and Marrow Transplantation Group (APBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). Transplant Cell Ther 29(3):151-163, 2023. e-Pub 2023. PMID: 36442770.
61. Nieto Y, Pasvolsky O, Bassett R, Ghanem S, Cuglievan B, Tewari P, Hosing C, Srour S, Ramdial J, Mahadeo K, Khazal S, Petropoulos D, Popat U, Qazilbash M, Kebriaei P, Champlin R, Shpall E. Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant. Res Sq, 2023. e-Pub 2023. PMID: 36798261.
62. Valdez BC, Yuan B, Murray D, Ramdial JL, Nieto Y, Popat U, Tang X, Andersson BS. Synergistic cytotoxicity of fludarabine, clofarabine, busulfan, vorinostat and olaparib in AML cells. Front Oncol 13:1287444, 2023. e-Pub 2023. PMID: 38074694.
63. Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol 40(33):JCO2102823, 2022. e-Pub 2022. PMID: 35704787.
64. Mehta RS, Saliba RM, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour SA, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor Transplantation. Transplant Cell Ther 28(10):695.e1-695.e10, 2022. e-Pub 2022. PMID: 35902049.
65. Saengboon S, Ramdial J, Saini N, Olson A, Im J, Hosing C, Popat U, Shpall E, Champlin R, Srour S. AML-528 Long-Term Outcomes After Haploidentical Stem Cell Transplantation (Haplo-SCT) for Hematologic Malignancies. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S259-S260, 2022. e-Pub 2022. PMID: 36163857.
66. Kalariya N, Ferreri C, Dillard C, Hawkins M, Manasanch E, Lee H, Weber D, Thomas S, Steiner R, Hosing C, Qazilbash M, Popat U, Orlowski R, Hildebrandt M, Patel K. CT-511 Clinical Characteristics and Response Outcomes in Older Multiple Myeloma Patients Who Received Idecabtagene Vicleucel: A Single Center Study. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S446, 2022. e-Pub 2022. PMID: 36164224.
67. Andersson BS, Thall PF, Ma J, Valdez BC, Bassett R, Chen J, Ahmed S, Alousi A, Bashir Q, Ciurea S, Gulbis A, Cool R, Kawedia J, Hosing C, Kebriaei P, Kornblau S, Myers A, Oran B, Rezvani K, Shah N, Shpall E, Parmar S, Popat UR, Nieto Y, Champlin RE. A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan?±?clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplant 57(8):1295-1303, 2022. e-Pub 2022. PMID: 35610308.
68. Sheikh IN, Alqahtani S, Ragoonanan D, Tewari P, Petropoulos D, Mahadeo KM, Popat U, Shpall EJ, Khazal S. Post-Transplant Cyclophosphamide after Matched Sibling and Unrelated Donor Hematopoietic Stem Cell Transplantation in Pediatric Patients with Acute Myeloid Leukemia. Int J Mol Sci 23(15), 2022. e-Pub 2022. PMID: 35955881.
69. Alatrash G, Saberian C, Bassett R, Thall PF, Ledesma C, Lu Y, Daher M, Valdez BC, Kawedia J, Popat U, Mehta R, Oran B, Nieto Y, Olson A, Anderlini P, Marin D, Hosing C, Alousi AM, Shpall EJ, Rondon G, Chen J, Qazilbash M, Champlin RE, Kebriaei P. Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes. Transplant Cell Ther 28(8):501.e1-501.e7, 2022. e-Pub 2022. PMID: 35618218.
70. Mehta RS, Saliba RM, Hayase E, Jenq RR, Abraham S, Rashid A, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour S, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Mycophenolate Mofetil: A Friend or a Foe with Post-Transplantation Cyclophosphamide and Tacrolimus Prophylaxis in HLA-Matched Donors?. Transplant Cell Ther 28(8):500.e1-500.e10, 2022. e-Pub 2022. PMID: 35662592.
71. Mehta RS, Saliba RM, Ghanem S, Alousi AM, Rondon G, Anderlini P, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Saini N, Srour SA, Champlin RE, Rezvani K, Shpall EJ. Haploidentical vs Matched Unrelated vs Matched Sibling Donor HCT with Post-Transplantation Cyclophosphamide. Transplant Cell Ther 28(7):395.e1-395.e11, 2022. e-Pub 2022. PMID: 35513252.
72. Valdez BC, Yuan B, Murray D, Nieto Y, Popat U, Andersson BS. Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells. Leuk Lymphoma 63(7):1-11, 2022. e-Pub 2022. PMID: 35188042.
73. Afrough A, Pasvolsky O, Ma J, Srour S, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Delgado R, Ullah MR, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Induction with VCD vs. VRD on the Outcome of Patients with Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther 28(6):307.e1-307.e8, 2022. e-Pub 2022. PMID: 35331973.
74. Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Loghavi S, Furudate K, Xiao L, Pierce S, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Konopleva M, Pemmaraju N, Popat U, Shpall E, Garcia-Manero G, Ravandi F, DiNardo CD, Kadia TM. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol 9(5):e350-e360, 2022. e-Pub 2022. PMID: 35483396.
75. Akin S, Hosing C, Khouri I, Ahmed S, Alousi A, Fowler N, Joseph J, Truxillo J, Ramdial JL, Maadani F, Rondon G, Daher M, Im JS, Steiner R, Westin J, Iyer SP, Dabaja B, Anderlini P, Popat UR, Qazilbash MH, Flowers CR, Shpall E, Champlin RE, Nieto Y, Srour SA. Autologous Stem Cell Transplantation for Large B-cell Lymphoma with Secondary Central Nervous System Involvement. Blood Adv 6(7):2267-2274, 2022. e-Pub 2022. PMID: 35008100.
76. Nieto Y, Gruschkus S, Valdez BC, Jones RB, Anderlini P, Hosing C, Popat U, Qazilbash M, Kebriaei P, Alousi A, Saini N, Srour S, Rezvani K, Ramdial J, Barnett M, Gulbis A, Shigle TL, Ahmed S, Iyer S, Lee H, Nair R, Parmar S, Steiner R, Dabaja B, Pinnix C, Gunther J, Cuglievan B, Mahadeo K, Khazal S, Chuang H, Champlin R, Shpall EJ, Andersson BS. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. Haematologica 107(4):899-908, 2022. e-Pub 2022. PMID: 33951890.
77. Gaballa MR, Banerjee P, Milton DR, Jiang X, Ganesh C, Khazal S, Nandivada V, Islam S, Kaplan M, Daher M, Basar R, Alousi A, Mehta R, Alatrash G, Khouri I, Oran B, Marin D, Popat U, Olson A, Tewari P, Jain N, Jabbour E, Ravandi F, Kantarjian H, Chen K, Champlin R, Shpall E, Rezvani K, Kebriaei P. Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia. Blood 139(12):1908-1919, 2022. e-Pub 2022. PMID: 34914826.
78. Ombres R, des Bordes JKA, Popat UR, Yennu S, Champlin RE, Mohile SG, Kebriaei P, Holmes HM. Serial frailty assessments following allogeneic stem cell transplant in older adults: A pilot study. J Geriatr Oncol 13(2):194-199, 2022. e-Pub 2022. PMID: 34493481.
79. Khanlari M, Wang X, Loghavi S, Wang SA, Li S, Thakral B, Bueso-Ramos CE, Yin CC, Kanagal-Shamanna R, Khoury JD, Patel KP, Popat UR, Medeiros LJ, Konoplev S. Value and pitfalls of assessing bone marrow morphologic findings to predict response in patients with myelofibrosis who undergo hematopoietic stem cell transplantation. Ann Diagn Pathol 56:151860, 2022. e-Pub 2022. PMID: 34823075.
80. Sheshadri A, Makhnoon S, Alousi AM, Bashoura L, Andrade R, Miller CJ, Stolar KR, Arain MH, Noor L, Balagani A, Jain A, Blanco D, Ortiz A, Taylor MS, Stenzler A, Mehta R, Popat UR, Hosing C, Ost DE, Champlin RE, Dickey BF, Peterson SK. Home-Based Spirometry Telemonitoring After Allogeneic Hematopoietic Cell Transplantation: Mixed Methods Evaluation of Acceptability and Usability. JMIR Form Res 6(2):e29393, 2022. e-Pub 2022. PMID: 35129455.
81. Bashir Q, Milton DR, Popat UR, Kebriaei P, Hosing C, Khouri IF, Rezvani K, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Al-Atrash G, Rondon G, Konopleva MY, Champlin RE, Shpall EJ, Qazilbash MH, Pemmaraju N. Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transplant 57(1):51-56, 2022. e-Pub 2022. PMID: 34629467.
82. Short NJ, Venugopal S, Qiao W, Kadia TM, Ravandi F, Macaron W, Dinardo CD, Daver N, Konopleva M, Borthakur G, Shpall EJ, Popat U, Champlin RE, Mehta R, Al-Atrash G, Oran B, Jabbour E, Garcia-Manero G, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Kantarjian H. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. J Hematol Oncol 15(1):12, 2022. e-Pub 2022. PMID: 35093134.
83. Oran B, Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia 36(1):257-262, 2022. e-Pub 2022. PMID: 34135465.
84. Kumar B, Afshar-Kharghan V, Mendt M, Sackstein R, Tanner MR, Popat U, Ramdial J, Daher M, Jimenez J, Basar R, Melo Garcia L, Shanley M, Kaplan M, Wan X, Nandivada V, Reyes Silva F, Woods V, Gilbert A, Gonzalez-Delgado R, Acharya S, Lin P, Rafei H, Banerjee PP, Shpall EJ. Engineered cord blood megakaryocytes evade killing by allogeneic T-cells for refractory thrombocytopenia. Front Immunol 13:1018047, 2022. e-Pub 2022. PMID: 36203567.
85. Valdez BC, Murray D, Yuan B, Nieto Y, Popat U, Andersson BS. ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells. Oncotarget 13:319-330, 2022. e-Pub 2022. PMID: 35154579.
86. Mehta RS, Saliba RM, Alsfeld LC, Jorgensen JL, Wang SA, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rondon G, Saini N, Srour SA, Rezvani K, Shpall EJ, Champlin RE, Alousi AM. Bone Marrow versus Peripheral Blood Graft for Haploidentical HCT with Post Transplantation Cyclophosphamide. Transplant Cell Ther 27(12):1003.e1-1003.e13, 2021. e-Pub 2021. PMID: 34537419.
87. Szewczyk NA, Ngo-Huang A, Soones TN, Adekoya LM, Fontillas RC, Ferguson JK, Gale-Capps HE, Kurse BC, Lindsay RJ, Ombres R, Rivera ZR, Gulbis AM, Neumann JL, Braveman BH, Marin D, Shigle TL, Whited L, Wallis WD, Sullivan H, Cao L, Champlin RE, Shpall E, Popat UR. Feasibility and Implementation of a Multimodal Supportive Care Program to Improve Outcomes in Older Patients Undergoing Allogeneic Stem Cell Transplantation. Transplant Cell Ther 27(12):1008-1014, 2021. e-Pub 2021. PMID: 34537421.
88. Yeh J, Whited L, Saliba RM, Rondon G, Banchs J, Shpall E, Champlin R, Popat U. Cardiac Toxicity after Matched Allogeneic Hematopoietic Cell Transplantation in the Post-Transplant Cyclophosphamide Era. Blood Adv 5(24):5599-5607, 2021. e-Pub 2021. PMID: 34592759.
89. Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Ramdial J, Saini N, Srour SA, Rezvani K, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplant Cell Ther 27(11):913.e1-913.e12, 2021. e-Pub 2021. PMID: 34329753.
90. Oran B, Ahn KW, Fretham C, Beitinjaneh A, Bashey A, Pawarode A, Wirk B, Scott BL, Savani BN, Bredeson C, Weisdorf D, Marks DI, Rizzieri D, Copelan E, Hildebrandt GC, Hale GA, Murthy HS, Lazarus HM, Cerny J, Liesveld JL, Yared JA, Yves-Cahn J, Szer J, Verdonck LF, Aljurf M, van der Poel M, Litzow M, Kalaycio M, Grunwald MR, Diaz MA, Sabloff M, Kharfan-Dabaja MA, Majhail NS, Farhadfar N, Reshef R, Olsson RF, Gale RP, Nakamura R, Seo S, Chhabra S, Hashmi S, Farhan S, Ganguly S, Nathan S, Nishihori T, Jain T, Agrawal V, Bacher U, Popat U, Saber W. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improves Transplant Outcomes in Older MDS Patients. Transplant Cell Ther 27(11):921.e1-921.e10, 2021. e-Pub 2021. PMID: 34403791.
91. Khouri IF, Milton DR, Gulbis AM, Jabbour EJ, Nastoupil L, Ledesma C, Anderlini P, Bashir Q, Daher M, Im JS, Iyer SP, Marin D, Mehta RS, Olson AL, Popat UR, Qazilbash M, Saini N, Samaniego F, Rondon G, Medeiros LJ, Champlin RE. 9-year follow-up of patients with relapsed follicular lymphoma after nonmyeloablative allogeneic stem cell transplant and autologous transplant. Clin Cancer Res 27(21):5847-5856, 2021. e-Pub 2021. PMID: 34380640.
92. Venugopal S, Shoukier M, Konopleva M, Dinardo CD, Ravandi F, Short NJ, Andreeff M, Borthakur G, Daver N, Pemmaraju N, Sasaki K, Montalban-Bravo G, Marx KR, Pierce S, Popat UR, Shpall EJ, Kanagal-Shamanna R, Garcia-Manero G, Kantarjian HM, Kadia TM. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. Cancer 127(19):3541-3551, 2021. e-Pub 2021. PMID: 34182597.
93. Shindiapina P, Pietrzak M, Seweryn M, McLaughlin E, Zhang X, Makowski M, Ahmed EH, Schlotter S, Pearson R, Kitzler R, Mozhenkova A, Le-Rademacher J, Little RF, Akpek G, Ayala E, Devine SM, Kaplan LD, Noy A, Popat UR, Hsu JW, Morris LE, Mendizabal AM, Krishnan A, Wachsman W, Williams N, Sharma N, Hofmeister CC, Forman SJ, Navarro WH, Alvarnas JC, Ambinder RF, Lozanski G, Baiocchi RA. Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial. Front Immunol 12:700045, 2021. e-Pub 2021. PMID: 34539628.
94. Lee H, Nakamura K, Narayanan S, Brown RA, Nash RA, Griffith LM, Steinmiller KC, Devine SM, Hutton GJ, Popat U, Racke MK, Georges GE, Bowen JD, Arnold DL. Brain volume change after high-dose immunosuppression and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis. Mult Scler Relat Disord 54:103149, 2021. e-Pub 2021. PMID: 34284316.
95. Pemmaraju N, Carter BZ, Bose P, Jain N, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daver NG, Popat U, Konopleva MY, Zhou L, Pierce S, Estrov ZE, Borthakur GM, Ohanian M, Qiao W, Masarova L, Wang X, Mak PY, Cortes J, Jabbour E, Verstovsek S. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv 5(16):3163-3173, 2021. e-Pub 2021. PMID: 34424319.
96. Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol 39(24):2710-2719, 2021. e-Pub 2021. PMID: 33929874.
97. Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver N, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian H. Long-term Results of Low-intensity Chemotherapy with Clofarabine or Cladribine Combined with Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia. Am J Hematol 96(8):914-924, 2021. e-Pub 2021. PMID: 33901324.
98. Yalniz FF, Saliba RM, Greenbaum U, Ramdial J, Popat U, Oran B, Alousi A, Olson A, Alatrash G, Marin D, Rezvani K, Hosing C, Im J, Mehta R, Qazilbash M, Joseph JJ, Rondon G, Kanagal-Shamanna R, Shpall E, Champlin R, Kebriaei P. Outcomes of second allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia. Transplant Cell Ther 27(8):689-695, 2021. e-Pub 2021. PMID: 34023569.
99. Ramdial JL, Mehta RS, Saliba RM, Alousi AM, Bashir Q, Hosing C, Kebriaei P, Olson AL, Oran B, Qazilbash MH, Srour SA, Andersson BS, Champlin RE, Popat U. Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. Bone Marrow Transplant 56(8):2005-2012, 2021. e-Pub 2021. PMID: 33846563.
100. Mishra A, Preussler JM, Bhatt VR, Bredeson C, Chhabra S, D'Souza A, Dahi PB, Hacker ED, Gowda L, Hashmi SK, Howard DS, Jakubowski A, Jayani R, Koll T, Lin RJ, Olin RL, Popat UR, Rodriguez C, Rosko A, Sabloff M, Sorror ML, Sung AD, Ustun C, Wood WA, Burns L, Artz A. Breaking the Age Barrier: Physicians' Perceptions on Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults. Transplant Cell Ther 27(7):617.e1-617.e7, 2021. e-Pub 2021. PMID: 33836312.
101. Mehta RS, Bassett R, Rondon G, Overman BJ, Popat UR, Hosing CM, Rezvani K, Qazilbash MH, Anderlini P, Jones RB, Kebriaei P, Marin D, Khouri IF, Oran B, Ciurea SO, Kondo K, Couriel DR, Shpall EJ, Champlin RE, Alousi AM. Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. Bone Marrow Transplant 56(6):1316-1324, 2021. e-Pub 2021. PMID: 33398094.
102. Olson AL, Saliba RM, Oran B, Chen J, Alousi A, Ahmed S, Bashir Q, Ciurea SO, Hosing C, Seon Im J, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Parmar S, Rezvani K, Shah N, Shpall E, Srour SA, Qazilbash M, Andersson BS, Champlin R, Popat UR. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol 144(1):74-81, 2021. e-Pub 2021. PMID: 32604096.
103. Oran B, Saliba RM, Mehta RS, Alousi AM, Marin D, Valdez BC, Chen J, Bashir Q, Ciurea SO, Olson AL, Hosing C, Kebriaei P, Rezvani K, Shpall EJ, Champlin RE, Andersson BS, Popat UR. Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 127(10):1598-1605, 2021. e-Pub 2021. PMID: 33471943.
104. Ahmed S, Bashir Q, Bassett R, Poon MC, Valdez B, Konoplev S, Alousi AM, Andersson BS, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Kim S, Nieto Y, Olson A, Oran B, Parmar S, Qazilbash MH, Rezvani K, Shah N, Shpall EJ, Champlin R, Popat U. Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplant Cell Ther 27(5):430.e1-430.e7, 2021. e-Pub 2021. PMID: 33965187.
105. Joseph J, Ma J, Hennawy F, Abdulrazzaq MN, Saini N, Patel RD, Hosing CM, Alousi AM, Anderlini P, Popat UR, Qazilbash MH, Shpall EJ, Srour S, Kebriaei P, Bashir Q, Nastoupil LJ, Westin JR, Rondon G, Champlin RE, Andersson BS, Nieto Y, Muzzafar T, Ahmed S. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplant Cell Ther 27(5):404.e1-404.e5, 2021. e-Pub 2021. PMID: 33965178.
106. Sheshadri A, Saliba R, Patel B, Ahmed T, Bueno LC, Arain MH, Mehta RS, Popat UR, Hosing CM, Rondon G, Bashoura L, Dickey BF, Champlin RE, Alousi AM. Azithromycin may increase hematologic relapse rates in matched unrelated donor hematopoietic cell transplant recipients who receive anti-thymocyte globulin, but not in most other recipients. Bone Marrow Transplant 56(3):745-748, 2021. e-Pub 2021. PMID: 33009515.
107. Srour SA, Saliba RM, Bashir Q, Popat UR, Ahmed S, Mehta RS, Delgado R, Rondon G, Parmar S, Kebriaei P, Hosing C, Manasanch EE, Lee HC, Patel KK, Orlowski RZ, Shpall E, Champlin RE, Qazilbash MH, Nieto Y. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplant Cell Ther 27(3):243.e1-243.e6, 2021. e-Pub 2021. PMID: 33781521.
108. Mehta RS, Saliba RM, Jan A, Shigle TL, Wang E, Nieto Y, Ciurea SO, Oran B, Im J, Olson A, Marin D, Qazilbash M, Khouri I, Rondon G, Anderlini P, Rezvani K, Popat U, Kebriaei P, Shpall E, Champlin R, Alousi A. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. Transplant Cell Ther 27(3):272.e1-272.e5, 2021. e-Pub 2021. PMID: 33781539.
109. Saberian C, Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Rondon G, Whited L, Gruschkus S, Fa'ak F, Daher M, Knape C, Safa H, Shoukier M, Suarez-Almazor ME, Marcotulli M, Ludford K, Gulbis AM, Konopleva M, Ohanian M, Ravandi F, Garcia-Manero G, Oran B, Popat UR, Mehta R, Alousi AM, Daver N, Champlin R, Diab A, Al-Atrash G. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. J Immunother Cancer 9(2), 2021. e-Pub 2021. PMID: 33637601.
110. Srour SA, Popat UR. Impact of Mixed Chimerism on Myelofibrosis Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 26(12):e301-e302, 2020. e-Pub 2020. PMID: 32949752.
111. Short NJ, Rafei H, Daver N, Hwang H, Ning J, Jorgensen JL, Kadia TM, DiNardo CD, Wang SA, Jabbour E, Popat U, Oran B, Cortes J, Konopleva M, Yilmaz M, Issa GC, Kantarjian H, Ravandi F. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. Blood Adv 4(24):6117-6126, 2020. e-Pub 2020. PMID: 33351107.
112. Hu B, Lin X, Lee HC, Huang X, Tidwell RSS, Ahn KW, Hu ZH, Jabbour E, Verstovsek S, Ravandi F, Garcia-Manero G, Kharfan-Dabaja MA, Hossain NM, Marks DI, Kamble RT, Inamoto Y, Kindwall-Keller T, Saad A, Litzow MR, Savani BN, Hale GA, Bacher U, Gerds AT, Liesveld JL, Ustun C, Olsson RF, Daly A, Grunwald MR, Solh M, DeFilipp Z, Aljurf M, Wirk B, Akpek G, Nishihori T, Cerny J, Seo S, Hsu JW, Champlin R, de Lima M, Alyea E, Popat U, Sobecks R, Scott BL, Kantarjian H, Cortes J, Saber W. Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. Leuk Lymphoma 61(12):1-10, 2020. e-Pub 2020. PMID: 32662346.
113. Popat UR, Sobecks RM, Scott BL, Gerds AT, Salit RB, Deeg HJ, Nakamura R, Saber W. Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase. Blood Adv 4(21):5562-5573, 2020. e-Pub 2020. PMID: 33170935.
114. Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U, Alousi AM, Hosing C, Giralt S, Rondon G, Woodworth G, Champlin RE. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv 4(21):5580-5588, 2020. e-Pub 2020. PMID: 33170934.
115. Nazha A, Hu ZH, Wang T, Lindsley RC, Abdel-Azim H, Aljurf M, Bacher U, Bashey A, Cahn JY, Cerny J, Copelan E, DeFilipp Z, Diaz MA, Farhadfar N, Gadalla SM, Gale RP, George B, Gergis U, Grunwald MR, Hamilton B, Hashmi S, Hildebrandt GC, Inamoto Y, Kalaycio M, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Liesveld JL, Litzow MR, Majhail NS, Murthy HS, Nathan S, Nishihori T, Pawarode A, Rizzieri D, Sabloff M, Savani BN, Schachter L, Schouten HC, Seo S, Shah NN, Solh M, Valcárcel D, Vij R, Warlick E, Wirk B, Wood WA, Yared JA, Alyea E, Popat U, Sobecks RM, Scott BL, Nakamura R, Saber W. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. Biol Blood Marrow Transplant 26(11):2139-2146, 2020. e-Pub 2020. PMID: 32781289.
116. Sheshadri A, Alousi A, Bashoura L, Stolar K, Baghaie S, Arain MH, Noor L, Balagani A, Jain A, Blanco D, Ortiz A, Peterson SK, Langhals R, Taylor M, Stenzler A, Mehta RS, Popat UR, Hosing C, Rondon G, Shen F, Li L, Cheng GS, Ost DE, Champlin RE, Dickey BF. Feasibility and Reliability of Home-based Spirometry Telemonitoring in Allogeneic Hematopoietic Cell Transplant Recipients. Ann Am Thorac Soc 17(10):1329-1333, 2020. e-Pub 2020. PMID: 32614241.
117. Abudayyeh A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Martinez CS, Page VD, Tarrand JJ, Kontoyiannis DP, Marin D, Oran B, Olson A, Jones R, Popat U, Champlin RE, Chemaly RF, Shpall EJ, Rezvani K. Development and validation of a risk assessment tool for BKPyV Replication in allogeneic stem cell transplant recipients. Transpl Infect Dis 22(5):e13395, 2020. e-Pub 2020. PMID: 32602954.
118. Saini N, Marin D, Ledesma C, Delgado R, Rondon G, Popat UR, Bashir Q, Hosing CM, Nieto Y, Alousi AM, Qazilbash MH, Ciurea S, Shpall E, Khouri I, Kantarjian H, Jabbour E, Ravandi F, Champlin RE, Kebriaei P. Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia. Blood 136(15):1786-1789, 2020. e-Pub 2020. PMID: 32492706.
119. Saini N, Bashir Q, Milton DR, Tang G, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Mehta R, Srour S, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv 4(19):4834-4837, 2020. e-Pub 2020. PMID: 33027527.
120. Gupta V, Kim S, Hu ZH, Liu Y, Aljurf M, Bacher U, Beitinjaneh A, Cahn JY, Cerny J, Copelan E, Gadalla SM, Gale RP, Ganguly S, George B, Gerds AT, Gergis U, Hamilton BK, Hashmi S, Hildebrandt GC, Kamble RT, Kindwall-Keller T, Lazarus HM, Liesveld JL, Litzow M, Maziarz RT, Nishihori T, Olsson RF, Rizzieri D, Savani BN, Seo S, Solh M, Szer J, Verdonck LF, Wirk B, Woolfrey A, Yared JA, Alyea EP, Popat UR, Sobecks RM, Scott BL, Nakamura R, Saber W. Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS. Blood Adv 4(19):4748-4757, 2020. e-Pub 2020. PMID: 33007075.
121. Joseph J, Popat U. Improving Survival After Transplant in Myelofibrosis. Clin Lymphoma Myeloma Leuk 20 Suppl 1:S72-S73, 2020. e-Pub 2020. PMID: 32862877.
122. Joseph J, Popat U. A Mildly Symptomatic Middle-Aged Woman with INT-1 Primary Myelofibrosis. Clin Lymphoma Myeloma Leuk 20(Supplement 1):S19, 2020. e-Pub 2020. PMID: 32862853.
123. Popat U, Mehta RS, Bassett R, Kongtim P, Chen J, Alousi AM, Anderlini P, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Lindsay R, Nieto Y, Olson A, Oran B, Qazilbash MH, Rondon G, Shpall EJ, Verstovsek S, Andersson BS, Champlin RE. Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant 26(8):1439-1445, 2020. e-Pub 2020. PMID: 32438043.
124. Srour SA, Kongtim P, Rondon G, Chen J, Petropoulos D, Ramdial J, Popat U, Kebriaei P, Qazilbash M, Shpall EJ, Champlin RE, Ciurea SO. Haploidentical Transplants for Patients with Relapse After the First Allograft. Am J Hematol. e-Pub 2020. PMID: 32619033.
125. Zhou Z, Nath R, Cerny J, Wang HL, Zhang MJ, Abdel-Azim H, Agrawal V, Ahmed G, Al-Homsi AS, Aljurf M, Alkhateeb HB, Assal A, Bacher U, Bajel A, Bashir Q, Battiwalla M, Bhatt VR, Byrne M, Cahn JY, Cairo M, Choe H, Copelan E, Cutler C, Damlaj MB, DeFilipp Z, De Lima M, Diaz MA, Farhadfar N, Foran J, Freytes CO, Gerds AT, Gergis U, Grunwald MR, Gul Z, Hamadani M, Hashmi S, Hertzberg M, Hildebrandt GC, Hossain N, Inamoto Y, Isola L, Jain T, Kamble RT, Khan MW, Kharfan-Dabaja MA, Kebriaei P, Kekre N, Khera N, Lazarus HM, Liesveld JL, Litzow M, Liu H, Marks DI, Martino R, Mathews V, Mishra A, Murthy HS, Nagler A, Nakamura R, Nathan S, Nishihori T, Olin R, Olsson RF, Palmisiano N, Patel SS, Patnaik MM, Pawarode A, Perales MA, Politikos I, Popat U, Rizzieri D, Sandmaier BM, Savani BN, Seo S, Shah NN, Uy GL, Valcárcel D, Verdonck LF, Waller EK, Wang Y, Weisdorf D, Wirk B, Wong E, Yared JA, Saber W. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv 4(13):3180-3190, 2020. e-Pub 2020. PMID: 32663298.
126. Kongtim P, Bittencourt M, Srour SA, Ramdial J, Rondon G, Chen J, Khouri I, Betul O, Popat U, Olson A, Bashir Q, Shpall EJ, Kebriaei P, Champlin RE, Ciurea SO. Haploidentical Transplants for Patients with Graft Failure After the First Allograft. Am J Hematol. e-Pub 2020. PMID: 32602112.
127. Olin RL, Fretham C, Pasquini MC, Arora M, Bhatt VR, Derman B, Giralt SA, Huang LW, Koll T, Lee SM, Lin RJ, Pang L, Popat UR, Weisdorf DJ, Artz A. Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. Blood Adv 4(12):2810-2820, 2020. e-Pub 2020. PMID: 32574365.
128. Schmidt S, Liu Y, Hu ZH, Williams KM, Lazarus HM, Vij R, Kharfan-Dabaja MA, Ortí G, Wiernik PH, Weisdorf D, Kamble RT, Herzig R, Wirk B, Cerny J, Bacher U, Chaudhri NA, Nathan S, Farhadfar N, Aljurf M, Gergis U, Szer J, Seo S, Hsu JW, Olsson RF, Maharaj D, George B, Hildebrandt GC, Agrawal V, Nishihori T, Abdel-Azim H, Alyea E, Popat U, Sobecks R, Scott BL, Holter Chakrabarty J, Saber W. The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. Biol Blood Marrow Transplant 26(6):1137-1143, 2020. e-Pub 2020. PMID: 32062061.
129. Cordas Dos Santos DM, Saliba RM, Patel R, Bashir Q, Saini N, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Ahmed H, Lee HC, Manasanch EE, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 26(6):1077-1083, 2020. e-Pub 2020. PMID: 31786242.
130. Gowin K, Ballen K, Ahn KW, Hu ZH, Ali H, Arcasoy MO, Devlin R, Coakley M, Gerds AT, Green M, Gupta V, Hobbs G, Jain T, Kandarpa M, Komrokji R, Kuykendall AT, Luber K, Masarova L, Michaelis LC, Patches S, Pariser AC, Rampal R, Stein B, Talpaz M, Verstovsek S, Wadleigh M, Agrawal V, Aljurf M, Angel Diaz M, Avalos BR, Bacher U, Bashey A, Beitinjaneh AM, Cerny J, Chhabra S, Copelan E, Cutler CS, DeFilipp Z, Gadalla SM, Ganguly S, Grunwald MR, Hashmi SK, Kharfan-Dabaja MA, Kindwall-Keller T, Kröger N, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Nathan S, Nishihori T, Olsson RF, Pawarode A, Rowe JM, Savani BN, Savoie ML, Seo S, Solh M, Tamari R, Verdonck LF, Yared JA, Alyea E, Popat U, Sobecks R, Scott BL, Nakamura R, Mesa R, Saber W. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv 4(9):1965-1973, 2020. e-Pub 2020. PMID: 32384540.
131. Yalniz FF, Patel KP, Bashir Q, Marin D, Ahmed S, Alousi AM, Chen J, Ciurea SO, Rezvani K, Popat UR, Shpall EJ, Champlin RE, Oran B. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. Cancer 126(10):2183-2192, 2020. e-Pub 2020. PMID: 32101640.
132. Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, Jabbour EJ, Mehta RS, Popat UR, Ravandi F, Alousi AM, Kadia TM, Konopleva M, DiNardo CD, Rezvani K, Shpall EJ, Sharma P, Kantarjian HM, Champlin RE, Daver N. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer 126(10):2193-2205, 2020. e-Pub 2020. PMID: 32125707.
133. Varma A, Abraham SC, Mehta RS, Saini NY, Honhar M, Rashid M, Chen J, Srour SA, Bashir Q, Rondon G, Oran B, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Marin D, Khouri IF, Ciurea SO, Qazilbash MH, Rezvani K, Anderlini P, Andersson BS, Shpall EJ, Champlin RE, Popat UR. Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Adv 4(7):1296-1306, 2020. e-Pub 2020. PMID: 32236526.
134. Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma With Chromosome 1q Gain and 1p Deletion After Autologous Hematopoietic Stem Cell Transplantation: propensity-score matched analysis: Outcome of 1q+/1p- MM pts after auto-HCT. Biol Blood Marrow Transplant 26(4):665-671, 2020. e-Pub 2020. PMID: 31881283.
135. Brown AL, Arts P, Carmichael CL, Babic M, Dobbins J, Chong CE, Schreiber AW, Feng J, Phillips K, Wang PPS, Ha T, Homan CC, King-Smith SL, Rawlings L, Vakulin C, Dubowsky A, Burdett J, Moore S, McKavanagh G, Henry D, Wells A, Mercorella B, Nicola M, Suttle J, Wilkins E, Li XC, Michaud J, Brautigan P, Cannon P, Altree M, Jaensch L, Fine M, Butcher C, D'Andrea RJ, Lewis ID, Hiwase DK, Papaemmanuil E, Horwitz MS, Natsoulis G, Rienhoff HY, Patton N, Mapp S, Susman R, Morgan S, Cooney J, Currie M, Popat U, Bochtler T, Izraeli S, Bradstock K, Godley LA, Krämer A, Fröhling S, Wei AH, Forsyth C, Mar Fan H, Poplawski NK, Hahn CN, Scott HS. RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. Blood Adv 4(6):1131-1144, 2020. e-Pub 2020. PMID: 32208489.
136. Srour SA, Singh H, McCarty J, de Groot E, Huls H, Rondon G, Qazilbash M, Ciurea S, Bardelli G, Buck J, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Wierda WG, Kantarjian H, Champlin RE, Cooper LJ, Kebriaei P. Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood 135(11):862-865, 2020. e-Pub 2020. PMID: 31961918.
137. DeFilipp Z, Ancheta R, Liu Y, Hu ZH, Gale RP, Snyder D, Schouten HC, Kalaycio M, Hildebrandt GC, Ustun C, Daly A, Ganguly S, Inamoto Y, Litzow M, Szer J, Savoie ML, Hossain N, Kharfan-Dabaja MA, Hamadani M, Reshef R, Bajel A, Schultz KR, Gadalla S, Gerds A, Liesveld J, Juckett MB, Kamble R, Hashmi S, Abdel-Azim H, Solh M, Bacher U, Lazarus H, Olsson R, Cahn JY, Grunwald MR, Savani BN, Yared J, Rowe JM, Cerny J, Chaudhri NA, Aljurf M, Beitinjaneh A, Seo S, Nishihori T, Hsu JW, Ramanathan M, Alyea E, Popat U, Sobecks R, Saber W. Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant 26(3):472-479, 2020. e-Pub 2020. PMID: 31669399.
138. Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, Bashir Q, Alousi A, Mehta R, Oran B, Popat U, Hosing C, Olson A, Daver N, Konopleva M, Champlin RE. Is There an Optimal Conditioning for Older Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation?. Blood 135(6):449-452, 2020. e-Pub 2020. PMID: 31826244.
139. Kongtim P, Hasan O, Perez JMR, Varma A, Wang SA, Patel KP, Chen J, Rondon G, Srour S, Bashir Q, Qazilbash M, Mehta R, Shpall EJ, Alousi A, Khouri I, Kebriaei P, Popat U, Champlin RR, Ciurea SO. Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 26(1):197-203, 2020. e-Pub 2020. PMID: 31518645.
140. Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long term results of a prospective phase II clinical trial. Haematologica 104(12):e555-e557, 2019. e-Pub 2019. PMID: 30948491.
141. Bashir Q, Chamoun K, Milton DR, Khan M, Ahmed S, Mehta R, Popat UR, Kebriaei P, Nieto Y, Oran B, Ciurea SO, Hosing C, Khouri I, Patel K, Manasanch EE, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years. Leuk Lymphoma 60(14):1-8, 2019. e-Pub 2019. PMID: 31282244.
142. Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver N, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO. Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. Am J Hematol 94(12):1382-1387, 2019. e-Pub 2019. PMID: 31595538.
143. Ambinder RF, Wu J, Logan B, Durand CM, Shields R, Popat UR, Little RF, McMahon DK, Cyktor J, Mellors JW, Ayala E, Kaplan LD, Noy A, Jones RJ, Howard A, Forman SJ, Porter D, Arce-Lara C, Shaughnessy P, Sproat L, Hashmi SK, Mendizabal AM, Horowitz MM, Navarro WH, Alvarnas JC. Allogeneic hematopoietic cell transplant for HIV patients with hematologic malignancies: the BMT CTN-0903/AMC-080 trial. Biol Blood Marrow Transplant 25(11):2160-2166, 2019. e-Pub 2019. PMID: 31279752.
144. Saini N, Ma J, Milton DR, Patel R, Varma A, Bashir Q, Delgado R, Mukherjee A, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Tang G, Mehta R, Srour S, Khouri IF, Iyer S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. Clin Cancer Res 25(22):6781-6787, 2019. e-Pub 2019. PMID: 31481508.
145. Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia. Ann Hematol 98(9):2233-2235, 2019. e-Pub 2019. PMID: 31243571.
146. Alatrash G, Kidwell KM, Thall PF, Di Stasi A, Chen J, Zope M, Crain AK, Champlin RE, Popat U, Shpall EJ, Jones RB, Andersson BS. Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS. Bone Marrow Transplant 54(8):1245-1253, 2019. e-Pub 2019. PMID: 30532055.
147. Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorror ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobecks R, Alyea E, Saber W, Brown JR. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clin Cancer Res 25(16):5143-5155, 2019. e-Pub 2019. PMID: 31253630.
148. Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Oran B, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SO. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant 25(7):1340-1346, 2019. e-Pub 2019. PMID: 30763728.
149. Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat UR. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica. e-Pub 2019. PMID: 31296578.
150. Chamoun K, Milton DR, Ledesma C, Young KH, Jabbour EJ, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Marin D, Molldrem JJ, Olson AL, Oran B, Popat UR, Rondon G, Champlin RE, Gulbis AM, Khouri IF. Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. Biol Blood Marrow Transplant 25(7):1347-1354, 2019. e-Pub 2019. PMID: 30826465.
151. Kongtim P, Parmar S, Milton DR, Perez JMR, Rondon G, Chen J, Chilkulwar AR, Al-Atrash G, Alousi A, Andersson BS, Im JS, Hosing CM, Bashir Q, Khouri I, Kebriaei P, Oran B, Popat U, Champlin R, Ciurea SO. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 54(6):839-848, 2019. e-Pub 2019. PMID: 30258129.
152. Ciurea SO, Hansrivijit P, Ciurea AM, Hymes S, Chen J, Rondon G, Hosing C, Popat U, Champlin RE. Curative potential of hematopoietic stem cell transplantation for advanced psoriasis. Am J Hematol 94(6):E176-E180, 2019. e-Pub 2019. PMID: 30900768.
153. Simkins A, Maiti A, Short NJ, Jain N, Popat U, Patel KP, Oo TH. Acquired amegakaryocytic thrombocytopenia and red cell aplasia in a patient with thymoma progressing to aplastic anemia successfully treated with allogenic stem cell transplantation. Hematol Oncol Stem Cell Ther 12(2):115-118, 2019. e-Pub 2019. PMID: 29409729.
154. Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol 6(5):e266-e275, 2019. e-Pub 2019. PMID: 30910541.
155. Maymani H, Lin P, Saliba RM, Popat U, Bashir Q, Shah N, Patel K, Parmar S, Kebriaei P, Hosing C, Ciurea S, Andersson B, Shpall E, Champlin R, Srour SA, Qazilbash MH. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biol Blood Marrow Transplant 25(5):1039-1044, 2019. e-Pub 2019. PMID: 30639822.
156. Ghobadi A, Milton DR, Gowda L, Rondon G, Chemaly RF, Hamdi A, Alousi A, Afrough A, Oran B, Ciurea S, Kebriaei P, Popat UR, Qazilbash MH, Shpall EJ, Champlin RE, Bashir Q. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. Curr Res Transl Med 67(2):51-55, 2019. e-Pub 2019. PMID: 30683577.
157. Shah MV, Saliba RM, Rondon G, Chen J, Soebbing D, Rus I, Alousi A, Oran B, Kebriaei P, Qazilbash M, Parmar S, Hosing C, Khouri IF, Popat UR, Champlin RE, Ciurea SO. Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. Bone Marrow Transplant 54(4):601-606, 2019. e-Pub 2019. PMID: 30337700.
158. Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. Am J Hematol 94(3):E72-E74, 2019. e-Pub 2019. PMID: 30548467.
159. Veltri L, Rezvani K, Oran B, Mehta R, Rondon G, Kebriaei P, Popat U, Nieto Y, Hosing C, Qazilbash M, Khouri I, Shpall E, Champlin R, Marin D. Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. Biol Blood Marrow Transplant 25(3):505-514, 2019. e-Pub 2019. PMID: 30308325.
160. Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma 60(2):442-452, 2019. e-Pub 2019. PMID: 30032678.
161. Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan-based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol 94(1):E2-E5, 2019. e-Pub 2019. PMID: 30300461.
162. Shah MV, Patel KP, Luthra R, Kanagal-Shamanna R, Mehrotra M, Bachegowda LS, Champlin RE, Verstovsek S, Popat UR. Sensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation. Br J Haematol 183(5):831-835, 2018. e-Pub 2018. PMID: 29265180.
163. Afrough A, Saliba RM, Hamdi A, Honhar M, Varma A, Cornelison AM, Rondon G, Parmar S, Shah ND, Bashir Q, Hosing C, Popat U, Weber DM, Thomas S, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24(11):2197-2203, 2018. e-Pub 2018. PMID: 30016656.
164. Radivoyevitch T, Dean RM, Shaw BE, Brazauskas R, Tecca HR, Molenaar RJ, Battiwalla M, Savani BN, Flowers MED, Cooke KR, Hamilton BK, Kalaycio M, Maciejewski JP, Ahmed I, Akpek G, Bajel A, Buchbinder D, Cahn JY, D'Souza A, Daly A, DeFilipp Z, Ganguly S, Hamadani M, Hayashi RJ, Hematti P, Inamoto Y, Khera N, Kindwall-Keller T, Landau H, Lazarus H, Majhail NS, Marks DI, Olsson RF, Seo S, Steinberg A, William BM, Wirk B, Yared JA, Aljurf M, Abidi MH, Allewelt H, Beitinjaneh A, Cook R, Cornell RF, Fay JW, Hale G, Chakrabarty JH, Jodele S, Kasow KA, Mahindra A, Malone AK, Popat U, Rizzo JD, Schouten HC, Warwick AB, Wood WA, Sekeres MA, Litzow MR, Gale RP, Hashmi SK. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leuk Res 74:130-136, 2018. e-Pub 2018. PMID: 30055822.
165. Valdez BC, Tang X, Li Y, Murray D, Liu Y, Popat U, Champlin RE, Andersson BS. Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells. Exp Hematol 67:49-59.e1, 2018. e-Pub 2018. PMID: 30102945.
166. Popat UR, Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Rezvani K, Qazilbash MH, Shah N, Srour SA, Shpall EJ, Champlin RE, Andersson BS. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol 5(11):e532-e542, 2018. e-Pub 2018. PMID: 30389035.
167. Kellner JN, Delemarre EM, Yvon E, Nierkens S, Boelens JJ, McNiece I, Olson A, Nieto Y, Ciurea S, Popat U, Ahmed S, Champlin R, Ramos J, Nishimoto M, Ma H, Ke Z, Thall P, Khoury JD, Negrin R, Andersson B, Parmar S. Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution. Oncotarget 9(86):35611-35622, 2018. e-Pub 2018. PMID: 30479692.
168. Chhabra S, Ahn KW, Hu ZH, Jain S, Assal A, Cerny J, Copelan EA, Daly A, DeFilipp Z, Gadalla SM, Gale RP, Ganguly S, Hamilton BK, Hildebrandt GC, Hsu JW, Inamoto Y, Kanate AS, Khoury HJ, Lazarus HM, Litzow MR, Nathan S, Olsson RF, Pawarode A, Ringden O, Rowe JM, Saad A, Savani BN, Schouten HC, Seo S, Shah NN, Solh M, Stuart RK, Ustun C, Woolfrey AE, Yared JA, Alyea EP, Kalaycio ME, Popat U, Sobecks RM, Saber W. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Adv 2(21):2922-2936, 2018. e-Pub 2018. PMID: 30396912.
169. Ciurea SO, Bittencourt MCB, Milton DR, Cao K, Kongtim P, Rondon G, Chen J, Konopleva M, Perez JMR, El Shazly MF, Aljadayeh M, Alvarez M, Im J, Al-Atrash G, Mehta R, Popat U, Bashir Q, Oran B, Hosing CM, Khouri IF, Kebriaei P, Champlin RE. Is a matched unrelated donor search needed for all allogeneic transplant candidates?. Blood Adv 2(17):2254-2261, 2018. e-Pub 2018. PMID: 30206098.
170. Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biol Blood Marrow Transplant 24(8):1602-1609, 2018. e-Pub 2018. PMID: 29501779.
171. Shah MV, Jorgensen JL, Saliba RM, Wang SA, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Patel KP, Popat UR, Rezvani K, Rondon G, Shpall EJ, Champlin RE, Oran B. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. Biol Blood Marrow Transplant 24(7):1514-1520, 2018. e-Pub 2018. PMID: 29448058.
172. Ciurea SO, Shah MV, Saliba RM, Gaballa S, Kongtim P, Rondon G, Chen J, Wallis W, Cao K, Konopleva M, Daver N, Cortes J, Ravandi F, Alousi A, Ahmed S, Popat U, Parmar S, Bashir Q, Betul O, Hosing C, Shpall EJ, Rezvani K, Khouri IF, Kebriaei P, Champlin RE. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant 24(6):1232-1236, 2018. e-Pub 2018. PMID: 28918304.
173. Ciurea SO, Chilkulwar A, Saliba RM, Chen J, Rondon G, Patel KP, Khogeer H, Shah AR, Randolph BV, Perez JMR, Popat U, Hosing CM, Bashir Q, Mehta R, Al-Atrash G, Im J, Khouri IF, Kebriaei P, Champlin RE. Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. Blood 131(26):2989-2992, 2018. e-Pub 2018. PMID: 29769261.
174. Oran B, Saliba RM, Carmazzi Y, de Lima M, Rondon G, Ahmed S, Alousi A, Andersson BS, Anderlini P, Alvarez M, Bashir Q, Ciurea S, Fernandez-Vina M, Hosing C, Kebriaei P, Korbling M, Cano P, Khouri I, Marin D, Nieto Y, Olson A, Popat U, Rezvani K, Qazilbash M, Shpall EJ, Champlin RE, Cao K. Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. Blood 131(11):1248-1257, 2018. e-Pub 2018. PMID: 29386198.
175. Hill BT, Ahn KW, Hu ZH, Aljurf M, Beitinjaneh A, Cahn JY, Cerny J, Kharfan-Dabaja MA, Ganguly S, Ghosh N, Grunwald MR, Inamoto Y, Kindwall-Keller T, Nishihori T, Olsson RF, Saad A, Seftel M, Seo S, Szer J, Tallman M, Ustun C, Wiernik PH, Maziarz RT, Kalaycio M, Alyea E, Popat U, Sobecks R, Saber W. Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. Biol Blood Marrow Transplant 24(3):581-586, 2018. e-Pub 2018. PMID: 29032274.
176. Ragon BK, Mehta RS, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. Bone Marrow Transplant 53(3):315-325, 2018. e-Pub 2018. PMID: 29269797.
177. Zhang X, Sun M, Liu S, Leung CH, Pang L, Popat UR, Champlin R, Holmes HM, Valero V, Dinney CP, Tripathy D, Edwards BJ. Risk factors for falls in older patients with cancer. BMJ Support Palliat Care 8(1):34-37, 2018. e-Pub 2018. PMID: 28860112.
178. Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. Leuk Lymphoma 59(2):515-518, 2018. e-Pub 2018. PMID: 28673185.
179. Tamari R, Oran B, Hilden P, Maloy M, Kongtim P, Papadopoulos EB, Rondon G, Jakubowski AA, Andersson BS, Devlin SM, Ahmed S, Popat UR, Ponce D, Chen J, Sauter C, Young JW, de Lima M, Perales MA, O'Reilly RJ, Giralt SA, Champlin RE, Castro-Malaspina H. Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24(5):1079-1087. e-Pub 2018. PMID: 29325829.
180. Zhang X, Sun M, McKoy JM, Bhulani NNA, Valero V, Barcenas CH, Popat UR, Sri MK, Shah JB, Dinney CP, Hedberg AM, Champlin R, Tripathy D, Holmes HM, Stroehlein JR, Edwards BJ. Malnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index. J Geriatr Oncol 9(1):81-83, 2018. e-Pub 2018. PMID: 28844850.
181. Cao K, Marin D, Sekine T, Rondon G, Zhao W, Smith NT, Daher M, Wang Q, Li L, Saliba RM, Pingali R, Popat U, Hosing C, Olson A, Oran B, Basar R, Mehta RS, Champlin R, Shpall EJ, Rezvani K. Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation. Front Immunol 9:2444, 2018. e-Pub 2018. PMID: 30405633.
182. Shah N, Cornelison AM, Saliba R, Ahmed S, Nieto YL, Bashir Q, Parmar S, Hosing C, Popat U, Shpall EJ, Champlin RE, Qazilbash M. Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. Eur J Haematol 99(6):532-535, 2017. e-Pub 2017. PMID: 28895206.
183. Rondón G, Saliba RM, Chen J, Ledesma C, Alousi AM, Oran B, Hosing CM, Kebriaei P, Khouri IF, Shpall EJ, Popat UR, Champlin RE, Ciurea SO. Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes. Biol Blood Marrow Transplant 23(12):2166-2171, 2017. e-Pub 2017. PMID: 28844946.
184. Im JS, Abraham SC, Saliba RM, Rondon G, Ross WA, Rashid A, Shpall EJ, Popat U, Qazilbash MH, Hosing C, Oran B, Shah N, Tewari P, Nieto Y, Kebriaei P, Champlin RE, Alousi AM. Histologic Grade 1 Is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease. Am J Surg Pathol 41(11):1483-1490, 2017. e-Pub 2017. PMID: 28834808.
185. Veltri LW, Milton DR, Delgado R, Shah N, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea S, Hosing C, Lee HC, Manasanch E, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer 123(18):3568-3575, 2017. e-Pub 2017. PMID: 28513828.
186. Bachegowda LS, Shah MV, Veltri LW, Tanase A, Popat U, Anderlini P, Chen J, Rondon G, Champlin RE, Ciurea SO. HLA-mismatched bone marrow transplantation in severe aplastic anemia. Bone Marrow Transplant 52(9):1347-1348, 2017. e-Pub 2017. PMID: 28692030.
187. Mehta RS, Saliba RM, Cao K, Kaur I, Rezvani K, Chen J, Olson A, Parmar S, Shah N, Marin D, Alousi A, Hosing C, Popat U, Kebriaei P, Champlin R, de Lima M, Skerrett D, Burke E, Shpall EJ, Oran B. Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. Biol Blood Marrow Transplant 23(8):1359-1366, 2017. e-Pub 2017. PMID: 28506845.
188. Khouri MR, Jabbour EJ, Gulbis AM, Turturro F, Ledesma C, Korbling M, Samuels BI, Ahmed S, Alousi AM, Ciurea SO, Marin D, Patel KK, Popat UR, Bueso-Ramos CE, Bassett RL, Khouri IF. Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation. Biol Blood Marrow Transplant 23(8):1405-1410, 2017. e-Pub 2017. PMID: 28495642.
189. Srour SA, Li S, Popat UR, Qazilbash MH, Lozano-Cerrada S, Maadani F, Alousi A, Kebriaei P, Anderlini P, Nieto Y, Jones R, Shpall E, Champlin RE, Hosing C. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results. Br J Haematol 178(4):561-570, 2017. e-Pub 2017. PMID: 28485023.
190. Pingali SR, Saliba RM, Anderlini P, Hosing C, Khouri I, Alousi AM, Nieto Y, Qazilbash MH, Champlin R, Popat UR. Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin Lymphoma. Biol Blood Marrow Transplant 23(7):1059-1063, 2017. e-Pub 2017. PMID: 28389254.
191. Yucel OK, Saliba RM, Rondon G, Ahmed S, Alousi A, Bashir Q, Ciurea SO, Popat U, Khouri I, Marin D, Rezvani K, Kebriaei P, Shpall EJ, Champlin RE, Oran B. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning. Cancer 123(14):2661-2670, 2017. e-Pub 2017. PMID: 28324640.
192. Kongtim P, Adekola K, Milton DR, Ramlal R, Jimenez A, Chen J, Rondon G, Ahmed S, Kebriaei P, Betul O, Hosing CM, Popat U, Khouri I, Jabbour E, Cortes JE, Kantarjian HM, Champlin RE, Ciurea SO. Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Leukemia 31(7):1654-1657, 2017. e-Pub 2017. PMID: 28400618.
193. Bachegowda LS, Saliba RM, Ramlal R, Kongtim P, Chen J, Rondon G, Wallis W, Alousi A, Ahmed S, Hosing CM, Parmar S, Qazilbash M, Khouri IF, Bashir Q, Oran B, Popat U, Shpall EJ, Marin D, Rezvani K, Kebriaei P, Champlin RE, Ciurea SO. Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. Blood 129(22):3031-3033, 2017. e-Pub 2017. PMID: 28351938.
194. Gerds AT, Woo Ahn K, Hu ZH, Abdel-Azim H, Akpek G, Aljurf M, Ballen KK, Beitinjaneh A, Bacher U, Cahn JY, Chhabra S, Cutler C, Daly A, DeFilipp Z, Gale RP, Gergis U, Grunwald MR, Hale GA, Hamilton BK, Jagasia M, Kamble RT, Kindwall-Keller T, Nishihori T, Olsson RF, Ramanathan M, Saad AA, Solh M, Ustun C, Valcárcel D, Warlick E, Wirk BM, Kalaycio M, Alyea E, Popat U, Sobecks R, Saber W. Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. Biol Blood Marrow Transplant 23(6):971-979, 2017. e-Pub 2017. PMID: 28288952.
195. Nieto Y, Valdez BC, Pingali SR, Bassett R, Delgado R, Nguyen J, Shah N, Popat U, Jones RB, Andersson BS, Gulbis A, Ahmed S, Bashir Q, Parmar S, Patel K, Myers A, Rondon G, Orlowski RZ, Champlin R, Qazilbash M. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Lancet Haematol 4(6):e283-e292, 2017. e-Pub 2017. PMID: 28522110.
196. Thompson PA, Stingo F, Keating MJ, Wierda WG, O'Brien SM, Estrov Z, Ledesma C, Rezvani K, Qazilbash M, Shah N, Parmar S, Popat U, Anderlini P, Yago N, Ciurea SO, Kebriaei P, Champlin R, Shpall EJ, Hosing CM. Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Br J Haematol 177(4):567-577, 2017. e-Pub 2017. PMID: 28295181.
197. Liu HD, Ahn KW, Hu ZH, Hamadani M, Nishihori T, Wirk B, Beitinjaneh A, Rizzieri D, Grunwald MR, Sabloff M, Olsson RF, Bajel A, Bredeson C, Daly A, Inamoto Y, Majhail N, Saad A, Gupta V, Gerds A, Malone A, Tallman M, Reshef R, Marks DI, Copelan E, Gergis U, Savoie ML, Ustun C, Litzow MR, Cahn JY, Kindwall-Keller T, Akpek G, Savani BN, Aljurf M, Rowe JM, Wiernik PH, Hsu JW, Cortes J, Kalaycio M, Maziarz R, Sobecks R, Popat U, Alyea E, Saber W. Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant 23(5):767-775, 2017. e-Pub 2017. PMID: 28115276.
198. Andersson BS, Thall PF, Valdez BC, Milton DR, Al-Atrash G, Chen J, Gulbis A, Chu D, Martinez C, Parmar S, Popat U, Nieto Y, Kebriaei P, Alousi A, de Lima M, Rondon G, Meng QH, Myers A, Kawedia J, Worth LL, Fernandez-Vina M, Madden T, Shpall EJ, Jones RB, Champlin RE. Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. Bone Marrow Transplant 52(4):580-587, 2017. e-Pub 2017. PMID: 27991894.
199. Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Marin D, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver N, Andreeff M, Ravandi F, Cortes J, Patel K, Champlin RE, Ciurea SO. Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. Am J Hematol 92(4):331-337, 2017. e-Pub 2017. PMID: 28052408.
200. Ge I, Saliba RM, Maadani F, Popat UR, Qazilbash MH, Ravi Pingali S, Shah N, Ahmed S, Bashir Q, Nieto Y, Champlin RE, Hosing C. Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma. Transfusion 57(4):1052-1057, 2017. e-Pub 2017. PMID: 28185276.
201. Varma A, Biritxinaga L, Saliba RM, Stich M, Jauch SF, Afrough A, Honhar M, Popat UR, Shafi MA, Shah N, Bashir Q, Dinh Y, Hosing C, Champlin RE, Qazilbash MH. Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant 23(4):581-587, 2017. e-Pub 2017. PMID: 28063964.
202. Badar T, Srour S, Bashir Q, Shah N, Al-Atrash G, Hosing C, Popat U, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma. Eur J Haematol 98(3):263-268, 2017. e-Pub 2017. PMID: 27862330.
203. Abudayyeh A, Hamdi A, Abdelrahim M, Lin H, Page VD, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Gaber AO, Oran B, Chemaly RF, Ahmed S, Abudayyeh I, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Rezvani K. Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients. Transpl Infect Dis 19(1), 2017. e-Pub 2017. PMID: 27862740.
204. Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stuve O, Arnold DL, Wener MH, Georges GE, Wundes A, Kraft GH, Bowen JD. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology 88(9):842-852, 2017. e-Pub 2017. PMID: 28148635.
205. Kebriaei P, Bassett R, Lyons G, Valdez B, Ledesma C, Rondon G, Oran B, Ciurea S, Alousi A, Popat U, Patel K, Ahmed S, Olson A, Bashir Q, Shah N, Jones R, Marin D, Rezvani K, Nieto Y, Khouri I, Qazilbash M, Hosing C, Shpall E, Champlin RE, Andersson BS. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biol Blood Marrow Transplant 23(2):285-292, 2017. e-Pub 2017. PMID: 27816651.
206. Oran B, Jorgensen JL, Marin D, Wang S, Ahmed S, Alousi AM, Andersson BS, Bashir Q, Bassett R, Lyons G, Chen J, Rezvani K, Popat U, Kebriaei P, Patel K, Rondon G, Shpall EJ, Champlin RE. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica 102(1):110-117, 2017. e-Pub 2017. PMID: 27540139.
207. Khouri IF, Sui D, Jabbour EJ, Samuels BI, Turturro F, Alatrash G, Anderlini P, Ahmed S, Oran B, Ciurea SO, Marin D, Olson A, Patel KK, Popat UR, Ledesma C, Kadia TM, Ferrajoli A, Burger JA, Jorgensen JL, Medeiros LJ, Bassett RL, Gulbis AM. Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL. Bone Marrow Transplant 52(1):28-33, 2017. e-Pub 2017. PMID: 27595282.
208. Bock F, Lu G, Srour SA, Gaballa S, Lin HY, Baladandayuthapani V, Honhar M, Stich M, Shah ND, Bashir Q, Patel K, Popat U, Hosing C, Korbling M, Delgado R, Rondon G, Shah JJ, Thomas SK, Manasanch EE, Isermann B, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 22(12):2159-2164, 2016. e-Pub 2016. PMID: 27638366.
209. Faiz SA, Iliescu C, Lopez-Mattei J, Patel B, Bashoura L, Popat U. Resolution of myelofibrosis-associated pulmonary arterial hypertension following allogeneic hematopoietic stem cell transplantation. Pulm Circ 6(4):611-613, 2016. e-Pub 2016. PMID: 28090305.
210. Mian I, Milton DR, Shah N, Nieto Y, Popat UR, Kebriaei P, Parmar S, Oran B, Shah JJ, Manasanch EE, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer 122(24):3831-3837, 2016. e-Pub 2016. PMID: 27680710.
211. Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Lombardi L, Alatrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri I, Champlin RE, Ciurea SO. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer 122(21):3316-3326, 2016. e-Pub 2016. PMID: 27404668.
212. Artz AS, Logan B, Zhu X, Akpek G, Bufarull RM, Gupta V, Lazarus HM, Litzow M, Loren A, Majhail NS, Maziarz RT, McCarthy P, Popat U, Saber W, Spellman S, Ringden O, Wickrema A, Pasquini MC, Cooke KR, International Blood FTCF, Research MT. The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. Haematologica 101(11):1426-1433, 2016. e-Pub 2016. PMID: 27662010.
213. Mulanovich VE, Desai PA, Popat UR. Allogeneic stem cell transplantation for HIV-positive patients with hematologic malignancies. AIDS 13(30):17, 2016. e-Pub 2016. PMID: 27536985.
214. Alatrash G, Thall PF, Valdez BC, Fox PS, Ning J, Garber HR, Janbey S, Worth LL, Popat U, Hosing C, Alousi AM, Kebriaei P, Shpall EJ, Jones RB, de Lima M, Rondon G, Chen J, Champlin RE, Andersson BS. Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant 22(10):1792-1800, 2016. e-Pub 2016. PMID: 27377901.
215. Gaballa S, Saliba RM, Srour S, Lu G, Brammer JE, Shah N, Bashir Q, Patel K, Bock F, Parmar S, Hosing C, Popat U, Delgado R, Rondon G, Shah JJ, Manasanch EE, Orlowski RZ, Champlin R, Qazilbash MH. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. Am J Hematol 91(10):E442-7, 2016. e-Pub 2016. PMID: 27420405.
216. Badar T, Cornelison AM, Shah ND, Bashir Q, Parmar S, Patel K, Hosing C, Popat U, Weber DM, Thomas SK, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement. Eur J Haematol 97(4):342-7, 2016. e-Pub 2016. PMID: 26773409.
217. Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su S, Maiti S, Dai J, Moriarity B, Forget MA, Senyukov V, Orozco A, Liu T, McCarty J, Jackson RN, Moyes JS, Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Kantarjian H, Keating M, Wierda W, Do KA, Largaespada DA, Lee DA, Hackett PB, Champlin RE, Cooper LJ. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest 126(9):3363-76, 2016. e-Pub 2016. PMID: 27482888.
218. Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer 122(17):2680-8, 2016. e-Pub 2016. PMID: 27203405.
219. Sarvaria A, Basar R, Mehta RS, Shaim H, Muftuoglu M, Khoder A, Sekine T, Gokdemir E, Kondo K, Marin D, Daher M, Alousi AM, Alsuliman A, Liu E, Oran B, Olson A, Jones RB, Popat U, Hosing C, Champlin R, Shpall EJ, Rezvani K. IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. Blood 128(10):1346-61, 2016. e-Pub 2016. PMID: 27439912.
220. Alvarnas JC, Le Rademacher J, Wang Y, Little RF, Akpek G, Ayala E, Devine S, Baiocchi R, Lozanski G, Kaplan L, Noy A, Popat U, Hsu J, Morris LE, Thompson J, Horowitz MM, Mendizabal A, Levine A, Krishnan A, Forman SJ, Navarro WH, Ambinder R. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. Blood 128(8):1050-8, 2016. e-Pub 2016. PMID: 27297790.
221. Sasaki K, Popat U, Jain P, Kadia T, Patel K, Patel K, Jain N, Takahashi K, Young K, Miranda RN, Oo TH, Lu H, Pemmaraju N. Successful treatment of aplastic anemia-paroxysmal nocturnal hemoglobinuria associated with eosinophilic fasciitis with matched unrelated donor allogeneic peripheral blood stem cell transplantation. Clin Case Rep 4(8):765-7, 2016. e-Pub 2016. PMID: 27525080.
222. Ustun C, Gotlib J, Popat U, Artz A, Litzow M, Reiter A, Nakamura R, Kluin-Nelemans HC, Verstovsek S, Gajewski J, Perales MA, George T, Shore T, Sperr W, Saber W, Kota V, Yavuz AS, Pullarkat V, Rogosheske J, Hogan W, Van Besien K, Hagglund H, Damaj G, Arock M, Horny HP, Metcalfe DD, Deeg HJ, Devine S, Weisdorf D, Akin C, Valent P. Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. Biol Blood Marrow Transplant 22(8):1348-1356, 2016. e-Pub 2016. PMID: 27131865.
223. Varma A, Saliba RM, Torres HA, Afrough A, Hosing C, Khouri IF, Nieto Y, Shah ND, Parmar S, Bashir Q, Ahmed S, Jones RB, Kebriaei P, Olson AL, Shpall EJ, Alousi AM, Qazilbash MH, Champlin RE, Popat U. Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. Bone Marrow Transplant 51(7):999-1001, 2016. e-Pub 2016. PMID: 26950376.
224. Sekine T, Marin D, Cao K, Li L, Mehta P, Shaim H, Sobieski C, Jones R, Oran B, Hosing C, Rondon G, Alsuliman A, Paust S, Andersson B, Popat U, Kebriaei P, Muftuoglu M, Basar R, Kondo K, Nieto Y, Shah N, Olson A, Alousi A, Liu E, Sarvaria A, Parmar S, Armstrong-James D, Imahashi N, Molldrem J, Champlin R, Shpall EJ, Rezvani K. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood 128(2):297-312, 2016. e-Pub 2016. PMID: 27247137.
225. Anderlini P, Saliba RM, Ledesma C, Plair T, Alousi AM, Hosing CM, Khouri IF, Nieto Y, Popat UR, Shpall EJ, Fanale MA, Hagemeister FB, Oki Y, Neelapu S, Romaguera JE, Younes A, Champlin RE. Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant 22(7):1333-1337, 2016. e-Pub 2016. PMID: 27064056.
226. Thompson PA, Perera T, Marin D, Oran B, Popat U, Qazilbash M, Shah N, Parmar S, Rezvani K, Olson A, Kebriaei P, Anderlini P, Rondon G, Alousi A, Ciurea S, Champlin RE, Bajel A, Szer J, Shpall EJ, Ritchie D, Hosing C. Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. Leuk Lymphoma 57(7):1607-15, 2016. e-Pub 2016. PMID: 26472485.
227. Kongtim P, Popat U. Allogeneic Hematopoietic Stem-Cell Transplantation in Myelofibrosis: Key Messages for Clinical Practice in the Era of Janus Kinase 1/2 Inhibitors. J Oncol Pract 12(7):633-4, 2016. e-Pub 2016. PMID: 27407159.
228. Chaudhury S, Sparapani R, Hu ZH, Nishihori T, Abdel-Azim H, Malone A, Olsson R, Hamadani M, Daly A, Bacher U, Wirk BM, Kamble RT, Gale RP, Wood WA, Hale G, Wiernik PH, Hashmi SK, Marks D, Ustun C, Munker R, Savani BN, Alyea E, Popat U, Sobecks R, Kalaycio M, Maziarz R, Hijiya N, Saber W. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. Biol Blood Marrow Transplant 22(6):1056-1064, 2016. e-Pub 2016. PMID: 26964698.
229. Shaffer BC, Ahn KW, Hu ZH, Nishihori T, Malone AK, Valcárcel D, Grunwald MR, Bacher U, Hamilton B, Kharfan-Dabaja MA, Saad A, Cutler C, Warlick E, Reshef R, Wirk BM, Sabloff M, Fasan O, Gerds A, Marks D, Olsson R, Wood WA, Costa LJ, Miller AM, Cortes J, Daly A, Kindwall-Keller TL, Kamble R, Rizzieri DA, Cahn JY, Gale RP, William B, Litzow M, Wiernik PH, Liesveld J, Savani BN, Vij R, Ustun C, Copelan E, Popat U, Kalaycio M, Maziarz R, Alyea E, Sobecks R, Pavletic S, Tallman M, Saber W. Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. J Clin Oncol 34(16):1864-71, 2016. e-Pub 2016. PMID: 27044940.
230. Aung FM, Lichtiger B, Rondon G, Yin CC, Alousi A, Ahmed S, Andersson BS, Bashir Q, Ciurea SO, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Shpall EJ, Champlin RE, Popat U. Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biol Blood Marrow Transplant 22(5):961-5, 2016. e-Pub 2016. PMID: 26921820.
231. Mehta RS, Saliba RM, Chen J, Rondon G, Hammerstrom AE, Alousi A, Qazilbash M, Bashir Q, Ahmed S, Popat U, Hosing C, Khouri I, Shpall EJ, Champlin RE, Ciurea SO. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol 173(3):444-55, 2016. e-Pub 2016. PMID: 26947769.
232. Abudayyeh A, Hamdi A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Gaber AO, Salahudeen A, Oran B, Chemaly RF, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Winkelmayer WC, Rezvani K. Symptomatic BK Virus Infection Is Associated with Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients. Am J Transplant 16(5):1492-502, 2016. e-Pub 2016. PMID: 26608093.
233. Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring JM, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG, Hanif A, Champlin R, Hari P, Gupta V. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. Biol Blood Marrow Transplant 22(3):432-40, 2016. e-Pub 2016. PMID: 26493563.
234. Cornelison AM, Saliba RM, Afrough A, Dinh Y, Nieto Y, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Shpall E, Champlin R, Qazilbash MH. Autologous hematopoietic stem cell transplantation in light chain amyloidosis (AL) with renal involvement. Bone Marrow Transplant 51(2):307-9, 2016. e-Pub 2016. PMID: 26479980.
235. Karuturi M, Younes A, Fayad L, Kwak L, Pro B, Shah J, Oki Y, Simien R, Liboon MJ, Hutto T, Feng L, Horowitz S, Nieto Y, Anderlini P, Alousi A, Popat U, Medeiros LJ, Miranda R, Fanale M. ICE (Ifosfamide, Carboplatin, Etoposide) with or without Bortezomib in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Randomized Phase II Trial. Leuk Lymphoma 57(2):445-447, 2016. e-Pub 2016. PMID: 25804933.
236. Kongtim P, Popat U, Jimenez A, Gaballa S, El Fakih R, Rondon G, Chen J, Bueso-Ramos C, Borthakur G, Pemmaraju N, Garcia-Manero G, Kantarjian H, Alousi A, Hosing C, Anderlini P, Khouri IF, Kebriaei P, Andersson BS, Oran B, Rezvani K, Marin D, Shpall EJ, Champlin RE, Ciurea SO. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression Free Survival for Patients with Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant 22(1):47-53, 2016. e-Pub 2016. PMID: 26343946.
237. Kyvernitakis A, Mahale P, Popat UR, Jiang Y, Hosry J, Champlin RE, Torres HA. Hepatitis C Virus Infection in Patients Undergoing Hematopoietic Cell Transplantation in the Era of Direct-Acting Antiviral Agents. Biol Blood Marrow Transplant 16(1):36-42, 2016. e-Pub 2016. PMID: 26712592.
238. Jacobs RW, Saliba RM, Sasaki K, Farhan S, Armas A, Shah ND, Bashir Q, Qureshi S, Rondon G, Hosing C, Popat U, Parmar S, Shah JJ, Wang M, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk 16(1):36-42, 2016. e-Pub 2016. PMID: 26702475.
239. Lu H, Champlin RE, Popat U, Pundole X, Escalante CP, Wang X, Qiao W, Murphy WA, Gagel RF. Ibandronate for the prevention of bone loss after allogeneic stem cell transplantation for hematologic malignancies: a randomized-controlled trial. Bonekey Rep 5:843, 2016. e-Pub 2016. PMID: 28018583.
240. Hosing C, Bassett R, Dabaja B, Talpur R, Alousi A, Ciurea S, Popat U, Qazilbash M, Shpall EJ, Oki Y, Nieto Y, Pinnix C, Fanale M, Maadani F, Donato M, Champlin R, Duvic M. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol 26(12):2490-5, 2015. e-Pub 2015. PMID: 26416896.
241. Lee HC, Saliba RM, Rondon G, Chen J, Charafeddine Y, Medeiros LJ, Alatrash G, Andersson BS, Popat U, Kebriaei P, Ciurea S, Oran B, Shpall E, Champlin R. Mixed T-lymphocyte chimerism after allogeneic hematopoietic transplantation is predictive for relapse of AML/MDS. Biol Blood Marrow Transplant 21(11):1948-54, 2015. e-Pub 2015. PMID: 26183077.
242. Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Vorinostat Combined with High-Dose Gemcitabine, Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant 21(11):1914-20, 2015. e-Pub 2015. PMID: 26071868.
243. Kazmi SM, Nusrat M, Gunaydin H, Cornelison AM, Shah N, Kebriaei P, Nieto Y, Parmar S, Popat UR, Oran B, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH, Bashir Q. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk 15(11):687-93, 2015. e-Pub 2015. PMID: 26361647.
244. Oran B, Cao K, Saliba RM, Rezvani K, de Lima M, Ahmed S, Hosing CM, Popat UR, Carmazzi Y, Kebriaei P, Nieto Y, Rondon G, Willis D, Shah N, Parmar S, Olson A, Moore B, Marin D, Mehta R, Fernández-Viña M, Champlin RE, Shpall EJ. Better allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica 100(10):1361-70, 2015. e-Pub 2015. PMID: 26250579.
245. Shah N, Thall PF, Fox PS, Bashir Q, Shah JJ, Parmar S, Lin P, Kebriaei P, Nieto Y, Popat UR, Hosing CM, Cornelison A, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. Leukemia 29(9):1945-8, 2015. e-Pub 2015. PMID: 25721897.
246. Afable M, Caimi PF, Hosing C, de Lima M, Khouri I, William BM, Nieto Y, Cooper BW, Anderlini P, Gerson SL, Lazarus HM, Champlin R, Popat U. Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of Treatment. Biol Blood Marrow Transplant 21(8):1529-1531, 2015. e-Pub 2015. PMID: 25937397.
247. Afrough A, Saliba RM, Hamdi A, El Fakih R, Varma A, Dinh YT, Rondon G, Cornelison AM, Shah ND, Bashir Q, Shah JJ, Hosing C, Popat U, Orlowski RZ, Champlin RE, Parmar S, Qazilbash MH. Outcome of Patients with Immunoglobulin Light Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 21(8):1413-7, 2015. e-Pub 2015. PMID: 25842049.
248. Oran B, Jimenez AM, De Lima M, Popat UR, Bassett R, Andersson B, Borthakur G, Bashir Q, Chen J, Ciurea SO, Jabbour E, Cortes J, Kebriaei P, Khouri IF, Qazilbash MH, Ravandi F, Rondon G, Lu X, Shpall EJ, Champlin RE. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 21(8):1405-1412, 2015. e-Pub 2015. PMID: 25840338.
249. Ciurea SO, Thall PF, Milton DR, Barnes TH, Kongtim P, Carmazzi Y, López AA, Yap DY, Popat U, Rondon G, Lichtiger B, Aung F, Afshar-Kharghan V, Ma Q, Fernández-Viña M, Champlin RE, Cao K. Complement-binding Donor-specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 21(8):1392-8, 2015. e-Pub 2015. PMID: 25985919.
250. El Fakih R, Fox P, Popat U, Nieto Y, Shah N, Parmar S, Oran B, Ciurea S, Kebriaei P, Hosing C, Ahmed S, Shah J, Orlowski R, Champlin R, Qazilbash M, Bashir Q. Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clin Lymphoma Myeloma Leuk 15(8):472-6, 2015. e-Pub 2015. PMID: 25963284.
251. Konopleva M, Benton CB, Thall PF, Zeng Z, Shpall E, Ciurea S, Kebriaei P, Alousi A, Popat U, Anderlini P, Nieto Y, Parmar S, Qiao W, Chen J, Rondon G, McMullin B, Wang RY, Lu H, Schober W, Woodworth G, Gulbis A, Cool R, Andreeff M, Champlin R. Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. Bone Marrow Transplant 50(7):939-946, 2015. e-Pub 2015. PMID: 25867648.
252. Thompson PA, Rezvani K, Hosing CM, Oran B, Olson AL, Popat UR, Alousi AM, Shah ND, Parmar S, Bollard C, Hanley P, Kebriaei P, Cooper L, Kellner J, McNiece IK, Shpall EJ. Umbilical cord blood graft engineering: challenges and opportunities. Bone Marrow Transplant 50(Suppl 2):S55-62, 2015. e-Pub 2015. PMID: 26039209.
253. Valdez BC, Li Y, Murray D, Ji J, Liu Y, Popat U, Champlin RE, Andersson BS. Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: enhancement of cytotoxicity with epigenetic modulators. Exp Hematol 43(6):448-61.e2, 2015. e-Pub 2015. PMID: 25704054.
254. Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, Shah N, Ahmed S, Oran B, Al Atrash G, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin RE. Phase II Trial Of Gvhd Prophylaxis with Post-Transplantation Cyclophosphamide Following Reduced-Intensity Busulfan/Fludarabine (Bu/Flu) Conditioning for Hematological Malignancies. Biol Blood Marrow Transplant 21(5):906-12, 2015. e-Pub 2015. PMID: 25667989.
255. Beitinjaneh A, Saliba RM, Medeiros LJ, Turturro F, Rondon G, Korbling M, Fayad L, Fanale MA, Alousi AM, Anderlini P, Betul O, Popat UR, Pro B, Khouri IF. Comparison of Survival in Patients with T-cell Lymphoma after Autologous and Allogeneic Stem Cell Transplantation as a Frontline Strategy or in Relapsed Disease. Biol Blood Marrow Transplant 21(5):855-9, 2015. e-Pub 2015. PMID: 25652691.
256. Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood 125(19):2885-92, 2015. e-Pub 2015. PMID: 25778529.
257. Kongtim P, Di Stasi A, Rondon G, Chen J, Adekola K, Popat U, Oran B, Kebriaei P, Andersson BS, Champlin RE, Ciurea SO. Can a Female Donor for a Male Recipient Decrease Relapse Rate for Patients with AML Treated with Allogeneic Hematopoietic Stem Cell Transplantation?. Biol Blood Marrow Transplant 21(4):713-9, 2015. e-Pub 2015. PMID: 25540936.
258. Daver N, Kantarjian H, Marcucci G, Pierce S, Brandt M, Dinardo C, Pemmaraju N, Garcia-Manero G, O'Brien S, Ferrajoli A, Verstovsek S, Popat U, Hosing C, Anderlini P, Borthakur G, Kadia T, Cortes J, Ravandi F. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol 168(5):646-53, 2015. e-Pub 2015. PMID: 25312977.
259. Rathi NK, Tanner AR, Dinh A, Dong W, Feng L, Ensor J, Wallace SK, Haque SA, Rondon G, Price KJ, Popat U, Nates JL. Low-, medium- and high-dose steroids with or without aminocaproic acid in adult hematopoietic SCT patients with diffuse alveolar hemorrhage. Bone Marrow Transplant 50(3):420-6, 2015. e-Pub 2015. PMID: 25531284.
260. Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stüve O, Arnold DL, Spychala ME, McConville KC, Harris KM, Phippard D, Georges GE, Wundes A, Kraft GH, Bowen JD. High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS): A 3-Year Interim Report. JAMA Neurol 72(2):159-69, 2015. e-Pub 2015. PMID: 25546364.
261. Gul Z, Bashir Q, Cremer M, Yusuf SW, Gunaydin H, Arora S, Slone S, Nieto Y, Sherwani N, Parmar S, Shah N, Dinh YT, Hosing CM, Popat UR, Kebriaei P, Shpall EJ, Giralt SA, Champlin RE, Qazilbash MH. Short-term Cardiac Toxicity of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Leuk Lymphoma 56(2):1-8, 2015. e-Pub 2015. PMID: 24882259.
262. Munoz J, Shah N, Rezvani K, Hosing C, Bollard CM, Oran B, Olson A, Popat U, Molldrem J, McNiece IK, Shpall EJ. Concise Review: Umbilical Cord Blood Transplantation: Past, Present, and Future. Stem Cells Transl Med 3(12):1435-43, 2014. e-Pub 2014. PMID: 25378655.
263. Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, Pingali SR, Konopleva M, Kongtim P, Alousi A, Qazilbash MH, Ahmed S, Bashir Q, Al-atrash G, Oran B, Hosing CM, Kebriaei P, Popat U, Shpall EJ, Lee DA, de Lima M, Rezvani K, Khouri IF, Champlin RE, Ciurea SO. Similar Transplant Outcomes for AML/MDS Patients with Haploidentical versus 10/10 HLA Matched Unrelated and Related Donors. Biol Blood Marrow Transplant 20(12):1975-81, 2014. e-Pub 2014. PMID: 25263628.
264. Ringdén O, Brazauskas R, Wang Z, Ahmed I, Atsuta Y, Buchbinder D, Burns LJ, Cahn JY, Duncan C, Hale GA, Halter J, Hayashi RJ, Hsu JW, Jacobsohn DA, Kamble RT, Kamani NR, Kasow KA, Khera N, Lazarus HM, Loren AW, Marks DI, Myers KC, Ramanathan M, Saber W, Savani BN, Schouten HC, Socie G, Sorror ML, Steinberg A, Popat U, Wingard JR, Mattsson J, Majhail NS. Second solid cancers after allogeneic hematopoietic cell transplantation using reduced intensity conditioning. Biol Blood Marrow Transplant 20(11):1777-84, 2014. e-Pub 2014. PMID: 25042734.
265. Khouri IF, Wei W, Korbling M, Turturro F, Ahmed S, Alousi A, Anderlini P, Ciurea S, Jabbour E, Oran B, Popat UR, Rondon G, Bassett RL, Gulbis A. BFR (bendamustine, fludarabine and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced risk of myelosuppression and severe graft-versus-host disease. Blood 124(14):2306-12, 2014. e-Pub 2014. PMID: 25145344.
266. Hamdi A, Afrough A, Muzzafar T, Popat UR, Hosing CM, Qazilbash MH, Lu G. Donor Cell-Derived Myelodysplastic Syndrome With Ring Chromosome 7 After Allogeneic Hematopoietic Stem Cell Transplant in 2 Patients With Lymphomas as Primary Disease. Clin Lymphoma Myeloma Leuk 14(5):e151-5, 2014. e-Pub 2014. PMID: 25022600.
267. Oran B, Kongtim P, Popat U, de Lima M, Jabbour E, Lu X, Chen J, Rondon G, Kebriaei P, Ahmed S, Andersson B, Alousi A, Ciurea S, Shpall E, Champlin RE. Cytogenetics, Donor Type and use of Hypomethylating Agents in Myelodysplastic Syndrome with Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 20(10):1618-25, 2014. e-Pub 2014. PMID: 24953017.
268. Falchi L, Mehrotra M, Newberry KJ, Lyle LM, Lu G, Patel KP, Luthra R, Popat U, Verstovsek S. ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant. Leukemia 28(10):2090-2, 2014. e-Pub 2014. PMID: 24854988.
269. Ustun C, Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S, Shanley R, Hogan WJ, Perales MA, Shore T, Baurmann H, Stuart R, Gruhn B, Doubek M, Hsu JW, Tholouli E, Gromke T, Godley LA, Pagano L, Gilman A, Wagner EM, Shwayder T, Bornhäuser M, Papadopoulos EB, Böhm A, Vercellotti G, Van Lint MT, Schmid C, Rabitsch W, Pullarkat V, Legrand F, Yakoub-Agha I, Saber W, Barrett J, Hermine O, Hagglund H, Sperr WR, Popat U, Alyea EP, Devine S, Deeg HJ, Weisdorf D, Akin C, Valent P. Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis. J Clin Oncol 32(29):3264-74, 2014. e-Pub 2014. PMID: 25154823.
270. Parmar S, de Lima M, Worth L, Petropoulos D, Lee D, Cooper L, Kongtim P, Alousi A, Hosing C, Popat U, Kebriaei P, McNiece I, Shpall E, Rondon G, Champlin R. Is there an expiration date for a cord blood unit in storage?. Bone Marrow Transplant 49(8):1109-12, 2014. e-Pub 2014. PMID: 24797184.
271. Zhou Y, Slack R, Jorgensen JL, Wang SA, Rondon G, de Lima M, Shpall E, Popat U, Ciurea S, Alousi A, Qazilbash M, Hosing C, O'Brien S, Thomas D, Kantarjian H, Medeiros LJ, Champlin RE, Kebriaei P. The Effect of Peritransplant Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk 14(4):319-26, 2014. e-Pub 2014. PMID: 24548609.
272. Parmar S, Kongtim P, Champlin R, Dinh Y, Elgharably Y, Wang M, Bashir Q, Shah JJ, Shah N, Popat U, Giralt SA, Orlowski RZ, Qazilbash MH. Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. Bone Marrow Transplant 49(8):1036-41, 2014. e-Pub 2014. PMID: 24887378.
273. Jabbour E, Daver N, Champlin R, Mathisen M, Oran B, Ciurea S, Khouri I, Cornelison AM, Ghanem H, Cardenas-Turanzas M, Popat U, Ravandi F, Giralt S, Garcia-Manero G, Cortes J, Kantarjian H, de Lima M. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol 89(4):395-8, 2014. e-Pub 2014. PMID: 24375514.
274. Hosing C, Saliba RM, Hamerschlak N, Kutner JM, Sakashita AM, Kondo AT, Rodrigues M, Fernande JF, Chiattone A, Chiattone VC, Barros JC, Chiattone CS, Chiattone R, Popat U, Qazilbash M, Tang XW, Wu D, Majilis A, de Lima M, Anguita T. Peripheral blood stem cell yield calculated using preapheresis absolute CD34+ cell count, peripheral blood volume processed, and donor body weight accurately predicts actual yield at multiple centers. Transfusion 54(4):1081-7, 2014. e-Pub 2014. PMID: 24118027.
275. Mehta RS, Di Stasi A, Andersson BS, Nieto Y, Jones R, de Lima M, Hosing C, Popat U, Kebriaei P, Oran B, Alousi A, Rezvani K, Qazilbash M, Bashir Q, Bollard C, Cooper L, Worth L, Tewari P, McNiece I, Willhelm K, Champlin R, Shpall EJ. The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation. Clin Lymphoma Myeloma Leuk 14(1):e1-5, 2014. e-Pub 2014. PMID: 24169268.
276. Gupta V, Malone AK, Hari PN, Ahn KW, Hu ZH, Gale RP, Ballen KK, Hamadani M, Olavarria E, Gerds AT, Waller EK, Costa LJ, Antin JH, Kamble RT, van Besien KM, Savani BN, Schouten HC, Szer J, Cahn JY, de Lima MJ, Wirk B, Aljurf MD, Popat U, Bejanyan N, Litzow MR, Norkin M, Lewis ID, Hale GA, Woolfrey AE, Miller AM, Ustun C, Jagasia MH, Lill M, Maziarz RT, Cortes J, Kalaycio ME, Saber W. Reduced Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research. Bio Blood Marrow Transplant 20(1):89-97, 2014. e-Pub 2014. PMID: 24161923.
277. Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH. A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/ Melphalan 140 followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. Biol Blood Marrow Transplant 19(10):1453-8, 2013. e-Pub 2013. PMID: 23872222.
278. Oran B, Popat U, Andersson B, Champlin R. Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk 13(Suppl 2):S282-8, 2013. e-Pub 2013. PMID: 24290213.
279. Chakhachiro ZI, Saliba RM, Okoroji GJ, Korbling M, Alousi AM, Betul O, Anderlini P, Ciurea SO, Popat U, Champlin R, Samuels BI, Medeiros LJ, Bueso-Ramos C, Khouri IF. Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission. Cancer 119(18):3318-25, 2013. e-Pub 2013. PMID: 23775587.
280. Yilmaz M, Chemaly RF, Han XY, Thall PF, Fox PS, Tarrand JJ, De Lima MJ, Hosing CM, Popat UR, Shpall E, Champlin RE, Qazilbash MH. Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience. Bone Marrow Transplant 48(9):1218-23, 2013. e-Pub 2013. PMID: 23503529.
281. Smith VR, Popat U, Ciurea S, Nieto Y, Anderlini P, Rondon G, Alousi A, Qazilbash M, Kebriaei P, Khouri I, de Lima M, Champlin R, Hosing C. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization. Am J Hematol 88(9):754-7, 2013. e-Pub 2013. PMID: 23749720.
282. Sasaki K, Lu G, Saliba RM, Bashir Q, Hosing C, Popat U, Shah N, Parmar S, Dinh Y, Ahmed S, Shpall EJ, Kebriaei P, Shah JJ, Orlowski RZ, Champlin R, Qazilbash MH. Impact Of t(11;14)(q13;q32) On The Outcome Of Autologous Hematopoietic Cell Transplantation In Multiple Myeloma. Biol Blood Marrow Transplant 19(8):1227-32, 2013. e-Pub 2013. PMID: 23733001.
283. Shah DP, Ghantoji SS, Shah JN, El Taoum KK, Jiang Y, Popat U, Hosing C, Rondon G, Tarrand JJ, Champlin RE, Chemaly RF. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother 66(8):1872-80, 2013. e-Pub 2013. PMID: 23572228.
284. Poon LM, Hamdi A, Saliba R, Rondon G, Ledesma C, Kendrick M, Qazilbash M, Hosing C, Jones RB, Popat UR, Nieto Y, Alousi A, Ciurea S, Shpall EJ, Champlin RE, Kebriaei P. Outcomes of adults with acute lymphoblastic leukemia (ALL) following relapse post allogeneic hematopoietic stem cell transplantation (HSCT). Biol Blood Marrow Transplant 19(7):1059-64, 2013. e-Pub 2013. PMID: 23644077.
285. Akpek G, Pasquini MC, Logan B, Agovi MA, Lazarus HM, Marks DI, Bornhaeüser M, Ringdén O, Maziarz RT, Gupta V, Popat U, Maharaj D, Bolwell BJ, Rizzo JD, Ballen KK, Cooke KR, McCarthy PL, Ho VT. Effects of spleen status on early outcomes after hematopoietic cell transplantation. Bone Marrow Transplant 48(6):825-31, 2013. e-Pub 2013. PMID: 23222382.
286. Karuturi M, Hosing C, Fanale M, Medeiros LJ, Alousi AM, de Lima MJ, Qazilbash MH, Kebriaei P, Younes A, Khouri I, Andersson BS, Champlin R, Anderlini P, Popat U. High-dose chemotherapy and Autologous Stem Cell Transplantation For Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). Biol Blood Marrow Transplant 19(6):991-4, 2013. e-Pub 2013. PMID: 23507470.
287. Poon LM, Bassett R, Rondon G, Hamdi A, Qazilbash M, Hosing C, Jones RB, Shpall EJ, Popat UR, Nieto Y, Worth LL, Cooper L, De Lima M, Champlin RE, Kebriaei P. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplant 48(5):666-70, 2013. e-Pub 2013. PMID: 23085830.
288. Hammerstrom AE, Howell J, Gulbis A, Rondon G, Champlin RE, Popat U. Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. Am J Hematol 88(4):301-5, 2013. e-Pub 2013. PMID: 23460378.
289. Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB. Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome. Biol Blood Marrow Transplant 19(3):410-7, 2013. e-Pub 2013. PMID: 23128322.
290. Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, Ciurea SO, de Lima MJ, Hosing C, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Khouri I, Champlin RE, Popat U. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol 160(6):798-805, 2013. e-Pub 2013. PMID: 23330820.
291. Jabbour E, Mathisen MS, Garcia-Manero G, Champlin R, Popat U, Khouri I, Giralt S, Kadia T, Chen J, Pierce S, Koca E, Daver N, Tanaka M, Rondon G, Oran B, Parmar S, Kantarjian H, de Lima M. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: A retrospective case-control study. Am J Hematol 88(3):198-200, 2013. e-Pub 2013. PMID: 23345254.
292. Oran B, Popat U, Rondon G, Ravandi F, Garcia-Manero G, Abruzzo L, Andersson BS, Bashir Q, Chen J, Kebriaei P, Khouri IF, Koca E, Qazilbash MH, Champlin R, de Lima M. Significance of Persistent Cytogenetic Abnormalities on Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission. Biol Blood Marrow Transplant 19(2):214-20, 2013. e-Pub 2013. PMID: 22982533.
293. Kebriaei P, Madden T, Wang X, Thall PF, Ledesma C, de Lima M, Shpall EJ, Hosing C, Qazilbash M, Popat U, Alousi A, Nieto Y, Champlin RE, Jones RB, Andersson BS. Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. Bone Marrow Transplant 48(1):26-31, 2013. e-Pub 2013. PMID: 22732703.
294. Poon LM, Di Stasi A, Popat U, Champlin RE, Ciurea SO. Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation. Am J Blood Res 3(3):260-4, 2013. e-Pub 2013. PMID: 23997988.
295. Kebriaei P, Basset R, Ledesma C, Ciurea S, Parmar S, Shpall EJ, Hosing C, Khouri I, Qazilbash M, Popat U, Alousi A, Nieto Y, Jones RB, de Lima M, Champlin RE, Andersson BS. Clofarabine Combined with Busulfan Provides Excellent Disease Control in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 18(12):1819-26, 2012. e-Pub 2012. PMID: 22750645.
296. Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE. Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 18(12):1835-44, 2012. e-Pub 2012. PMID: 22796535.
297. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 367(24):2305-15, 2012. e-Pub 2012. PMID: 23234514.
298. Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplant in Patients with Refractory Lymphoid Malignancies. Biol Blood Marrow Transplant 18(11):1677-86, 2012. e-Pub 2012. PMID: 22643322.
299. Beitinjaneh AM, Saliba R, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Anderlini P, Dinh Y, Qureshi S, Rondon G, Champlin RE, Giralt SA, Qazilbash MH. Durable Responses after Donor Lymphocyte Infusion for Patients with Residual Multiple Myeloma following Non-myeloablative Allogeneic Stem Cell Transplantation. Leuk Lymphoma 53(8):1525-9, 2012. e-Pub 2012. PMID: 22242817.
300. Joseph RW, Bayraktar UD, Kim TK, St John LS, Popat U, Khalili J, Molldrem JJ, Wieder ED, Komanduri KV. Vitamin D receptor upregulation in alloreactive human T cells. Hum Immunol 73(7):693-8, 2012. e-Pub 2012. PMID: 22548720.
301. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Ledesma C, Andersson BS, Jones R, Popat UR, Hosing CM, Nieto Y, Qazilbash MH, Ueno NT, Giralt SA, de Lima MJ, Champlin RE. Donor leukocyte infusions (DLIs) in recurrent hodgkin lymphoma (HL) following allogeneic stem cell transplantation: ten-year experience at the M.D. anderson cancer center. Leuk Lymphoma 53(6):1239-41, 2012. e-Pub 2012. PMID: 22132837.
302. Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 119(26):6373-8, 2012. e-Pub 2012. PMID: 22586182.
303. Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 118(9):2507-15, 2012. e-Pub 2012. PMID: 21887685.
304. Bashir Q, Munsell MF, Giralt S, de Padua Silva L, Sharma M, Couriel D, Chiattone A, Popat U, Qazilbash MH, Fernandez-Vina M, Champlin RE, de Lima MJ. Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplantation. Leuk Lymphoma 53(5):915-9, 2012. e-Pub 2012. PMID: 22023525.
305. Kebriaei P, Saliba R, Rondon G, Chiattone A, Luthra R, Anderlini P, Andersson B, Shpall E, Popat U, Jones R, Worth L, Ravandi F, Thomas D, O'Brien S, Kantarjian H, de Lima M, Giralt S, Champlin R. Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact of Tyrosine Kinase Inhibitors on Treatment Outcomes. Biol Blood Marrow Transplant 18(4):584-92, 2012. e-Pub 2012. PMID: 21867666.
306. Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 87(3):272-6, 2012. e-Pub 2012. PMID: 22231283.
307. Anderlini P, Saliba RM, Ledesma C, Chancoco C, Alousi AM, Shpall EJ, Popat UR, Hosing CM, Khouri IF, Nieto Y, Ciurea S, Younes A, Fanale MA, Acholonu S, Valverde R, Champlin RE. Gemcitabine, fludarabine and melphalan (G-FM) as a reduced-intensity conditioning regimen for allogeneic stem cell transplantation in relapsed and refractory hodgkin lymphoma: preliminary results. Leuk Lymphoma 53(3):499-502, 2012. e-Pub 2012. PMID: 21859247.
308. Popat U, de Lima MJ, Saliba RM, Anderlini P, Andersson BS, Alousi AM, Hosing C, Nieto Y, Parmar S, Khouri IF, Kebriaei P, Qazilbash M, Champlin RE, Giralt SA. Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR. Bone Marrow Transplant 47(2):212-6, 2012. e-Pub 2012. PMID: 21423123.
309. Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Feasibility of autologous hematopoietic stem cell transplantation in patients aged >/=70 years with multiple myeloma. Leuk Lymphoma 53(1):118-22, 2012. e-Pub 2012. PMID: 21780997.
310. Hou P, Popat UR, Lindsay RJ, Jackson EF, Choi H. A practical approach for a wide range of liver iron quantitation using a magnetic resonance imaging technique. Radiol Res Pract 2012:207391, 2012. e-Pub 2012. PMID: 23365743.
311. Alatrash G, Pelosini M, Saliba RM, Koca E, Rondon G, Andersson BS, Chiattone A, Zhang W, Giralt SA, Cernosek AM, Kebriaei P, Alousi AM, Popat UR, Hosing C, Khouri IF, Champlin RE, de Lima MJ. Platelet Recovery Prior to Allogeneic Stem Cell Transplant Predicts Posttransplant Outcomes in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant 17(12):1841-5, 2011. e-Pub 2011. PMID: 21684343.
312. Joseph RW, Alousi A, Konda B, Komanduri K, Neumann J, Trevino C, Stolar K, Qazilbash M, Hosing C, Kebriaei P, Couriel DR, Champlin RE, Saliba R, Popat U. High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. Am J Hematol 86(11):954-6, 2011. e-Pub 2011. PMID: 21948087.
313. Bashir Q, Andersson BS, Fernandez-Vina M, de Padua Silva L, Giralt S, Chiattone A, Wei W, Sharma M, Anderlini P, Shpall EJ, Popat U, Rodrigues M, Champlin RE, de Lima M. Unrelated Donor Transplantation for Acute Myelogenous Leukemia in First Remission. Biol Blood Marrow Transplant 17(7):1067-71, 2011. e-Pub 2011. PMID: 21087679.
314. Fanale M, Fayad L, Pro B, Samaniego F, Liboon MJ, Nunez C, Horowitz S, Anderlini P, Popat U, Ji Y, Kwak LW, Younes A. Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. Br J Haematol 154(2):284-6, 2011. e-Pub 2011. PMID: 21517809.
315. Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL, Popat U, Madden T, Hosing C, Alousi A, Rondon G, Kebriaei P, Shpall EJ, Jones RB, Champlin RE. Clofarabine±Fludarabine with Once Daily IV Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS. Bio Blood Marrow Transplant 17(6):893-900, 2011. e-Pub 2011. PMID: 20946966.
316. Ciurea SO, Saliba RM, Rondon G, Patah PA, Aung F, Cano P, Andersson BS, Kebriaei P, Popat U, Fernandez-Vina M, Champlin RE, de Lima M. Outcomes of patients with myeloid malignancies treated with allogeneic hematopoietic stem cell transplantation from matched unrelated donors compared with one-human leukocyte antigen mismatched related donors using HLA typing at 10 loci. Biol Blood Marrow Transplant 17(6):923-9, 2011. e-Pub 2011. PMID: 20969970.
317. Hosing C, Smith V, Rhodes B, Walters K, Thompson R, Qazilbash M, Khouri I, de Lima M, Balzer RJ, McMannis J, Champlin R, Giralt S, Popat U. Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation. Transfusion 51(6):1300-13, 2011. e-Pub 2011. PMID: 21575005.
318. Kazmi SM, Saliba RM, Donato M, Wang M, Hosing C, Qureshi S, Anderlini P, Popat U, Champlin RE, Giralt SA, Qazilbash MH. Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. Bone Marrow Transplant 46(4):510-5, 2011. e-Pub 2011. PMID: 20581887.
319. Samuelson S, Sandmaier BM, Heslop HE, Popat U, Carrum G, Champlin RE, Storb R, Prchal JT, Gooley TA, Deeg HJ. Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age. Br J Haematol 153(1):76-82, 2011. e-Pub 2011. PMID: 21323890.
320. Jabbour E, Cortes J, Santos FP, Jones D, O'Brien S, Rondon G, Popat U, Giralt S, Kebriaei P, Jones RB, Kantarjian H, Champlin R, de Lima M. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 117(13):3641-7, 2011. e-Pub 2011. PMID: 21156844.
321. Kebriaei P, Madden T, Kazerooni R, Wang X, Thall PF, Ledesma C, Nieto Y, Shpall EJ, Hosing C, Qazilbash M, Popat U, Khouri I, Champlin RE, Jones RB, Andersson BS. Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies. Biol Blood Marrow Transplant 17(3):412-20, 2011. e-Pub 2011. PMID: 20674757.
322. Anderlini P, Acholonu SA, Okoroji GJ, Bassett RE, Shpall EJ, Qazilbash MH, Popat UR, Worth LL, Giralt SA, Champlin RE. Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia. Leuk Lymphoma 52(1):137-41, 2011. e-Pub 2011. PMID: 20939697.
323. Parmar S, Andersson BS, Couriel D, Munsell MF, Fernandez-Vina M, Jones RB, Shpall EJ, Popat U, Anderlini P, Giralt S, Alousi A, Cano P, Bosque D, Hosing C, Silva Lde P, Westmoreland M, Wathen JK, Berry D, Champlin RE, de Lima MJ. Prophylaxis of Graft-Versus-Host Disease in Unrelated Donor Transplantation With Pentostatin, Tacrolimus, and Mini-Methotrexate: A Phase I/II Controlled, Adaptively Randomized Study. J Clin Oncol 29(3):294-302, 2011. e-Pub 2011. PMID: 21149654.
324. Efebera YA, Qureshi SR, Cole SM, Saliba R, Pelosini M, Patel RM, Koca E, Mendoza FL, Wang M, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MH. Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma. Biol Blood Marrow Transplant 16(8):1122-1129, 2010. e-Pub 2010. PMID: 20178853.
325. Sharma M, Qureshi SR, Champlin RE, Popat U, Giralt S, Qazilbash MH. The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes. Am J Hematol 85(7):502-4, 2010. e-Pub 2010. PMID: 20575022.
326. Silva Lde P, Patah PA, Saliba RM, Szewczyk NA, Gilman L, Neumann J, Han XY, Tarrand J, Ribeiro R, Gulbis A, Shpall EJ, Jones R, Popat U, Walker JA, Petropoulos D, Chiattone A, Stewart J, El-Zimaity M, Anderlini P, Giralt S, Champlin RE, de Lima M. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type. Haematologica 95(7):1183-90, 2010. e-Pub 2010. PMID: 20410183.
327. Ramos CA, Saliba RM, de Pádua Silva L, Khorshid O, Shpall EJ, Giralt S, Patah PA, Hosing CM, Popat UR, Rondon G, Nieto Y, Champlin RE, de Lima M. Resolved hepatitis B virus infection is not associated with worse outcomes after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 16(5):686-694, 2010. e-Pub 2010. PMID: 20056165.
328. Ciurea SO, de Lima M, Giralt S, Saliba R, Bueso-Ramos C, Andersson BS, Hosing CM, Verstovsek S, Champlin RE, Popat U. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant 16(4):555-9, 2010. e-Pub 2010. PMID: 20005966.
329. Parmar S, Del Lima M, Zou Y, Patah PA, Liu P, Cano P, Rondon G, Pesoa S, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Kebriaei P, Shpall EJ, Giralt S, Champlin RE, Stastny P, Fernandez-Vina M. Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood 114(14):2884-7, 2009. e-Pub 2009. PMID: 19654407.
330. Qazilbash MH, Amjad AI, Qureshi S, Qureshi SR, Saliba RM, Khan ZU, Hosing C, Giralt SA, De Lima MJ, Popat UR, Yusuf SW, Champlin RE. Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction. Biol Blood Marrow Transplant 15(10):1265-70, 2009. e-Pub 2009. PMID: 19747634.
331. de Souza JA, Saliba RM, Patah P, Rondon G, Ribeiro R, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Efebera Y, Champlin RE, de Lima M. Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15(9):1094-9, 2009. e-Pub 2009. PMID: 19660722.
332. Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 15(7):812-6, 2009. e-Pub 2009. PMID: 19539212.
333. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of Filgrastim-Induced Stem Cell Mobilization after Prior Lenalidomide in Patients with Multiple Myeloma. Biol Blood Marrow Transplant 15(6):718-23, 2009. e-Pub 2009. PMID: 19450756.
334. Hosing C, Saliba RM, Ahlawat S, Körbling M, Kebriaei P, Alousi A, De Lima M, Okoroji JG, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I, Popat U. Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 84(6):335-7, 2009. e-Pub 2009. PMID: 19384931.
335. Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C, Kebraei P, Harrell R, Rondon G, Giralt SA, Anderlini P, Popat U, Pro B, Samuels B, Hagemeister F, Medeiros LJ, Champlin RE, Khouri IF. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113(18):4144-52, 2009. e-Pub 2009. PMID: 19168784.
336. Ramos CA, Saliba RM, de Pádua L, Khorshid O, Shpall EJ, Giralt S, Patah PA, Hosing CM, Popat UR, Rondon G, Khouri IF, Nieto YL, Champlin RE, de Lima M. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica 94(2):249-57, 2009. e-Pub 2009. PMID: 19144658.
337. Efebera YA, Thandi RS, Saliba RM, Popat U, De Lima M, Alousi A, Hosing C, Rondon G, Champlin R, Giralt S. The Impact of Pre-Stem Cell Transplant Ferritin Level on Late Transplant Complications: An Analysis to Determine the Potential Role of Iron Overload on Late Transplant Outcomes. Internet J Hematol 7(1), 2009. e-Pub 2009. PMID: 25356072.
338. Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelosini M, Khan FB, Jones RB, Hosing C, Mendoza F, Weber DM, Wang M, Popat U, Alousi A, Anderlini P, Champlin RE, Giralt S. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant 14(12):1401-7, 2008. e-Pub 2008. PMID: 19041063.
339. Appel SH, Engelhardt JI, Henkel JS, Siklos L, Beers DR, Yen AA, Simpson EP, Luo Y, Carrum G, Heslop HE, Brenner MK, Popat U. Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology 71(17):1326-34, 2008. e-Pub 2008. PMID: 18936424.
340. Tam CS, Nussenzveig RM, Popat U, Bueso-Ramos CE, Thomas DA, Cortes JA, Champlin RE, Ciurea SE, Manshouri T, Pierce SM, Kantarjian HM, Verstovsek S. The natural history and treatment outcome of blast phase BCR-ABL negative myeloproliferative neoplasms. Blood 112(5):1628-37, 2008. e-Pub 2008. PMID: 18566326.
341. Alousi AM, Saliba RM, Okoroji GJ, Macapinlac HA, Hosing C, Korbling M, Samuels BI, Popat U, Kebriaei P, Anderlini P, Qazilbash MH, de Lima M, Giralt SA, Champlin RE, Khouri IF. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol 142(5):786-92, 2008. e-Pub 2008. PMID: 18564354.
342. Hosing C, Saliba RM, Okoroji GJ, Popat U, Couriel D, Ali T, De Padua Silva L, Kebriaei P, Alousi A, De Lima M, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I. High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. Ann Oncol 19(6):1166-71, 2008. e-Pub 2008. PMID: 18272911.
343. Zetterberg E, Popat U, Hasselbalch H, Prchal J, Palmblad J. Angiogenesis in pulmonary hypertension with myelofibrosis. Haematologica 93(6):945-6, 2008. e-Pub 2008. PMID: 18460649.
344. Nash RA, Stuve O, Bowen JD, Frohman EM, Griffith LM, Hutton GJ, Kraft GH, Popat U, Racke MK, Muraro PA. Autologous HSCT for advanced MS: is the glass half-empty or really half-full?. Brain 131(Pt 2):e89, 2008. e-Pub 2008. PMID: 17908695.
345. Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant 13(9):1066-72, 2007. e-Pub 2007. PMID: 17697969.
346. Oran B, Giralt S, Couriel D, Hosing C, Shpall EJ, de Meis E, Khouri IF, Qazilbash M, Anderlini P, Kebriaei P, Popat U, Carrasco-Yalan A, Champlin RE, de Lima M. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 21(12):2540-4. e-Pub 2007. PMID: 17611563.
347. Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I, Couriel D, Qazilbash M, Anderlini P, Kebriaei P, Ghosh S, Carrasco-Yalan A, de Meis E, Anagnostopoulos A, Donato M, Champlin RE, de Lima M. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 13(4):454-62, 2007. e-Pub 2007. PMID: 17382251.
348. Samuelson SJ, Popat U, Prchal JT. Marrow fibrosis does not account for circulating CD34+ cells in myelofibrosis with myeloid metaplasia. Haematologica 92(4 e47):ELT02, 2007. e-Pub 2007. PMID: 17405759.
349. Oran B, Donato M, Aleman A, Hosing C, Korbling M, Detry MA, Wei C, Anderlini P, Popat U, Shpall E, Giralt S, Champlin RE. Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment. Biol Blood Marrow Transplant 13(4):469-77, 2007. e-Pub 2007. PMID: 17382253.
350. Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant 39(5):279-83, 2007. e-Pub 2007. PMID: 17262062.
351. Chen GL, Liu E, Naidoo K, Popat U, Coetzer TL, Prchal JT. Idiopathic myelofibrosis without dacryocytes. Haematologica 91(Suppl 6), 2006. e-Pub 2006.
352. Hosing C, Qazilbash MH, Kebriaei P, Giralt S, Davis MS, Popat U, Anderlini P, Shpall EJ, McMannis J, Korbling M, Champlin RE. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br J Haematol 133(5):533-537, 2006. e-Pub 2006. PMID: 16681642.
353. Popat U, Frost A, Liu E, Guan Y, Durette A, Reddy V, Prchal JT. High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension. Blood 107(9):3486-3488, 2006. e-Pub 2006. PMID: 16418333.
354. Popat U, Heslop HE, Durett A, May R, Krance RA, Brenner MK, Carrum G. Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). Bone Marrow Transplant 37(6):547-52, 2006. e-Pub 2006. PMID: 16462757.
355. Rousseau RF, Biagi E, Dutour A, Yvon ES, Brown MP, Lin T, Mei Z, Grilley B, Popek E, Heslop HE, Gee AP, Krance RA, Popat U, Carrum G, Margolin JF, Brenner MK. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood 107(4):1332-1341, 2006. e-Pub 2006. PMID: 16249392.
356. Couriel D, Hosing C, Saliba R, Shpall EJ, Andelini P, Popat U, Donato M, Champlin R. Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work?. Biol Blood Marrow Transplant 12(1 Suppl 2):37-40, 2006. e-Pub 2006. PMID: 16399600.
357. Lamba R, Carrum G, Myers GD, Bollard CM, Krance RA, Heslop HE, Brenner MK, Popat U. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab. Bone Marrow Transplant 36(9):797-802, 2005. e-Pub 2005. PMID: 16151431.
358. Biagi E, Rousseau R, Yvon E, Schwartz M, Dotti G, Foster A, Havlik-Cooper D, Grilley B, Gee A, Baker K, Carrum G, Rice L, Andreeff M, Popat U, Brenner M. Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res 11(19 Pt 1):6916-23, 2005. e-Pub 2005. PMID: 16203783.
359. Popat U, Frost A, Liu E, May R, Bag R, Reddy V, Prchal JT. New onset of myelofibrosis in association with pulmonary arterial hypertension. Ann Intern Med 143(6):466-467, 2005. e-Pub 2005. PMID: 16172450.
360. Popat U, Carrum G, May R, Lamba R, Krance RA, Heslop HE, Brenner MK. CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors. Bone Marrow Transplant 35(12):1127-32, 2005. e-Pub 2005. PMID: 15834432.
361. Xu M, Bruno E, Chao J, Huang S, Finazzi G, Fruchtman SM, Popat U, Prchal JT, Barosi G, Hoffman R, Consortium MPD. Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood 105(11):4508-15, 2005. e-Pub 2005. PMID: 15705794.
362. Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP, Spivak JL, Smith BD, Klingemann HG, Fruchtman S, Hoffman R, Consortium MD. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 105(10):4115-9, 2005. e-Pub 2005. PMID: 15671439.
363. Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, Gresik MV, Gee AP, Russell HV, Brenner MK, Rooney CM, Heslop HE. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. Blood 105(5):1898-904, 2005. e-Pub 2005. PMID: 15542583.
364. Biagi E, Dotti G, Yvon E, Lee E, Pule M, Vigouroux S, Gottschalk S, Popat U, Rousseau R, Brenner M. Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes. Blood 105(6):2436-42, 2005. e-Pub 2005. PMID: 15536147.
365. Xu M, Bruno E, Chao J, Ni H, Lindgren V, Nunez R, Mahmud N, Finazzi G, Fruchtman SM, Popat U, Liu E, Prchal JT, Rondelli D, Barosi G, Hoffman R. The constitutive mobilization of bone marrow repopulating cells into the peripheral blood in idiopathic myelofibrosis. Blood 105(4):1699-1705, 2005. e-Pub 2005. PMID: 15471948.
366. Rice L, Popat U. Every case of essential thrombocythemia should be tested for the Philadelphia chromosome. Am J Hematol 78(1):71-73, 2005. e-Pub 2005. PMID: 15609281.
367. Popat U, Krance R. Haematopoietic stem cell transplantation for autoimmune disorders: the American perspective. Br J Haematol 126(5):637-49, 2004. e-Pub 2004. PMID: 15327514.
368. Sun W, Popat U, Hutton G, Zang YC, Krance R, Carrum G, Land GA, Heslop H, Brenner M, Zhang JZ. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain 127(Pt 5):996-1008, 2004. e-Pub 2004. PMID: 14985264.
369. Popat U, Hosing C, Saliba RM, Anderlini P, van Besien K, Przepiorka D, Khouri IF, Gajewski J, Claxton D, Giralt S, Rodriguez M, Romaguera J, Hagemeister F, Ha C, Cox J, Cabanillas F, Andersson BS, Champlin RE. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant 33(10):1015-23, 2004. e-Pub 2004. PMID: 15048145.
370. Ganguly S, Carrum G, Nizzi F, Heslop HE, Popat U. Transfusion-related acute lung injury (TRALI) following allogeneic stem cell transplant for acute myeloid leukemia. Am J Hematol 75(1):48-51, 2004. e-Pub 2004. PMID: 14695632.
371. Massarweh S, Lewitton M, Popat U, Lynch GR. Small-cell cancers, and an unusual reaction to chemotherapy. Case 2. Synchronous renal cell carcinoma and limited-stage small-cell lung cancer. J Clin Oncol 21(12):2439-40, 2003. e-Pub 2003. PMID: 12805345.
372. Biagi E, Yvon E, Dotti G, Amrolia PJ, Takahashi S, Popat U, Marini F, Andreeff M, Brenner MK, Rousseau RF. Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells. Hum Gene Ther 14(6):545-59, 2003. e-Pub 2003. PMID: 12718765.
373. Heslop H, Rooney C, Brenner M, Krance R, Carrum G, Gahn B, Bollard C, Khan S, Gee A, Popat U, Gresik M, Przepiorka D, Kuehnle I, Grilley B. Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease. Hum Gene Ther 11(10):1465-75, 2000. e-Pub 2000. PMID: 10910143.
374. Popat U, Przepiork D, Champlin R, Pugh W, Amin K, Mehra R, Rodriguez J, Giralt S, Romaguera J, Rodriguez A, Preti A, Andersson B, Khouri I, Claxton D, de Lima M, Donato M, Anderlini P, Gajewski J, Cabanillas F, van Besien K. High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome. J Clin Oncol 16(1):63-9, 1998. e-Pub 1998. PMID: 9440724.
375. Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton DF, Kliche KO, Andreeff M, Champlin RE. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 89(4):1133-42, 1997. e-Pub 1997. PMID: 9028934.
376. Sekhar M, Prentice HG, Popat U, Anderson D, Janmohammed R, Roberts I, Britt RP. Idiopathic myelofibrosis in children. Br J Haematol 93(2):394-7, 1996. e-Pub 1996. PMID: 8639435.
377. Corbett TJ, Saw H, Popat U, MacMahon E, Cohen BJ, Knowles WA, Beard S, Prentice HG. Successful treatment of parvovirus B19 infection and red cell aplasia occurring after an allogeneic bone marrow transplant. Bone Marrow Transplant 16(5):711-3, 1995. e-Pub 1995. PMID: 8547870.
378. Bichile LS, Saraswati K, Popat UR, Nanivadekar SA, Deodhar LP. Acute Campylobacter jejuni enteritis in 385 hospitalised patients. J Assoc Physicians India 40(3):164-6, 1992. e-Pub 1992. PMID: 1634481.
379. Nanivadekar SA, Sawant PD, Patel HD, Shroff CP, Popat UR, Bhatt PP. Relapse of Helicobacter pylori infection after different treatment regimens. A 3-month follow-up study. J Assoc Physicians India 38(1):712-5, 1990. e-Pub 1990. PMID: 2092026.
380. Nanivadekar SA, Sawant PD, Patel HD, Shroff CP, Popat UR, Bhatt PP. Association of peptic ulcer with Helicobacter pylori and the recurrence rate. A three year follow-up study. J Assoc Physicians India 38(1):703-6, 1990. e-Pub 1990. PMID: 2092024.
381. Vishwanathan C, Varty PP, Nanivadekar SA, Popat UR, Changlani TT. Carcinoma of stomach in childhood. Indian J Gastroenterol 7(4):244, 1988. e-Pub 1988. PMID: 3182027.
382. Nanivadekar, Punamia KV, Popat UR, Dhabhar BN, Bichile LS. A study of eleven patients accidentally exposed to Chlorine fumes. Indian Practitioner:311-315, 1987. e-Pub 1987.
383. Daruwala, Desai JH, Popat UR, Punjabi AH. Sudden Infant death syndrome (crib death). Indian Practitioner:189-195, 1987. e-Pub 1987.
384. Parikh, Shah VK, Popat UR. Prevention of Rheumatic Fever. Indian Practitioner:1055-1059, 1986. e-Pub 1986.

Invited Articles

1. Popat U, Krance R. Haematopoietic stem cell transplantation for autoimmune disorders: the American perspective. Br J Haematol 126(5):637-49, 2004. e-Pub 2004. PMID: 15327514.
2. Rice L, Popat U. Hemolytic Anemias. PIER American College of Physician’s online textbook, 2004. e-Pub 2004.
3. Popat U, Carrum G, Heslop HE. Haemopoietic stem cell transplantation for acute lymphoblastic leukaemia. Cancer Treat Rev 29(1):3-10, 2003. e-Pub 2003. PMID: 12633575.

Review Articles

1. Kröger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M, Gupta V, Hamad N, Harrison C, Hernandez-Boluda JC, Koschmieder S, Jain T, Mascarenhas J, Mesa R, Popat UR, Passamonti F, Polverelli N, Rambaldi A, Robin M, Salit RB, Schroeder T, Scott BL, Tamari R, Tefferi A, Vannucchi AM, McLornan DP, Barosi G. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group. Lancet Haematol 11(1):e62-e74, 2024. e-Pub 2024. PMID: 38061384.
2. Polverelli N, Hernández-Boluda JC, Czerw T, Barbui T, D'Adda M, Deeg HJ, Ditschkowski M, Harrison C, Kröger NM, Mesa R, Passamonti F, Palandri F, Pemmaraju N, Popat U, Rondelli D, Vannucchi AM, Verstovsek S, Robin M, Colecchia A, Grazioli L, Damiani E, Russo D, Brady J, Patch D, Blamek S, Damaj GL, Hayden P, McLornan DP, Yakoub-Agha I. Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematol 10(1):e59-e70, 2023. e-Pub 2023. PMID: 36493799.
3. Kröger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, Rambaldi A, Mesa R, Tefferi A, Griesshammer M, Gupta V, Harrison C, Alchalby H, Vannucchi AM, Cervantes F, Robin M, Ditschkowski M, Fauble V, McLornan D, Ballen K, Popat UR, Passamonti F, Rondelli D, Barosi G. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia 29(11):2126-33, 2015. e-Pub 2015. PMID: 26293647.
4. Deeg HJ, Bredeson C, Farnia S, Ballen K, Gupta V, Mesa RA, Popat U, Hari P, Saber W, Seftel M, Tamari R, Petersdorf EW. Hematopoietic cell transplantation as curative therapy for patients with myelofibrosis: Long-term success in all age groups. Biol Blood Marrow Transplant 21(11):1883-7, 2015. e-Pub 2015. PMID: 26371371.
5. Perales MA, Ceberio I, Armand P, Burns LJ, Chen R, Cole PD, Evens AM, Laport GG, Moskowitz CH, Popat U, Reddy NM, Shea TC, Vose JM, Schriber J, Savani BN, Carpenter PA, for Blood AS, Transplantation M. The Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 21(6):971-83, 2015. e-Pub 2015. PMID: 25773017.
6. El Fakih R, Popat U. Janus Kinase Inhibitors and Stem Cell Transplantation in Myelofibrosis. Clin Lymphoma Myeloma Leuk 15(Supplement):S34-S42, 2015. e-Pub 2015. PMID: 26297276.
7. Adekola K, Popat U, Ciurea SO. An update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors. Bone Marrow Transplant 49(11):1352-9, 2014. e-Pub 2014. PMID: 25089599.
8. Champlin R, de Lima M, Kebriaei P, Rondon G, Fisher T, Jabbour E, Cortés JE, Kantarjian H, Anderlini P, Alousi A, Hosing C, Shpall E, Popat U, Qazilbash M, Andersson B, Giralt S. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma 9(3):S261-5, 2009. e-Pub 2009. PMID: 19778850.
9. Burt RK, Cohen B, Rose J, Petersen F, Oyama Y, Stefoski D, Katsamakis G, Carrier E, Kozak T, Muraro PA, Martin R, Hintzen R, Slavin S, Karussis D, Haggiag S, Voltarelli JC, Ellison GW, Jovanovic B, Popat U, McGuirk J, Statkute L, Verda L, Haas J, Arnold R. Hematopoietic stem cell transplantation for multiple sclerosis. Arch Neurol 62(6):860-4, 2005. e-Pub 2005. PMID: 15956156.

Other Articles

1. Nieto Y, Banerjee P, Kaur I, Basar R, Li Y, Daher M, Rafei H, Kerbauy LN, Kaplan M, Marin D, Griffin L, Barnett M, Bassett R, Uprety N, Shrestha R, Silva FR, Islam S, Ganesh C, Borneo Z, Ramdial J, Ramirez A, Hosing C, Alousi A, Popat U, Qazilbash M, Ahmed S, Iyer S, Sainz TP, Vega F, Fowlkes NW, Alexis K, Emig M, Harstrick A, Overesch A, Shpall EJ, Rezvani K Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Nat Med 31(8):2816, 2025. PMID: 40571757.
2. Alkhunaizi M, Patel B, Bueno L, Bhan N, Ahmed T, Arain MH, Saliba R, Rondon G, Dickey BF, Bashoura L, Ost DE, Li L, Wang S, Shpall E, Champlin RE, Mehta R, Popat UR, Hosing C, Alousi AM, Sheshadri A Corrigendum to 'Risk Factors for Bronchiolitis Obliterans Syndrome after Initial Detection of Pulmonary Impairment after Hematopoietic Cell Transplantation' [Transplantation and Cellular Therapy 29/3 (2023) 204-204]. Transplant Cell Ther, 2024. PMID: 39561968.
3. Sureda A, Carpenter PA, Bacigalupo A, Bhatt VR, de la Fuente J, Ho A, Kean L, Lee JW, Sánchez-Ortega I, Savani BN, Schetelig J, Stadtmauer EA, Takahashi Y, Atsuta Y, Koreth J, Kröger N, Ljungman P, Okamoto S, Popat U, Soiffer R, Stefanski HE, Kharfan-Dabaja MA Correction to. Bone Marrow Transplant 59(9):1335, 2024. PMID: 38907026.
4. Pasvolsky O, Popat UR Unravelling ALL: The Keys to Improved Post-Transplant Survival in Acute Lymphoblastic Leukemia. Transplant Cell Ther 28(8):415-416, 2022. PMID: 35914901.
5. Oran B, Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K Correction to: Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia 36(1):298, 2022. PMID: 34876697.

Editorials

1. Devine, S, Popat, UR. When remission alone might be good enough. Blood Advances 10(4):1334-1335, 2026.
2. Devine SM, Popat U. When remission alone might be good enough. Blood Adv 10(4):1334-1335, 2026. PMID: 41701490.
3. Devine SM, Popat U. When remission alone might be good enough. Blood Adv 10(4):1334-1335, 2026. PMID: 41733979.

Abstracts

1. Sarubbi C, Miatech J, Forsberg MA, Demla AE, Rahman Z, Pawelek J, Mitchell D, Donald S, Garcia C, Suello K, Codrington K, Hunter L, Garcia R, Martinez CS, Rondon G, Al-Atrash G, Aljawai YM, Alousi AM, Bashir Q, Champlin RE, Chen GL, Hosing C, Im JS, Kebriaei P, Khouri IF, Lin P, Marin D, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Popat UR, Smallbone P, Srour SA, Tewari P, Flowers CR, Shpall EJ, Fingrut WB. Optimizing Essential, Complex Hematologic Care for Patients Living with Disabilities. 2026 Tandem Meetings of ASTCT and CIBMTR 32(2, Supplement):S306-S307, 2062. e-Pub 2062.
2. Ramdial JL, Chien K, Oran B, Mehta RS, Popat UR, Kebriaei P, Rezvani K, Al-Atrash G, Chen GL, Nieto Y, Maiti A, Short NJ, Issa G, Borthakur G, Champlin RE, Shpall EJ, DiNardo CD. A Phase II open-label study of Olutasidenib Post-Transplant Maintenance Therapy for Patients with IDH1-Mutated Myeloid Malignancies. 2026 Tandem Meetings of ASTCT and CIBMTR 32(2, Supplement):S408-S409, 2026. e-Pub 2026.
3. Rafique AJ, Research DeenTrainee AF, Bashir Q, Saini NY, Aljawai YM, Hosing C, Popat UR, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Srour SA. Impact of Renal Function on Autologous Stem Cell Transplantation (ASCT) Outcomes for AL Amyloidosis. 2026 Tandem Meetings of ASTCT and CIBMTR 32(2, Supplement):S422-S423, 2026. e-Pub 2026.
4. Popat UR, Hosing C, Bassett RL, Alousi AM, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Smallbone P, Srour SA, Bazinet A, Garcia-Manero G, Champlin RE, Shpall EJ. A Phase 2 Trial of Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa, and Venetoclax (Cladillac) Conditioning for High-Risk MDS. 2026 Tandem Meetings of ASTCT and CIBMTR 32(2, Supplement):S57, 2026. e-Pub 2026.
5. Aljawai YM, Milton DR, Mehta RS, Smallbone P, Ramdial JL, Kebriaei P, Chen GL, Hosing C, Popat UR, Nieto Y, Marin D, Champlin RE, Shpall EJ. Older Donor Age Is Not Associated with Inferior Survival in Contemporary Haploidentical Transplantation. 2026 Tandem Meetings of ASTCT and CIBMTR 32(2, Supplement):S410-S411, 2026. e-Pub 2026.
6. Popat UR, Bassett RL, Alousi AM, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Hosing C, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Smallbone P, Srour SA, Champlin RE, Shpall EJ. Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa, and Venetoclax (Cladillac) Conditioning for High-Risk AML: A Phase 2 Trial. 2026 Tandem Meetings of ASTCT and CIBMTR 32(2, Supplement):S139, 2026. e-Pub 2026.
7. Aljawai YM, Milton DR, Ramdial JL, Chen GL, Smallbone P, Kebriaei P, Popat UR, Oran B, Champlin RE, Shpall EJ, Mehta RS. Non-Myeloablative/Reduced Intensity Is Associated with Comparable Survival Outcomes to Myeloablative Conditioning in Haploidentical HCT. 2026 Tandem Meetings of ASTCT and CIBMTR 32(2, Supplement):S144, 2026. e-Pub 2026.
8. Smallbone P, Rondon G, Folse J, Ledesma C, Oran B, Aljawai YM, Chen GL, Ramdial JL, Marin D, Popat UR, Champlin RE, Shpall EJ. Third Allogeneic Hematopoietic Stem Cell Transplantation: Feasibility and Efficacy of a Single Institution. 2026 Tandem Meetings of ASTCT and CIBMTR 32(2, Supplement):S407, 2026. e-Pub 2026.
9. Forsberg MA, Pirtle R, Daher M, Kaur I, Shaftoe S, Castro miranda KM, Popat UR, Washington D, Asfaw T, Ramirez A, Mulanovich VE, Nieto Y, Basar R, Fingrut WB, Lin P, Oran B, Alousi AM, Kebriaei P, Srour SA, Ramdial JL, Saini NY, Chen GL, Im JS, Aljawai YM, Khouri IF, Olson AL, Mehta RS, Bashir Q, Champlin RE, Shpall EJ, Rezvani K, Marin D. Administration of Off-the-Shelf, Expanded, Most Closely HLA Matched, Third Party Viral Specific T cells for the Therapy of Adenovirus Related Disease in Adult Immunocompromised Patients. 2026 Tandem Meetings of ASTCT and CIBMTR 32(2, Supplement):S529, 2026. e-Pub 2026.
10. Miatech J, Mehta RS, Ramdial JL, Rondon G, Alatrash G, Aljawai YM, Alousi AM, Bashir Q, Chen GL, Hosing C, Fingrut WB, Kebriaei P, Khouri IF, Marin D, Nieto Y, Olson AL, Oran B, Popat UR, Qazilbash MH, Smallbone P, Srour SA, Tanner MR, Rezvani K, Champlin RE, Shpall EJ, Saliba RM. Adverse Impact of MMF in AML/MDS Patients with High HCT-CI Receiving Matched Allogeneic Stem Cell Transplantation with PTCy-Based GvHD Prophylaxis. 2026 Tandem Meetings of ASTCT and CIBMTR 32(2, Supplement):S257-S258, 2026. e-Pub 2026.
11. Smallbone P, Loghavi S, Al-Atrash G, Takahashi K, Rondon G, Mazouzi K, Ramdial JL, Aljawai YM, Patel KP, Routbourt M, Hammond D, Yilmaz M, Short NJ, Daver N, Marin D, Champlin RE, Popat UR, Shpall EJ, Oran B. Clonal Dynamics of FLT3-ITD Positive Acute Myeloid Leukemia Following Relapse after Allogeneic Stem Cell Transplantation. 2026 Tandem Meetings of ASTCT and CIBMTR 32(2, Supplement):S394, 2026. e-Pub 2026.
12. Al Malki MM, Chen Y, Jain T, Keyzner A, Solh MM, Popat UR, Donato M, Pineiro L, Fernandez HF, Gill SI, Snow A, Uberti J, White T, Wang Y, Nguyen C, Louis C, Chattopadhyay S, Matzko M, Reshef R. TSC-101 Eliminates Recipient Hematopoietic Cells and Demonstrates Potential for Improved Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT (allo-HCT) with Reduced Intensity Conditioning (RIC): Updated Results from the Phase 1 (ALLOHA) Trial. 2026 Tandem Meetings of ASTCT and CIBMTR 32(2, Supplement):S150-S151, 2026. e-Pub 2026.
13. Smallbone P, Medford J, Andersen C, Qiao Y, Rondon G, Gilmore K, Rollins J, Folse J, Samms N, Oran B, Hosing C, Kebriaei P, Aljawai YM, Chen GL, Im JS, Popat UR, Champlin RE, Alousi AM, Roth M, Shpall EJ. Persistent Symptom Burden and Unmet Needs in Long-Term Survivors of Allogeneic Hematopoietic Cell Transplantation: An Analysis Using the MD Anderson Symptom Inventory (MDASI-BMT). 2026 Tandem Meetings of ASTCT and CIBMTR 32(2, Supplement):S61, 2026. e-Pub 2026.
14. Shah R, Luo Z, Fontillas RC, Holder B, Szewczyk N, Ayers AA, Popat UR, Shpall EJ, Strati P, Nze C, Jain P, Wang M, Westin J, Neelapu SS, Ng A, Shin KY, Ahmed S, Ngo-Huang A, Chihara D. Baseline Physical Function Predicts Toxicity Outcomes after Chimeric Antigen Receptor T-cell Therapy in Non-Hodgkin Lymphoma. 2026 Tandem Meetings of ASTCT and CIBMTR 32(2, Supplement):S454-S455, 2026. e-Pub 2026.
15. Handley G, Borjan J, Vuong N, Bhatti M, Hosing C, Marin D, Popat UR, Champlin RE, Shpall EJ, Alousi AM, Chemaly RF, Spallone A. Development of a Pilot Program to Reduce Nitazoxanide Utilization at a Major Cancer Center in Patients with Discordant Norovirus Testing. 2026 Tandem Meetings of ASTCT and CIBMTR 32(2, Supplement):S534-S535, 2026. e-Pub 2026.
16. Szewczyk N, Fontillas RC, Ngo-Huang A, Ferguson J, Rivera Z, Popat UR. Co-Morbidities and Frailty in an Aging Population As a Barrier for Allogeneic Stem Cell Transplantation; Impact of an Enhanced Recovery Program. 2026 Tandem Meetings of ASTCT and CIBMTR 32(2, Supplement):S473, 2026. e-Pub 2026.
17. Bashir Q, Thall PF, Xu X, Kawedia JD, Knape C, Delgado R, Popat UR, Hosing C, Aljawai YM, Chen GL, Fingrut WB, Im JS, Kebriaei P, Marin D, Nieto Y, Ahmed S, Olson AL, Oran B, Ramdial JL, Saini NY, Smallbone P, Srour SA, Pasvolsky O, Thomas SK, Ye C, Patel KK, Champlin RE, Shpall EJ, Qazilbash MH. Evaluate the Safety and Efficacy of Short Versus Long Infusion Schedules of Evomela As Conditioning for Autologous Stem Cell Transplantation in Multiple Myeloma.Interpret Bayesian Modeling Results Assessing the Relationship between Melphalan Exposure (AUC) and Depth of Response or Progression-Free Survival.Identify Potential Pharmacokinetic (AUC) Targets That May Guide Individualized Evomela Dosing Strategies, Particularly for Patients with High-Risk Cytogenetics. 2026 Tandem Meetings of ASTCT and CIBMTR 32(2, Supplement):S419-S420, 2026. e-Pub 2026.
18. Miatech J, Mehta RS, Ramdial JL, Rondon G, Alatrash G, Aljawai YM, Alousi AM, Bashir Q, Chen GL, Hosing C, Fingrut WB, Kebriaei P, Khouri IF, Marin D, Nieto Y, Olson AL, Oran B, Popat UR, Qazilbash MH, Smallbone P, Srour SA, Tanner MR, Rezvani K, Champlin RE, Shpall EJ, Saliba RM. MMF Use Is Associated with Increased Early Infections in AML/MDS Patients Undergoing Allogeneic Transplant with PTCy-Based GvHD Prophylaxis. 2026 Tandem Meetings of ASTCT and CIBMTR 32(2, Supplement):S535-S536, 2026. e-Pub 2026.
19. Al Malki MM, Chen Y, Jain T, Keyzner A, Solh M, Popat U, Donato M, Pineiro L, Fernandez H, Gill S, Snow A, Uberti J, Abedin S, Gooptu M, Angelos M, Pantin J, Ahn KW, Bhandarkar R, Chattopadhyay S, Jaglowski S, Louis C, Matzko M, Morrison L, Pérez W, Poggio E, Reshef R. Trials in progress: Design of a registrational Phase 2 trial (ALLOHA) using an external control arm for TSC-101 for prevention of relapse post allogeneic HCT in patients with ALL, AML, or MDS. Blood 67th ASH Annual Meeting & Exposition 146(Supplement 1):2400, 2025. e-Pub 2025.
20. Bazinet A, Montalban-Bravo G, Bataller A, Chien K, Hammond D, Sasaki K, Bouligny I, Swaminathan M, Jen W, Kugler E, Loghavi S, Kanagal-Shamanna R, Pierce S, Chen J, Kadia T, DiNardo C, Borthakur G, Daver N, Jabbour E, Ravandi F, Oran B, Hosing C, Ramdial J, Alousi A, Olson A, Shpall E, Champlin R, Kantarjian H, Garcia-Manero G, Popat U. Allogeneic stem cell transplantation-related outcomes in chronic myelomonocytic leukemia: Data from a large academic center. Blood 67th ASH Annual Meeting & Exposition 146(Supplement 1):4294, 2025. e-Pub 2025.
21. Bazinet A, Garcia-Manero G, Bataller A, Montalban-Bravo G, Sasaki K, Chien K, Hammond D, Bouligny I, Swaminathan M, Jen W, Kugler E, Kadia T, DiNardo C, Ravandi F, Kanagal-Shamanna R, Gener-Ricos G, Braish J, Urrutia S, Briski R, Rodriguez Sevilla JJ, Chen J, Pierce S, Oran B, Hosing C, Ramdial J, Alousi A, Olson A, Shpall E, Champlin R, Kantarjian H, Popat U. Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes. Blood 67th ASH Annual Meeting & Exposition 146(Supplement 1):6075, 2025. e-Pub 2025.
22. Marvin-Peek J, DiNardo C, Loghavi S, Ravandi F, Borthakur G, Daver N, Kadia T, Jabbour E, Dunbar A, Tang G, Short N, Haddad F, Jabbour J, Kugler E, Maiti A, Issa G, Takahashi K, Bhalla K, Pemmaraju N, Valero YA, Sasaki K, Shpall E, Popat U, Ramdial J, Champlin R, Garcia-Manero G, Kantarjian H, Senapati J. ASXL1 mutations are associated with adverse outcomes in european leukemianet (ELN) 2024 favorable risk patients with Acute Myeloid Leukemia (AML) treated with venetoclax (VEN) containing low-intensity therapy (LIT). Blood 67th ASH Annual Meeting & Exposition 146(Supplement 1):3399, 2025. e-Pub 2025.
23. Al Malki MM, Chen Y, Jain T, Keyzner A, Solh M, Popat U, Donato M, Pineiro L, Fernandez H, Gill S, Snow A, Uberti J, White T, Wang Y, Nguyen C, Louis C, Chattopadhyay S, Matzko M, Reshef R. TSC-101 eliminates recipient hematopoietic cells and demonstrates potential for improved relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT: Updated results from the Phase 1 (ALLOHA) trial. Blood 67th ASH Annual Meeting & Exposition 146(Supplement 1):2391, 2025. e-Pub 2025.
24. Goulart H, Park G, Bose P, Kantarjian H, Garcia-Manero G, Dunbar A, Kadia T, Jabbour E, Chien K, Hammond D, Abbas H, Montalban-Bravo G, DiNardo C, Sasaki K, Daver N, Loghavi S, Popat U, Jain N, Masarova L, Buni M, Pemmaraju N. Characteristics and outcomes for patients with concomitant myeloproliferative neoplasms (MPN) and autoimmune disorders. Blood 67th ASH Annual Meeting & Exposition 146(Supplement 1):2037, 2025. e-Pub 2025.
25. Sarubbi C, Miatech J, Forsberg M, Demla A, Rahman Z, Pawelek J, Mitchell D, Donald S, Garcia C, Suello K, Codrington K, Hunter L, Garcia R, Martinez C, Rondon G, Alatrash G, Aljawai Y, Alousi A, Bashir Q, Champlin R, Chen G, Hosing C, Im J, Kebriaei P, Khouri I, Lin P, Marin D, Mehta R, Nieto Y, Olson A, Oran B, Qazilbash M, Ramdial J, Popat U, Smallbone P, Srour S, Tewari P, Flowers C, Shpall E, Fingrut W. Optimizing essential, complex hematologic care for patients living with disabilities. Blood 67th ASH Annual Meeting & Exposition 146(Supplement 1):4392, 2025. e-Pub 2025.
26. Jamison T, Jabbour E, Jain N, Karrar O, Haddad F, Kebriaei P, Khouri I, Popat U, Yang H, Senapati J, Kugler E, Garris R, Garcia-Manero G, Kantarjian H, Short N. Latency between detectable low-level measurable residual disease (MRD) by next-generation sequencing and overt relapse following flow cytometry MRD-negative remission in patients with acute lymphoblastic leukemia: Implications for the optimal frequency of MRD monitoring. Blood 67th ASH Annual Meeting & Exposition 146(Supplement 1):1558, 2025. e-Pub 2025.
27. Forsberg M, Kaur I, Pirtle R, Daher M, Basar R, Washington D, Asfaw T, Castro K, Ramirez A, Shaftoe S, Oran B, Lin P, Nieto Y, Mulanovich V, Ariza-Heredia E, Aljawai Y, Chen G, Alousi A, Kebriaei P, Fingrut W, Im J, Khouri I, Olson A, Mehta R, Popat U, Ramdial J, Srour S, Saini N, Smallbone P, Bashir Q, Champlin R, Shpall E, Rezvani K, Marin D. Administration of off-the-shelf, expanded, most closely HLA matched, third party viral specific T cells for the therapy of adenovirus related disease in adult immunocompromised patients. Blood 67th ASH Annual Meeting & Exposition 146(Supplement 1):5951, 2025. e-Pub 2025.
28. Saliba RM, Srour S, Hosing C, Rondon G, Kaur I, Popat U, Oran B, Kebriaei P, Alousi A, Alatrash G, Mehta R, Martinez C, Straubel M, Tanner M, Olson A, Fingrut W, Ramdial J, Aljawai Y, Smallbone P, Rezvani K, Shpall E, Champlin R. CD34+/TNC ratio predicts relapse in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide. Blood 67th ASH Annual Meeting & Exposition 146(Supplement 1):5994, 2025. e-Pub 2025.
29. Azevedo RS, Kantarjian H, Senapati J, Bouligny I, Bazinet A, Jen W, Alousi A, Popat U, Shpall E, Pemmaraju N, Jain N, Kugler E, Belgarde C, Jabbour E, Garcia-Manero G, DiNardo C, Daver N, Ravandi F, Kadia T. Cladribine, cytarabine, and venetoclax-based regimens are associated with durable remissions in patients (pts) with newly diagnosed Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation. Blood 67th ASH Annual Meeting & Exposition 146(Supplement 1):1630, 2025. e-Pub 2025.
30. Hosing C, Saliba RM, Alousi A, Alatrash G, Aljawai Y, Bashir Q, Chen G, Fingrut W, Im J, Kebriaei P, Marin D, Nieto Y, Olson A, Oran B, Qazilbash M, Ramdial J, Smallbone P, Popat U, Champlin R, Maadani F, Guillermo-Pacheco M, Rezvani K, Shpall E, Kadia T, Srour S. Allogeneic stem cell transplant for T-prolymphocytic leukemia: A single center analysis. Blood 67th ASH Annual Meeting & Exposition 146(Supplement 1):1869, 2025. e-Pub 2025.
31. Li Z, Chien K, Lyu Y, Sasaki K, Bouligny I, Wei Y, Montalban-Bravo G, Loghavi S, Bataller A, Popat U, Kantarjian H, Bazinet A, Garcia-Manero G. Evaluating the impact of stem cell transplantation in myelodysplastic syndrome using machine learning and comparative modeling. Blood 67th ASH Annual Meeting & Exposition 146(Supplement 1):5644, 2025. e-Pub 2025.
32. Saliba RM, Miatech J, Ramdial J, Rondon G, Alatrash G, Alousi A, Bashir Q, Chen G, Fingrut W, Hosing C, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat U, Qazilbash M, Smallbone P, Srour S, Tanner M, Rezvani K, Champlin R, Shpall E, Mehta R. MMF is associated with higher non-relapse mortality and inferior survival in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide based gvhd prophylaxis. Blood 67th ASH Annual Meeting & Exposition 146(Supplement 1):5996, 2025. e-Pub 2025.
33. Shah R, Luo Z, Fontillas R, Holder B, Szewczyk N, Ayers A, Popat U, Shpall E, Strati P, Nze C, Jain P, Wang M, Westin J, Neelapu S, Ng A, Shin K, Ahmed S, Ngo-Huang A, Chihara D. Prehabilitation prior to CAR T-cell therapy in non-Hodgkin lymphoma: Baseline physical function and toxicity outcomes. Blood 67th ASH Annual Meeting & Exposition 146(Supplement 1):2719, 2025. e-Pub 2025.
34. Gagelmann N, Schroeder T, Salit R, Gurnari C, Pagliuca S, Rautenberg C, Robin M, Rubio M, Maciejewski J, Rambaldi A, Finazzi MC, Angelucci E, Gambella M, Reinhardt HC, Metzdorf J, Chiusolo P, Popat U, Ayuk F, Bacigalupo A, Scott B, Kroeger N. An integrative prognostic model for transplant outcomes in myelofibrosis. Blood 67th ASH Annual Meeting & Exposition 146(Supplement 1):912, 2025. e-Pub 2025.
35. Smallbone P, Loghavi S, Alatrash G, Dinc-Oran A, Takahashi K, Rondon G, Mazouzi K, Popat U, Champlin R, Daver N, Yilmaz M, Short N, Ramdial J, Aljawai Y, Patel K, Routbort M, Hammond D, Marin D, Shpall E, Oran B. Clonal dynamics of FLT3-ITD positive acute myeloid leukemia following relapse after allogeneic stem cell transplantation. Blood 67th ASH Annual Meeting & Exposition 146(Supplement 1):592, 2025. e-Pub 2025.
36. Popat U, Bassett R, Alousi A, Alatrash G, Aljawai Y, Bashir Q, Chen G, Fingrut W, Hosing C, Im J, Kebriaei P, Marin D, Nieto Y, Olson A, Oran B, Qazilbash M, Ramdial J, Saini N, Smallbone P, Srour S, Champlin R, Shpall E. Myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa, and venetoclax (Cladillac) conditioning for high-risk AML: A phase 2 trial. Blood 67th ASH Annual Meeting & Exposition 146(Supplement 1):378, 2025. e-Pub 2025.
37. Shaim H, Mendt M, Lee H, Kumar B, Ramirez A, Kaur I, Mallory T, Aquino A, Olivares P, Hensley C, Kaplan M, Banerjee P, Basar R, Wilson J, Ramdial J, Popat U, Afshar-Kharghan V, Cooper N, Rezvani K, Shpall E. GMP compliant CRISPR/Cas9 gene editing of B2 microglobulin in cord blood derived megakaryocytes and platelets for patients with refractory thrombocytopenia. Blood 67th ASH Annual Meeting & Exposition 146(Supplement 1):1368, 2025. e-Pub 2025.
38. Smallbone P, Medford J, Andersen C, Qiao Y, Rondon G, Gilmore K, Rollins J, Folse J, Samms N, Oran B, Hosing C, Kebriaei P, Aljawai Y, Chen G, Im J, Popat U, Champlin R, Alousi A, Roth M, Shpall E. Persistent symptom burden and unmet needs in long-term survivors of allogeneic hematopoietic cell transplantation: An analysis using the MD anderson symptom inventory (MDASI-BMT). Blood 67th ASH Annual Meeting & Exposition 146(Supplement 1):6058, 2025. e-Pub 2025.
39. Aljawai Y, Milton D, Mehta R, Marin D, Nieto Y, Chen G, Oran B, Smallbone P, Hosing C, Pasvolsky O, Alousi A, Kebriaei P, Popat U, Champlin R, Shpall E. Older donor age is not associated with inferior survival in contemporary haploidentical transplantation. Blood 67th ASH Annual Meeting & Exposition 146(Supplement 1):168, 2025. e-Pub 2025.
40. Oran B, Thall P, Alatrash G, Im J, Ramdial J, Bassett R, Popat U, Kebriaei P, Smallbone P, Jewell J, Champlin R, Shpall E. Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for high-risk acute leukemia following allogeneic stem cell transplantation. Blood 67th ASH Annual Meeting & Exposition 146(Supplement 1):2511, 2025. e-Pub 2025.
41. Popat UR. Improving Transplant Outcomes in Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk SOHO 2025 Annual Meeting 25(Supplement I):S77-S78, 2025. e-Pub 2025.
42. Aljawai YM, Smallbone P, Alousi AM, Bashir Q, Chen GL, Fingrut WB, Hosing CM, Kebriaei P, Marin D, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rezvani K, Champlin RE, Shpall EJ, Mehta RS. Impact of Donor Age and Donor-Recipient Sex Mismatch on Hematopoietic Cell Transplantation Outcomes. 2025 Tandem Meetings of ASTCT and CIBMTR 31(2, Supplement):S261, 2025. e-Pub 2025.
43. Hosing CM, Saliba RM, Alousi AM, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Smallbone P, Srour SA, Bazinet A, Garcia-Manero G, Champlin RE, Andersson BS, Shpall EJ, Popat UR. Allogeneic Stem Cell Transplant with Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Conditioning Regimen in Older Patients with High Risk MDS. 2025 Tandem Meetings of ASTCT and CIBMTR 31(2, Supplement):S182, 2025. e-Pub 2025.
44. Srour SA, Saliba RM, Ramdial JL, Smallbone P, Im JS, Olson AL, Kusy CC, Oran B, Chen GL, Qazilbash MH, Kebriaei P, Hosing CM, Khouri IF, Alousi AM, Bashir Q, Marin D, Nieto Y, Shpall EJ, Champlin RE, Popat UR. Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis. 2025 Tandem Meetings of ASTCT and CIBMTR 31(2, Supplement):S63, 2025. e-Pub 2025.
45. Al Malki MM, Keyzner A, Popat UR, Chen Y, Suh HC, Jain T, Solh MM, Snow A, Pineiro L, Gill SI, Gowda L, Uberti J, White T, Wang Y, Nguyen C, Louis C, Chattopadhyay S, Matzko M, Reshef R. TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial (NCT05473910). 2025 Tandem Meetings of ASTCT and CIBMTR 31(2, Supplement):S59-S60, 2025. e-Pub 2025.
46. Cervoni-Curet FN, Milton DR, Garcia R, Hunter L, Ledesma C, Martinez CS, Rondon G, Carmazzi Y, Cao K, Al-Atrash G, Aljawai YM, Alousi AM, Bashir Q, Chen GL, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Mehta RS, Nieto Y, Olson AL, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Smallbone P, Saini NY, Srour SA, Champlin RE, Flowers C, Shpall EJ, Fingrut WB. Disparities in Allograft Access in the Era of Post-Transplant Cyclophosphamide (PTCy)-Based Graft-Versus-Host Disease Prophylaxis. 2025 Tandem Meetings of ASTCT and CIBMTR 31(2, Supplement):S49-50, 2025. e-Pub 2025.
47. Popat UR, Alousi AM, Bassett RL, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Mehta RS, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Shpall EJ. Jak Inhibitor Itacitinib with Ptcy and Tacrolimus to Prevent Gvhd in a Myeloablative Fractionated Busulfan Regimen: A Phase 2 Trial. 2025 Tandem Meetings of ASTCT and CIBMTR 31(2, Supplement):S30, 2025. e-Pub 2025.
48. Popat UR, Bassett RL, Alousi AM, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Marin D, Mehta RS, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Smallbone P, Srour SA, Valdez BC, Champlin RE, Andersson BS, Shpall EJ. Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Allogeneic Stem Cell Transplantation in Very High-Risk AML/MDS: A Phase 2 Trial. 2025 Tandem Meetings of ASTCT and CIBMTR 31(2, Supplement):S27-S28, 2025. e-Pub 2025.
49. Kawedia JD, Hilaire MR, Liu X, Drisgill A, Gulbis AM, Nieto Y, Popat UR, Andersson BS, Salamone SJ, Shpall EJ. Evaluation of Busulfan Exposure Calculations Using Novel Busulfan Immunoassay with Standard Mass Spectrometry Based Analytical Method. 2025 Tandem Meetings of ASTCT and CIBMTR 31(2, Supplement):S540, 2025. e-Pub 2025.
50. Artz A, Ahn KW, Liu W, DiNardo CD, Muffly LS, Popat UR, Pullarkat V, Miller C, Ridgeway J, Burns LJ. Outcomes of Adults with Acute Myeloid Leukemia Who Received Venetoclax Therapy before Allogeneic Hematopoietic Cell Transplantation. 2025 Tandem Meetings of ASTCT and CIBMTR 31(2, Supplement):S439-S440, 2025. e-Pub 2025.
51. Sami SS, Bashir Q, Saini NY, Aljawai YM, Hosing CM, Popat UR, Becnel MR, Kaufman GP, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Srour SA. Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis. 2025 Tandem Meetings of ASTCT and CIBMTR 31(2, Supplement):S421-S422, 2025. e-Pub 2025.
52. Deen AF, Bashir Q, Saini NY, Aljawai YM, Hosing CM, Popat UR, Becnel MR, Kaufman GP, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Srour SA. Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis. 2025 Tandem Meetings of ASTCT and CIBMTR 31(2, Supplement):S418-S419, 2025. e-Pub 2025.
53. Deen AF, Bashir Q, Saini NY, Aljawai YM, Hosing C, Popat U, Becnel MR, Kaufman GP, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Srour SA. Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis. Blood 66th ASH Annual Meeting & Exposition 144(Supplement 1):1922, 2024. e-Pub 2024.
54. Alatrash G, Knape C, Whited L, Sui D, Haymaker CL, Yeh J, Marcotulli M, Sukhumalchandra P, John LS, Lu H, Duenas DE, Wistuba I, Perez JM, Espiridion BS, Bassett RL, Kadia TM, DiNardo CD, Ravandi F, Ramdial J, Mehta RS, Alousi AM, Oran B, Khouri IF, Bashir Q, Hosing C, Qazilbash MH, Im JS, Kebriaei P, Bachireddy P, Molldrem JJ, Jorgensen JL, Wang SA, WANG W, Popat U, Shpall EJ, Champlin RE, Kantarjian HM, Daver N. A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation. Blood 66th ASH Annual Meeting & Exposition 144(Supplement 1):1047, 2024. e-Pub 2024.
55. Malki MHD, Keyzner A, Popat U, Chen Y, Suh HC, Jain T, Solh MM, Snow A, Gill S, Gowda L, Uberti J, Buonomo E, Wang Y, Nabilsi N, White T, Nguyen C, Murray J, MacBeath G, Louis C, Chattopadhyay S, Matzko M, Reshef R. TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial. Blood 66th ASH Annual Meeting & Exposition 144(Supplement 1):924, 2024. e-Pub 2024.
56. Rafaeli N, Saliba RM, Senapati J, Daver N, Smallbone P, Kebriaei P, Marin D, Popat U, Kadia TM, Ravandi F, Chen G, Champlin RE, Shpall EJ, Oran B. Primary Induction Failure Acute Myeloid Leukemia: Immediate Use of Allogeneic Stem Cell Transplantation Vs. Further Induction Chemotherapy. Blood 66th ASH Annual Meeting & Exposition 144(Supplement 1):2191, 2024. e-Pub 2024.
57. Nguyen D, Ravandi F, Wang SA, Jorgensen JL, WANG W, Loghavi S, Lee J, Bachireddy P, DiNardo CD, Chien KS, Montalban-Bravo G, Issa GC, Maiti A, Valero YA, Daver N, Jabbour E, Kadia TM, Pemmaraju N, Yilmaz M, Nguyen DT, Popat U, Shpall EJ, Garcia-Manero G, Kantarjian H, Short NJ. Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML. Blood 66th ASH Annual Meeting & Exposition 144(Supplement 1):1007, 2024. e-Pub 2024.
58. Marvin-Peek J, Kantarjian HM, Jen W, Borthakur G, Daver N, Maiti A, Short NJ, Kornblau SM, Pemmaraju N, Kugler E, Bazinet A, Alvarado-Valero Y, Abbas HA, Garcia-Manero G, Popat U, Shpall EJ, Ravandi F, DiNardo CD, Kadia TM. Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax. Blood 66th ASH Annual Meeting & Exposition 144(Supplement 1):3572, 2024. e-Pub 2024.
59. Hammond D, Sasaki K, Takahashi K, Shpall EJ, Popat U, Oran B, Al-Atrash G, Patel KK, Westin JR, Neelapu SS, Alvarado-Valero Y, Chien KS, Daver N, Montalban-Bravo G, Maiti A, Yilmaz M, Jabbour E, Pemmaraju N, Swaminathan M, Ishizawa J, Jain N, Ferrajoli A, Ravandi F, Kornblau SM, Borthakur G, Garcia-Manero G, Kantarjian HM, Reville PK, Abbas HA. Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies. Blood 66th ASH Annual Meeting & Exposition 144(Supplemental 1):1837, 2024. e-Pub 2024.
60. Swaminathan M, Abbas HA, Garcia-Manero G, Daver N, Kadia TM, DiNardo CD, Borthakur G, Jabbour E, Pemmaraju N, Valero YA, Ohanian M, Jain N, Short NJ, Bose P, Takahashi K, Hwang H, Huang X, Edelkamp P, Pierce S, Popat U, Shpall EJ, Champlin RE, Kantarjian HM, Ravandi F. Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods. Blood 66th ASH Annual Meeting & Exposition 144(Supplemental 1):3817, 2024. e-Pub 2024.
61. Aljawai YM, Chen G, Oran B, Fingrut WB, Alousi AM, Bashir Q, Hosing C, Kebriaei P, Marin D, Popat U, Qazilbash MH, Ramdial J, Smallbone P, Rezvani K, Champlin RE, Shpall EJ, Mehta RS. Impact of Donor Age and Donor-Recipient Sex Mismatch on HLA-Matched Related and Unrelated Donor Hematopoietic Cell Transplantation Outcomes. Blood 66th ASH Annual Meeting & Exposition 144(Supplement 1):7441-7442, 2024. e-Pub 2024.
62. Aljawai YM, Saliba RM, Chen G, Oran B, Fingrut WB, Alousi AM, Bashir Q, Hosing C, Kebriaei P, Marin D, Olson AL, Popat U, Qazilbash MH, Ramdial J, Rondon G, Smallbone P, Srour SA, Champlin RE, Shpall EJ. Improved Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation with Younger Donors. Blood 66th ASH Annual Meeting & Exposition 144(Supplement 1):7442, 2024. e-Pub 2024.
63. Rafaeli N, Marin D, Ledesma C, Jain N, Tewari P, Khouri IF, Olson AL, Alatrash G, Short NJ, Jabbour E, Rezvani K, Alousi AM, Popat U, Champlin RE, Shpall EJ, Kebriaei P. Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia. Blood 66th ASH Annual Meeting & Exposition 144(Supplement 1):2810, 2024. e-Pub 2024.
64. Ramdial J, Clemente L, Banerjee P, Dabaja BS, Al-Atrash G, Alousi AM, Oran B, Popat U, Im JS, Srour SA, Chen G, Kebriaei P, Hosing C, Marin D, Rezvani K, Shpall EJ, Champlin RE. Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation in Patients with High-Risk Myeloid Malignancies. Blood 66th ASH Annual Meeting & Exposition 144(Supplement 1):4841, 2024. e-Pub 2024.
65. Popat U, Bassett RL, Alousi AM, Alatrash G, Aljawai YM, Bashir Q, Chen G, Fingrut WB, Hosing C, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial J, Saini NY, Smallbone P, Srour SA, Valdez BC, Champlin RE, Andersson BS, Shpall EJ. Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial. Blood 66th ASH Annual Meeting & Exposition 144(Supplement 1):506, 2024. e-Pub 2024.
66. Srour SA, Saliba RM, Ramdial J, Smallbone P, Im JS, Olson AL, Kusy CC, Oran B, Chen G, Qazilbash MH, Kebriaei P, Hosing C, Khouri IF, Alousi AM, Bashir Q, Marin D, Nieto Y, Shpall EJ, Champlin RE, Popat U. Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis. Blood 66th ASH Annual Meeting & Exposition 144(Supplement 1):3514, 2024. e-Pub 2024.
67. Oran B, Marin D, Bashir Q, Ahmed S, Olson AL, Popat U, Kebriaei P, Shpall EJ, Jain V, Champlin RE. Long-Term Follow-up of Crenolanib Maintenance after Allogeneic Transplantation in Newly Diagnosed and Relapsed FLT3 Mutated AML. Blood 66th ASH Annual Meeting & Exposition 144(Supplement 1):1497, 2024. e-Pub 2024.
68. Sami SS, Bashir Q, Saini NY, Aljawai YM, Hosing C, Popat U, Becnel MR, Kaufman GP, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Srour SA. Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis. Blood 66th ASH Annual Meeting & Exposition 144(Supplement 1):1923, 2024. e-Pub 2024.
69. Saliba RM, Aljawai YM, Alousi AM, Oran B, Popat U, Champlin RE, Shpall EJ. Predictors of Graft-Versus-Host Disease with Post-Transplant Cyclophosphamide. Blood 66th ASH Annual Meeting & Exposition 144(Supplemental 1):4890, 2024. e-Pub 2024.
70. Shaim H, Mendt MC, Lee H, Kumar B, Cho MS, Ramirez A, Kaur I, Mallory T, Aquino A, Olivares P, Hensley C, Friedman K, Kaplan M, Nunez Cortes AK, Wilson J, Ramdial J, Popat U, Afshar-Kharghan V, Rezvani K, Shpall EJ. Large Scale Manufacturing of GMP Grade Cord Blood Derived Megakaryocytes for Chemotherapy Induced Thrombocytopenia. Blood 66th ASH Annual Meeting & Exposition 144(Supplement 1):3926, 2024. e-Pub 2024.
71. Smallbone P, Sekhar M, Srour SA, Shpall EJ, Popat UR. Hematopoietic Stem Cell Transplantation in Patients with Myelofibrosis and Splanchnic Vein Thrombosis. 2024 Tandem Meetings of ASTCT and CIBMTR 30(Issue 2, Supplement):S103, 2024. e-Pub 2024.
72. Malki MM, Keyzner A, Suh, HC, Popat UR, Dwivedi N, Kothari AS, Buonomo E, Wang Y, Abelowitz N, Murray J, MacBeath G, Barton D, Chattopadhyay S, Reshef R. TSC-100 and TSC-101, TCR-T Cell Therapies That Target Residual Recipient Cells after Reduced Intensity Conditioning Transplantation, Induce Complete Donor Chimerism with Favorable Prognosis: Early Results of a Phase 1 Trial. 2024 Tandem Meetings of ASTCT and CIBMTR 30(2, Supplement):S1-S2, 2024. e-Pub 2024.
73. Nieto Y, Valdez BC, Thall P, Bassett R, Ramdial J, Srour SA, Saini NY, Hosing C, Alousi AA, Qazilbash MH, Popat UR, Barnett M, Gulbis AM, Shigle TL, Pacheco MV, Ledesma C, Ahmed S, Iyer SP, Nair R, Strati P, Westin JR, Champlin RE, Shpall EJ, and Andersson BS. The Combination of the PARP Inhibitor Olaparib with High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplant (ASCT) Demonstrates High Activity for Refractory Lymphomas, Including Prior Failures of CAR-T. 2024 Tandem Meetings of ASTCT and CIBMTR 30(2, Supplement):S36, 2024. e-Pub 2024.
74. Saengboon S, Ciurea SO, Popat UR, Qazilbash MH, Ramdial J, Kebriaei P, Shpall EJ, Champlin RE, and Srour SA. Survival Outcomes after Relapse in Patients Who Underwent Haploidentical Stem Cell Transplantation (haplo-SCT). 2024 Tandem Meetings of ASTCT and CIBMTR, 2024. e-Pub 2024.
75. Ramdial J, Valdez BC, Lin R, Thall P, Wei A, Hosing C, Srour SA, Popat UR, Qazilbash MH, Alousi AM, Barnett M, Gulbis AM, Shigle TL, Shpall EJ, Andersson BS, Nieto Y. Gemcitabine (Gem) /Clofarabine (Clo) /Busulfan (Bu) (GemCloBu): A New Myeloablative Conditioning Regimen with Reduced Toxicity and High Activity for Allogeneic Stem-Cell Transplant (alloSCT) for Aggressive Lymphomas. 2024 Tandem Meetings of ASTCT and CIBMTR, 2024. e-Pub 2024.
76. Smallbone P, Saengboon S, Bashir Q, Nelson BE, Ramdial J, Saini NY, Hosing C, Popat UR, Delgado R, Becnel M, Lee HC, Orlowski R, Shpall EJ, Champlin RE, Qazilbash MH, Srour SA. Impact of Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) on AL Amyloidosis Outcomes. 2024 Tandem Meetings of ASTCT and CIBMTR 30(2, Supplement):S388-S389, 2024. e-Pub 2024.
77. Ramdial J, Lin R, Thall P, Valdez BC, Hosing C, Srour SA, Popat UR, Qazilbash MH, Alousi AM, Shpall EJ, Barnett M, Jimenez E, Gulbis AM, Shigle TL, Andersson BS, and Nieto Y. A Comparison of Gemcitabine/Clofarabine/Busulfan (Gem/Clo/Bu) Myeloablative Conditioning with Fludarabine/Melphalan (Flu/Mel) Reduced Intensity Conditioning for Allogeneic Stem-Cell Transplant (alloSCT) for Aggressive Lymphomas. 2024 Tandem Meetings of ASTCT and CIBMTR, 2024. e-Pub 2024.
78. Kawedia JD, Liu X, Sui D, Gulbis AM, Ramdial J, Srour SA, Popat UR, Nieto Y, Kebriaei P, Saini NY, Lin P, Aljawai Y, Pasvolsky O, Lee HC, Orlowski RZ, Thomas SK, Patel KK, Knape C, Delgado R, Champlin RE, Shpall EJ, Qazilbash MH, Thall P, and Bashir Q. Lower PG-Free Mel (Evomela) Clearance and Higher Exposure Are Associated with Better Treatment Response in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. 2024 Tandem Meetings of ASTCT and CIBMTR, 2024. e-Pub 2024.
79. Nguyen D, Ravandi F, Wang SA, Jorgensen JL, Wang W, Chien KS, Montalban-Bravo G, Issa GC, Maiti A, Valero YA, Daver N, DiNardo CD, Jabbour E, Kadia TM, Pemmaraju N, Yilmaz M, Lee J, Bachireddy P, Popat UR, Garcia-Manero G, Kantarjian HM, Short NJ. A Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML. Blood 65th ASH Annual Meeting & Exposition 142(Supplement 1):322, 2023. e-Pub 2023.
80. Alkhaldi H, Reinhardt A, Barnett M, Kundu S, Hosing C, Ramdial J, Saini N, Srour S, Alousi A, Kebriaei P, Popat U, Qazilbash M, Champlin R, Shpall EJ, Gulbis A, Shigle TL, Dabaja B, Pinnix C, Ahmed S, Steiner R, Andersson BS, Nieto Y. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. Transplant Cell Ther 2023 Tandem Meetings of ASTCT and CIBMTR 29(11):690-694, 2023. e-Pub 2023. PMID: 37607645.
81. Senapati J, Loghavi S, Reville PK, Daver N, Borthakur G, DiNardo CD, Jabbour E, Short NJ, Pemmaraju N, Maiti A, Issa GC, Popat UR, Alousi A, Shpall EJ, Sasaki K, Garcia-Manero G, Ravandi F, Kadia TM. Outcomes of Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) and TP53 mutation/Loss Treated on the Phase 2 Study of Venetoclax (Ven) Added to Alternating Cladribine (Clad) Plus Low-Dose Cytarabine (LDAC) and Azacitidine (Aza): A Subgroup Analysis. Blood 65th ASH Annual Meeting & Exposition 142(Supplement 1):4282, 2023. e-Pub 2023.
82. Hosing C, Braunstein Z, McLaughlin E, Valdez BC, Andersson BS, Popat UR, Vasu S, Bezzera E, Sanchez-Petitto G, Wall SA, Jaglowski SM, Penza S, Choe H, Wei L, Nakkula R, Cash A, Champlin RE, Lima MD, Devine SM, Lee DA, Brammer JE. Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with T-Cell Malignancies: Final Results of a Phase I/II Trial. Blood 65th ASH Annual Meeting & Exposition 142(Supplement 1):184, 2023. e-Pub 2023.
83. Atluri H, DiGennaro J, Patel KP, Routbort M, Oran B, Issa GC, Short NJ, Daver N, Kadia TM, Ravandi F, Popat UR, Champlin RE, Shpall EJ, Pierce S, Kanagal-Shamanna R, Ok CY, Tang G, Wang SA, Luthra R, Lasry A, Nadorp B, Chroni A, Eisfeld A, Aifantis I, Al Ali NH, Sallman DA, Lancet J, Chan O, Padron E, Xie Z, Medeiros L, DiNardo CD, Komrokji RS, Loghavi S. Clinical and Prognostic Implications of WT1 Mutations in De Novo and Relapsed Acute Myeloid Leukemia. Blood 65th ASH Annual Meeting & Exposition 142(Supplement 1):959, 2023. e-Pub 2023.
84. Marcoux C, Saliba RM, Wallis W, Khazal S, Ragoonanan D, Rondon G, Tewari P, Popat UR, Oran B, Olson AL, Bashir Q, Qazilbash MH, Alousi A, Hosing C, Nieto Y, Alatrash G, Marin D, Rezvani K, Khouri IF, Srour SA, Champlin RE, Shpall EJ, Kebriaei P. Incidence and Risk Factors of Veno-Occlusive Disease Are Different in Younger Versus Older Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Blood 65th ASH Annual Meeting & Exposition 142(Supplement 1):4920, 2023. e-Pub 2023.
85. Velarde AM, Saliba RM, Ledesma C, Shpall EJ, Qazilbash MH, Popat UR, Bashir Q, Nieto Y, Marin D, Oran B, Olson AL, Srour SA, Alousi A, Ramdial J, Kebriaei P, Ferrajoli A, Wierda WG, Champlin RE, Hosing C. Allogeneic Transplant for CLL Richter's Transformation: Single Center Retrospective Analysis. Blood 65th ASH Annual Meeting & Exposition 142(Supplement 1):7086, 2023. e-Pub 2023.
86. Qazilbash MH, Khan HN, Milton DR, Pasvolsky O, Tanner MR, Popat UR, Kebriaei P, Hosing C, Khouri IF, Rezvani K, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Alatrash G, Rondon G, Konopleva MY, Champlin RE, Shpall EJ, Bashir Q, Pemmaraju N. Patient Characteristics and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood 65th ASH Annual Meeting & Exposition 142(Supplement 1):4988, 2023. e-Pub 2023.
87. Pasvolsky O, Patel KK, Bashir Q, Rauf M, Sui D, Srour SA, Tanner MR, Popat UR, Saini NY, Hosing C, Ramdial J, Manasanch EE, Lee HC, Kaufman GP, Thomas SK, Weber DM, Becnel MR, Tang G, Orlowski RZ, Patel D, Champlin RE, Nieto Y, Shpall EJ, Qazilbash MH. Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hematopoietic Stem Cell Transplantation. Blood 65th ASH Annual Meeting & Exposition 142(Supplement 1):7070, 2023. e-Pub 2023.
88. Bashir Q, Konopleva MY, Abueg G, Ramdial J, Hosing C, Srour SA, Alousi A, Popat UR, Nieto Y, Alatrash G, Champlin RE, Shpall EJ, Qazilbash MH, Pemmaraju N. Tagraxofusp Maintenance Post-Hematopoietic Stem Cell Transplantation Provides Long-Term Survival and Manageable Safety for a Patient with Blastic Plasmacytoid Dendritic Cell Neoplasm. Blood 65th ASH Annual Meeting & Exposition 142(Supplement 1):7058, 2023. e-Pub 2023.
89. Bashir Q, Thall P, Sui D, Kawedia J, Knape C, Delgado R, Schindler JL, Popat UR, Kebriaei P, Hosing C, Khouri IF, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Alatrash G, Rondon G, Lee HC, Thomas SK, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Phase 1/2 Trial to Jointly Optimize Dose and Administration Schedule of Evomela in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Blood 65th ASH Annual Meeting & Exposition 142(Supplement 1):4972, 2023. e-Pub 2023.
90. Khouri IF, Alzahrani K, Gulbis A, Sasaki K, Jain N, Short NJ, Kadia TM, Daher M, MD, Rafei H, Im JS, Marin D, Olson AL, Popat UR, Qazilbash MH, Ramdial J, Rondon G, Srour SA, Kebriaei P, Shpall EJ, Kantarjian HM, Champlin RE, Jabbour E. Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed CD22 (+) Lymphoid Malignancies: Long-Term Survival Results. Blood 65th ASH Annual Meeting & Exposition 142(Supplement 1):233, 2023. e-Pub 2023.
91. Pasvolsky O, Patel KK, Bashir Q, Rauf M, Sui D, Srour S, Tanner MR, Popat UR, Saini N, Hosing C, Ramdial JL, Manasanch E, Lee HC, Kaufman G, Thomas SK, Weber DM, Becnel M, Tang G, Orlowski RZ, Patel D, Champlin RE, Nieto Y, Shpall EJ, Qazilbash MH. Daratumumab-based maintenance in patients with relapsed multiple myeloma after salvage autologous hematopoietic stem cell transplantation. HemaSphere EHA2023 Hybrid Congress 7(S3):e002748c, 2023. e-Pub 2023.
92. Popat UR, Lontos K, Bassett R, Kawedia J, Valdez BC, Gulbis A, Alousi AM, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Mehta RS, Nieto Y, Oran B, Olson A, Qazilbash MH, Ramdial JL, Saini N, Srour SA, Kadia T, Daver N, Short N, Rezvani K, Shpall EJ, Champlin RE, Andersson BS. Myeloablative fractionated busulfan based condition regimen in AML/MDS results of a randomized trial. HemaSphere EHA2023 Hybrid Congress 7(S3):e069901e, 2023. e-Pub 2023.
93. Senapati J, Kantarjian H, Bazinet A, Reville P, Borthakur G, Daver N, Dinardo C, Bataller A, Jabbour E, Short N, Popat UR, Alousi AM, Shpall EJ, Garcia-Manero G, Ravandi F, Kadia T. Superior outcomes after allogeneic stem cell transplantation among patients ≥60 years treated with cladribine, low dose cytarabine plus venetoclax for newly diagnosed acute myeloid leukemia. HemaSphere EHA2023 Hybrid Congress 7(S3):e2853482, 2023. e-Pub 2023.
94. Nieto Y, Yang Z, Valdez BC, Kundu S, Bassett R, Barnett M, Bashir Q, Ramdial J, Saini NY, Srour SA, Im JS, Kebriaei P, Popat UR, Gulbis AM, Cool R, Shigle TL, Wallis WD, Yeh J, Delgado R, Qureshi S, Lee HC, Manasanch E, Orlowski RZ, Thomas SK, Shpall EJ, Andersson BJ, Qazilbash MH. Safety and Efficacy of a New High-Dose Chemotherapy (HDC) Regimen of Panobinostat (Pano), Gemcitabine (Gem), Busulfan (Bu) and Melphalan (Mel) (Pano/GBM) with Autologous Stem Cell Transplant (ASCT) for Patients (pts) with High-Risk (HR) or Refractory/Relapsed (R/R) Myeloma (MM) – Matched Pair Comparisons with a Concurrent Control Cohort. Transplant Cell Ther 2023 Tandem Meetings of ASTCT and CIBMTR 29(Issue 2, Supplement):S31-S32, 2023. e-Pub 2023.
95. Shi D, Hosing C, Khouri IF, Saengboon S, Saini NY, Ramdial JL, Akin S, Bashir Q, Steiner R, Dabaja B, Pnnix C, Ahmed S, Alousi AM, Anderlini P, Kebriaei P, Qazilbash MH, Popat UR, Shpall EJ, Champlin RE, Nieto Y, Srour SA. Long-Term Outcomes after Autologous Stem Cell Transplant (ASCT) for Primary Central Nervous System Lymphoma (PCNSL). Transplant Cell Ther 2023 Tandem Meetings of ASTCT and CIBMTR 29(Issue 2, Supplement):S383, 2023. e-Pub 2023.
96. Pasvolsky O, Bassett R, Chanem S, Cuglievan B, Priti T, Hosing C, Srour S, Ramdial JL, Mahadeo KM, Khazal SJ, Petropoulos D, Popat UR, Qazilbash MH, Kebriaei P, Champlin RE, Shpall EJ, Nieto Y. Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing First Autologous Hematopoietic Stem Cell Transplant. Transplant Cell Ther 2023 Tandem Meetings of ASTCT and CIBMTR 29(Issue 2, Supplement):S378-S37, 2023. e-Pub 2023. PMID: 38124057.
97. Popat UR, Saliba RM, Mehta RS, Alousi AM, Al-Atrash G, Bashir Q, Hosing CM, Gulbis A, Im JS, Kebriaei P, Khouri IF, Kawedia JD, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Shigle TL, Srour SA, Rezvani K, Qazilbash MH, Andersson BS, Shpall EJ, Champlin RE. Myeloablative Fractionated Busulfan Fludarabine and Thiotepa Regimen for Haploidentical Donor Transplantation. Transplant Cell Ther 2023 Tandem Meetings of ASTCT and CIBMTR 29(Issue 2, Supplement):S167, 2023. e-Pub 2023.
98. Carmona SN, Saengboon S, Bashir Q, Al-Atrash G, Cox N, Borthakur G, Vickers MR, Ramdial J, Kebriaei P, Popat, UR, Qazilbash MH, Shpall EJ, Champlin, RE, Srour SA. Impact of Smoking on Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation. Transplant Cell Ther 2023 Tandem Meetings of ASTCT and CIBMTR 29(Issue 2, Supplement):S147-S148, 2023. e-Pub 2023.
99. Saengboon S, Khouri IF, Hosing C, Ramdial JL, Saini NY, Akin S, Shi D, Steiner R, Malpica L, Ahmed S, Westin JR, Dabaja B, Wu SY, Alousi AM, Kebriaei P, Qazilbash MH, Popat UR, Champlin RE, Shpall EJ, Nieto Y, Srour SA. Timing of Autologous Stem Cell Transplantation (ASCT) in Patients with Primary Central Nervous System Lymphoma (PCNSL). Transplant Cell Ther 2023 Tandem Meetings of ASTCT and CIBMTR 29(Issue 2, Supplement):S385-S386, 2023. e-Pub 2023.
100. Popat UR, Saliba RM, Mehta RS, Alousi AM, Al-Atrash G, Bashir Q, Chen J, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Khouri IF, Kawedia JD, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Rezvani K, Qazilbash MH, Kantarjian H, Andersson BS, Champlin RE, Shpall EJ. Myeloablative Fractionated Busulfan Regimens in Matched Donor Transplantation. Transplant Cell Ther 2023 Tandem Meetings of ASTCT and CIBMTR 29(Issue 2, Supplement):S164-S165, 2023. e-Pub 2023.
101. Kawedia JD, Liu X, Ramdial J, Srour SA, Mehta RS, Popat UR, Nieto Y, Saini NY, Kebriaei P, Knape C, Gulbis AM, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Creatinine Clearance Is Associated with Propylene Glycol-Free Melphalan (Evomela) Pharmacokinetics and Gastrointestinal Toxicities in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Transplant Cell Ther 2023 Tandem Meetings of ASTCT and CIBMTR 29(Issue 2, Supplement):S438-S439, 2023. e-Pub 2023.
102. Shindiapina P, Pietrzak M, Seweryn M, McLaughlin E, Zhang X, Makowski M, Ahmed E, Pearson R, Kitzler R, Le-Rademacher JG, Little RF, Akpek G, Ayala E, Devine SM, Kaplan LD, Noy A, Popat UR, Hsu JW, Morris LE, Mendizabal A, Baiocchi R. Update on Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials. Transplant Cell Ther 2023 Tandem Meetings of ASTCT and CIBMTR 29(Issue 2, Supplement):S67-S68, 2023. e-Pub 2023.
103. Schoettler ML, Carreras E, Cho B, Dandoy CE, Ho VT, Jodele S, Moiseev I, Ortega IS, Srivastava A, Atsuta Y, Carpenter PA, Koreth J, Kröger N, Ljungman PT, Okamoto S, Popat UR, Shaw BE, Soiffer RJ, Sureda A, Williams A, Vasu S. Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplant Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation (EBMT), American Society for Transplantation and Cellular Therapy (ASTCT), Asia-Pacific Blood and Marrow Transplantation Group (APBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). Transplant Cell Ther 2023 Tandem Meetings of ASTCT and CIBMTR 29(Issue 2, Supplement):S130-S131, 2023. e-Pub 2023.
104. Chan KH, Ramdial JL, Hosing C, Srour SA, Alousi AM, Kebriaei P, Popat UR, Qazilbash MH, Ahmed S, Iyer SP, Lee HJ, Nair R, Steiner R, Strati P, Dabaja B, Fang P, Gunter JR, Pinnix C, Wu SY, Cuglievan B, Mahadeo KM, Champlin RE, Shpall EJ, Nieto Y. Outcome of Patients with Classical Hodgkin Lymphoma (cHL) Relapsing after an Autologous Stem-Cell Transplant (ASCT). Transplant Cell Ther 2023 Tandem Meetings of ASTCT and CIBMTR 29(Issue 2, Supplement):S382, 2023. e-Pub 2023.
105. Champlin RE, Lustig EB, Bashir Q, Oran B, Kornblau SM, Hosing C, Alousi AM, Popat UR, McCarty JM, Thall PF, Dabaja BS, Liu WH, Dang G, Castro K, Ramirez A, Spiotto M, Wu S, Fang P, Kaur I, Rezvani K, Shpall EJ, Reisner Y. First in Human Study of Anti-Viral Veto Cells Enabling Successful Engraftment without Severe Gvhd in Non-Myeloablative T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation (HSCT). Blood 64th ASH Annual Meeting and Exposition 140(Supplement 1):2120–2122, 2022. e-Pub 2022.
106. Ozcan G, Popat UR, Kebriaei P, Alousi AM, Alatrash G, Bashir Q, Mehta RS, Ramdial JL, Rondon G, Shpall EJ, Champlin RE, Oran B. Transplant Outcomes for TP53 AML and MDS in a Contemporary Era. Blood 64th ASH Annual Meeting and Exposition 140(Supplement 1):10620–10621, 2022. e-Pub 2022.
107. Oran B, Champlin RE, Thall PF, McCarty JM, Zhang W, Marin D, Mehta RS, Alousi AM, Alatrash G, Popat UR, Kantarjian H, Bashir Q, Shpall EJ, Konopleva M. Phase II Trial of Venetoclax (Ven) in Combination with Azacitidine (AZA) As Maintenance Therapy for High-Risk Acute Leukemia Following Allogeneic Stem Cell Transplantation (SCT). Blood 64th ASH Annual Meeting and Exposition 140(Supplement 1):10561–10562, 2022. e-Pub 2022.
108. Pasvolsky O, Saliba RM, Popat UR, Alousi AM, Mehta RS, Yeh J, Alatrash G, Masood A, Ramdial JL, Rondon G, Kebriaei P, Champlin RE, Shpall EJ, Oran B. Efficacy of Azacitidine Post-Transplant Maintenance for FLT3-Negative Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood 64th ASH Annual Meeting and Exposition 140(Supplement 1):10550–10551, 2022. e-Pub 2022.
109. Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao K. Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis. Blood 64th ASH Annual Meeting and Exposition 140(Supplement 1):10530–10531, 2022. e-Pub 2022.
110. Reville PK, Kantarjian H, Borthakur G, Pemmaraju N, Daver N, DiNardo CD, Sasaki K, Short N, Issa GC, Ohanian M, Jabbour E, Montalban-Bravo G, Maiti A, Jain N, Ferrajoli A, Bhalla KN, Takahashi K, Rausch CR, Hammond D, Malla R, Quagliato K, Brandt M, Popat UR, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM. Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study. Blood 64th ASH Annual Meeting and Exposition 140(Supplement 1):9041–9043, 2022. e-Pub 2022.
111. Senapati J, Kantarjian H, Ravandi F, DiNardo CD, Takahashi K, Hammond D, Sasaki K, Chien KS, Kanagal-Shamanna R, Popat UR, Pierce SA, Jabbour E, Champlin RE, Garcia-Manero G, Kadia TM. Outcomes of Older Patients with Aplastic Anemia Treated with Frontline Anti-Thymocyte Globulin (ATG)-Based Immunosuppressive Therapy. Blood 64th ASH Annual Meeting and Exposition 140(Supplement 1):8652–8654, 2022. e-Pub 2022.
112. Maiti A, DiNardo CD, Ohanian M, Pemmaraju N, Daver N, Borthakur G, Ravandi F, Issa GC, Garcia-Manero G, Jain N, Kadia TM, Masarova L, Wierda WG, Yilmaz M, Alvarado Y, Jabbour E, Short N, Takahashi K, Loghavi S, Patel KP, Montalbano K, Pierce SA, Bivins CA, Mehta RS, Alatrash G, Popat UR, Kebriaei P, Oran B, Shpall EJ, Champlin RE, Kantarjian H, Konopleva M. Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial. Blood 64th ASH Annual Meeting and Exposition 140(Supplement 1):7725–7728, 2022. e-Pub 2022.
113. Pasvolsky O, Saliba RM, Ledesma C, Popat UR, Alousi AM, Olson AL, Oran B, Hosing C, Bashir Q, Qazilbash MH, Short N, Ravandi F, Champlin RE, Shpall EJ, Kebriaei P. Prognostic Significance of Measurable Residual Disease for Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission and Beyond. Blood 64th ASH Annual Meeting and Exposition 140(Supplement 1):7695–7696, 2022. e-Pub 2022.
114. Yeh J, Saliba RM, Wang C, Fang Z, Figgins B, Ahmed S, Yilmaz M, Daver N, Mehta RS, Alatrash G, Marin D, Popat UR, Champlin RE, Shpall EJ, Oran B. Efficacy and Safety of Gilteritinib Vs. Sorafenib As Post-Transplant Maintenance in Patients with FLT3-ITD Acute Myeloid Leukemia. Blood 64th ASH Annual Meeting and Exposition 140(Supplement 1):7686–7688, 2022. e-Pub 2022.
115. Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao K. Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis. Blood 64th ASH Annual Meeting and Exposition 140(Supplement 1):7649–7650, 2022. e-Pub 2022.
116. Ramdial JL, Clemente-Sevilla L, Soebbing D, Dabaja BS, Thall PF, Alatrash G, Alousi AM, Mehta RS, Popat UR, Kebriaei P, Oran B, Rezvani K, Shpall EJ, Champlin RE. A Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation to Decrease Disease Relapse in Patients with High-Risk Myeloid Malignancies. Blood 64th ASH Annual Meeting and Exposition 140(Supplement 1):7484–7485, 2022. e-Pub 2022.
117. Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao K. HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT. Blood 64th ASH Annual Meeting and Exposition 140(Supplement 1):4880–4881, 2022. e-Pub 2022.
118. Bazinet A, Kantarjian H, Arani N, Popat UR, DiNardo CD, Daver N, Yilmaz M, Abbas HA, Short N, Issa GC, Jabbour E, Pierce SA, Chen J, Garcia R, Konopleva M, Garcia-Manero G, Alousi AM, Shpall EJ, Champlin RE, Borthakur G, Ravandi F, Kadia TM. Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Acute Myeloid Leukemia: Analysis of Outcomes and Contemporary Trends Spanning 10 Years. Blood 64th ASH Annual Meeting and Exposition 140(Supplement 1):4872–4875, 2022. e-Pub 2022.
119. Hosing C, McLaughlin E, Braunstein Z, Valdez BC, Wei L, Popat UR, Andersson BS, Vasu S, Larkin KT, Jaglowski S, Penza S, Saad A, Choe H, Wall SA, Cash A, Nakkula R, Champlin RE, de Lima MJG, Lee DA, Brammer JE. Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with Aggressive T-Cell Malignancies in a Phase I/II Trial. Blood 64th ASH Annual Meeting and Exposition 140(Supplement 1):1885–1886, 2022. e-Pub 2022.
120. Nieto Y, Valdez BC, Thall PF, Ramdial JL, Srour SA, Hosing C, Saini N, Alousi AM, Qazilbash MH, Popat UR, Gulbis A, Shigle TL, Bassett R, Guillermo-Pacheco M, Ledesma C, Strati P, Ahmed S, Steiner R, Westin J, Nair R, Iyer SP, Champlin RE, Shpall EJ, Andersson BS. High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas. Blood 64th ASH Annual Meeting and Exposition 140(Supplement 1):1183-1184, 2022. e-Pub 2022.
121. Macaron W, Ravandi F, Kadia TM, DiNardo CD, Issa GC, Daver N, Wang SA, Jorgensen JL, Patel K, Loghavi S, Konopleva M, Yilmaz M, Jabbour E, Maiti A, Abbas HA, Shpall EJ, Popat UR, Alatrash G, Pierce SA, Kantarjian H, Short N. Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission. Blood 64th ASH Annual Meeting and Exposition 140(Supplement 1):543–545, 2022. e-Pub 2022.
122. Srour SA, Mehta RS, Shah N, Qazilbash MH, Im J, Bashir Q, Saini N, Nieto Y, Khouri IF, Daher M, Kebriaei P, Popat UR, Manasanch EE, Lee HC, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Rezvani K. Phase II study of umbilical cord blood–derived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with high-risk multiple myeloma (HRMM). J Clin Oncol 2022 ASCO Annual Meeting I 40(16_suppl):abstr 8009, 2022. e-Pub 2022.
123. Ong F, Ravandi F, Popat UR, Kadia TM, Daver NG, Dinardo CD, Konopleva M, Borthakur G, Shpall EJ, Oran B, Alatrash G, Mehta RS, Jabbour E, Yilmaz M, Issa GC, Garcia-Manero G, Maiti A, Abbas H, Champlin RE, Short J. Impact of induction approach on post-stem cell transplant (SCT) outcomes in older adults with newly diagnosed acute myeloid leukemia (AML). J Clin Oncol 2022 ASCO Annual Meeting I 40(16_suppl):abstr 7038, 2022. e-Pub 2022.
124. Popat UR, Mehta RS, Thall P, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Marin D, ieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Daver N, Ravandi F, Shpall EJ, Champlin RE, Andersson BS. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial. Transplant Cell Ther 2022 Tandem Meetings of ASTCT and CIBMTR 28(3, Supplement):S78-S79, 2022. e-Pub 2022.
125. Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Gulbis AM, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Konopleva M, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial. Transplant Cell Ther 2022 Tandem Meetings of ASTCT and CIBMTR 28(3, Supplement):S82-S83, 2022. e-Pub 2022.
126. Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, VAldez BC, Rezvani K, Qazilbash MH, Kadia TM, Kantarjian H, Shpall EJ, Champlin RE, Andersson BS. Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial. Transplant Cell Ther 2022 Tandem Meetings of ASTCT and CIBMTR 28(3, Supplement):S293, 2022. e-Pub 2022.
127. Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Rezvani K, Qazilbash MH, Shpall EJ, Andersson BS, Champlin RE. Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. Transplant Cell Ther 2022 Tandem Meetings of ASTCT and CIBMTR 28(3, Supplement):S83-S84, 2022. e-Pub 2022.
128. Srour SA, Saengboon S, Nelson BE, Ramdial J, Bashir Q, Vickers MR, Saini NY, Hosing C, Popat UR, Delgado R, Lee HC, Kaufamn G, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan Dose Intensity for Autologous Stem Cell Transplantation (ASCT) in AL Amyloidosis. Transplant Cell Ther 2022 Tandem Meetings of ASTCT and CIBMTR 28(3, Supplement):S426, 2022. e-Pub 2022.
129. Kawedia JD, Liu X, Ramdial J, Srour SA, Mehta RS, Popat UR, Nieto Y, Saini NY, Kebriaei P, Knape C, Gulbis AM, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Captisol-Enabled Melphalan (Evomela) Pharmacokinetics between Short and Long Infusion Arms in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Transplant Cell Ther 2022 Tandem Meetings of ASTCT and CIBMTR 28(3, Supplement):S461-S462, 2022. e-Pub 2022.
130. Qazilbash MH, Bashir Q, Rauf M, Sui D, Srour SA, Popat UR, Saini NY, Hosing C, Ramdial J, Manasanch E, Lee HC, Kaufman G, Thomas S, Weber D, Becnel M, Tang G, Orlowski RZ, Guzman M, Champlin RE, Shpall EJ, Patel KK. Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hemaptopoietic Stem Cell Transplantation. Transplant Cell Ther 2022 Tandem Meetings of ASTCT and CIBMTR 28(3, Supplement):S404-S405, 2022. e-Pub 2022.
131. Nelson BE, Ramdial J, Bashir Q, Saini NY, Hosing C, Popat UR, Delgado R, Lee HC, Kaufman G, Orlowski RZ, Champlin RE, Qazilbash MH, Srour SA. Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy. Transplant Cell Ther 2022 Tandem Meetings of ASTCT and CIBMTR 28(3, Supplement):S414-S415, 2022. e-Pub 2022.
132. Kawedia JD, Anderson T, Popat UR, Andersson BS, Champlin RE, Kebriaei P. Washout Time to Avoid Drug-Drug Interaction between Blinatumomab and Busulfan during Hematopoietic Stem Cell Transplant Conditioning. Transplant Cell Ther 2022 Tandem Meetings of ASTCT and CIBMTR 28(3, Supplement):S461, 2022. e-Pub 2022.
133. Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash M, Kadia TM, Kantarjian H, Shpall EJ, Champlin RE, Andersson BS. Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial. Blood 63rd ASH Annual Meeting and Exposition 138(Supplement 1):1803, 2021. e-Pub 2021.
134. Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Rezvani K, Qazilbash MH, Shpall EJ, Andersson BS, Champlin RE. Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. Blood 63rd ASH Annual Meeting and Exposition 138(Supplement 1):1802, 2021. e-Pub 2021.
135. Bashir Q, Thall PF, Sui D, Ramdial JL, Srour SA, Mehta RS, Popat UR, Nieto Y, Saini N, Kebriaei P, Manasanch EE, Lee HC, Kaufman GP, Thomas SK, Patel KK, Orlowski RZ, Knape CG, Kawedia JD, Champlin RE, Shpall EJ, Liu X, Qazilbash MH. A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule and Dose of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma. Blood 63rd ASH Annual Meeting and Exposition 138(Supplement 1):3941, 2021. e-Pub 2021.
136. Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Gulbis A, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Konopleva M, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial. Blood 63rd ASH Annual Meeting and Exposition 138(Supplement 1):2879, 2021. e-Pub 2021.
137. Al-Juhaishi T, Malek AE, Milton DR, Ramdial JL, Daher M, Olson AL, Srour SA, Alatrash G, Oran B, Mehta RS, Khouri IF, Bashir Q, Shah N, Ciurea SO, Rondon G, Maadani F, Hosing C, Marin D, Kebriaei P, Rezvani K, Nieto Y, Anderlini P, Alousi A, Qazilbash MH, Popat UR, Champlin RE, Shpall EJ, Mulanovich V, Ahmed S. Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. Blood 63rd ASH Annual Meeting and Exposition 138(Supplement 1):1779, 2021. e-Pub 2021.
138. Popat UR, Bassett R, Thall PF, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Daver N, Ravandi F, Shpall EJ, Champlin RE, Andersson BS, Mehta RS. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial. Blood 63rd ASH Annual Meeting and Exposition 138(Supplement 1):556, 2021. e-Pub 2021.
139. Hosing C, Braunstein Z, Ali AM, Valdez BC, Andersson BS, Popat UR, Vasu S, Larkin K, Penza S, Choe H, Saad A, de Lima MJG, Wei L, McLaughlin E, Nakkula R, Campbell A, Trikha P, Puto M, William BM, Champlin RE, Lee DA, Brammer JE. Romidepsin in Conditioning and Maintenance Mitigates Relapse Risk and Enhances NK-Cell Cytotoxicity in Patients Receiving Allogeneic Stem Cell Transplant for Aggressive T-Cell Malignancies: Results of a Phase I/II Clinical Trial. Blood 63rd ASH Annual Meeting and Exposition 138(Supplement 1):553, 2021. e-Pub 2021.
140. Nelson BE, Ramdial JL, Bashir Q, Saini N, Hosing C, Popat UR, Delgado R, Lee HC, Kaufman GP, Orlowski RZ, Champlin RE, Qazilbash MH, Srour SA. Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy. Blood 63rd ASH Annual Meeting and Exposition 138(Supplement 1):482, 2021. e-Pub 2021.
141. Reville PK, Kantarjian H, Borthakur G, Pemmaraju N, DiNardo CD, Sasaki K, Daver N, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Bhalla KN, Jabbour EJ, Ferrajoli A, Takahashi K, Rausch CR, Malla R, Marek K, Brandt M, Popat UR, Andreeff M, Garcia-Manero G, Konopleva M, Ravandi F, Kadia TM. Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood 63rd ASH Annual Meeting and Exposition 138(Supplement 1):367, 2021. e-Pub 2021.
142. Mehta RS, Bassett R, Olson A, Chen J, Ganesh C, Alousi A, Anderlini P, Al-Atrash G, Bashir Q, Ciurea S, Hosing C, Im J, Kebriaei P, Khouri I, Marin D, Molldrem J, Nieto Y, Oran B, Rezvani K, Qazilbash M, Srour S, Shpall E, Champlin R, Andersson B, Popat U. Post-Transplant Cyclophosphamide in HLA-Matched and Haploidentical Transplant Recipients Receiving a Myeloablative Fractionated Busulfan Conditioning Regimen: Results of a Phase II Study. Clin Lymphoma Myeloma Leuk SOHO 2021 Annual Meeting 21(Supplemental 1):S258, 2021. e-Pub 2021.
143. Bashir Q, Milton DR, Rezvani K, Saini NY, Shpall EJ, Srour SA, Popat UR, Konopleva M, Pemmaraju N, Champlin RE, Qazilbash MH. Phase 2 Study of Tagraxofusp Therapy for Patients with BPDCN Post‑Autologous or Post-Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther 2021 TCT Meetings of ASTCT and CIBMTR 27(3, Supplement):S432, 2021. e-Pub 2021.
144. Afrough A, Srour SA, Bashir Q, Saini NY, Hosing C, Popat UR, Kebriaei P, Delgado R, Murphy R, Manasanch E, Lee HC, Kaufman G, Patel KK, Thomas S, Webber D, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Induction with VRD Vs. VCD on the Outcome of Patients with Multiple Myeloma after an Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther 2021 TCT Meetings of ASTCT and CIBMTR 27(3, Supplement):S405-S406, 2021. e-Pub 2021.
145. Afrough A, Alsfeld LC, Delgado R, Popat UR, Kebriaei P, Oran B, Saini NY, Srour SA, Hosing C, Manasanch E, Lee HC, Kaufman G, Patel KK, Orlowski RZ, Pinnix C, Dabaja B, Thomas S, Weber D, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Transplant Cell Ther 2021 TCT Meetings of ASTCT and CIBMTR 27(3, Supplement):S411-S412, 2021. e-Pub 2021.
146. Ramdial JL, Gaballa MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini N, Nieto Y, Hosing C, Popat UR, Murphy R, Lee HC, Patel KK, Manasanch EE, Thomas SK, Weber DM, Kaufman GP, Orlowski RZ, Champlin RE, Qazilbash MH. Outcomes in Patients with AL (Light-Chain) Cardiac Amyloidosis. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):11-13, 2020. e-Pub 2020.
147. Oran B, Alousi AM, Mehta RS, Marin D, Kebriaei P, Popat UR, OLson AL, McCarty JM, Ramos JD, Bassett R, Keer HN, Thall PF, Champlin RE. Minimal Residual Disease Eradication with Guadecitabine (SGI-110) in the Post-Transplant Setting. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):10-11, 2020. e-Pub 2020.
148. Saberian C Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Daher M, Gruschkus SK, Knape C, Whited L, Gulbis A, Marcotulli M, Rondon G, Popat UR, Mehta RS, Konopleva M, Oran B, Ohanian M, Ravandi F, Garcia-Manero G, Alousi AM, Daver N, Champlin RE, Diab A, Alatrash G. Lower Risk of Graft Versus Host Disease after Exposure to Checkpoint Inhibitors with the Use of Post-Transplant Cyclophosphamide Prophylaxis. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):1, 2020. e-Pub 2020.
149. Srour SA, Bashir Q, Milton DR, Nieto Y, Mehta RS, Saini N, Delgado R, Rondon G, Hosing C, Ciurea SO, Popat UR, Khouri IF, Kebriaei P, Manasanch EE, Manasanch EE, Patel KK, Shpall EJ, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH. Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):24-25, 2020. e-Pub 2020.
150. Afrough A, Srour SA, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Shpall EJ, Delgado R, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Prognostic Impact of Beta 2 Microglobulin in Patients with Immunoglobulin Light-Chain Amyloidosis Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):20-21, 2020. e-Pub 2020.
151. Bashir Q, Rezvani K, Saini N, Shpall EJ, Srour SA, Popat UR, Milton DR, Pemmaraju N, Champlin RE, Qazilbash MH. Phase 2 Study of Tagraxofusp Therapy for BPDCN Patients Post-Autologous or Post-Allogeneic Hematopoietic Cell Transplantation. Blood 62nd ASH Annual Meeting & Exposition 136(Supplement 1):5, 2020. e-Pub 2020.
152. Oran B, Ciurea SO, Mehta RS, Alousi AM, Rondon G, Popat UR, Marin D, Daher M, Im JS, Kebriaei P, Alatrash G, Champlin RE. Transplant Outcomes with Fludarabine and Melphalan in High Risk AML Patients By Donor Types. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):20-21, 2020. e-Pub 2020.
153. Afrough A, Alsfeld LC, Delgado R, Popat UR, Kebriaei P, Oran B, Saini N, Srour SA, Hosing C, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Weber DM, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):22, 2020. e-Pub 2020.
154. Kadia TM, Borthakur G, Pemmaraju N, Daver N, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Bravo GM, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Kanagal-Shamanna R, Takahashi K, Malla R, Marek K, Brandt M, Popat UR, Andreeff M, Cortes JE, Garcia-Manero G, Konopleva M, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood 62nd ASH Annual Meeting & Exposition 136(Supplement 1):17-19, 2020. e-Pub 2020.
155. Andersson BS, Thall P, Valdez BC, Ma J, Chen J, Ahmed S, Alousi AM, Bashir Q, Ciurea SO, Gulbis A, Hosing C, Jones RB, Kawedia J, Kebriaei P, Kornblau SM, Myers A, Oran B, Rezvani K, Shah N, Shpall EJ, Parmar S, Popat UR, Nieto Y, Champlin RE. A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine ± Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS. Blood 62nd ASH Annual Meeting & Exposition 136(Supplement 1):37-38, 2020. e-Pub 2020.
156. Oran B, Ciurea SO, Kebriaei P, Mehta RS, Popat UR, Hosing C, McCarty JM, Hindman B, Messahel B, Champlin RE. Safety, Tolerability and Efficacy of Crenolanib Administered Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in Patients with FLT3 Mutant AML. Blood 62nd ASH Annual Meeting and Exposition, 2020. e-Pub 2020.
157. Saini N, Ma J, Timmons M, Alousi AM, Anderlini P, Andersson BS, Hosing C, Ramdial J, Kebriaei P, Popat UR, Qazilbash M, Shpall EJ, Srour SA, Valdez BC, Dabaja BS, Pinnix CC, Gunther JR, Maadani F, Rondon G, Champlin RE, Nieto Y. High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) with Consolidative Radiation Therapy (RT) for Relapsed or Refractory (R/R) Primary Mediastinal B-Cell Lymphoma (PMBCL): 20-Year Experience at MD Anderson Cancer Center (MDACC). Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):32-33, 2020. e-Pub 2020.
158. Mukherjee A, Milton DR, Jabbour E, Daver N, Gulbis A, Ledesma G, Konopleva M, DiNardo CD, Ravandi F, Kadia TM, Alatrash G, Alousi AM, Daher M, Marin D, Olson AL, Oran B, Kebriaei P, Saini N, Srour SA, Popat UR, Im JS, Mehta R, Rondon G, Kantarjian HM, Champlin RE, Khouri IF. Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax- Based Therapy. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):13-14, 2020. e-Pub 2020.
159. Oran B, Alatrash G, Alousi AM, Mehta RS, Hosing C, Popat UR, Im JS, McCarty JM, Ramos JD, Keer HN, Thall PF, Champlin RE. Maintenance Treatment with Guadecitabine (SGI-110) in High Risk MDS and AML Patients after Allogeneic Stem Cell Transplantation. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):29-30, 2020. e-Pub 2020.
160. Srour SA, Nieto Y, Iyer SP, Miranda RN, Maadani F, Rondon G, Saini N, Strati P, Daher M, Nair R, Dabaja BS, Popat UR, Qazilbash MH, Shpall EJ, Flowers C, Champlin RE, Hosing C, Khouri IF. Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):40-41, 2020. e-Pub 2020.
161. Khouri IF, Gruschkus SK, Ledesma C, Anderlini P, Bashir Q, Daher M, Iyer SP, Marin D, Mehta R, Olson AL, Popat UR, Samaniego F, Qazilbash MH, Im JS, Rondon G, Champlin RE, Gulbis A, Young KH. Autologous Vs. Allogeneic Stem Cell Transplantation in Double-Expressor Lymphoma. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):24-25, 2020. e-Pub 2020.
162. Khouri IF, Gruschkus SK, Gulbis A, Ledesma C, Jain N, Kadia TM, Pemmaraju N, Anderlini P, Bashir Q, Daher M, Kebriaei P, Marin D, Mehta R, Popat UR, Saini N, Srour SA, Im JS, Fayad L, Nair R, Iyer SP, Strati P, Samaniego F, Nastoupil LJ, Flowers C, Rondon G, Kantarjian HM, Champlin RE, Jabbour E. Nonmyeloablative Allogeneic Stem Cell Transplantation with or without Inotuzumab Ozogamicin for Lymphoid Malignancies. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):10-12, 2020. e-Pub 2020.
163. Mehta RS, Saliba RM, Jan A, Shigle TL, Wang E, Rondon G, Nieto Y, Ciurea S, Oran B, Im JS, Olson AL, Marin D, Qazilbash MH, Khouri IF, Anderlini P, Rezvani K, Popat UR, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft Versus Host Disease. Blood 62nd ASH Annual Meeting & Exposition 136(Supplement 1):39-40, 2020. e-Pub 2020.
164. Saini N, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing C, Nieto Y, Kebriaei P, Alousi AM, Mehta RS, Srour SA, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis. Blood 62nd ASH Annual Meeting & Exposition 136(Supplement 1):9-10, 2020. e-Pub 2020.
165. Nieto Y, Gruschkus SK, Jones RB, Valdez BC, Timmons M, Hosing C, Anderlini P, Kebriaei P, Popat UR, Qazilbash MH, Alousi AM, Srour SA, Saini N, Ramdial J, Im JS, Shpall EJ, Rezvani K, Gulbis A, Shigle TL, Mahadeo M, Khazal S, Khouri IF, Dabaja BS, Pinnix CC, Gunther JR, Lee H, Ahmed S, Steiner RE, Iyer SP, Nair R, Parmar S, Cuglievan B, Maadani F, Rondon G, Champlin RE, Andersson BS. Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. Blood 62nd ASH Annual Meeting & Exposition 136(Supplement 1):17-18, 2020. e-Pub 2020.
166. Afrough A, Alsfeld LC, Srour SA, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Shpall EJ, Delgado R, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with t(11;14) Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood 62nd ASH Annual Meeting & Exposition 136(Supplement 1):18-19, 2020. e-Pub 2020.
167. Ramdial JL, Ma J, Milton DR, Delgado R, Bashir Q, Srour SA, Saini N, Nieto Y, Hosing C, Popat UR, Murphy R, Lee HC, Patel KK, Manasanch EE, Thomas SK, Kaufman GP, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. PBSC Mobilization for Auto-HSCT in Myeloma: Growth Factors Vs Growth Factors + Chemotherapy. Blood 62nd ASH Annual Meeting & Exposition 136(Supplement 1):6-7, 2020. e-Pub 2020.
168. Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Alousi AM, Alatrash G, Bashir Q, Ciurea S, Hosing C, Im JS, Kebriaei P, Olson AL, Oran B, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Outcomes of Prospective Phase II Clinical Trial. Blood 62nd ASH Annual Meeting & Exposition 136(Supplement 1):10-11, 2020. e-Pub 2020.
169. Srour SA, Bashir Q, Milton DR, Nieto Y, Mehta RS, Saini N, Delgado R, Rondon G, Ciurea SO, Popat UR, Khouri IF, Kebriaei P, Manasanch EE, Hosing C, Patel KK, Lee HC, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):23-24, 2020. e-Pub 2020.
170. Kadia TM, Borthakur G, Takahashi K, DiNardo CD, Daver N, Pemmaraju N, Jabbour E, Jain N, Short NJ, Qiao W, Adewale L, Rausch CR, Pierce SA, Alvarao Y, Alousi AM, Popat UR, Khouri IF, Garcia-Manero G, Konopleva M, Cortes JE, Ravandi F, Kantarjian HM. Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML). Blood 62nd ASH Annual Meeting & Exposition 136(Supplement 1):20-22, 2020. e-Pub 2020.
171. Joseph J, Milton D, Al-Atrash G, Alousi A, Bashir Q, Daher M, Im J, Mehta R, Olson A, Oran B, Saini N, Srour S, Bose P, Pemmarau N, Verstovsek S, Andersson B, Champlin R, Popat U. Myeloablative Fludarabine and Busulfan Regimen in Myelofibrosis (MF): Long-Term Outcomes and Analysis of Prognostic Factors. Clin Lymphoma Myeloma Leuk SOHO 2020 Annual Meeting 20(Supplement 1):S333, 2020. e-Pub 2020.
172. Saberian C, Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Daher M, Gruschkus S, Knape C, Whited L, Gulbis A, Cornelison-Marcotulli M, Rondon G, Popat U, Mehta R, Konopleva M, Oran B, Ohanian M, Ravandi F, Garcia-Manero G, Alousi A, Daver N, Champlin R, Diab A, Al-Atrash G. Post-Transplant Cyclophosphamide Reduces the Incidence of Acute Graft Versus Host Disease in AML/MDS Patients Who Receive Checkpoint Inhibitors After Allogeneic Stem Cell Transplant. Clin Lymphoma Myeloma Leuk SOHO 2020 Annual Meeting 20(Supplement 1):S201-S202, 2020. e-Pub 2020.
173. Yalniz F, Saliba R, Greenbaum U, Ramdial J, Alousi A, Joseph J, Olson A, Alatrash G, Marin D, Rezvani K, Hosing C, Im J, Shpall E, Mehta R, Qazilbash M, Popat U, Oran B, Champlin R, Kebriaei P. Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients with Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk SOHO 2020 Annual Meeting 20(Supplement 1):S202, 2020. e-Pub 2020.
174. Joseph J, Popat U. Improving Survival After Transplant in Myelofibrosis. Clin Lymphoma Myeloma Leuk SOHO 2020 Annual Meeting 20(Supplement 1):S72-S73, 2020. e-Pub 2020.
175. Joseph J, Popat U. A Mildly Symptomatic Middle-Aged Woman with INT-1 Primary Myelofibrosis. Clin Lymphoma Myeloma Leuk SOHO 2020 Annual Meeting 20(Supplement 1):S19, 2020. e-Pub 2020.
176. Khanlari M, Loghavi S, Popat UR, Bueso-Ramos CE, Medeiros LJ, Konoplev S. Delayed Resolution of Bone Marrow Morphological Changes of Myelofibrosis Following Successful Stem Cell Transplant and Molecular Clearance of Disease: A Cautionary Tale. Clin Lymphoma Myeloma Leuk SOHO 2020 Annual Meeting 20(Supplement 1):S340-S341, 2020. e-Pub 2020.
177. Srour SA, Milton D, Bashir Q, Mehta R, Ciurea SO, Daher M, Popat U, Khouri I, Kebriaei P, Delgado R, Rondon G, Manasanch EE, Patel K, Lee HC, Shpall E, Orlowski R, Champlin R, Qazilbash MH. Survival trends in multiple myeloma after autologous hematopietic stem cell transplantation. HemaSphere 25th Congress of the European Hematology Association Virtual Edition 4(S1):487, 2020. e-Pub 2020.
178. Popat U, Mehta RS, Bassett Jr R, Olson A, Chen J, Ganesh C, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Daher M, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Srour SA, Rezvani K, Qazilbash MH, Molldrem J, Shpall EJ, Champlin RE, Andersson BS. Myeloablative fractionated busulfan conditioning regimen in older patients: results of a phase II study. HemaSphere 25th Congress of the European Hematology Association Virtual Edition 4(S1):637, 2020. e-Pub 2020.
179. Khouri I, Milton D, Ledesma C, Nastoupil L, Jabbour E, Anderlini P, Bashir Q, Daher M, Im J, Marin D, Mehta R, Olson A, Popat U, Qazilbash M, Samaniego F, Swaminathan I, Rondon G, Medeiros LJ, Gulbis A, Champlin R. Improved survival with non-myeloablative allogeneic transplantation (NMAT) compared to autologous stem cell transplantation (ASCT) for patients >60 years with relapsed follicular lymphoma (FL). HemaSphere 25th Congress of the European Hematology Association Virtual Edition 4(S1):647, 2020. e-Pub 2020.
180. Khouri I, Milton D, Wang Y, Ledesma C, Jabbour E, Swaminathan I, Anderlini P, Qaiser B, Daher M, Kebriaei P, Marin D, Mehta R, Olson A, Popat U, Srour S, Qazilbash M, Samaniego F, Fayad L, Nastoupil L, Im J, Flowers C, Rondon G, Champlin R, Gulbis A, Young K. Clinical relevance of MYC/BCL2, cell of origin and conditioning regimen in patients with relapsed diffuse large b-cell lymphoma (DLBCL) treated with allogeneic stem cell transplantation (ALLOSCT). HemaSphere 25th Congress of the European Hematology Association Virtual Edition 4(S1):657, 2020. e-Pub 2020.
181. Srour SA, Kongtim P, Chen J, Rondon G, Hosing C, Popat U, Bashir Q, Qazilbash M, Kebriaei P, Petropoulos. Second allogeneic stem cell transplantation with haploidentical grafts for post-transplant relapse. HemaSphere 25th Congress of the European Hematology Association Virtual Edition 4(S1):645, 2020. e-Pub 2020.
182. Joseph J, Milton D, Chen J, Al-Atrash G, Alousi A, Bashir Q, Ciurea S, Daher M, Im J, Mehta R, Olson A, Oran B, Saini N, Srour S, Andersson B, Champlin R, Popat U. Myeloablative fludarabine and busulfan regimen in myelofibrosis: long term outcomes and analysis of prognostic factors. HemaSphere 25th Congress of the European Hematology Association Virtual Edition 4(S1):507, 2020. e-Pub 2020.
183. Yalniz F, Milton D, Greenbaum U, Popat U, Nieto Y, Srour S, Saini N, Kebriaei P, Oran B, Al-Atrash G, Delgado R, Champlin R, Qazilbash M, Bashir Q. Characteristics and outcomes of patients with multiple myeloma who developed therapy related myeloid neoplasms following autologous stem cell transplantation. HemaSphere 25th Congress of the European Hematology Association Virtual Edition 4(S1):366, 2020. e-Pub 2020.
184. Joseph J, Milton D, Chen J, Al-Atrash G, Alousi A, Bashir Q, Ciurea S, Daher M, Im J, Mehta R, Olson A, Oran B, Saini N, Srour S, Andersson B, Champlin R, Popat U. Myeloablative fludarabine and busulfan regimen in myelofibrosis: Long term outcomes and analysis of prognostic factors. J Clin Oncol 2020 ASCO Annual Meeting I 38(15_suppl):e19520, 2020. e-Pub 2020.
185. Ramdial J, Ma J, Milton DR, Delgado R, Bashir Q, Srour SA, Saini N, Nieto Y, Hosing CM, Popat UR, Lee, HC, Patel K, Yalniz FF, Champlin RE, Qazilbash MH. Peripheral Blood Stem Cell Mobilization for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Growth Factors Only Vs. Growth Factors + Chemotherapy. BBMT 2020 TCT Meetings of ASTCT and CIBMTR 26(3, Supplemental):S286-S287, 2020. e-Pub 2020.
186. Mishra A, Preussier JM, Al-Mansour Z, Bachanova V, Bhatt VR, Bredeson C, Chhabra S, D'Souza A, Dahi PB, DeFilipp Z, Gowda L, Hacker ED, Hashmi S, Howard DS, Jakubowski AA, Jayani R, Johnson L, Koll T, Lin RJ, McCurdy SR, Michaelis LC, Muffly L, Nathwani N, Olin RL, Popat UR, Rodriguez C, Rosko A, Runaas L, Sabloff M, Shore TB, Shune L, Sorror ML, Sung AD, Ustun C, Wood W, Burns LJ, Artz AS. Transplant Physicians’ Attitudes on Candidacy for Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Patients: The Need for a Standardized Geriatric Assessment (GA) Tool. BBMT 2020 TCT Meetings of ASTCT and CIBMTR 26(3, Supplement):S45-S46, 2020. e-Pub 2020.
187. Yeh J, Whited LK, Saliba RM, Rondon G, Popat UR. Cardiac Toxicities after HLA-Matched Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): Post-Transplant Cyclophosphamide (PTCy) Is Not Associated with Higher Incidence of Cardiotoxicity. BBMT 2020 TCT Meetings of ASTCT and CIBMTR 26(3, Supplement):S393-S394, 2020. e-Pub 2020.
188. Shindiapina P, Pietrzak M, Seweryn M, McLaughlin E, Zhang X, Makowski M, Lyberger J, Chang H, Ahmed E, Pearson R, Kitzler R, Le-Rademacher JG, Little RF, Akpek G, Ayala E, Devine SM, Kaplan LD, Noy A, Popat UR, Hsu J, Morris LE, Mendizabal A, Krishnan A, Hofmeister CC, Forman SJ, Navarro WH, Alvarnas JC, Ambinder RF, Behbehani G, Lozanski G, Baiocchi R. Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT-CTN-0903/AMC-080 and BMT-CTN-0803/AMC-071 Trials. BBMT 2020 TCT Meetings of ASTCT and CIBMTR 26(3, Supplement):S304, 2020. e-Pub 2020.
189. Popat UR, Saliba RM, Szewczyk N, Lindsay R, Rivera Z, Ferguson J, Fontillas RC, Adekoya L, Gale H, Lee CA, Cao L, Sullivan HB, Chen J, Rondon G, McMullin B, Shigle TL, Whited LK, Gulbis AM, Soones TN, Ngo-Huang A, Champlin RE. Enhanced Recovery Program in Older Patients Undergoing Allogeneic Stem Cell Transplantation (ER-SCT): First Year Outcomes. BBMT 2020 TCT Meetings of ASTCT and CIBMTR 26(3, Supplemental):S49-S50, 2020. e-Pub 2020.
190. Qazilbash MH, Ramdial J, Bashir Q, Milton DR, Patel RD, Popat UR, Hosing CM, Kebriaei P, Alousi AM, Ciurea SO, Konopleva M, Champlin RE, Pemmaraju N. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for BPDCN. BBMT 2020 TCT Meetings of ASTCT and CIBMTR 26(3, Supplement):S106-S107, 2020. e-Pub 2020.
191. Srour SA, Milton DR, Bashir Q, Mehta RS, Saini N, Ciurea SO, Popat UR, Khouri IF, Kebriaei P, Delgado R, Rondon G, Manasanch E, Patel K, Lee HC, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. BBMT 2020 TCT Meetings of ASTCT and CIBMTR 26(3, Supplement):S238-S239, 2020. e-Pub 2020.
192. Popat U, Mehta RS, Bassett R, Olson A, Chen J, Ganesh C, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Sa S, Rezvani K, Qazilbash MH, Molldrem JJ, Shpall EJ, Champlin RE, Andersson BS. Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study. BBMT 2020 TCT Meetings of ASTCT and CIBMTR 26(3, Supplement):S6-S7, 2020. e-Pub 2020.
193. Popat UR, Saliba RM, Mehta RS, Olson A, Chen J, Ganesh C, Woodworth G, McMullin B, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Srour SA, Rezvani K, Qazilbash MH, Molldrem JJ, Shpall EJ, Andersson BS, Champlin RE. Comparison of Post-Transplant Cyclophosphamide and Tacrolimus and Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen. BBMT 2020 TCT Meetings of ASTCT and CIBMTR 26(3, Supplement):S125, 2020. e-Pub 2020.
194. Gupta V, Kennedy J, Capo-Chichi JM, Kim S, Ahn KW, Hu ZH, Alyea EP, Popat UR, Sobecks RM, Scott BL, Nakamura R, Saber W. Impact of Genetic Mutations on the Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia with Antecedent Myeloproliferative Neoplasm. BBMT 2020 TCT Meetings of ASTCT and CIBMTR 26(3, Supplement):S12, 2020. e-Pub 2020.
195. Bashir Q, Thall P, Milton DR, Kawedia JD, Kebriaei P, Patel K, Andersson BS, Nieto Y, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing CM, Popat UR, Oran B, Ciurea SO, Lin P, Weber D, Thomas S, Lee HC, Manasanch E, Orlowski RZ, Shpall EJ, Williams L, Champlin RE, Qazilbash MH. Conditioning with Busulfan Plus Melphalan (Bu-Mel) Results in More Prolonged Progression-Free Survival (PFS) Versus Melphalan (Mel) Alone before Autologous Stem Cell Transplantation (auto-HCT) in Patients with High-Risk Multiple Myeloma (MM): Long-Term Results of a Randomized, Phase 3 Trial. BBMT 2020 TCT Meetings of ASTCT and CIBMTR 26(3, Supplement):S241-S242, 2020. e-Pub 2020.
196. Oran B, Ahn KW, Fretham C, Shah MV, Nakamura R, Scott BL, Sobecks R, Popat U, Saber W. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Flurabine Improves Transplant Outcomes in Older MDS Patients. Blood 61st ASH Annual Meeting 134(Supplement_1):253, 2019. e-Pub 2019.
197. Ciurea SO, Varma A, Kongtim P, Srour S, Bashir Q, Alousi AM, Mehta RS, Oran B, Popat U, Hosing C, Rondon G, Chen J, Olson AL, Konopleva MY, Champlin RE. Optimal Conditioning for Older Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Propensity Score Analysis. Blood 61st ASH Annual Meeting & Exposition 134(Supplement_1):42, 2019. e-Pub 2019. PMID: 31724003.
198. Popat U, Saliba RM, Mehta RS, Olson AL, Chen J, Ganesh C, Rondon G, Woodword G, McMullin B, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing C, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Srour S, Rezvani K, Qazilbash MH, Molldrem JJ, Shpall EJ, Andersson BS, Champlin RE. Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen. Blood 61st ASH Annual Meeting & Exposition 134(Supplement_1):3296, 2019. e-Pub 2019.
199. Zeng K, Ma H, Popat U, Nieto Y, Ciurea SO, Olson AL, Lyu M, Huang M, Nishiimoto M, Qazilbash MH, Ramos JD, Shpall EJ, Champlin RE, Parmar S, Andersson BS. Allogeneic Cord Blood Regulatory T Cells Can Prevent Graft Vs. Host Disease and Preserve Graft Vs Leukemia Effect: Update on Phase I/II Clinical Trial. Blood 61st ASH Annual Meeting & Exposition 134(Supplement_1):4547, 2019. e-Pub 2019.
200. Oran B, Champlin RE, Wang F, Jeyakumar N, Garcia-Manero G, Kantarjian HM, Saliba RM, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients. Blood 61st ASH Annual Meeting & Exposition 134(Supplement_1):47, 2019. e-Pub 2019. PMID: 31723997.
201. Shindiapina P, Pietrzak M, Seweryn M, McLaughlin E, Zhang X, Makowski M, Lyberger J, Chang H, Ahmed CE, Prouty A Pearson R, Kitzler R, Le-Rademacher J, Little RF, Akpek G, Ayala E, Devine S, Noy A, Kaplan LD, Popat U, Hsu JW, Morris LE, Mendizabal AM, Hofmeister CC, Wachsman W, Forman SJ, Navarro WH, Alvarnas JC, Ambinder RF, Behbehani GK, Lozanski G, Baiocchi RA. Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials. Blood 61st ASH Annual Meeting & Exposition 134(Supplement_1):4525, 2019. e-Pub 2019.
202. Mukherjee A, Milton DR, Gulbis A, Ledesma C, Jabbour E, Alousi AM, Bashir Q, Daher M, Oran B, Olson AL, Marin D, Srour S, Kebriaei P, Mehta RS, Nemeth KP, Popat U, Im JS, Champlin RE, Khouri IF. Post-Transplant Cyclophosphamide (PT-Cy) Based Haploidentical Cell Transplantation (Haplo) Versus Rabbit Anti-Thymocyte Globulin (r-ATG) Based HLA Matched Unrelated Donor (MUD) Transplantation in Patients (pts) with Relapsed/Refractory Lymphoma. Blood 61st ASH Annual Meeting & Exposition 134(Supplement_1):4530, 2019. e-Pub 2019.
203. Popat U, Mehta RS, Bassett R, Olson AL, Chen J, Ganesh C, Alousi AM, Anderlini A, Alatrash G, Bashir B, Ciurea SO, Hosing C, Im JS, Kebriaei P, If K, Marin D, Nieto Y, Oran B, Saini N, Srour S, Rezvani K, Qazilbash M, Molldrem JJ, Shpall EJ, Andersson BS, Champlin ES. Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study. Blood 61st ASH Annual Meeting & Exposition 134(Supplement_1):256, 2019. e-Pub 2019.
204. Koller P, Saliba RM, Ledesma C, Rondon G, Popat U, Alousi AM, Mehta RS, Oran B, Olson AL, Hosing C, Qazilbash MH, Khouri IF, Ciurea SO, Shpall EJ, Jorgensen JL, Wang SA, Jain N, Jabbour E, Kantargjian HM, Champlin RE, Konopleva MY, Kebriaei P. Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression. Blood 61st ASH Annual Meeting & Exposition 134(Supplement_1):4598, 2019. e-Pub 2019.
205. Khouri IF, Milton DR, Ledesma C, Nastoupil LJ, Jabbour E, Anderlini P, Bashir Q, Ciurea SO, Daher M, Fayad LE, Im JS, Iyer SP, Marin D, Mehta RS, Molldrem JJ, Olson AL, Oran B, Popat U, Qazilbash M, Srour S, Samaniego F, Rondon G, Medeiros J, Gulbis A, Champlin RE. Nonmyeloablative Allogeneic Transplantation (NMAT) Confers an Overall Survival Benefit with Similar Non-Relapse Mortality When Compared to Autologous Stem Transplantation (ASCT) for Patients (pts) with Relapsed Follicular Lymphoma (FL). Blood 61st ASH Annual Meeting & Exposition 134(Supplement_1):322, 2019. e-Pub 2019.
206. Yalniz FF, Saliba RM, Yucel OK, Garcia-Manero G, Ramdial J, Popat U, Ciurea SO, Kebriaei P, Alousi AM, Alatrash G, Bashir Q, Hosing C, Marin D, Mehta R, Olson AL, Rezvani K, Shpall EJ, Rondon G, Champlin RE, Oran B. Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation. Blood 61st ASH Annual Meeting & Exposition 134(Supplement_1):512, 2019. e-Pub 2019.
207. Champlin RE, Popat U, Oran B, Ciurea SO, Kebriaei P, Alousi AM, Alatrash G, Bashir Q, Khouri IF, Hosing C, Anderlini P, Jones RB, Marin D, Mehta R, Nieto Y, Olson AL, Qazilbash MH, Rezvani K, Shpall EJ, Chen J, Rondon G, McMullin B, Al Jahdhami VP, Kawedia J, Valdez, BC, Ma J, Thall PF, Andersson BS. A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS. Blood 61st ASH Annual Meeting & Exposition 134(Supplement_1):257, 2019. e-Pub 2019.
208. Pemmaraju N, Carter BZ, Kantarjian HM, Cortes JE, Bose P, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daverr NG, Popat U, Konopleva MY, Ohanian M, Pierce SA, Zhou L, Estrov ZE, Borthakur GM, Mak PY, Jain N, Jabbour E, Verstovsek S. Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis. Blood 61st ASH Annual Meeting & Exposition 134(Supplement_1):555, 2019. e-Pub 2019.
209. Olin RL, Fretham C, Pasquini MC, Arora M, Bhatt VR, Derman B, Giralt SA, Huang LW, Koll TT, Lee SM, Lin RJ, Pang L, Popat U, Weisdorf DJ, Artz AS. Cognitive Impairment Is Associated with Inferior Survival and Increased Non-Relapse Mortality in Older Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients: A Multicenter Retrospective Study. Blood 61st ASH Annual Meeting & Exposition 134(Supplement_1):4606, 2019. e-Pub 2019.
210. Olson AL, Lin R, Bdaiwi M, Thall PF, Rafei H, Kaur I, Li L, Abueg G, Timmons M, Chemaly R, Marinn D, Alousi AM, Ahmed S, Ciurea SO, Hosing C, Kebriaei P, Jones RB, Andersson BS, Oran B, Abuddayeh A, Popat U, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. Blood 61st ASH Annual Meeting & Exposition 134(Supplement_1):3596, 2019. e-Pub 2019.
211. Wang Y, Young KH, Milton DR, Ledesma C, Jabbour E, Xu-Monette Y, Molldrem JJ, Anderlini P, Alousi P, Alousi AM, Bashir Q, Daher M, Fayad LE, Iyer SP, Kebriaei P, Marin D, Mehta RS, Olson AL, Popat U, Samaniego F, Westin JR, Qazilbash MH, Im JS, Rondon G, Gulbis A, Champlin RE, Khouri IF. Clinical Relevance of MYC/BCL2 and Cell of Origin in Patients with Relapsed Diffuse Large B-Cell Lymphoma Treated with Autologous Stem Cell Transplantation. Blood 61st ASH Annual Meeting & Exposition 134(Supplement_1):2021, 2019. e-Pub 2019.
212. Short NJ, Rafei H, Daver NG, Hwang Y, Ning J, Cortes JE, Jorgensen JL, Kadia TM, DiNardo CD, Wang SA, Jabbour E, Popat U, Oran B, Konopleva MY, Garcia-Manero G, Borthakur GM, Bhalla KN, Issa GC, Kantarjian HM, Ravandi F. Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy. Blood 61st ASH Annual Meeting 134(Supplement_1):735, 2019. e-Pub 2019.
213. Kongtim P, Hasan O, Perez JMR, Varma A, Chen J, Rondon G, Srour S, Bashir Q, Qazilbash MH, Mehta R, Shpall EJ, Alousi AM, Khouri IF, Kebriaei P, Popat UR, Champlin RE, Ciurea SO. Development and validation of a novel disease risk model for patients with AML receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2019 ASCO Annual Meeting I 37(15_suppl):7016, 2019. e-Pub 2019.
214. Mehta R, Bassett R, Olson A, Chen J, Ganesh C, Alousi A, Anderlini P, Al-Atrash G, Bashir Q, Cirea S, Hosing C, Im J, Jones R, Kebriaei P, Khouri I, Marin D, Molldrem J, Nieto Y, Oran B, Rezvani K, Qazilbash M, Srour S, Shpall E, Andersson B, Champlin R, Popat U. Post-Transplant Cyclophosphamide in HLA Mached and Haploidentical Transplant Recipients Receiving Myeloablative Timed Sequential Busulfan Conditioning Regimen: Results of a Phase II Study. HemaSphere 24th EHA Congress 3(S1):706, 2019. e-Pub 2019.
215. Qazilbash M, Bashir Q, Milton D, Patel R, Popat U, Hosing C, Kebriaei P, Ciurea S, Konopleva M, Champlin R, Pammaraju N. Outcomes of autologous and allogeneic hematopoietic stem cell transplantation for BPDCN. HemaSphere 24th EHA Congress 3(S1):711-712, 2019. e-Pub 2019.
216. El Shazly M, Belal AA, Farouk M, Srour S, Popat U, Kebriaei P, Patel K, Mehta RS, Lee HC, Manasanch EE, Orlowski R, Champlin R, Qazilbash M, Bashir Q. Impact of different maintenace therapy options after autologous hematopoietic stem cell transplantation in multiple myeloma at MD Anderson Cancer Center. HemaSphere 24th EHA Congress 3(S1):636-637, 2019. e-Pub 2019.
217. Khouri I, Milton D, Young K, Ledesma C, Alousi A, Bashir Q, Ciurea S, Im J, Marin D, Mehta R, Alatrash G, Molldrem J, Olson Am Oran B, Popat U, Qazilbash M, Rondon G, Nastoupil L, Samaniego F, Fayad L, Hagemeister F, Medeiros LJ, Champlin R, Gulbis A. Rituximab-beam and autologous stem cell transplant (ASCT) for patients (PTS) with relapsed follicular lymphoma (FL) not able to receive an allogeneic sct: 8-year median follow-up results. HemaSphere 24th EHA Congress 3(S1):720, 2019. e-Pub 2019.
218. Srour SA, Saliba R, Popat U, Oran B, Mehta R, Kebriaei P, Bashir Q, Olson A, Chen J, Hosing C, Khouri I, Qazilbash M, Shpall E, Champlin R, Ciurea S. Haploidentical transplantation for acute myeloid leukemia patients with detectable disease at transplant. HemaSphere 24th EHA Congress 3(S1):272, 2019. e-Pub 2019.
219. Mukherjee A, Milton DR, Jabbour E, Konopleva M, Dinardo CD, Gulbis A, Ravandi F, Daver NG, Kadia TM, Oran B, Popat UR, Ciurea SO, Im J, Kebriaei P, Mehta RS, Kantarjian HM, Champlin RE, Khouri IF. Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with acute leukemia following venetoclax-based therapy. J Clin Oncol 2019 ASCO Annual Meeting 37(15_suppl):7047, 2019. e-Pub 2019.
220. Popat UR, Mehta RS, Bassett R, Olson AL, Alousi A, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing C, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Shpall EJ, Champlin RE, Andersson B. Post-transplant cyclophosphamide in matched and haploidentical transplant recipients receiving myeloablative timed sequential busulfan conditioning regimen: Results of a phase II study. J Clin Oncol 2019 ASCO Annual Meeting 37(15_suppl):7007, 2019. e-Pub 2019.
221. Srour SA, Milton D, Bashir Q, Mehta RS, Delgado R, Rondon G, Nieto Y, Hosing CM, Popat UR, Ciurea SO, Patel K, Lee HC, Manasanch E, Thomas S, Weber D, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan Dose Intensity for Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma. Biol Blood Marrow Transplant 2019 TCT Meetings of ASBMT & CIBMTR 25(3, Supplement):S21, 2019. e-Pub 2019.
222. Saini N, Saliba RM, Patel RD, Abdulrazzaq MN, Hosing CM, Alousi AM, Anderlini P, Popat UR, Qazilbash MH, Shpall EJ, Kebriaei P, Nastoupil LJ, Westin JR, Rondon G, Andersson BS, Champlin RE, Muzzafar TR, Nieto Y, Ahmed S. Does Cell of Origin Classification Impact Outcomes in Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplant. Biol Blood Marrow Transplant 2019 TCT Meetings of ASBMT & CIBMTR 25(3, Supplement):S394-S395, 2019. e-Pub 2019.
223. Popat UR, Saliba RM, Olson A, Mehta RS, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Molldrem JJ, Nieto Y, Oran B, Qazilbash MH, Rezvani K, Rondon G, Shpall EJ, Varma A, Andersson BS, Champlin RE. Comparison of Tacrolimus and Post-Transplant Cyclophosphamide (PTCy) with Tacrolimus and Methotrexate (Tac/MTX) Gvhd Prophylaxis in Patients with AML Undergoing Transplantation from Matched Related or Unrelated Donors. Biol Blood Marrow Transplant 2019 TCT Meetings of ASBMT & CIBMTR 25(3, Supplement):S235-S236, 2019. e-Pub 2019.
224. Szewczyk N, Neumann JL, Kruse B, Pang L, Ngo-Huang A, Ferguson J, Gale H, Adekoya L, Popat UR. Experience with Applying and Improving Feasibility of an Enhanced Recovery Model for Allogenic Stem Cell Transplant Patients Aged 65 and Older. Biol Blood Marrow Transplant 2019 TCT Meetings of ASBMT & CIBMTR 25(3, Supplement):S432, 2019. e-Pub 2019.
225. Mukherjee A, Milton D, Ledesma C, Olson A, Alatrash G, Anderlini P, Alousi AM, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Molldrem JJ, Oran B, Popat UR, Qazilbash MH, Rondon G, Champlin RE, Gulbis AM, Khouri IF. Influence of the Intensity of the Allogeneic Conditioning Regimen on the Risk of Hemorrhagic Cystitis (HC) in Patients Receiving Post- Transplant Cyclophosphamide (PT-Cy) As Gvhd Prophylaxis. Biol Blood Marrow Transplant 2019 TCT Meetings of ASBMT & CIBMTR 25(3, Supplement):S147-S148, 2019. e-Pub 2019.
226. Gupta V, Liu Y, Hu YL, Ahn KW, Alyea III EP, Popat UR, Sobecks RM, Scott BL, Saber W. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) with Antecedent History of Philadelphia-Negative Myeloproliferative Neoplasm with De Novo AML and with AML Arising from Myelodysplastic Syndrome: A Study from the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant 2019 TCT Meetings of ASBMT & CIBMTR 25(3, Supplement):S107, 2019. e-Pub 2019.
227. Saliba RM, Alousi AM, Andersson BS, Chen J, Mehta RS, Molldrem JJ, Champlin RE, Popat UR. Higher Pre-Transplant IL-2 Levels Correlate with Higher Incidence of Acute Graft-Versus-Host Disease. Biol Blood Marrow Transplant 2019 TCT Meetings of ASBMT & CIBMTR 25(3, Supplement):S245, 2019. e-Pub 2019.
228. Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Molldrem JJ, Shpall EJ, Andersson BJ, Champlin RE, Popat UR. Myeloablative Conditioning Using Timed Sequential Busulfan in Older Patients with Acute Myeloid Leukemia: Long Term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant 2019 TCT Meetings of ASBMT & CIBMTR 25(3, Supplement):S116-S117, 2019. e-Pub 2019.
229. Patel B, Sheshadri A, Saliba RM, Rondon G, Ahmed T, Arain MH, Mehta RS, Popat UR, Hosing CM, Bashoura L, Dickey BF, Champlin RE, Alousi AM. Azithromycin Exposure Following Hematopoietic Stem Cell Transplantation Is Associated with an Increased Risk of Cancer Relapse in Acute Leukemia. Biol Blood Marrow Transplant 2019 TCT Meetings of ASBMT & CIBMTR 25(3, Supplement):S231-S232, 2019. e-Pub 2019.
230. Varma A, Abraham SC, Saini N, Bashir Q, Rondon G, Srour SA, Mehta RS, Olson A, Oran B, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Marin D, Khouri IF, Ciurea SO, Qazilbash MH, Rezvani K, Shpall EJ, Champlin RE, Popat UR. Idiopathic Portal Hypertension Related Refractory Ascites (IPHRA) after Allogeneic Stem Cell Transplant. Biol Blood Marrow Transplant 2019 TCT Meetings of ASBMT & CIBMTR 25(3, Supplement):S144-S145, 2019. e-Pub 2019.
231. Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Popat U, Hosing C, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mukherjee A, Mehta RS, Khouri IF, Ciurea SO, Shpall EJ, Hasan O, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan-Based Autologous Transplantation in the Octogenarian Multiple Myeloma Patient Population. Blood 60th ASH Annual Meeting & Exposition 132(Supplement_1):4608, 2018. e-Pub 2018.
232. Varma A, Saini NY, Sui D, Milton DR, Hasan O, Mukherjee A, Bashir Q, Rondon G, Srour SA, Popat U, Hosing C, Nieto Y, Kebriaei P, Alousi AM, Mehta RS, Khouri IF, Weber DM, Thomas SK, Manasanch EE, Lee HC, Patel KK, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. Blood 60th ASH Annual Meeting & Exposition 132(Supplement_1):4609, 2018. e-Pub 2018.
233. Popat U, Mehta RS, Bassett Jr RL, Olson AL, Chen J, Ahmed S, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing C, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Shpall EJ, Champlin RE, Andersson BS. Timed Sequential Busulfan and Post-Transplantation Cyclophosphamide in Matched and Haploidentical Transplantation: Results of a Phase II Study. Blood 60th ASH Annual Meeting & Exposition 132(Supplement_1):3373, 2018. e-Pub 2018.
234. Santos, DMD, Saliba RM, Patel R, Bashir Q, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Lee HC, Manasanch EE, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Older Age As a Prognostic Factor for Overall Survival for Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Blood 60th ASH Annual Meeting & Exposition 132(Supplement_1):2144, 2018. e-Pub 2018.
235. Patel R, Saini NY, Varma A, Hasan O, Bashir Q, Delgado R, Popat U, Hosing C, Mukherjee A, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Outcome of Autologous Stem Cell Transplantation in Waldenström's Macroglobulinemia. Blood 60th ASH Annual Meeting & Exposition 132(Supplement_1):2149, 2018. e-Pub 2018.
236. Oran B, Ciurea SO, Marin D, McCarty JM, Bashir Q, Ahmed S, Olson AL, Popat U, Nieto Y, Kebriaei P, Shpall EJ, Agrawal T, Champlin RE. Safety Analysis of Intra-Patient Dose- Study of Crenolanib Maintenance Therapy in Patients with FLT3 Mutant AML Following Allogeneic Hematopoietic Stem Cell Transplant. Blood 60th ASH Annual Meeting & Exposition 132(Supplement_1):3426, 2018. e-Pub 2018.
237. Kongtim P, Parmar S, Milton DR, Perez JMR, Rondon G, Chen J, Chilkulwar A, Alatrash G, Alousi AM, Andersson BS, Im JS, Hosing C, Bashir Q, Khouri IF, Kebriaei P, Oran B, Popat U, Champlin RE, Ciurea SO. Hematopoietic Cell Transplant-Composite Risk (HCT-CR) — a Novel Prognostic Model to Predict Transplant Outcomes. Blood 60th ASH Annual Meeting & Exposition 132(Supplement_1):2141, 2018. e-Pub 2018.
238. Daher M, Cao K, Basar R, Marin D, Sekine T, Rondon G, Zhao W, Smith NT, Wang Q, Li L, Saliba RM, Pingali SRK, Popat U, Hosing C, Olson AL, Oran B, Mehta RS, Champlin RE, Shpall EJ, Rezvani K. Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation after Double Cord Blood Transplantation. Blood 60th ASH Annual Meeting and Exposition 132(Supplement_1):2077, 2018. e-Pub 2018.
239. Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Oran B, Hosing C, Bashir Q, Olson AL, Nieto, Y Alousi AM, Kebriaei P, Srour S, Mehta RS, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad LE, Lee HJ, Fowler NH, Parmar S, Westin JR, Hagemeister FB, Champlin RE, Ciurea SO. Allogeneic Transplantation for Lymphoid Malignancies with Fludarabine and Melphalan Conditioning and Different Donor Types. Blood 60th ASH Annual Meeting & Exposition 132(Supplement_1):3356, 2018. e-Pub 2018.
240. Khouri IF, Milton DR, Ledesma C, Jabbour EJ, Alatrash G, Anderlini P, Alousi AM, Bashir Q, Ciurea SO, Hymes S, Marin D, Molldrem JJ, Olson AL, Oran B, Popat U, Qazilbash MH, Rondon G, Champlin RE, Gulbis A. Influence of the Intensity of the Conditioning Regimens on the Risks of Gvhd in Patients Receiving Rituximab Prophylaxis during Allogeneic Stem Cell Transplantation (alloSCT). Blood 60th ASH Annual Meeting & Exposition 132(Supplement_1):4584, 2018. e-Pub 2018.
241. Ciurea SO, Bittencourt CB, Milton DR, Cao K, Kongtim P, Rondon G, Chen J, Konopleva MY, Perez JMR, Elshazly M, Aljadayeh M, Alvarez M, Im JS, Alatrash G, Mehta RS, Popat U, Bashir Q, Oran B, Hosing C, Khouri IF, Kebriaei P, Champlin RE. Is a Matched Unrelated Donor Search Needed for All Allogeneic Transplant Candidates?. Blood 60th ASH Annual Meeting & Exposition 132(Supplement_1):3450, 2018. e-Pub 2018.
242. Senyak Z, Mesa RA, Kroeger N, Besien KV, Saber W, Silver RT, Orazi A, Palmer J, Harrison CN, Verstovsek S, Popat U, Woerhle MJ, Brazeau A, Husen BV, Prager M, Harper C, Larroque B, Scherber RM. Results from the Myeloproliferative Neoplasm Patient Care Survey: Patient Care Opportunities and Challenges. Blood 60th ASH Annual Meeting & Exposition 132(Supplement_1):4289, 2018. e-Pub 2018.
243. Saini NY, Patel RD, Varma A, Bashir Q, Hasan O, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Long-Term Durable Responses after Autologous Stem Cell Transplantation in POEMS Syndrome. Blood 60th ASH Annual Meeting & Exposition 132(Supplement_1):4606, 2018. e-Pub 2018.
244. Nazha A, Hu ZH, Wang T, Hamilton BK, Majhail NS, Lindsley RC, Sobecks R, Popat U, Scott BL, Saber W. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes: On Behalf of the CIBMTR Chronic Leukemia Committee. Blood 60th ASH Annual Meeting & Exposition 132(Supplement_1):206, 2018. e-Pub 2018.
245. Lin P, Veltri LW, Rezvani K, Oran B, Ahmed S, Alatrash G, Mehta RS, Rondon G, Kebriaei P, Popat U, Nieto Y, Hosing C, Jones RB, Qazilbash MH, Khouri IF, Shpall EJ, Champlin RE, Marin D. Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. Blood 60th ASH Annual Meeting & Exposition 132(Supplement_1):4667, 2018. e-Pub 2018.
246. Saini NY, Varma A, Ma J, Milton DR, Patel R, Hasan O, Bashir Q, Nieto Y, Mukherjee A, Delgado R, Rondon G, Popat U, Hosing C, Kebriaei P, Alousi AM, Ahmed S, Mehta RS, Ciurea SO, Khouri IF, Shpall EJ, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of t(11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis. Blood 60th ASH Annual Meeting and Exposition 132(Supplement_1):4607, 2018. e-Pub 2018.
247. Gowin KL, Ballen KK, Ahn KW, Hu ZH, Liu Y, Masarova L, Verstovsek S, Coakley M, Jain T, Kuykendall A, Komrokji R, Wadleigh M, Patches S, Arcasoy M, Green M, Kandarpa M, Talpaz M, Ali H, Gupta V, Devlin R, Michaelis LC, Hobbs GS, Stein BL, Pariser A, Gerds AT, Kuber K, Rampal R, Alyea III EP, Popat U, Sobecks R, Scott BL, Mesa R, Saber W. Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score. Blood 60th ASH Annual Meeting & Exposition 132(Supplement_1):4288, 2018. e-Pub 2018.
248. Khouri IF, Milton DR, Ledesma C, Erwin WD, Jabbour EJ, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Im JS, Marin D, Mehta RS, Molldrem JJ, Olson AL, Oran B, Popat U, Qazilbash MH, Rondon G, Champline RE, Medeiros J, Gulbis A. Durability Results of Non-Myeloablative (NMA) Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed Follicular Lymphoma: 17- Year Experience. Blood 60th ASH Annual Meeting & Exposition 132(Supplement_1):4651, 2018. e-Pub 2018.
249. Schmidt SA, Chakrabarty JH, Liu Y, Hu ZH, Williams KM, Alyea III EP, Popat U, Sobecks R, Scott BL, Saber W. Tyrosine Kinase Inhibitors with or without Donor Lymphocyte Infusion Continue to Provide Long-Term Survival after Relapse of Chronic Myeloid Leukemia Following Hematopoietic Cell Transplantation. Blood 60th ASH Annual Meeting and Exposition 132(Supplement_1):704, 2018. e-Pub 2018.
250. Oran B, Garcia-Manero G, Saliba RM, Alatrash G, Jabbour EJ, Popat U, Ravandi F, Kadia TM, Cortes JE, Alousi AM, Konopleva MY, DiNardo CD, Rezvani K, Alfayez M, Shpall EJ, Sharma P, Champlin RE, Kantarjian HM, Daver NG. Post Allogeneic Stem Cell Transplant (SCT) Cyclophosphamide Improves Progression Free Survival (PFS) in Pts with AML/MDS Treated with CTLA-4 or PD-1 Blockade Prior to SCT. Blood 60th ASH Annual Meeting & Exposition 132(Supplement_1):483, 2018. e-Pub 2018.
251. Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Alousi AM, Hosing C, Kebriaei P, Popat U, Giralt S, Ahmed S, Shpall EJ, Andersson BS, Bashir Q, Ciurea SO, Rezvani K, Woodworth G, Champlin RE. Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. Blood 60th ASH Annual Meeting & Exposition 132(Supplement_1):971, 2018. e-Pub 2018.
252. Zhang X, Sun M, Geng Y, Dinney CPN, Popat UR, Champlin RE, Valero V, Tripathy D, Hedberg AM, Stroehlein JR, Edwards BJA. Malnutrition and overall survival in older patients with cancer. J Clin Oncol 2018 ASCO Annual Meeting 36(15_suppl):e22015, 2018. e-Pub 2018.
253. Oran B, Ciurea S, Marin D, McCarty J, Bashir Q, Ahmed S, Olson A, Popat U, Nieto Y, Kebriaei, Shpall E, Agrawal T, Champlin R. Intra-patient dose-escalation study of crenolanib maintenance therapy in patients with FLT3 mutant AML who had undergone allogeneic hematopoietic stem cell transplant (allo-hsct). HemaSphere 23rd EHA Congress, 2018. e-Pub 2018.
254. Qazilbash M, Bashir Q, Thall P, Milton D, Shah N, Patel K, Andersson B, Nieto Y, Kebriaei P, Valdez B, Kawedia J, Parmar S, Delgado R, Ahmed S, Hosing C, Popat U, Shpall E, Weber D, Thomas S, Manasanch E, Lee H, Orlowski R, Champlin R. Busulfan + Melphalan was associated with a longer PFS compared to melphalan alone in high-risk multiple myeloma in a randomized phase 3 clinical trial. HemaSphere 23rd EHA Congress, 2018. e-Pub 2018.
255. Popat U, Bassett R, Aung F, Valdez B, Ahmed S, Alousi A, Bashir Q, Hosing C, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash M, Rezvani K, Mehta R, Shpall EJ, Ciurea S, Andersson B, Champlin R. Eltrombopag to improve platelet recovery in haploidentical stem cell transplants (Haplo-SCT): Results of a Phase II Trial Plus a Comparison to Control Patients. HemaSphere 23rd EHA Congress, 2018. e-Pub 2018.
256. Edwards BJA, Zhang X, Pang L, Sun M, Geng Y, Hedberg AM, Tripathy D, Champlin R, Popat UR, Dinney CPN. Vitamin D deficiency in older cancer patients with solid tumors, effect on overall survival. J Clin Oncol 2018 ASCO Annual Meeting 36(15_suppl):e22038, 2018. e-Pub 2018.
257. Abudayyeh A, Abdelrahim M, Lin HY, Page VD, Rondon G, andersson B, Martinez C, Kontoyiannis DP, Marin D, Gaber AO, Oran B, Chemaly R, Olson AL, Jones RB, Popat UR, Shpall EJ, Rezvani K. Development and validation of a risk assessment tool for symptomatic BKV infection. J Clin Oncol 2018 ASCO Annual Meeting 36(15_suppl):7057, 2018. e-Pub 2018.
258. Srour SA, Desai P, Ciurea SO, Bashir Q, Olson A, Ahmed S, Bose P, Mehta RS, Pemmaraju N, Alousi AM, Verstovsek S, Champlin RE, Popat UR. Immunosuppression Withdrawal is an Effective Treatment of Relapse after Allogeneic Stem Cell Transplant for Myelofibrosis. Biol Blood Marrow Transplant 2018 BMT Tandem Meetings 24(3, Supplement):S196-S197, 2018. e-Pub 2018.
259. Qazilbash MH, Milton D, Bashir Q, Shah N, Nieto Y, Popat UR, Mehta RS, Kebriaei P, Delgado R, Rondon G, Weber D, Thomas S, Lee HC, Manasanch E, Patel K, Orlowski RZ, Champlin RE. Continuing Improvement in the Outcome of Patients with Multiple Myeloma Undergoing Auto-HCT Over Three Decades. Biol Blood Marrow Transplant 2018 BMT Tandem Meetings 24(3, Supplement):S50-S51, 2018. e-Pub 2018.
260. Bashir Q, Milton D, Popat UR, Oran B, Nieto Y, Kebriaei P, Ciurea SO, Ahmed S, Mehta RS, Olson A, Parmar S, Alatrash G, Hosing CM, Shah N, Patel K, Weber D, Thomas S, Manasanch E, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Maintenance Therapy in High-Risk Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2018 BMT Tandem Meetings 24(3, Supplement):S254, 2018. e-Pub 2018.
261. Shah MV, Saliba RM, Ciurea SO, Oran B, Olson A, Bose P, Bashir Q, Ahmed S, Alousi AM, Mehta RS, Pemmaraju N, Verstovsek S, Popat UR. Transplant Outcomes for Patients with Secondary Acute Myeloid Leukemia (AML) Arising From Myeloproliferative Neoplasms (MPN). Biol Blood Marrow Transplant 2018 BMT Tandem Meetings 24(3, Supplement):S322-S323, 2018. e-Pub 2018.
262. Kongtim P, Parmar S, Milton D, Rondon G, Chen J, Oran B, Popat UR, Hosing CM, Bashir Q, Kebriaei P, Khouri IF, Champlin RE, Ciurea SO. Validation of a Predictive Model for Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome Receiving Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2018 BMT Tandem Meetings 24(3, Supplement):S107, 2018. e-Pub 2018.
263. Brammer JE, Valdez BC, Champlin RE, Andersson BS, Popat UR, Hosing CM. Romidepsin (Rom) in Combination with Fludarabine (Flu) and Busulfan (Bu) Conditioning Followed by Rom Maintenance in Patients with T-Cell Malignancies Receiving Allogeneic Stem Cell Transplant (Allo-SCT): Early Results of a Phase I/II Trial. Biol Blood Marrow Transplant 2018 BMT Tandem Meetings 24(3, Supplement):S262-S263, 2018. e-Pub 2018.
264. Gowda L, Alijadayeh M, Marin DC, Ledesma C, Rondon G, Popat U, Alousi AM, Oran B, Shah MV, Ahmed S, Kanagal-Shamanna R, Ciurea SO, Shpall EJ, Luthra R, Hosing C, Qazilbash MH, Rezvani K, Jabbour EJ, Patel KP, Ravandi F, Kantarjian HM, Champlin RE, Kebriaei P. Early Maintenance with Tyrosine Kinase Inhibitors Post Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Improves Survival in Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. Blood 59th ASH Annual Meeting 130(Supplement 1):1992, 2017. e-Pub 2017.
265. Qazilbash MH, Bashir Q, Thall PF, Milton DR, Shah N, Patel KK, Andersson BS, Nieto Y, Kebriaei P, Valdez BC, Kawedia J, Parmar S, Delgado R, Ahmed S, Hosing C, Popat U, Shpall EJ, Weber DM, Thomas SK, Manasanch EE, Lee HC, Orlowski RZ, and Champlin RE. A Randomized Phase III Trial of Busulfan + Melphalan Vs Melphalan Alone for Multiple Myeloma. Blood 59th ASH Annual Meeting 130(Supplement 1):399, 2017. e-Pub 2017.
266. Pemmaraju N, Carter BZ, Kantarjian HM, Bose P, Kadia T, Jabbour EJ, DiNardo CD, Daver N Estrov Z, Cortes JE, Garcia-Manero G, Zhou L, Mak PY, Salinas K, Tuttle CK, Pierce S, Popat U, Verstovsek S. Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis. Blood 59th ASH Annual Meeting 130(Supplement 1):256, 2017. e-Pub 2017.
267. Oran B, Saliba RM, Jorgensen JL, Shah MV, Marin DC, Wang SA, Ahmed S, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Rezvani K, Popat U, Rondon G, Kebriaei P, Shpall EJ, Champlin RE. The Prognostic Impact of Minimal Residual Disease on Risk of Progression and Progression Free Survival in Acute Myeloid Leukemia. Blood 59th ASH Annual Meeting 130(Supplement 1):2031, 2017. e-Pub 2017.
268. Chhabra S, Ahn KW, Hu ZH, Jain S, Stuart RK, Kalaycio M, Popat U, Sobecks R, Alyea III E, Saber W. Comparison of Outcomes after Myeloablative Versus Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia. Blood 59th ASH Annual Meeting 130(Supplement 1):600, 2017. e-Pub 2017.
269. Kim HT, Hu ZH, Ahn KW, Davids M, Volpe V, Alyea E, Popat U, Sobecks R, Saber W, Brownn J. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocyteic Leukemia Patients Who Underwent Reduced Intensity Conditioning Allogeneit HCT: A CIBMTR Report. Blood 59th ASH Annual Meeting 130(Supplement 1):667, 2017. e-Pub 2017.
270. Kongtim P, Parmar S, Milton DR, rondon G, Chen J, Oran B, Popat U, Hosing C, Bashir Q, Kebriaei P, Khouri IF, Champlin RE, Ciurea SO. Validation of a Predictive Model for Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome Receiving Hematopoietic Stem Cell Transplantation. Blood 59th ASH Annual Meeting 130(Supplement 1):4511, 2017. e-Pub 2017.
271. Srour SA, Desai P, Ciurea SO, Bashir Q, Oran B, Olson AL, Ahmed S, bose P, Mehta RS, Pemmaraju N, Verstovsek S, Champlin RE, Popat U. Myeloid Mixed Chimerism and Relapse in Myelofibrosis after Allogeneic Stem Cell Transplant. Blood 59th ASH Annual Meeting 130(Supplement 1):2007, 2017. e-Pub 2017.
272. Ciurea SO, Soebbing D, Rondon G, Cao K, Alatrash G, Ahmed S, Popat U, Oran B, Bashir Q, Kebriaei P, Kaur I, Rezvani K, Shpall EJ, Lee DA, Champlin RE. Interim Results of a Phase 2 Clinical Trial Using Mb-IL21 Ex Vivo Expanded NK Cells to Enhance Graft Versus Leukemia Effect for Patients with Myeloid Malignancies after Haploidentical Transplantation. Blood 59th ASH Annual Meeting 130(Supplement 1):3179, 2017. e-Pub 2017.
273. Hu B, Lin X, Lee HC, Huang X, Slack R, Jabbour EJ, Verstovsek S, Ravandi F, Garcia-Manero G, Champlin RE, Hu ZH, Ahn KW, Lee Y, Popat U, Sobecks R, Alyea E, Kantarjian HM, Cortes JE, Saber W. Optimal Timing of Allogeneic Stem Cell Transplantation (Allo-SCT) for Chronic Myeloid Leukemia (CML) Patients in the Tyrosine Kinase Inhibitor (TKI) Era. Blood 59th ASH Annual Meeting 130(Supplement 1):4582, 2017. e-Pub 2017.
274. Nieto Y, Thall PF, Valdez BC, Ma J, Timmons M, Trapp M, Ahmed S, Shpall EJ, Jones RB, Hosing C, Anderlini P, Popat U, Qazilbash MH, Alousi A, Gulbis A, Ledesma C, Champlin RE, Andersson BS. Gemcitabine/Clofarabine/Busulfan: A New Myeloablative Reduced-Toxicity Conditioning Regimen with High Activity for Allogeneic Stem-Cell Transplant (alloSCT) in Aggressive Lymphomas. Blood 59th ASH Annual Meeting 130(Supplement 1):1966, 2017. e-Pub 2017.
275. Ciurea SO, Saliba RM, Chen J, Rondon G, Popat U, Parmar S, Andersson B, Alousi AM, Ahmed S, Bashir Q, Alatrash G, Hosing C, Olson AL, Mehta RS, Rezvani K, Shpall EJ, Khouri IF, Kebriaei P, Champlin RE. Allogeneic Transplantation for TP53+ AML: Prognostic Factors for Survival. Blood 59th ASH Annual Meeting 130(Supplement 1):1938, 2017. e-Pub 2017.
276. Oran B, Garcia-Manero G, Saliba RM, Alatrash G, Jabbour EJ, Popat U, Ravandi F, Alousi AM, Kadia T, Konopleva M, DiNardo CD, Pierce S, Rezvani K, Shpall EJ, Sharma P, Champlin RE, Kantarjian HM, Daver N. Post-Transplant Cyclophosphamide Improves Progression Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients with Prior CTLA-4 or PD-1 Blockade. Blood 59th ASH Annual Meeting 130(Supplement 1):3209, 2017. e-Pub 2017.
277. Kebriaei P, Huls H, Olivares S, Orozco AF, Su S, Maiti SN, de Groot E, Smith A, Yang Y, Rondon G, Qazilbash MH, Ciurea SO, Alousi AM, Nieto Y, Marin DC, Popat U, Hosing C, Kantarjian HM, Rezvani K, Shpall EJ, Champlin RE, Cooper LJN, Singh H. Long Term Follow up after Adoptive Transfer of CD19-Specific CAR+ T Cells Genetically Modified Via Non-Viral Sleeping Beauty S ystem Following Hematopoietic Stem Cell Transplantation (HSCT). Blood 59th ASH Annual Meeting 130(Supplement 1):2059, 2017. e-Pub 2017.
278. Gowda L, Saliba RM, Shah MV, Rondon G, Badar I, Olson AL, Ciurea SO, Kebriaei P, Srour SA, Parmar S, Nieto Y, Ahmed S, Mehta RS, Alatrash G, Marin DC, Andersson BS, Oran B, Bashir Q, Qazilbash MH, Hosing C, Khouri IF, Alousi AM, Anderlini P, Shpall EJ, Champlin RE, Popat U. Graft Failure Post Allogeneic Stem Cell Transplant: Conditioning Regimen Improves Engraftment and Survival. Blood 59th ASH Annual Meeting 130(Supplement 1):3267, 2017. e-Pub 2017.
279. Oran B, Garcia-Manero G, Saliba RM, Al-Atrash G, Jabbour E, Popat U, Ravandi F, Alousi A, Kadia T, Konopleva M, Dinardo C, Rezvani K, Shpall EJ, Sharma P, Champlin RE, Kantarjian HM, Daver N. Improved Acute Graft-versus Host Disease (aGVHD) and Progression Free Survival with Post-Transplant Cyclophosphamide in AML/MDS Patients (pts) with Prior CTLA-4 or PD-1 Blockade. Clin Lymphoma Myeloma Leuk XXVIII International Association for Comparative Research on Leukemia & Related Diseases Symposium Meeting 17(10_Supplement):S11, 2017. e-Pub 2017.
280. Ciurea S, Saliba R, Shah M, Gaballa S, Rondon G, Chen J, Gulbis A, Wallis W, Oran B, Alousi A, Bashir Q, Ahmed S, Marin D, Rezvani K, Shpall E, Qazilbash M, Popat U, Khouri I, Hosing C, Kebriaei P, Daver N, Konopleva M, Pemmaraju N, Ravandi F, Cortes J, Kantarjian H, Champlin R. Haploidentical transplantation is safe and effective for older patients with AML/MDS. HemaSphere 22nd EHA Congress, 2017. e-Pub 2017.
281. Kebriaei P, Saliba R, Wallis W, Garris R, Ledesma C, Rondon G, Popat U, Alousi A, Ahmed S, Oran B, Shpall E, Ciurea S, Ravandi F, Rezvani K, Marin D, Champlin R, Kantarjian H, Jabbour E. Predictive factors for developing veno-occlusivie disease in patients with acute lymphoblastic leukemia treated with inotozumab ozogamicin followed by allogeneic hematopoietic stem cell transplantation. HemaSphere 22nd EHA Congress, 2017. e-Pub 2017.
282. Edwards BJA, Zhang X, Sun M, Song J, Dinney CPN, Popat UR, Champlin RE, Valero V, Tripathy D, Hedberg AM, Stroelein JR. Prognostic significance of geriatric assessment. J Clin Oncol 2017 ASCO Annual Meeting 35(15_suppl):e18140, 2017. e-Pub 2017.
283. Popat UR, Saliba R, Oran B, Ahmed S, Alousi AM, Bashir Q, Ciurea SO, Hosing C, Kebriaei P, Khouri IF, Marin D, Nieto Y, Olson AL, Qazilbash MH, Rezvani K, Valdez B, Jones RB, Shpall EJ, Andersson B, Champlin RE. Better Survival With Fludarabine And Timed Sequential Busulfan Regimen In Older Patients with AML/MDS. J Clin Oncol 2017 ASCO Annual Meeting 35(15_suppl):7046, 2017. e-Pub 2017.
284. Ambinder RF, Wu J, Logan B, Durand C, Shields, R, Popat UR, Little RF, Mcmahon D, Mellors JW, Ayala E, Kaplan LD, Noy A, Howard A, Forman SJ, Mendizabal AM, Horowitz MM, Navarro WH, Alvarnas JC. Allogeneic hematopoietic cell transplant (alloHCT) for hematologic malignancies in human immunodeficiency virus infected (HIV) patients (pts): Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0903)/AIDS Malignancy Consortium (AMC-080) trial. J Clin Oncol 2017 ASCO Annual Meeting 35(15_suppl):7006, 2017. e-Pub 2017.
285. Shah MV, Patel KP, Luthra R, Shamanna RK, Mehrotra M, Champlin RE, Verstovsek S, Popat UR. Real Time PCR Detects Relapse of JAK2 V617F Myelofibrosis Earlier Than Pyrosequencing after Allogeneic Transplantation. Biol Blood Marrow Transplant 2017 BMT Tandem Meetings 23(3, Supplement):S298-S299, 2017. e-Pub 2017.
286. Shah MV, Saliba RM, Jorgensen JL, Wang SA, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Patel KP, Popat UR, Rezvani K, Rondon G, Shpall EJ, Champlin RE, Oran B. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia Patients. Biol Blood Marrow Transplant 2017 BMT Tandem Meetings 23(3, Supplemental):S40-S41, 2017. e-Pub 2017.
287. Hill L, Saliba RM, Chen J, Rondon G, Qazilbash MH, Popat UR, Shah N, Neumann JL, Hymes SR, Hosing CM, Kebriaei P, Oran B, Nieto Y, Olson A, Ciurea SO, Marin D, Champlin RE, Shpall EJ, Alousi AM. Predictors for Steroid Tapering in Patients with Acute Graft-Versus-Host Disease and Their Impact on Graft-Versus-Host Disease Response and Non-Relapse Mortality: Older Age and Co-Morbidities Are Associated with Quicker Tapering and Worse Outcomes. Biol Blood Marrow Transplant 2017 BMT Tandem Meetings 23(3, Supplement):S371, 2017. e-Pub 2017.
288. Nieto Y, Bassett R, Ahmed S, Anderlini P, Hosing CM, Popat UR, Andersson BS, Valdez BC, Shpall EJ, Qazilbash MH, Kebriaei P, Alousi AM, Guillermo M, Oki Y, Fanale MA, Hagemeister F, Dabaja B, Pinnix C, Milgrom S, Champlin RE, Jones RB. Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem Cell Transplant (ASCT) in Hodgkin's Lymphoma Patients at High Risk of Post-Transplant Recurrence—Comparison with a Concurrent Matched Cohort. Biol Blood Marrow Transplant 2017 BMT Tandem Meetings 23(3, Supplement):S268, 2017. e-Pub 2017.
289. Maymani H, Popat UR, Bashir Q, Shah N, Patel K, Parmar S, Kebriaei P, Hosing CM, Ciurea SO, Andersson BS, Shpall EJ, Champlin RE, Qazilbash MH. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biol Blood Marrow Transplant 2017 BMT Tandem Meetings 23(3, Supplement):S289-S290, 2017. e-Pub 2017.
290. Zhang X, Sun M, Shah JB, Dinney CPN, Popat UR, Champlin RE, Valero V, Tripathy D, Hedberg AM, Edwards BJA. Prevalence of vitamin D insufficiency and falls in older cancer patients. 2017 Cancer Survivorship Symposium 35(5_suppl):138, 2017. e-Pub 2017.
291. Hosing C, Mohyuddin GR, Faisal MS, Bashir Q, Shah N, Patel K, Popat U, Parmar S, Rondon G, Weber D, Delgado R, Manasanch EE, Thomas S, Orlowski R, Champlin R, Qazilbash M. A Case Control Study of Syngeneic Transplantation Versus Autologous Transplantation for Multiple Myeloma: Two Decades of Experience at MD Anderson. Clin Lymphoma Myeloma Leuk 16th International Myeloma Workshop 17(1, Supplement):e8, 2017. e-Pub 2017.
292. Makowski M, Ahmed E, Schlotter S, Pearson R, Kitzler R, Alvarnas JC, Rademacher JL, Wang Y, Little RF, Akpek G, Ayala E, Devine SM, Kaplan LD, Noy A, Popat UR, Hsu JW, Morris LE, Thompson J, Horowitz MH, Mendizabal AM, Levine AM, Krishnan A, Hade E, Hofmesiter CC, Forman SJ, Navarro WH, Ambinder RF, Lozanski G, Baiocchi RA. Evaluation of Immune Recovery Following Autologous Hematopoietic Cell Transplantation in HIV-Related Lymphoma: Results of the BMT CTN 0803/AMC 071 Trial. Blood 58th ASH Annual Meeting 128(22):1346, 2016. e-Pub 2016.
293. Bashir Q, El Shazly M, Milton DR, Patel K, Shah N, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea SO, Hosing C, Lee H, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Autologous Stem Cell Transplantation in Myeloma Patients Aged ≥ 75 Years. Blood 58th ASH Annual Meeting 128(22):3453, 2016. e-Pub 2016.
294. Hill BT, Ahn KW, Hu ZH, Kalaycio M, Maziarz RT, Cortes JE, Alyea E, Popat UR, Soebecks RM, Saber W. Assessment of Human Leukocyte Antigen (HLA) Type on Outcomes of Allogeneic Transplant for Chronic Lymphocytic Leukemia (CLL). Blood 58th ASH Annual Meeting 128(22):2256, 2016. e-Pub 2016.
295. Srour SA, Saliba RM, Delgado R, Qazilbash MH, Bashir Q, Shah N, Popat UR, Ahmed S, Patel K, JOnes R, Rondon G, Champlin RE, Nieto Y. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Blood 58th ASH Annual Meeting 128(22):3314, 2016. e-Pub 2016.
296. Masarova L, Popat UR, Bose P, Champlin RE, Cortes JE, Kantarjian HM, Verstovsek S. Allogeneic Stem Cell Transplantation Versus Medical Therapy in Patients with Advanced Myelofibrosis: Matched Survival Analysis and the Effect of JAK2 Inhibitor Therapy. Blood 58th ASH Annual Meeting 128(22):4687, 2016. e-Pub 2016.
297. Cerrada SL, Marin D, Rondon G, Ledesma C, Popat UR, Olson A, Alousi A, Oran B, Ahmed S, Ciurea SO, Patel K, Shpall EJ, Hosing C, Qazilbash MH, Shah N, Rezvani K, Jabbour E, Kantarjian HM, Champlin RE, Kebriaei P. Additional Consolidation after Attaining Second Complete Remission Results in Superior Outcomes after Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia. Blood 58th ASH Annual Meeting 128(22):4680, 2016. e-Pub 2016.
298. Yucel OK, Saliba RM, Rondon G, Ahmed S, Alousi A, Bashir Q, Ciurea SO, Popat UR, Marin D, Rezvani K, Kebriaei P, Shpall EJ, Champlin RE, Oran B. Hematopoietic Stem Cell Transplantation with Reduced Intensity Conditioning in Older Patients with Myelodysplastic Syndromes. Blood 58th ASH Annual Meeting 128(22):5847, 2016. e-Pub 2016.
299. Cornelison AM, Saliba RM, Ahmed S, Nieto Y, Bashir Q, Shah N, Parmar S, Patel K, Hosing C, Popat UR, Shpall EJ, Champlin RE, Qazilbash MH. Durable Remission and Survival in Relapsed/Refractory Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation. Blood 58th ASH Annual Meeting 128(22):5884, 2016. e-Pub 2016.
300. Kongtim P, Adekola KUA, Milton DR, Ramlal R, Jimenez AM, Chen J, Rondon G, Ahmed S, Oran B, Popat UR, Cortes J, Champlin RE, Ciurea SO. Haploidentical Donors in Addition to Transplantation in Chronic Phase Associate with Improved Gvhd-Free Relapse-Free Survival (GRFS) for Patients with Advanced CML. Blood 58th ASH Annual Meeting 128(22):4583, 2016. e-Pub 2016.
301. Mohyuddin CR, Faisal MS, Shah N, Bashir Q, Hosing C, Patel K, Popat UR, Parmar S, Rondon G, Delgado R, Weber DM, Shah JJ, Thomas S, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. A Case Control Study of Syngeneic Transplantation Versus Autologous Transplantation for Multiple Myeloma: Two Decades of Experience at MD Anderson. Blood 58th ASH Annual Meeting 128(22):4613, 2016. e-Pub 2016.
302. Chihara D, Kantarjian HM, Newberry KJ, Ravandi F, Ng D, Bose P, DiNardo CD, Pemmaraju N, Kadia TM, Borthakur G, Konopleva M, Garcia-Manero G, Popat UR, Cortes JE, Verstovsek S. Survival Outcome of Patients with Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms. Blood 58th ASH Annual Meeting 128(22):1940, 2016. e-Pub 2016.
303. Shah N, Thall PF, Milton DR, Bashir Q, Parmar S, Lin P, Kebriaei P, Nieto Y, Popat UR, Hosing C, Cornelison A, Delgado R, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Phase I/II Trial of Lenalidomide and High-Dose Melphalan with Autologous Stem Cell Transplantation for Relapsed Myeloma: Updated Results. Blood 58th ASH Annual Meeting 128(22):2269, 2016. e-Pub 2016.
304. Srour SA, Khouri IF, Lozano-Cerrada S, Nieto Y, Alousi M, Popat UR, Qazilbash MH, Anderlini P, Kebriaei P, Shpall EJ, Champlin RE, Hosing C. Rituximab Combined with BEAM and Autologous Stem Cell Transplantation for Older Patients with Relapsed Aggressive B-Cell Lymphomas. Blood 58th ASH Annual Meeting 128(22):2270, 2016. e-Pub 2016.
305. Oran B, Muftuoglu M, Kaur I, Li L, Yvon E, Abueg G, Bassett R, Thall PF, Marin D, Alousi AM, Ahmed S, Ciurea SO, Shah N, Hosing C, Olson AL, Parmar S, JOnes R, Popat UR, Andersson BS, Champlin RE, Shpall EJ, Rezvani K. Most Closely HLA-Matched Third Party Allogeneic CMV Specific T-Cells Generated Using the Cytokine Capture System for the Treatment of CMV Infections after Allogeneic Stem Cell Transplantation. Blood 58th ASH Annual Meeting 128(22):4547, 2016. e-Pub 2016.
306. Cerrada SL, Marin D, Rondon G, Ledesma C, Popat UR, Olson AL, Alousi AM, Oran B, Ahmed S, Ciurea SO, Patel K, Shpall EJ, Hosing C, Qazilbash MH, Shah N, Rezvani K, Jabbour E, Kantarjian HM, Champlin RE, Kebriaei P. Impact of New Anti-Leukemia Agents on Transplant Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) in Second Complete Remission. Blood 58th ASH Annual Meeting 128(22):4676, 2016. e-Pub 2016.
307. Veltri LW, Milton DR, Shah N, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea SO, Hosing C, Lee H, Manasanch EE, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Outcome of Autologous Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Multiple Myeloma. Blood 58th ASH Annual Meeting 128(22):4626, 2016. e-Pub 2016.
308. Ciruea SO, Lee DA, Denman C, Schafer J, Bassett Jr RL, Cao K, Rondon G, Chen J, Soebbing D, Willis DB, Ahmed S, Bashir Q, Kebriaei P, Khouri IF, Oran B, Parmar S, Popat UR, Hosing C, Yvon E, Rezvani K, Shpall EJ, Champlin RE. Safety and Feasibility of Administration of High Doses of Ex Vivo Expanded NK Cells for Prevention of Disease Relapse after Transplantation for Patients with Myeloid Malignancies - Final Results of a Phase I Clinical Trial. Blood 58th ASH Annual Meeting 128(22):500, 2016. e-Pub 2016.
309. Olson AL, Muftuoglu M, Kaur I, Li L, Abueg G, Chemaly R, Yvon E, Thall PF, Marin D, Alousi AM, Ahmed S, Ciurea SO, Hosing C, Kebriaei P, Jones R, Andersson BS, Shah N, Oran B, Abudayyeh A, Popat UR, Champlin RE, Shpall EJ, Rezvani K. Efficacy of Third Party BK Virus (BKV) Specific Cytotoxic T-Lymphocytes Generated By Ex Vivo Expansion for the Treatment of BKV Infection in Stem Cell Transplant Recipients, a Phase 2 Trial. Blood 58th ASH Annual Meeting 128(22):504, 2016. e-Pub 2016.
310. Kebriaei P, Wei W, Thall PF, Ledesma C, Valdez BC, Popat UR, Olson AL, Alousi AM, Oran B, Ahmed S, Ciurea SO, Patel K, Shpall EJ, Hosing C, Patel K, Shpall EJ, Hosing C, Qazilbash MH, Shah N, Marin D, Rezvani K, nIeto Y, Champlin RE, Andersson BS. Busulfan (Bu) in Combination with Double Nucleoside Analogues Fludarabine (Flu) and Clofarabine (Clo) Plus Vorinostat As a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Leukemia. Blood 58th ASH Annual Meeting 128(22):64, 2016. e-Pub 2016.
311. Yucel OK, Saliba RM, Rondon G, Ahmed S, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Khouri IF, Nieto Y, Popat UR, Marin D, Rezvani K, Kebriaei P, Shah N, Olson AL, Shpall EJ, Champlin RE, Oran B. Comparable Outcomes of Therapy-Related and De Novo Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. Blood 58th ASH Annual Meetingi 128(22):2276, 2016. e-Pub 2016.
312. Hill L, Saliba RM, Chen J, Rondon G, Qazilbash MH, Popat UR, Shah N, Neumann JL, Hymes SR, Hosing C, Kebriaei P, Nieto Y, Oran B, Olson A, Ciurea SO, Rezvani K, Marin D, Champlin RE, Shpall EJ, Alousi AM. Predictors for Steroid Tapering in Patients with Acute Graft-Versus-Host Disease and Their Impact on Graft-Versus-Host Disease Response and Non-Relapse Mortality: Older Age and Co-Morbidities Are Associated with Quicker Tapering and Worse Outcomes. Blood 58th ASH Annual Meeting 128(22):3424, 2016. e-Pub 2016.
313. Brown AL, Hahn CN, Carmichael C, Wilkins E, Babic M, Chong CE, Li XC, Michaud J, Cannon P, Poplawski N, Altree M, Phillips K, Jaensch L, Fine M, Schreiber AW, Feng J, Rawlings L, Vakulin C, Butcher C, D'Andrea R, Lewis ID, Patton N, Forsyth C, Mapp S, Fan HM, Susman R, Morgan S, Cooney J, Currie MS, Popat UR, Bradstock K, Sorrell AD, Owen CJ, Horwitz MS, Hiwase D, Kramer A, Frohling S, Godley LA, Churpek JE, Scott HS. Expanded Phenotypic and Genetic Heterogeneity in the Clinical Spectrum of FPD-AML: Lymphoid Malignancies and Skin Disorders Are Common Features in Carriers of Germline RUNX1 Mutations. Blood 58th ASH Annual Meeting 128(22):1212, 2016. e-Pub 2016.
314. Srour SA, Lozano S, Nieto Y, Alousi A, Popat UR, Qazilbash MH, Anderlini P, Kebriaei P, Shpall E, Champlin R, Hosing C. High-dose versus standard-dose rituximab with beam in autologous stem cell transplantation (sct) for relapsed aggressive b-cell non-hodgkin's lymphomas (nhl). HemaSphere 21st EHA Congress, 2016. e-Pub 2016.
315. Hu B, Sasaki K, Bashir Q, Shah N, Patel KK, Popat UR, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen JL, Shah JJ, Manasanch EE, Weber DM, thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Depth of response post autologous hematopoietic stem cell transplantation (auto-HCT) to predict outcome in high risk multiple myeloma (MM). J Clin Oncol 2016 ASCO Annual Meeting 34(15_suppl):8019, 2016. e-Pub 2016.
316. Srour SA, Khouri IF, Nieto Y, Popat UR, Qazilbashd MH, Anderlini P, Kebriaei P, Shpall EJ, Champlin RE, Hosing C. High-dose versus standard-dose rituximab with BEAM in autologous stem cell transplantation (SCT) for relapsed aggressive b-cell non-Hodgkin’s lymphomas (NHL). J Clin Oncol 2016 ASCO Annual Meeting 34(15_suppl):7524, 2016. e-Pub 2016.
317. Nieto Y, Bassett R, Hosing C, Jones RB, Valdez BC, Kingham A, Ahmed S, Alousi AM, Anderlini P, Popat UR, Qazilbash M, Shpall EJ, Kebriaei P. Comparison of High-Dose Gemcitabine, Busulfan and Melphalan (GEM/BU/MEL) and BEAM in Concurrent Patient Cohorts with Mature T-CELL NON-Hodgkin's Lymphoma (T-NHL) Receiving an Autologous Stem Cell Transplantation (ASCT). Biol Blood Marrow Transplant 2016 BMT Tandem Meetings 22(3, Supplement):S227-S228, 2016. e-Pub 2016.
318. Qazilbash MH, Chen J, Valdez BC, Sasaki K, Kawedia JD, Bashir Q, Hosing CM, Kebriaei P, Nieto Y, Shah N, Patel K, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Timed Sequential Busulfan Is Safe in Patients with Relapsed or High-Risk Multiple Myeloma. Biol Blood Marrow Transplant 2016 BMT Tandem Meetings 22(3, Supplement):S228-S229, 2016. e-Pub 2016.
319. Kawedia JD, Myers AL, Kramer MA, Gulbis AM, Champlin RE, Andersson BS, Popat UR. In Contrast to Phenytoin, Levetiracetam Does Not Increase Busulfan Clearance When Given As Anti-Seizure Prophylaxis. Biol Blood Marrow Transplant 2016 BMT Tandem Meetings 22(3, Supplement):S328-S329, 2016. e-Pub 2016.
320. Lindsay R, Saliba R, Choi H, Ping Z, Ramlal R, Alousi AM, Jones RB, Champlin RE, Popat UR. Transfusion History Is the Most Significant Predictor of Iron Overload after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 2016 BMT Tandem Meetings 22(3, Supplement):S336-S337, 2016. e-Pub 2016.
321. Sasaki K, Bashir Q, Shah N, Hosing C, Popat UR, Nieto Y, Parmar S, Shah J, Weber D, Thomas S, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Multiple Myeloma by Ethnicity in the Setting of Autologous Stem Cell Transplant. Biol Blood Marrow Transplant 2016 BMT Tandem Meetings 22(3, Supplement):S231-S232, 2016. e-Pub 2016.
322. Badar T, Bashir Q, Shah N, Alatrash G, Hosing C, Popat UR, Nieto Y, Shah J, Orlowski RZ, Champlin RE, Qazilbash MH. Predictors of Inferior Clinical Outcome in Patients with Standard Risk Multiple Myeloma. Biol Blood Marrow Transplant 2016 BMT Tandem Meetings 22(3, Supplement):S216-S217, 2016. e-Pub 2016.
323. Popat UR, Lyons G, Bassett R, Chen J, Valdez BC, Kawedia JD, Ahmed S, Alousi AM, Anderlini P, Bashir Q, Ciurea SO, Hosing C, JOnes RB, Kebriaei P, Khouri IF, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Patel K, Qazilbash MH, Rezvani K, Shah N, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Timed Sequential Busulfan is Safe and Appears Promising in Older Patients with AML/MDS. Biol Blood Marrow Transplant 2016 BMT Tandem Meetings 22(3, Supplement):S33-S34, 2016. e-Pub 2016.
324. Mahale P, Kyvernitakis A, Hosry J, Popat UR, Torres HA. Acute Exacerbation and Reactivation of Chronic Hepatitis C Virus Infection in Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 2016 BMT Tandem Meetings 22(3, Supplement):S178, 2016. e-Pub 2016.
325. Mehta RS, Saliba RM, Cao K, Kaur I, Rezvani K, Chen J, Olson A, Parmar S, Shah N, Marin D, Alousi AM, Hosing C, Popat UR, Kebriaei P, Champlin RE, McNiece IK, De Lima M, Skerrett D, Burke E, Shpall EJ, Oran B. Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation Following Reduced Intensity Conditioning Regimens. Blood 57th ASH Annual Meeting 126(23):1190, 2015. e-Pub 2015.
326. Khouri IF, Saliba RM, Ledesma C, Jabbour EJ, Turturro F, Alatrash G, Ahmed S, Oran B, Patel KK, Olson A, Marin D, Popat UR, Suki TS, Jorgensen JL, Medeiros LJ, and Gulbis AM. Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Blood 57th ASH Annual Meeting 126(23):2011, 2015. e-Pub 2015.
327. Im JS, Saliba RM, Abraham SC, Ross W, Rondon G, Rashid A, Shpall EJ, Popat UR, Qazilbash M, Hosing CM, Oran B, Shah N, Champlin RE, and Alousi AM. Histologic Confirmation for Patients Presenting with Gastrointestinal Graft Versus Host Disease: How to Interpret Histologic Grade 1 (Does It Matter)?. Blood 57th ASH Annual Meeting 126(23):1933, 2015. e-Pub 2015.
328. Popat UR, Ray G, Bassett Jr RL, Poon MYC, Valdez BC, Konoplev S, Ahmed S, Alousi AM, Andersson B, Bashir Q, Ciurea SO, Hosing CM, Jones R, Kebriaei P, Khouri IF, Kim S, Nieto Y, Olson AL, Oran B, Parmar S, Qazilbash MH, Rezvani K, Shah N, Shpall EJ, Champlin RE. Eltrombopag for Post-Transplant Thrombocytopenia: Results of Phase II Randomized Double Blind Placebo Controlled Trial. Blood 57th ASH Annual Meeting 126(23):738, 2015. e-Pub 2015.
329. Schaffer BC, Ahn KW, Hu ZH, Popat UR, Kalaycio M, Maziarz, RT, Alyea E, Sobecks RM, Pavletic SZ, Tallman MS, and Saber W. A Prognostic System Predictive of Outcomes in Persons Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Blood 57th ASH Annual Meeting 126(23):64, 2015. e-Pub 2015.
330. Desai P, Chen J, Liu D, Wu J, Ahmed S, Oran B, Ciurea SO, Alousi AM, Verstovsek, Champlin RE, Popat UR. Patient Choice and Lack of Medicare Coverage for HCT Are the Major Reasons Why Transplant Eligible Myelofibrosis Patients Do Not Undergo Transplant. Blood 57th ASH Annual Meeting 126(23):3324, 2015. e-Pub 2015.
331. Saaki K, Shah N, Bashir Q, Hosing CM, Popat UR, Nieto Y, Parmar S, Shah JJ, Weber D, Weissinger D, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash RE. Outcome of Patients with Light Chain Multiple Myeloma Compared to IgG/IgA Myeloma after Autologous Stem Cell Transplant. Blood 57th ASH Annual Meeting 126(23):3194, 2015. e-Pub 2015.
332. Alousi AM, Bassett R, Chen J, Overman BJ, Hosing CM, Popat UR, Shpall EJ, Nieto Y, Qazilbash MH, Khouri IF, Kebriaei P, Ahmed S, Shah N, Rezvani K, Kondo K, Ciurea SO, Hymes SR, Neumann JL, Molldrem JJ, Plair TR, and Champlin RE. A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids. Blood 57th ASH Annual Meeting 126(23):854, 2015. e-Pub 2015.
333. Kebriaei P, Ciurea SO, Huls MH, Singh, H, Olivares S, Su S, Figliola MJ, Kumar P, Jena B, Forget MA, Ang S, Jackson R, Liu T, McNiece IK, Rondon G, Hackett P, Kantarjian HM, Lee DA, Popat UR, Alousi AM, Oran B, Shah N, Hosing CM, Marin D, Rezvani K, Shpall EJ, Champlin RE. Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19 + Malignancies. Blood 57th ASH Annual Meeting 126(23):862, 2015. e-Pub 2015.
334. Ragon BK, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Pentostatin Therapy for Steroid-Refractory Acute Graft Versus Host Disease: Identifying Those Who May Benefit. Blood 57th ASH Annual Meeting 126(23):3136, 2015. e-Pub 2015.
335. Kongtim P, Popat UR, Jimenez AM, Gabella S, El Fakih RO, Rondon G, Chen J, Bueso-Ramos CE, Borthakur G, Pemmaraju N, Garcia-Manero G, Kantarjian HM, Alousi AM, Hosing CM, Anderlini P, Khouri IF, Kebriaei P, Andersson BS, Oran B, Rezvani K, Marin D, Shpall EJ, Champlin RE, Ciurea SO. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Survival for Patients with Chronic Myelomonocytic Leukemia. Blood 57th ASH Annual Meeting 126(23):4347, 2015. e-Pub 2015.
336. Khouri IF, Sui D, Turturro F, Erwin WD, Bassett Jr RL, Korbling M, Valverde R, Ahmed S, Alousi AM, Anderlini P, Bashir Q, Ciurea SO, Oran B, Olson A, Popat UR, Patel KK, Qazilbash MH, Fanale MA, Fayad LE, Nastoupil L, Westin JR, Gulbis AM, Medeiros LJ, Young KH, Jessop A. In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials. Blood 57th ASH Annual Meeting 126(23):3192, 2015. e-Pub 2015.
337. Kebriaei P, Basset Jr RL, Ledesma C, Rondon G, Oran B, Ciurea SO, Alousi AM, Popat UR, Patel KK, Ahmed S, Olson AL, Bashir Q, Shah N, Jones R, Rezvani K, Nieto Y, Khouri IF, Qazilbash MH, Hosing CM, Shpall EJ, Champlin RE, Andersson BS. Clofarabine (Clo) Plus Busulfan (Bu) Is an Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results. Blood 57th ASH Annual Meeting 126(23):4376, 2015. e-Pub 2015.
338. Brammer JE, Saliba RM, Jorgensen JL, Ledesma C, Rondon G, Poon M, Koh LP, Dibb W, Fan G, Saliba CK, Wang S, Popat UR, Shpall EJ, Ravandi F, Kantarjian H, Maziarz RT, Champlin RE, Hosing CM, Kebriaei P. Multi-Center Analysis of the Effect of Disease Subtype and Minimal Residual Disease on Allogeneic Stem Cell Transplantation Outcomes in T-Cell Acute Lymphoblastic Leukemia (T-ALL). Blood 57th ASH Annual Meeting 126(23):4408, 2015. e-Pub 2015.
339. Gaballa S, Ge I, El Fakih RO, Brammer JE, Wang SA, Lee DA, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom AE, Al-Atrash G, Korblling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi AM, Nieto Y, Qazilbash M, Hosing CM, Popat UR, Shpall EJ, Khouri IF, Champlin RE, Ciurea SO. Results of a Two-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem-Cell Transplantation. Blood 57th ASH Annual Meeting 126(23):152, 2015. e-Pub 2015.
340. Pingali SR, Saliba R, Anderlini P, Hosing CM, Khouri IF, Alousi AM, Kebriaei P, Nieto Y, Qazilbash MH, Fanale MA, Shpall EJ, Champlin RE, Popat U. Age over 55 Years at Diagnosis Increases Risk of Second Malignancies after Auto-Transplantation for Hodgkin's Lymphoma Patients. Blood 57th ASH Annual Meeting 126(23):3186, 2015. e-Pub 2015.
341. Gerds AT, Kalaycio ME, Ahn KW, Hu ZH, Alyea EP, Popat UR, Sobecks RM, Saber W. Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes: A Center for International Blood and Marrow Transplant Registry (CIBMTR®) Study. Blood 57th ASH Annual Meeting 126(23):2003, 2015. e-Pub 2015.
342. Shah JJ, Feng L, Manasanch EE, Weber D, Thomas SK, Turturro F, Shah N, Popat UR, Nieto Y, BAshir Q, Munoz SC, Landry A, Mendoza K, Champlin RE, Qazlibash MH, Orlowski RZ. Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. Blood 57th ASH Annual Meeting 126(23):187, 2015. e-Pub 2015.
343. Oran B, Jorgensen JL, WAng SA, Marin D, Popat UR, Chen J, Ciurea SO, Ahmed S, Bashir Q, Rezvani K, Shpall EJ, Kebriaei P, Champlin RE. Minimal Residual Disease Detected By Multiparameter Flow Cytometry and Complex Karyotype Are the Major Prognostic Factors for Relapse after HCT. Blood 57th ASH Annual Meeting 126(23):4342, 2015. e-Pub 2015.
344. Im JS, Saliba RM, Abraham SC, Rashid A, Ross W, Nieto Y, Shpall EJ, Oran B, Olson A, Ahmed S, Popat UR, g R, Qazilbash MH, Shah N, Champlin RE, Alousi AM. Gastrointestinal Acuity Score (GAS): A Comprehensive Risk Score Incorporating Histologic Grade and Clinical Factors to Predict Need for Second Line Therapy, Non-Relapse Mortality, and Overall Survival in Lower Gastrointestinal Graft Vs. Host Disease. Blood 57th ASH Annual Meeting 126(23):3128, 2015. e-Pub 2015.
345. Mehta RS, Saliba RM, Chen J, Rondon G, Hammerstrom AE, Alousi AM, Qazilbash MH, Bashir Q, Ahmed S, Popat UR, Hosing CM, Khouri IF, Shpall EJ, Champlin RE, Ciurea SO. Post-Transplantation High Dose Cyclophosphamide As Gvhd Prophylaxis in 9/10 HLA-Matched Unrelated Donors Hematopoietic Stem Cell Transplantation. Blood 57th ASH Annual Meeting 126(23):3135, 2015. e-Pub 2015.
346. Shah JJ, Feng L, Weber D, Thomas SK, Wang M, Turturro F, Qazilbash MH, Shah N, Bashir Q, Popat UR, Manasanch EE, Munoz SC, Landry A, Mendoza K, Nieto Y, Champlin RE, Orlowski RZ. Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood 57th ASH Annual Meeting 126(23):3155, 2015. e-Pub 2015.
347. Rondon G, Saliba RM, Chen J, Ledesma C, Alousi AM, Oran B, Hosing CM, Kebriaei P, Khouri IF, Shpall EJ, Popat UR, Champlin RE, Ciurea SO. Fluid Overload As New Toxicity Category Has a Strong Impact on Non Relapse Mortality and Survival in Allogeneic Hematopoietic Stem Cell Transplantation. Blood 57th ASH Annual Meeting 126(23):4321, 2015. e-Pub 2015.
348. Ramlal R, Gaballa S, Chen J, Rondon G, Oran B, Ahmed S, Bashir Q, Rezvani K, Marin D, Alousi AM, Kebriaei P, Qazilbash M, Hosing C, Popat UR, Shpall EJ, Champlin RE, and Ciurea SO. Outcomes of Haploidenitical Stem Cell Transplants for De Novo Acute Myeloid Leukemia, Myelodysplastic Syndrome and Acute Myeloid Leukemia Arising from MDS: The MD Anderson Experience. Blood 57th ASH Annual Meeting 126(23):3225, 2015. e-Pub 2015.
349. Nieto Y, Bassett R, Anderlini P, Hosing CM, Alousi AM, Popat UR, Andersson BS, Valdez BC, Shpall EJ, Ahmed S, Qazilbash M, Guillermo M, Oki Y, Fanale MA, Hagemeister FB, Dabaja BS, Pinnix CC, Milgrom SA, Tewari P, Champlin RE, Jones R. Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem-Cell Transplant (ASCT) without Post-ASCT Maintenance, in Hodgkins Lymphoma Patients at High Risk of Post-Transplant Recurrence Comparison with a Concurrent Matched Cohort Treated with BEAM. Blood 57th ASH Annual Meeting 126(23):1980, 2015. e-Pub 2015.
350. Nieto Y, Valdez BC, Thall PF, Wei W, Jones R, Hosing CM, Ahmed S, Popat UR, Shpall EJ, Qazilbash M, Gulbis AM, Anderlini P, Shah N, Bashir Q, Alousi AM, Oki Y, Hagemeister FB, Champlin RE, and Andersson BS. Double Epigenetic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma. Blood 57th ASH Annual Meeting 126(23):1992, 2015. e-Pub 2015.
351. Popat U, Bassett R, Chen J, Alousi A, Anderlini P, Ahmed S, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Olson A, Oran B, Qazilbash M, Rondon G, Shpall EJ, Verstovsek S, Andersson BS, Champlin R. Allogeneic Transplantation for Myelofibrosis: High Dose Intensity and Early Disease State are Favorable Prognostic Factors. HemaSphere 20th EHA Congress, 2015. e-Pub 2015.
352. Kebriaei P, Huls H, Ciurea S, Liu T, Singh H, Su S, Hosing C, Olivares S, Figliola M, Kumar P, Jena B, Maiti S, McNiece I, Lee D, Tewari P, Popat U, Alousi A, b O, Shah N, Rezvani K, Forget M, Ang S, Jackson R, Rondon G, Kantarjian H, Hackett P, Shpall E, Champlin R, Cooper L. Donor-derived, CD19-directed, car-modified t cells infused after allogeneic hematopoietic stem cell transplantation as pre-emptive donor lymphocyte infusion in patients with CD19+ malignancies. HemaSphere 20th EHA Congress, 2015. e-Pub 2015.
353. Ciurea S, Kongtim P, Popat U, Aung F, Champlin R, Cao K. Compliment-binding donor-specific anti-HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantation. HemaSphere 20th EHA Congress, 2015. e-Pub 2015.
354. Pundole X, Champlin RE, Popat UR, Escalante CP, Murphy WA, Gagel RF, Lu H. A randomized controlled trial of ibandronate for the prevention of bone loss following allogeneic stem cell transplantation. J Clin Oncol 2015 ASCO Annual Meeting 33(15_suppl):7029, 2015. e-Pub 2015.
355. Popat UR, Bassett RL, Chen J, Alousi AM, Anderlini P, Ciurea SO, Hosing C, Jones RB, Kebriaei P, Khouri IF, Konoplev S, De Lima MJG, Nieto Y, Oran B, Qazilbash QH, Rondon G, Shpall EJ, Verstovsek S, Andersson B, Champlin RE. Allogeneic transplantation for myelofibrosis: Final analysis of a prospective study after a median. J Clin Oncol 2015 ASCO Annual Meeting 33(15_suppl):7008, 2015. e-Pub 2015.
356. Kyvernitakis A, Mahale P, Popat UR, Jiang Y, Champlin RE, Torres HA. Hepatitis C virus infection in patients undergoing hematopoietic cell transplantation in the era of direct-acting antiviral agents. J Clin Oncol 2015 ASCO Annual Meeting 33(15_suppl):7090, 2015. e-Pub 2015.
357. Popat UR, Saliba R, Oran B, Chen J, Alousi AM, Ahmed S, Bashir Q, Ciurea SO, Hosing C, Jones RB, Kebriaei P, Khouri IF, Nieto YL, Olson A, Parmar S, Shah N, Shpall EJ, Qazilbash MH, Andersson BS, Champlin RE. Cytogenetics and Blast Count Determine Transplant Outcomes in Advanced AML. Biol Blood Marrow Transplant 2015 BMT Tandem Meetings 21(2, Supplement):S304, 2015. e-Pub 2015.
358. Baljevic M, Cao K, Champlin RE, Popat UR, Hosing C, Shah N, Parmar S, Rezvani K, Olson A, Shpall EJ, Oran B. Dual Donor T-Cell Chimerism Does Not Predict Poor Prognosis after Double Cord Blood Allogeneic Transplantation. Biol Blood Marrow Transplant 2015 BMT Tandem Meetings 21(2, Supplement):S157, 2015. e-Pub 2015.
359. Duong H, Akhatari M, Ahn KW, Hu ZH, Popat UR, Alyea III EP, Maziarz RT, Kalaycio ME, Saber W. Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant 2015 BMT Tandem Meetings 21(2, Supplement):S30-S31, 2015. e-Pub 2015.
360. Brammer JE, Saliba R, Kantarjian H, Thomas D, Jorgensen JL, Gaballa S, Ledesma C, Popat UR, Shpall EJ, Champlin RE, Hosing C, Kebriaei P. Allogeneic Stem Cell Transplantation (Allo-SCT) for the Treatment of T-Cell Acute Lymphoblastic Leukemia (T-ALL); Evaluation of Minimal Residual Disease and Prognostic Factors at the MD Anderson Cancer Center (MDACC). Biol Blood Marrow Transplant 2015 BMT Tandem Meetings 21(2, Supplement):S80, 2015. e-Pub 2015.
361. Badar T, Parmar S, Cornelison AM, Shah N, Bashir Q, Patel K, Hosing C, Popat UR, Champlin RE, Qazilbash MH. Outcome of Patients with Systemic Light Chain (AL) Amyloidosis with Concurrent Renal and Cardiac Involvement. Biol Blood Marrow Transplant 2015 BMT Tandem Meetings 21(2, Supplement):S130, 2015. e-Pub 2015.
362. Sasaki K, Saliba R, Lu G, Shah N, Bashir Q, Patel K, Bock F, Parmar S, Hosing C, Popat UR, Delgado R, Rondon G, Champlin RE, Qazilbash MH. Outcome of Patients with Multiple Myeloma with t(4;14) after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2015 BMT Tandem Meetings 21(2, Supplement):S202-S203, 2015. e-Pub 2015.
363. Brammer JE, Khouri IF, Gaballa S, Ledesma C, Anderlini P, Andersson BS, Popat UR, Bashir Q, Hosing C, Champlin RE, Ciurea SO. Safety and Efficacy of Non-Myeloablative (NMA) Melphalan-Based Conditioning for Haploidentical Allogenic Stem Cell Transplantation (HaploSCT) in Patients with Advanced Lymphoma. Biol Blood Marrow Transplant 2015 BMT Tandem Meetings 21(2, Supplement):S195-S196, 2015. e-Pub 2015.
364. Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver N, Andreeff M, Ravandi F, Cortes J, Champlin RE, Ciurea SO. Minimal Residual Disease By PCR Testing Is a Significant Predictor of Disease Relapse in Patients with FLT3 Positive AML after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2015 BMT Tandem Meetings 21(2, Supplement):S81-S82, 2015. e-Pub 2015.
365. Gaballa S, Saliba R, Brammer JE, Lu G, Shah N, Bashir Q, Parmar S, Bock F, Hosing C, Popat UR, Delgado R, Rondon G, Shah J, Manasanch E, Orlowski RZ, Champlin RE, Qazilbash MH. Clinical Outcomes of Multiple Myeloma Patients with TP53 Gene Deletion after Autologous Stem Cell Transplantation: The MD Anderson Cancer Center Experience. Biol Blood Marrow Transplant 2015 BMT Tandem Meetings 21(2, Supplement):S85, 2015. e-Pub 2015.
366. Cornelison AM, Saliba R, Ahmed S, Nieto YL, Bashir Q, Shah N, Parmar S, Hosing C, Popat UR, Shpall EJ, Champlin RE, Qazilbash MH. Autologous Hematopoietic Stem Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM) in the Inpatient (Inpt) Vs. Outpatient (Outpt) Settings: Impact of Hematopoietic Stem Cell Comorbidity Index (HCT-CI). Biol Blood Marrow Transplant 2015 BMT Tandem Meetings 21(2, Supplement):S114, 2015. e-Pub 2015.
367. Hosing C, Munsell M, Su A, Sadeghi T, Rezvani K, Oran B, Marin D, Dworsky S, Popat UR, Wilson J, Alousi AM, Shah N, Olson A, Jones RB, Kebriaei P, Qazilbash MH, Parmar S, McNiece I, Champlin RE, Shpall EJ. Ex-Utero Plus in Utero Collection of Umbilical Cord Blood (CB) for Banking Yields Higher Total Nucleated Cell Counts (TNC) Compared to Either Procedure Alone. Biol Blood Marrow Transplant 2015 BMT Tandem Meetings 21(2, Supplement):S154-S155, 2015. e-Pub 2015.
368. Thompson PA, Perera T, Marin D, Oran B, Popat UR, Qazilbash MH, Shah N, Parmar S, Rezvani K, Olson A, Kebriaei P, Rondon G, Alousi AM, Ciurea SO, Champlin RE, Bajel A, Szer J, Shpall EJ, Ritchie DS, Hosing C. Results of Allogeneic Double Umbilical Cord Blood Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant 2015 BMT Tandem Meetings 21(2, Supplement):S48, 2015. e-Pub 2015.
369. Qazilbash MH, Thall P, Fox PS, Kebriaei P, Bashir Q, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Dinh Y, Hosing C, Popat UR, Lin P, Shah J, Orlowski RZ, Champlin RE. A Randomized Phase III Trial of Busulfan + Melphalan Vs Melphalan Alone for Multiple Myeloma. Biol Blood Marrow Transplant 2015 BMT Tandem Meetings 21(2, Supplement):S87-S88, 2015. e-Pub 2015.
370. Valdez BC, Murray D, LI Y, Katigbak K, Ji J, Liu Y, Popat UR, Champlin RE, Andersson BS. Comparison of the Cytotoxicity of Cladribine and Clofarabine When Combined with Fludarabine and Busulfan in AML Cells: Enhancement of Cytotoxicity with Epigenetic Modulators. Biol Blood Marrow Transplant 2015 BMT Tandem Meetings 21(2, Supplement):S194-S195, 2015. e-Pub 2015.
371. Gaballa S, Kongtim P, Rondon G, Chen J, Popat U, Ahmed S, Hosing C, Oran B, Kebriaei P, Parmar S, Shah N, Khouri I, Champlin R, Ciurea S. Feasibility and Outcomes of Haploidentical Transplantation for Elderly Patients with Advanced Hematological Malignancies: The MD Anderson Cancer Center Experience. Blood 56th ASH Annual Meeting 124(21):1245, 2014. e-Pub 2014.
372. Pingali S, Milton D, Popat U, Hosing C, Bashir Q, Alousi A, Jones R, Nieto Y, Kebriaei P, Qazilbash M, Andersson B, Shpall E, Khouri I, Champlin R, Ciurea S. Transplant Outcomes of 9/10 HLA Matched Unrelated Donors (MUD) Treated with Post-Transplant Cyclophosphamide for Prevention of Graft Versus Host Disease. Blood 56th ASH Annual Meeting 124(21):2486, 2014. e-Pub 2014.
373. Bock F, Lu G, Shah N, Bashir Q, Patel K, Popat U, Hosing C, Gaballa S, Korbling M, Delgado R, Rondon G, Orlowski R, Shah J, Manasanch E, Champlin R, Qazilbash M. Clinical Characteristics and Outcomes in Patients with Multiple Myeloma and CKS1B Gene Gain/Amplification after Autologous Stem Cell Transplantation. Blood 56th ASH Annual Meeting 124(21):2521, 2014. e-Pub 2014.
374. Oran B, Cao K, Saliba R, Hosing C, Popat U, de Lima M, Carmazzi Y, Alousi A, Kebriaei P, Nieto Y, Rondon G, Willis D, Shah N, Parmar S, Olson A, Moore B, Champlin R, Rezvani K, Shpall E. Higher Allele Level HLA Matching Improves Prognostication after Double Umbilical Cord Blood (dUCB) Transplantation for Hematological Malignancies. Blood 56th ASH Annual Meeting 124(21):2532, 2014. e-Pub 2014.
375. Oran B, Saliba R, Andersson B, de Lima M, Popat U, Khouri I, Kebriaei P, Bashir Q, Ahmed S, Shpall E, Champlin R, Rondon G. Improved Progression-Free Survival with Minimal Toxicity after Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Hematological Malignancy. Blood 56th ASH Annual Meeting 124(21):2533, 2014. e-Pub 2014.
376. Chaudhury S, Hijiya N, Hu Z, Sparapani R, Kalaycio M, Alyea E, Popat U, Saber W. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. Blood 56th ASH Annual Meeting 124(21):2534, 2014. e-Pub 2014.
377. Tamari R, Oran B, Hilden P, Papadopoulos E, Kongtim P, Rondon G, Jakubowski A, Andersson B, Devlin S, Ahmed S, Young J, Popat U, Chen J, de Lima M, O'Reilly R, Giralt S, Champlin R, Castro-Malaspina H. Allo- HSCT for Advanced Myelodysplastic Syndrome:MSKCC Vs MDACC. Blood 56th ASH Annual Meeting 124(21):2546, 2014. e-Pub 2014.
378. Khouri I, Saliba R, Xu-Monette Z, Korbling M, Rondon G, Valverde R, Alousi A, Anderlini P, Ahmed S, Ciurea S, Fayad L, Oran B, Parmar S, Popat U, Westin J, Turturro F, Medeiros J, Gulbis A, Young K. Outcomes Following Allogeneic Stem Cell Transplantation (AlloSCT) in Patients with Primary Mediastinal (PMBL), Germinal Center B (GCB) and Non-GCB Cell-like Diffuse Large B Cell Lymphomas (DLBCL). Blood 56th ASH Annual Meeting 124(21):2563, 2014. e-Pub 2014.
379. Afable M, Caimi P, Hosing C, de Lima M, Khouri I, William B, Nieto Y, Cooper B, Anderlini P, Campagnaro E, Gerson S, Lazarus H, Champlin R, Popat U. Brentuximab Vedotin (BV) Does Not Impair Autologous Peripheral Blood Stem Cell Mobilization and Collection in Refractory/Relapsed CD30+ Lymphoma Patients Undergoing High-Dose Chemotherapy and Autologous Stem Cell Transplant (HDC-ASCT). Blood 56th ASH Annual Meeting 124(21):3854, 2014. e-Pub 2014.
380. Popat U, Fox P, Bassett R, Chen J, Valdez B, Kawedia J, Ahmed S, Alousi A, Bashir Q, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Olson A, Oran B, Parmar S, Qazilbash M, Shah N, Shpall E, Andersson B, Champlin R. Myeloablative Timed Sequential Busulfan Is Safe in Older Patients. Blood 56th ASH Annual Meeting 124(21):3859, 2014. e-Pub 2014.
381. Shah N, Thall P, Fox P, Bashir Q, Shah J, Parmar S, Kebriaei P, Neito Y, Popat U, Hosing C, Patel K, Lin P, Shpall E, Orlowski R, Champlin R, Qazilbash M. Phase I/II Trial of Lenalidomide and High Dose Melphalan with Autologous Stem Cell Transplantation for Relapsed Myeloma. Blood 56th ASH Annual Meeting 124(21):3981, 2014. e-Pub 2014.
382. Alvarnas J, Rademacher J, Wang Y, Little R, Akpek G, Ayala E, Devine S, Kaplan L, Noy A, Popat U, Thompson J, Horowitz M, Mendizabal A, Navarro W, Ambinder R. Autologous Hematopoietic Stem Cell Transplantation (AHCT) in Patients with Chemotherapy-Sensitive, Relapsed/Refractory (CSRR) Human Immunodeficiency Virus (HIV)-Associated Lymphoma (HAL): Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0803)/AIDS Malignancy Consortium (AMC-071) Trial. Blood 56th ASH Annual Meeting 124(21):674, 2014. e-Pub 2014.
383. Artz A, Logan B, Zhu X, Akpek G, Martino R, Gupta V, Lazarus H, Litzow M, Loren A, Majhail N, Maziarz R, McCarthy P, Popat U, Saber W, Spellman S, Ringden O, Cooke K, Pasquini M. Pre-Transplant C-Reactive Protein (CRP), Ferritin and Albumin As Biomarkers to Predict Transplant Related Mortality (TRM) after Allogeneic Hematopoietic Cell Transplant (HCT). Blood 56th ASH Annual Meeting 124(21):422, 2014. e-Pub 2014.
384. Mian I, Milton D, Popat U, Shah N, Nieto Y, Kebriaei P, Parmar S, Ahmed S, Shah J, Orlowski R, Qazilbash M, Bashir Q, Champlin R. Effect of Timing and Duration of Maintenance Lenalidomide in Myeloma Patients after Autologous Stem Cell Transplantations. Blood 56th ASH Annual Meeting 124(21):194, 2014. e-Pub 2014.
385. Shah J, Feng L, Manasanch E, Weber D, Thomas S, Turturro F, Alexanian R, Shah N, Popat U, Nieto Y, Bashir Q, Qazilbash M, Champlin R, Orlowski R. Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. Blood 56th ASH Annual Meeting 124(21):33, 2014. e-Pub 2014.
386. Ahmed S, Shpall E, Gulbis A, Jones R, Martinez C, Rondon G, Rezvani K, Oran B, Olson A, Shah N, Parmar S, Popat U, Alousi A, Nieto Y, Hosing C, Bashir Q, Kebriaei P, Qazilbash M, Champlin R, Mulanovich V. Assessment of Incidence Toxoplasma Gondii Infection and Outcomes in Allogeneic Stem Cell Patients. Blood 56th ASH Annual Meeting 124(21):1187, 2014. e-Pub 2014.
387. Williams L, Qazilbash M, Shi Q, Shah N, Bashir Q, Champlin R, Popat U, Kebriaei P, Parmar S, Limaye A, Cleeland C. Symptom Burden of Busulfan + Melphalan Versus Melphalan Alone for Multiple Myeloma. Blood 56th ASH Annual Meeting 124(21):1277, 2014. e-Pub 2014.
388. Kongtim P, Pingali SR, Jimenez AM, Rondon G, Chen J, Oran B, Kebriaei P, Hammerstrom A, Ferro R, Lombardi L, Korbling M, Popat UR, Parmar S, Lee DA, Cooper L, Rezvani K, Shpall EJ, Champlin RE, Ciurea SO. Haploidentical transplantation (HaploSCT) with post-transplant cyclophosphamide (PTCy) and melephalan-based conditioning: a retrospective analysis of the first 100 patients treated at MD Anderson Cancer Center. J Clin Oncol 2014 ASCO Annual Meeting 32(15_suppl):7017, 2014. e-Pub 2014.
389. Qazilbash M, Thall PF, Fox PS, Kebriaei P, Bashir Q, Shah N, Andersson B, Nieto Y, Valdez B, Parmar S, Dinh Y, Hosing C, Popat UR, Shah JJ, Orlowski RZ, Champlin RE. Randomized phase III trial of busulfan plus melphalan versus melphalan alone for multiple myeloma. J Clin Oncol 2014 ASCO Annual Meeting 35(15_suppl):8538, 2014. e-Pub 2014.
390. El Fakih RO, Nieto Y, Fox PS, Shah N, Parmar S, Oran B, Ciurea SO, Kebriaei P, Hosing C, Popat UR, Ahmed S, Shah JJ, Orlowski RZ, Dinh Y, Champlin RE, Qazilbash MH, Bashir Q. Autologous stem cell transplantation in dialysis-dependent myeloma patients. J Clin Oncol 2014 ASCO Annual Meeting 32(15_suppl):8601, 2014. e-Pub 2014.
391. Biritxinaga L, Jauch SF, Popat UR, Shafi MA, Shah N, Bashir Q, Dinh Y, Hosing C, Champlin RE, Qazilbash MH. Impact of Hepatitis B Core Antibody (HBcAb) Seropositivity on the Outcome of High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant 2014 BMT Tandem Meetings 20(2, Supplement):S46-S47, 2014. e-Pub 2014.
392. Qazilbash MH, Thall P, Fox PS, Shah N, Bashir Q, Shah J, Parmar S, Kebriaei P, Nieto Y, Dinh Y, Popat UR, Hosing C, Lin P, Shpall EJ, Orlowski R, Champlin RE. Phase I/II Trial of Lenalidomide and High-Dose Melphalan As Preparative Regimen for Relapsed Myeloma. Biol Blood Marrow Transplant 2014 BMT Tandem Meetings 20(2, Supplement):S47, 2014. e-Pub 2014.
393. Anderlini P, Saliba R, Ledesma C, Chancoco CM, Alexander TR, Alousi AM, Hosing C, Khouri IF, Nieto YL, Popat UR, Shpall EJ, Fanale MA, Oki Y, Romaguera JE, Neelapu SS, Younes A, Champlin RE. Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation For Relapsed/Refractory Hodgkin Lymphoma In The Brentuximab Vedotin Era. Biol Blood Marrow Transplant 2014 BMT Tandem Meetings 20(2, Supplement):S72, 2014. e-Pub 2014.
394. Chu D, Valdez BC, Fox PS, Thall P, Worth L, Popat UR, Jones RB, Shpall EJ, Hosing C, Alousi AM, Rondon G, Kebriaei P, Champlin RE, Andersson BS. Clofarabine ± Fludarabine with IV Busulfan and Allogeneic Stem Cell Transplantation for Advanced Myeloid Leukemia (ML) and MDS. Biol Blood Marrow Transplant 2014 BMT Tandem Meetings 20(2, Supplement):S152-S153, 2014. e-Pub 2014.
395. Pingali SR, Milton D, di Stasi A, Patel RD, Kebriaei P, Popat UR, Alousi AM, Anderlini P, Qazilbash MH, Hosing C, Rezvani K, Bashir Q, Oran B, Shpall EJ, Khouri IF, Champlin RE, Ciurea SO. Haploidentical Transplantation for Advanced Hematologic Malignancies Using Melphalan-Based Conditioning – Mature Results from a Single Center. Biol Blood Marrow Transplant 2014 BMT Tandem Meetings 20(2, Supplement):S40-S41, 2014. e-Pub 2014.
396. Pingali SR, Denai M, Di Stasi A, Kebriaei P, Popat UR, Alousi A, Anderlini P, Parmar S, Hosing CM, Andersson BS, Bashir Q, Ahmed S, Oran B, Shpall EJ, Khouri I, Konopleva M, Alatrash G, Champlin RE, Ciurea SO. Haploidentical Transplantation For Patients With Advanced Hematologic Malignancies With Melphalan-Based Conditioning – Interim Results From a Phase II Clinical Trial. Blood 55th ASH Annual Meeting 122(21):4523, 2013. e-Pub 2013.
397. Oran B, Poon M, Chen J, Rondon G, Ahmed S, Andersson BS, Qaiser Bashir Q, Ciurea SO, Hosing CM, Parmar S, Qazilbash MH, Popat UR, Nieto Y, Alousi A, Jones RB, Rezvani K, de Lima M, Shpall EJ, Champlin RE, Kebriaei P. Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblatic Leukemia (ALL) With First Complete Remission (CR). Blood 55th ASH Annual Meeting 122(21):2142, 2013. e-Pub 2013.
398. Nieto Y, Thall PF, Valdez BC, Hosing CM, Ahmed S, Jones RB, Shah N, Anderlini P, Qazilbash MH, Popat UR, Bashir Q, Shpall EJ, Alousi A, Kebriaei P, Fox P, Bassett R, Chancoco C, Oki Y, Fanale MA, Fowler N, Hagemeister F, Romaguera JE, Champlin RE, Andersson BS. Vorinostat (SAHA) Combined With High-Dose Gemcitabine/Busulfan/Melphalan (SAHA/Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Patients With Refractory Lymphomas. Blood 55th ASH Annual Meeting 122(21):2095, 2013. e-Pub 2013.
399. Ahmed S, Di Stasi A, Shpall EJ, Khouri IF, Alousi AM, Ciurea SO, Bashir Q, Qazilbash M, Jones RB, Nieto Y, Parmar S, Kebriaei P, Shah N, Rezvani K, Hosing CM, Oran B, Andreeff M, Anderlini P, Andersson BS, Champlin RE, Popat U. Development of Donor Cell Derived Leukemia After Allogeneic Stem Cell Transplant. Blood 55th ASH Annual Meeting 124(21):2083, 2013. e-Pub 2013.
400. Shah JJ, Baladandayuthapani V, Weber CM, Thomas SK, Alexanian R, Wang M, Qazilbash MH, Champlin RE, Shah N, Bashir Q, Popat UR, Nieto Y, Ahmed S, Parmar S, Orlowski RZ. Phase II Study Of The Combination Of MLN 9708 With Lenalidomide As Maintenance Therapy Post Autologous Stem Cell Transplant In Patients With Multiple Myeloma. Blood 55th ASH Annual Meeting 122(21):1983, 2013. e-Pub 2013.
401. Daver N, Kantarjian HM, Faderl SH, Garcia-Manero G, O'Brien S, Ferrajoli A, Verstovsek S, Popat U, Hosing CM, Kadia TM, Cortes JE, Ravandi F, Anderlini P. Clinical Characteristics and Outcomes In Patients With Acute Promyelocytic Leukemia (APL) and Hyperleukocytosis. Blood 55th ASH Annual Meeting 122(21):1343, 2013. e-Pub 2013.
402. Ustun C, Reiter A, Scott BL, Nakamura R, Gandhi D, Kreil S, Shanley R, Hogan WJ, Perales MA, Shore TB, Baurmann H, Stuart RK, Gruhn B, Doubek M, Hsu JW, Tholouli E, Gromke T, Godley LA, Pagano L, Gilman A, Wagner EM, Shwayder T, Bornhaeuser M, Papadopoulos EB, Boehm A, Vercellotti GM, Lint MTV, Schmid C, Rabitsch W, Pullarkat V, Barrett AJ, Hermine O, Hagglund HG, Sperr WR, Popat UR, Devine SM, Deeg HJ, Weisdorf DJ, Akin C, Valent P. Allogeneic Hematopoietic Cell Transplantation Is Effective In Patients With Advanced Systemic Mastocytosis: A Multicenter Retrospective Analysis. Blood 55th ASH Annual Meeting 122(21):2145, 2013. e-Pub 2013.
403. Di Stasi A, Poon LM, Ferro R, Milton D, Rondon G, Wang SA, Hamdi A, Qazilbash MH, Ahmed S, Khouri I, Oran B, Hosing CM, Kebriaei P, Alousi A, Popat UR, Shpall EJ, Lee DA, Rezvani K, Champlin RE, Ciurea SO. Transplant Outcomes For Patients With AML/MDS Using Melphalan-Based Conditioning. Blood 55th ASH Annual Meeting 122(21):2167, 2013. e-Pub 2013.
404. Kongtim P, Popat UR, De Lima M, Garcia-Manero G, Jabbour EJ, Chen J, Rondon G, Abruzzo LV, Ciurea SO, Shpall EJ, Champlin RE, Oran B. MD Anderson Scoring System (MDACC) Predicts Outcomes After Hematopoietic Stem Cell Transplantation (HSCT) Better Than Other Prognostic Classifications In MDS. Blood 55th ASH Annual Meeting 122(21):3340, 2013. e-Pub 2013.
405. Nieto Y, Shah N, Popat UR, Jones RB, Bashir Q, Bassett R, Valdez BC, Andersson BS, Parmar S, Orlowski RZ, Shah JJ, Thomas SK, Wang M, Champlin RE, Qazilbash M. High-Dose Gemcitabine Combined With Busulfan and Melphalan (Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Refractory and Relapsed Myeloma. Blood 55th ASH Annual Meeting 122(21):3346, 2013. e-Pub 2013.
406. Popat UR, Oran B, Hosing CM, Kebriaei P, Rezvani K, Parmar S, Shah N, Bollard CM, Molldrem JJ, Nieto Y, Andersson BS, Alousi A, Jones RB, Cooper LJN, Qazilbash MH, Bashir Q, Ahmed S, Bosque D, Chen J, McCarty J, Rondon G, Munsell M, McNiece IK, Kaur I, Yvon E, Annandale K, Olchesky S, J de Lima M, Champlin RE, Miller L, Paradiso L, Koh L, Zweidler-McKay PA, Shpall EJ. Ex Vivo Fucosylation Of Cord Blood Accelerates Neutrophil and Platelet Engraftment. Blood 55th ASH Annual Meeting 122(21):691, 2013. e-Pub 2013.
407. Khouri IF, Wei W, Valverde R, Korbling M, Turturro F, Gulbis AM, Guillermo-Pacheco M, Ahmed S, Alousi A, Oran B, Anderlini P, Ciurea SO, Hosing CM, Popat UR, Jabbour E, Champlin RE, Bassett R. Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning: A Novel Regimen Inducing Immunosuppression Without Myelosuppression. Blood 55th ASH Annual Meeting 122(21):541, 2013. e-Pub 2013.
408. Anderlini P, Saliba RM, Ledesma C, Chancoco CM, Alexander T, Alousi A, Hosing CM, Khouri I, Nieto Y, Popat UR, Shpall EJ, Fanale MA, Oki Y, Romaguera JE, Neelapu S, Younes A, Champlin RE. Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM). Blood 55th ASH Annual Meeting 122(21):410, 2013. e-Pub 2013.
409. Khouri IF, Saliba RM, Challagundla P, Ledesma C, Korbling M, Gulbis AM, Guillermo-Pacheco M, Ahmed S, Anderlini P, Bashir Q, Oran B, Ciurea SO, Hosing CM, Kebriaei P, Popat UR, Jabbour E, Champlin RE, Jorgensen JL. Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis. Blood 55th ASH Annual Meeting 122(21):3349, 2013. e-Pub 2013.
410. Khouri IF, Saliba RM, Xu-Monette ZY, Rondon G, Valverde R, Korbling M, Gulbis AM, Anderlini P, Ahmed S, Hosing CM, Popat UR, Kebriaei P, Fayad LE, Westin JR, Turturro F, Medeiros LJ, Champlin RE, Young KH. Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan ( 90 YIT). Blood 55th ASH Annual Meeting 122(21):3350, 2013. e-Pub 2013.
411. Nusrat M, Kazmi SM, Cornelison AM, Kebriaei P, Nieto Y, Oran B, Orlowski RZ, Parmar S, Popat UR, Shah JJ, Shah N, Champlin RE, Qazilbash MH, Bashir Q. Outcomes Among High Risk and Standard Risk Multiple Myeloma Patients Treated With High Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. Blood 55th ASH Annual Meeting 122(21):3358, 2013. e-Pub 2013.
412. Adekola KUA, Bashir Q, Shah N, Pingali SR, Parmar S, Popat UR, Hosing CM, Champlin RE, Qazilbash MH. Characteristics Of Multiple Myeloma Patients With 6-Year Or Longer Progression-Free Survival After a Single Autologous Transplant. Blood 55th ASH Annual Meeting 124(21):3366, 2013. e-Pub 2013.
413. Patel K, Feng L, Oki Y, Qazilbash M, Muzzafar T, Weber DM, Fowler N, Popat UR, Thomas SK, Fanale MA, Nieto Y, Shah N, Bashir Q, Hagemeister FB, Orlowski RZ, Shah JJ. Plasmablastic Lymphoma: 28 Patient Single Institution Experience. Blood 55th ASH Annual Meeting 122(21):4310, 2013. e-Pub 2013.
414. Pingali SR, Saliba RM, Smith VR, Maadani F, Adekola KUA, Popat UR, Qazilbash MH, Bashir Q, Khouri I, Kebriaei P, Ciurea SO, Anderlini P, Shah N, Nieto Y, Champlin RE, Hosing CM. Number Of Apheresis Days To Reach Target Stem Cell Dose May Be a Predictor Of Secondary Myelodysplastic Syndrome and Acute Myelogenous Leukemia. Blood 55th ASH Annual Meeting) 122(21):4515, 2013. e-Pub 2013.
415. Ghobadi A, Hamdi A, Kongtim P, Milton D, Alousi A, Anderlini P, Ciurea SO, Oran B, Khouri I, Parmar S, Qazilbash MH, Kebriaei P, Popat UR, Rezvani K, Chemaly RF, Shpall EJ, Champlin RE, Bashir Q. The Effect Of CMV Reactivation On Relapse and Survival In Patients With AML and MDS After Allogeneic Stem Cell Transplant (allo-HCT). Blood 55th ASH Annual Meeting 122(21):4531, 2013. e-Pub 2013.
416. Oran B, Kongtim P, de Lima M, Popat UR, Garcia-Manero G, Jabbour EJ, Abruzzo LV, Chen J, Rondon G, Andersson BS, Alousi AM, Ciurea SO, Shpall EJ, Champlin RE. Prior Hypomethylating Agents or Chemotherapy Does Not Improve The Outcome of Allogeneic Hematopoietic Transplantation for High Risk MDS. Blood 55th ASH Annual Meeting 122(21):305, 2013. e-Pub 2013.
417. Shah RA, Mohite S, Baladandayyuthapani V, Thomas SK, Weber DM, Wang M, Alexanian R, Qazilbash MH, Popat UR, Champlin RE, Shah N, Bashir Q, Parmar S, Nieto Y, Ahmed S, Orlowski RZ, Shah JJ. Circulating Plasma Cells By Routine Complete Blood Count Identify Patients With Similar Outcome As Plasma Cell Leukemia. Blood 55th ASH Annual Meeting 122(21):5356, 2013. e-Pub 2013.
418. Cornelison AM, Dinh Y, Sharma M, Shah N, Bashir Q, Parmar S, Hosing CM, Popat UR, Champlin RE, Qazilbash MH. Bortezomib With High-Dose Melphalan, Arsenic Trioxide, and Ascorbic Acid In a Preparative Regimen For Multiple Myeloma: 5-Year Follow Up. Blood 55th ASH Annual Meeting 122(21):5547, 2013. e-Pub 2013.
419. Aung FM, Lichtiger B, Alousi A, Ahmed S, Anderlini P, Andersson BS, Bashir Q, Ciurea SO, Jones RB, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash MH, Shah N, Khouri I, Shpall EJ, Champlin RE, Popat UR. Pure Red Cell Aplasia In Major ABO Mismatched Allogeneic Hematopoietic Cell Transplantation Is Associated With Severe Pancytopenia. Blood 55th ASH Annual Meeting 122(21):5449, 2013. e-Pub 2013.
420. Popat UR, Bassett R, Chen J, Alousi AM, Anderlini P, Ciurea SO, Hosing C, Jones RB, Kebriaei P, Khouri IF, Konoplev S, De Lima M, Nieto Y, Oran B, Qazilbash MH, Rondon G, Shpall EJ, Verstovsek S, Andersson B, Champlin RE. Allogeneic Transplantation for Myelofibrosis: Benefit of Dose Intensity. J Clin Oncol 2013 ASCO Annual Meeting 31(15_suppl):7011, 2013. e-Pub 2013.
421. Jimenez AM, De Lima M, Popat UR, g B, Abruzzo L, Andersson B, Garcia-Manero G, Jabbour E, Chen J, Bashir Q, Ciurea SO, Kebriaei P, Ahmed S, Khouri IF, Kongtim P, Qazilbash MH, Rondon G, Shpall EJ, Champlin RE, Oran B. Impact of monosomal karyotype and FLT3 status on post-transplant relapse in acute myeloid leukemia (AML). J Clin Oncol 2013 ASCO Annual Meeting 31(15_suppl):7010, 2013. e-Pub 2013.
422. Nash R, Hutton GJ, Racke M, Popat U, Devine SM, Georges G, Griffith L, Muraro PA, Openshaw H, Sayre P, Stuve O, Arnold D, Spychala M. Treatment of Severe Relapsing-Remitting Multiple Sclerosis with High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation: 2-Year Follow-up Results of the HALT MS Clinical Trial (Immune Tolerance Network: ITN033AI). Biol Blood Marrow Transplant 2013 BMT Tandem Meetings 19(2, Supplement):S129, 2013. e-Pub 2013.
423. Cornelison AM, Parmar S, Bashir Q, Shah N, Howell J, Hosing C, Popat U, Champlin RE, Qazilbash M. Autologous Hematopoietic Stem Cell Transplantation in Light Chain Amyloidosis (AL) With Renal Involvement. Biol Blood Marrow Transplant 2013 BMT Tandem Meetings 19(2, Supplemental):S234-S235, 2013. e-Pub 2013.
424. Parmar S, Howell J, Wang M, Khan M, Bashir Q, Shah N, Shah J, Popat U, Dinh Y, Giralt SA, Champlin RE, Orlowski R, Qazilbash M. High Dose Therapy Improves Survival in Systemic Light Chain Amyloidosis. Biol Blood Marrow Transplant 2013 BMT Tandem Meetings 19(2, Supplemental):S125-S126, 2013. e-Pub 2013.
425. Howell J, Parmar S, Bashir Q, Shah N, Hosing C, Popat U, Cornelison M, Champlin RE, Qazilbash M. Fluid Retention and Weight Gain During Peripheral Blood Hematopoietic Stem Cell Mobilization in Light Chain Amyloidosis. Biol Blood Marrow Transplant 2013 BMT Tandem Meetings 19(2, Supplemental):S183-S184, 2013. e-Pub 2013.
426. Fauble V, Emanuel RM, Geyer HL, Dueck AC, Kroeger N, Scott BL, Gerds AT, Popat UR, Giralt SA, Gupta V, Ross D, Knight E, Fuentes AK, Andersen CL, Ejerblad E, Birgegard G, Johansson P, Andreasson B, Sackmann F, Demory JL, Tam CS, Michiels JJ, Radia DH, Boxer M, Mesa RA. Myeloproliferative Neoplasm Quality Of Life (MPN-QOL) Study Group: Observational Study Of Quality Of Life and Symptomatic Response In Myelofibrosis Patients Receiving Undergoing Treatment With Conventional Therapy, The Measures Trial and Allogeneic Stem Cell Transplant, The Symptoms Trial. Blood 55th ASH Annual Meeting 122(21):4090, 2013. e-Pub 2013.
427. Alousi AM, Saliba RM, Chen J, Andersson BS, Khouri I, Qazilbash MH, Popat UR, Hosing CM, Ciurea SO, Shpall EJ, Jones RB, Kebriaei P, Nieto Y, Anderlini P, deLima M, Rondon G, Champlin RE. A Matched Controlled Analysis of Post-Transplant Cyclophosphamide (CY) Versus Tacrolimus and Mini-Dose Methotrexate in Matched Sibling and Unrelated Donor Transplant Recipients Receiving Reduced-Intensity Conditioning: Post-Transplant CY Is Associated with Higher Rates of Acute Gvhd. Blood 54rd ASH Annual Meeting 120(21):4200, 2012. e-Pub 2012.
428. Khan D, Patel K, Thomas SK, Weber DM, Delasalle KB, Hosing CM, Popat UR, Bashir Q, Shah N, Parmar S, Champlin RE, Qazilbash M. Feasibility of Hematopoietic Stem Cell Collection and Cryopreservation in Waldenstrom's Macroglobulinemia. Blood 54rd ASH Annual Meeting 120(21):4128, 2012. e-Pub 2012.
429. Khouri IF, Rima SM, Turturro F, Korbling M, Ledesma C, Rondon G, Alousi AM, Anderlini P, Bashir Q, Ciurea SO, Hosing CM, Popat UR, Charafeddine Y, Oki Y, Fayad LE, Champlin RE. Bortezomib and BEAM-Rituximab Reduced-Intensity Conditioning for High-Risk Lymphoma Patients Who Are Not Eligible for Nonmyeloablative Allogeneic Stem Cell Transplantation. Blood 54rd ASH Annual Meeting 120(21):4157, 2012. e-Pub 2012.
430. Benton CB, Konopleva M, Saliba RM, Shpall EJ, Ciurea SO, Kebriaei P, Alousi AM, Popat UR, Anderlini P, Nieto Y, Parmar S, Zeng Z, Chen JJ, Rondon G, McMullin B, Wang R, Lu H, Schober WD, Woodworth GG, Gulbis A, Cool R, Qiao W, Thall PF, Andreeff M, and Champlin RE. Leukemia Cell Mobilization with Plerixafor Plus G-CSF with Busulfan/Fludarabine and Allogeneic Hematopoietic Cell Transplantation in Patients with AML/MDS Is Associated with Decreased Complete Chimerism and GvHD, and Increased Risk of Relapse. Blood 54rd ASH Annual Meeting 120(21):360, 2012. e-Pub 2012.
431. Shah JJ, Weber DM, Thomas SK, Alexanian R, Wang M, Qazilbash M, Parmar S, Shah N, Bashir Q, Popat UR, Hilder B, and Orlowski RZ. Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood 54rd ASH Annual Meeting 120(21):4082, 2012. e-Pub 2012.
432. de Lima M, Parmar S, Chen JJ, Giralt SA, Rondon G, Popat UR, Alousi AA, Lee HC, Woodworth GG, Hosing CM, Shpall E, Kebriaei P, Manero GG, Champlin RE, and Saliba RM. Low Dose Azacitidine (AZA) Reduces the Incidence of Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Blood 54rd ASH Annual Meeting 120(21):742, 2012. e-Pub 2012.
433. Parmar S, Howell J, Wang M, Khan MA, Bashir Q, Shah JJ, Shah N, Popat UR, Giralt SA, Orlowski RZ, and Qazilbash M. High Dose Therapy Improves Survival in Systemic Light Chain Amyloidosis: 14 Year Follow up. Blood 54rd ASH Annual Meeting 120(21):750, 2012. e-Pub 2012.
434. Shah JJ, Orlowski RZ, Thomas SK, Alexanian R, Wang M, Qazilbash MH, Popat UR, Parmar S, Shah N, Bashir Q, Champlin RE, and Weber DM. Final Results of a Phase I/II Trial of the Combination of Concurrent Lenalidomide, Thalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Myeloma. Blood 54rd ASH Annual Meeting 120(21):75, 2012. e-Pub 2012.
435. Shah JJ, Thomas SK, Weber DM, Wang M, Alexanian R, Qazilbash MH, Bashir Q, Parmar S, Shah N, Popat UR, Orlowski RZ. Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood 54rd ASH Annual Meeting 120(21):4081, 2012. e-Pub 2012.
436. Gul Z, Bashir Q, Nieto Y, Sherwani N, Parmar S, Shah N, Dinh YT, Hosing CM, Popat UR, Kebriaei P, Shpall EJ, Giralt SA, Champlin RE, Qazilbash MH. Cardiac Toxicity After High-Dose Melphlan and Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Blood 54rd ASH Annual Meeting 120(21):2027, 2012. e-Pub 2012.
437. Gul Z, Khan H, Bashir Q, Shah N, Parmar S, Dinh YT, Hosing CM, Popat UR, Kebriaei P, Anderlini P, Shpall EJ, Giralt S, Champlin RE, and Qazilbash MH. EBMT Risk Score for Pre Transplant Risk Assessment in Patients with Multiple Myeloma. Blood 54rd ASH Annual Meeting 120(21):3094, 2012. e-Pub 2012.
438. Nash RA, Hutton GJ, Racke MK, Popat UR, Devine SM, Georges GE, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stuve O, Arnold DL, Spychala M, Lim N, Malhotra S, Phippard D, Wundes A, Kraft GH, and Bowen JD. Treatment of Severe Relapsing-Remitting Multiple Sclerosis with High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation: 2-Year Follow-up Results of the HALT MS Clinical Trial (Immune Tolerance Network: ITN033AI). Blood 54rd ASH Annual Meeting 120(21):962, 2012. e-Pub 2012.
439. Hamdi A, Poon LM, Saliba RM, Rondon G, Ledesma C, Qazilbash M, Hosing CM, Jones RB, Popat UR, Nieto Y, Alousi AM, Ciurea SO, Shpall EJ, Champlin RE, Kebriaei P. Outcomes of Adults with Acute Lymphoblastic Leukemia (ALL) Following Relapse After First Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Blood 54rd ASH Annual Meeting 120(21):4215, 2012. e-Pub 2012.
440. Patel K, Saliba RM, Shah N, Bashir Q, Thomas SK, Dinh YT, Hosing CM, Popat UR, Parmar S, Giralt SA, Champlin RE, and Qazilbash MH. Autologous Stem Cell Transplantation in Waldenstrom's Macroglobulinemia. Blood 54rd ASH Annual Meeting 120(21):4533, 2012. e-Pub 2012.
441. Najera JE, Sudhakar T, Bashir Q, Shah N, Champlin RE, Qazilbash MH, Giralt S, Hosing C, Popat UR, Ciruea SO. Neurotoxicity after high-dose melphalan. J Clin Oncol 2012 ASCO Annual Meeting 30(15_suppl):6546, 2012. e-Pub 2012.
442. Sasaki K, Lu G, Hosing C, Popat UR, Ahmed S, Shah N, Bashir Q, Dinh Y, Orlowski RZ, Champlin RE, Qazilbash M. Impact of t (11;14) on the outcome of autologous hematopoietic cell transplantation (Auto-HCT) in multiple myeloma. J Clin Oncol 2012 ASCO Annual Meeting 30(15_suppl):8040, 2012. e-Pub 2012.
443. Bashir Q, Parmar S, Dinh Y, Qureshi S, Rondon G, Popat UR, Nieto Y, Jones RB, Champlin RE, Qazilbash M, Shah N. Association of bone marrow plasma cell infiltration pre-auto transplant with adverse outcomes in multiple myeloma. J Clin Oncol 2012 ASCO Annual Meeting 30(15_suppl):8102, 2012. e-Pub 2012.
444. Poon LM, Bassett R, Rondon G, Worth LL, Cooper L, Popat UR, Nieto Y, de Lima MJ, Champlin RE, Kebriaei P. Outcomes of second allogeneic hematopoietic stem cell transplantation (SCT) for patients with acute lymphoblastic leukemia (ALL). J Clin Oncol 2012 ASCO Annual Meeting 30(15_suppl):6540, 2012. e-Pub 2012.
445. Hosing C, Saliba R, Singh L, Popat U, Qazilbash M, Anderlini P, Nieto Y, Alousi A, Frazier E, Dabaja E, Champlin R, Duvic M. Total skin Electron Beam radiation therapy and allogeneic haematopoietic stem cell transplantation in advanced mycosis fungoides and Sezary syndrome. Bone Marrow Transplantation 38th Annual EBMT Meeting 47(Suppl 1):S85, 2012. e-Pub 2012.
446. Farhan S, Lin H, Baladandayuthapani V, Shah N, Bashir Q, Hosing C, Popat U, Parmar S, Dinh Y, Qureshi S, Rondon G, Giralt S, Champlin R, Qazilbash M. Outcome of patients with nonsecretory multiple myeloma after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012 BMT Tandem Meetings 18(2, Supplemental):S248-S249, 2012. e-Pub 2012.
447. Hammerstrom AE, Howell JE, Gulbis AM, Wilhelm KL, Hart JW, Popat UR. Observational study of tacrolimus-induced posterior reversible encephalopathy syndrome in allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2012 BMT Tandem Meetings 18(2, Supplemental):S375-S376, 2012. e-Pub 2012.
448. Nieto Y, Jones RB, Liu P, Anderlini P, Popat U, Andersson B, Shpall EJ, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Chancoco C, Bashir Q, Ciurea S, Parmar S, Champlin R. Comparison of gemcitabine, busulfan and melpahlan (Gem/Bu/Mel) with beeam and busulfan/melphalan (Bu/Mel) in concurrent cohorts of refractory hodgkin's lymphoma (HL) patients receiving an autologous stem-cell transplant. Biol Blood Marrow Transplant 2012 BMT Tandem Meetings 18(2, Supplemental):S206-S207, 2012. e-Pub 2012.
449. Nieto Y, Jones RB, Popat U, Andersson B, Valdez B, Thall P, Shpall EJ, Chancoco C, Alousi A, Anderlini P, Hosing C, Qazilbash M, Bashir Q, Kebriaei P, Khouri I, Ciurea S, Parmar S, Rondon G, Champlin R. Gemcitabine, Busulfan and Melphalan (Gem/Bu/Mel) is a new high-dose chemotherapy (HDC) reimen with high activity in refractory or poor-risk relapsed non-hodgkin's lymphoma (NHL) patients receiving an autologous stem-cell transplant (ASCT). Biol Blood Marrow Transplant 2012 BMT Tandem Meetings 18(2, Supplement):S206, 2012. e-Pub 2012.
450. Ahmed S, Dinh Y, Rondon G, Andersson B, Jones R, Bashir Q, Shah N, Popat U, Champlin RE, Qazilbash MH, Kebriaei P. Comparison of busulfan + melphalan to melphalan 200 mg/m2 as preparative regimen for autologous transplantation in multiple myeloma. Biol Blood Marrow Transplant 2012 BMT Tandem Meetings 18(2, Supplement):S251, 2012. e-Pub 2012.
451. Nieto Y, Thall PF, Andersson BS, Popat UR, Anderlini P, Valdez BC, Shpall EJ, Qazilbash M, Alousi AM, Chancoco C, Hosing CM, Kebriaei P, Bashir Q, Shah N, Khouri I, Ciurea SO, McMullin B, Rondon G, Champlin R, Jones R. High-Dose Infusional Gemcitabine (Gem) Combined with Busulfan (Bu) and Melphalan (Mel) (GemBuMel) with Autologous Stem-Cell Transplant (ASCT) in Patients with Refractory Lymphoid Malignancies. Blood 53rd ASH Annual Meeting 118(21):3083, 2011. e-Pub 2011.
452. Anguita T, Chiattone A, Hamerschlak N, Saliba RM, Tang XW, Wu D, Majilis A, Sakashita AM, Chiattone VC, Barros JC, Chiattone CS, Kutner JM, Rodrigues M, Kondo AT, Okoroji GJ, Mac-Donald Bley do Nascimento C, Fernandes JF, Popat U, Champlin RE, Anderlini P, de Lima M, Hosing CM. Prediction of Apheresis Peripheral Blood Stem Cell Yield Based on Pre Apheresis Absolute Peripheral Blood Stem Cell Counts. Blood 53rd ASH Annual Meeting 118(21):4047, 2011. e-Pub 2011.
453. Saliba RM, Chiattone A, Majlis A, Chiattone VC, Rondon G, Sakashita AM, Hamerschlak N, Kutner JM, Shpall EJ, Anderlini P, Khouri I, Qazilbash MH, Popat U, Champlin R, Hosing CM, de Lima M. Predictors of Stem Cell Yield Via Apheresis in Patients Undergoing Stem Cell Mobilization. Blood 53rd ASH Annual Meeting 118(21):4058, 2011. e-Pub 2011.
454. Qazilbash M, Thall PF, Liu P, Orlowski RZ, Bashir Q, Shah N, Kebriaei P, Parmar S, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Shah JJ, de Lima M, Champlin R, Giralt S. A Randomized Phase II Trial of Fludarabine/Melphalan 140 Vs Fludarabine/ Melphalan 100 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. Blood 53rd ASH Annual Meeting 118(21), 2011. e-Pub 2011.
455. de Lima M, Ahmed S, Shpall EJ, Rondon G, Chen J, Woodworth GG, Chiattone A, Chu DT, Popat UR, Campos SR, Alousi AM, Hosing CM, Parmar S, Kebriaei P, Khouri IF, Cortes JE, Issa JPJ, Champlin R. Sequential Therapy with Allogeneic Transplant Followed by Low-Dose Azacitidine for CML Patients That Failed Multiple Tyrosine Kinase Inhibitors. Blood 53rd ASH Annual Meeting 118(21):3106, 2011. e-Pub 2011.
456. Ahmed S, Lin H, Baladandayuthapani V, Khan MA, Lu G, Rondon G, Qureshi S, Dinh YT, Bashir Q, Shah N, Parmar S, Hosing CM, Popat U, Giralt SA, Orlowski RZ, Shah JJ, Champlin R, Qazilbash MH. Impact of Non High-Risk Chromosomal Abnormalities on the Outcome of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Blood 53rd ASH Annual Meeting 118(21):333, 2011. e-Pub 2011.
457. Khouri IF, Saliba RM, Valverde R, Samuels BI, Korbling M, Alousi AM, Anderlini P, Bashir Q, de Lima M, Hosing C, Kebriaei P, Nieto Y, Popat UR, Qazilbash M, Neelapu S, Fowler NH, Samaniego F, Wang L, Champlin R, Macapinlac HA. Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90yttrium Ibritumomab Tiuxetan (90YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results. Blood 53rd ASH Annual Meeting 118(21):662, 2011. e-Pub 2011.
458. Andersson BS, de Lima MJ, Saliba RM, Shpall EJ, Popat U, Jones R, Nieto Y, Hosing CM, Kebriaei P, Alousi AM, Worth LL, Madden T, Gulbis A, Chen JJ, Rondon G, McAdams P, McMullin B, Andreeff M, Champlin R. Pharmacokinetic Dose Guidance of IV Busulfan with Fludarabine with Allogeneic Stem Cell Transplantation Improves Progression Free Survival in Patients with AML and MDS; Results of a Randomized Phase III Study. Blood 53rd ASH Annual Meeting 118(21):892, 2011. e-Pub 2011.
459. Khouri IF, Saliba RM, Korbling M, Alousi AM, Popat U, Anderlini P, Ciurea SO, Kebriaei P, Qazilbash MH, Champlin R, Jr BR. Nonmyeoablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for Lymphoid Malignancies: Immunosuppression without Myelosuppression and without Acute Gvhd. Blood 53rd ASH Annual Meeting 118(21):894, 2011. e-Pub 2011.
460. Zipp L, Saliba RM, Valverde R, Okoroji GJ, Korbling K, Samuels BI, Bruzzo LV, Alousi AM, Andersson BS, Hosing CM, Erwin B, Anderlini P, Popat UR, Kebriaei P, Macapinlac HA, Champlin R, Khouri IF. Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90 Ibritumomab Tiuxetan (Zevalin ® ) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies. Blood 53rd ASH Annual Meeting 118(21):2005, 2011. e-Pub 2011.
461. Popat U, Andersson BS, Bassett R, Ciurea S, Rondon G, Alousi AM, Anderlini P, Hosing C, Jones R, Kebriaei P, Nieto Y, Khouri I, Shpall EJ, Verstovsek S, Qazilbash M, de Lima MJ, Champlin R. Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: PK Guided IV Busulfan Dose Intensity Results in Improved Event Free Survival. Blood 53rd ASH Annual Meeting 118(21):2006, 2011. e-Pub 2011.
462. Anderlini P, Saliba RM, Ledesma C, Chancoco CM, Acholonu S, Valverde R, Popat UR, Hosing CH, Alousi AM, Shpall EJ, Nieto Y, Ciurea SO, Khouri I, Champlin R. Gemcitabine, Fludarabine, and Melphalan (G-FM) as Reduced-Intensity Conditioning (RIC) Regimen for Allogeneic Stem Cell Transplantation (Allo-SCT) in Relapsed and Refractory Hodgkin Lymphoma (HL). Blood 53rd ASH Annual Meeting 118(21):3083, 2011. e-Pub 2011.
463. Rathi N, Dinh A, Haque SA, Feng L, Liu S, Dong W, Nates JL, Price KJ, Popat U. Outcomes of High Dose Steroid Treatment with or without Aminocaproic Acid in Critically Ill Stem Cell Transplant Recipients with Diffuse Alveolar Hemorrhage. Blood 53rd ASH Annual Meeting 118(21):3058, 2011. e-Pub 2011.
464. Zhou Y, Jorgensen JL, Saliba RM, Wang SA, Rondon G, Ledesma C, Andersson BS, de Lima MJ, Shpall EJ, Popat U, Ciurea SO, Alousi AM, Qazilbash M, Hosing CM, Medeiros LJ, Champlin R, Kebriaei P. Pre-Transplant Minimal Residual Disease Detected by Multiparameter Flow Cytometric Analysis Predicts for Disease Relapse in Adult Patients with Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Stem Cell transplantation. Blood 53rd ASH Annual Meeting 118(21):3072, 2011. e-Pub 2011.
465. Nash RA, Hutton GJ, Racke MK, Popat UR, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stuve O, Arnold DL, Wruck L, Wundes A, Kraft GH, Bowen JD. Treatment of Severe Relapsing-Remitting Multiple Sclerosis with High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation: Early Results of the HALT MS Clinical Trial (Immune Tolerance Network: ITN033AI). Blood 53rd ASH Annual Meeting 118(21):3075, 2011. e-Pub 2011.
466. Beitinjaneh A, Saliba RM, Okoroji GJ, Korbling M, Alousi AM, Popat U, Anderlini P, Bashir Q, Andersson BS, Kebriaei P, Hosing CM, Qazilbash M, Fanale MA, Pro B, Champlin R, Khouri I. Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M.D. Anderson Cancer Center Experience. Blood 53rd ASH Annual Meeting 118(21):4118, 2011. e-Pub 2011.
467. Farhan S, Lin H, Baladandayuthapani V, Shah N, Bashir Q, Hosing CM, Popat U, Parmar S, Dinh YT, Qureshi S, Rondon G, Giralt S, Champlin R, Qazilbash MH. Response Before Autologous Hematopoietic Stem Cell Transplantation Is An Important Predictor of Outcome in Multiple Myeloma. Blood 53rd ASH Annual Meeting 118(21):4119, 2011. e-Pub 2011.
468. Shah N, Bashir Q, Parmar S, Dinh YT, Qureshi S, Rondon G, Popat UR, Nieto Y, Jones R, Champlin R, Qazilbash MH. Increased Bone Marrow Plasma Cell Infiltration Pre-Transplant Is Associated with Worse Outcomes in Patients Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation for Multiple Myeloma. Blood 53rd ASH Annual Meeting 118(21):4135, 2011. e-Pub 2011.
469. Kazmi S, Lu G, Shah N, Bashir Q, Parmar S, Orlowski RZ, Shah JJ, Hosing CM, Popat U, Dinh YT, Qureshi S, Rondon G, Giralt S, Champlin R, Qazilbash MH. A Comparative Study of the Outcome of High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation in Patients with High-Risk or Standard-Risk Myeloma Treated Concurrently. Blood 53rd ASH Annual Meeting 118(21):4156, 2011. e-Pub 2011.
470. Popat U, Bassett R, de Padua Silva L, Alousi AM, Anderlini P, Hosing CM, Jones R, Kebriaei P, Khouri I, Shpall EJ, Qazilbash MH, Garcia-Manero G, Andersson BS, Champlin R, de Lima MJ. Long Term Results of Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome: Analysis of Prognostic Factors. Blood 53rd ASH Annual Meeting 118(21):4531, 2011. e-Pub 2011.
471. Chiattone A, Saliba RM, Chiattone VC, Tang X, Hammerschiak N, Maadani F, Qazilbash MH, Popat U, Kebriaei P, champlin R, Hosing CM, DeLima M. Determinants of Higher Pre-Apheresis CD34+ Count in Patients Undergoing Autologous Hematopoietic Stem Cell Mobilization. Blood 53rd ASH Annual Meeting 118(21):4387, 2011. e-Pub 2011.
472. Chakhachiro ZI, Saliba RM, Okoroji GJ, Korbling M, Alousi AM, Hosing CM, DeLima M, Anderlini P, Popat U, Samuels BI, Medeiros LJ, Bueso-Ramos CE, Champlin RE, Khouri IF. 12-Year Experience with High-Dose Rituximab-Containing Autologous Stem Cell Transplantation for SOX11-Positive Mantle Cell Lymphoma Patients in First Remission: Emerging Lymphoma-Free Survival Plateau After 3 Years. Blood 53rd ASH Annual Meeting 118(21):4138, 2011. e-Pub 2011.
473. Anderlini P, Acholonu S, Okoroji GJ, Giralt SA, Jones R, Hosing CM, Qazilbash MH, Nieto Y, Andersson BS, Popat UR, Ueno NT, de Lima M, Champlin RE. Donor Leukocyte Infusions (DLIs) for Recurrent Hodgkin Lymphoma (HL) Following Allogeneic Stem Cell Transplantation (allo-SCT): Ten-Year Experience at the M.D. Anderson Cancer Center. Blood 53rd ASH Annual Meeting 118(21):4460, 2011. e-Pub 2011.
474. Beitinjaneh A, Saliba R, Okoroji G, Alousi AM, Popat UR, Korbling M, Anderlini P, Qazilbash M, Kebriaei P, Hosing C, Champlin RE, Khouri IF. Autologous stem cell transplantation (ASCT) as upfront or salvage therapy for noncutaneous T-cell lymphoma (TCL): The University of Texas M. D. Anderson Cancer Center (MDACC) experience. J Clin Oncology 2011 ASCO Annual Meeting 29(15_suppl):6565, 2011. e-Pub 2011. PMID: 28020173.
475. Khouri IF, Saliba R, Korbling M, Alousi AM, Popat UR, Anderlini P, Kebriaei P, Qazilbash M, Champlin RE, Bassett RL. Bendamustine in combination with fludarabine and rituximab: A novel nonmyeloablative conditioning for allogeneic stem cell transplantation (AST) in patients with lymphoid malignancies. J Clin Oncology 2011 ASCO Annual Meeting 29(15_suppl):e18511, 2011. e-Pub 2011. PMID: 28023240.
476. Andersson BS, Valdez BC, Thall PF, Wang X, Worth LL, Popat U, Alousi A, Hosing C, Jones RB, Shpall EJ, de Lima M, Champlin RE. Clofarabine ± Fludarabine and IV Busulfan With Allogeneic Stem Cell Transplantation for Advanced Myeloid Leukemia (ML) and MDS. Biol Blood Marrow Transplant 2011 BMT Tandem Meetings 17(2, Supplement):S293, 2011. e-Pub 2011.
477. Aung FM, Lichtiger B, Alousi A, Hosing C, Qazilbash M, de Lima M, Kebriaei P, Khouri I, Champlin RE, Popat U. The Incidence and Natural History of Pure Red Cell Aplasia in Major ABO Mismatched Hematopoietic Stem Cell Transplantation in Patients Receiving Modern Reduce Intensity and Reduced Toxicity Regimens. Biol Blood Marrow Transplant 2011 BMT Tandem Meetings 17(2, Supplement):S153, 2011. e-Pub 2011.
478. Beitinjaneh A, Shah N, Bashir Q, Parmar S, Hosing C, Popat U, Anderlini P, Dinh Y, Qureshi S, Rondon G, Champlin RE, Giralt SA, Qazilbash MH. Donor-Lymphocyte Infusion in Patients With Persistent or Recurrent Multiple Myeloma After Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2011 BMT Tandem Meetings 17(2, Supplement):S340, 2011. e-Pub 2011.
479. Ciurea SO, Saliba RM, Rondon G, Sharma M, Montes N, Bosque D, McMannis J, Fernandez-Vina M, Xie S, Konopleva M, Parmar S, Nieto Y, Kebriaei P, Qazilbash M, Alousi A, Popat U, Hosing CM, Shpall EJ, Khouri IF, de Lima M, Champlin RE. Haploidentical Stem Cell Transplantation for Minorities. Biol Blood Marrow Transplant 2011 BMT Tandem Meetings 17(2, Supplement):S227, 2011. e-Pub 2011.
480. Lecagoonporn S, Watson M, Popat U, Champlin R, Langford R, Cesario S, Young A. Predictive Effects of Malnutrition Indicators for Morbidity and Mortality Among Blood and Marrow Transplantation Recipients: A Retrospective Chart Review. Biol Blood Marrow Transplant 2011 BMT Tandem Meetings 17(2, Supplement):S193, 2011. e-Pub 2011.
481. Yilmaz M, Han XY, DeLima MJ, Hosing CM, Popat UR, Champlin RE, Qazilbash MH. Incidence and Outcome of Adenovirus infection in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients. Biol Blood Marrow Transplant 2011 BMT Tandem Meetings 17(2, Supplement):S290, 2011. e-Pub 2011.
482. Ciurea SO, Saliba RM, Rondon G, Patah PA, Aung F, Andersson BS, Kebriaei P, Popat U, Fernandez-Vina M, Champlin RE, de Lima M. Superior Outcomes with Matched Unrelated Donors Compared with One Human Leukocyte Antigen Mismatched Related Donors In Allogeneic Hematopoietic Stem Cell Transplantation. Blood 52nd ASH Annual Meeting 116(21):907, 2010. e-Pub 2010.
483. Sharma MR, Ravandi F, Chiattone A, Kebriaei P, Popat U, Giralt S, Bashir Q, Qazilbash MH, Nieto Y, Yuen CH, Parmar S, Kantarjian HM, Cortes J, Kadia T, Borthakur G, Champlin RE, de Lima M. Treatment of FLT3-ITD Positive AML Relapsing After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) with Sorafenib. Blood 52nd ASH Annual Meeting 116(21):3471, 2010. e-Pub 2010.
484. Sharma M, Saliba RM, Qazilbash MH, Okoroji GJ, Popat U, de Lima M, Champlin R, Hosing C. Poor FEV1 or DLco on Pre-Transplant PFT Does Not Compromise Outcomes In Patients Undergoing a Reduced-Intensity Allogeneic Progenitor Cell Transplant. Blood 52nd ASH Annual Meeting 116(21):1322, 2010. e-Pub 2010.
485. Vigil KJ, Adachi JA, Jiang Y, Popat U, Mahani MG, Granwehr BP, Gaeta S, Malik I, Champlin R, Raad II, Chemaly RF. Novel Influenza A (2009/H1N1) Infection In Patients with Hematological Malignancies During the 2009 Pandemic Outbreak: Early Antiviral Treatment Improves Survival. Blood 52nd ASH Annual Meeting 116(21):1731, 2010. e-Pub 2010.
486. Fanale MA, Lai CM, McLaughlin P, Romaguera J, Fayad L, Hagemeister F, Samaniego F, Rodriguez MA, Neelapu SS, Shah JJ, Kwak L, Dong W, Reed V, Dabaja BS, Popat U, Younes A. Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP. Blood 52nd ASH Annual Meeting 116(21):2812, 2010. e-Pub 2010.
487. Nieto Y, Anderlini P, Popat U, Liu P, Andersson BS, Shpall EJ, Kebriaei P, Hosing C, Alousi AM, Qazilbash MH, Ciurea SO, Parmar S, Champlin RE, Jones R. Gemcitabine, Busulfan and Melphalan (GemBuMel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity In Refractory Hodgkin’s Lymphoma (HL) Patients Receiving An Autologous Stem-Cell Transplant (ASCT): A Contemporaneous Comparison with BEAM and Busulfan/Melphalan (BuMel). Blood 52nd ASH Annual Meeting 116(21):690, 2010. e-Pub 2010.
488. Kebriaei P, Ledesma C, Culotta K, Shpall EJ, Ciurea SO, Alousi AM, De Lima M, Popat U, Thomas DA, Champlin RE, Andersson BS. Clofarabine (Clo) and Busulfan (Bu) as a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) In Patients (pts) with Acute Lymphoblastic Leukemia (ALL). Blood 52nd ASH Annual Meeting 116(21):3484, 2010. e-Pub 2010.
489. Shah JJ, Orlowski RZ, Alexanian R, Wang M, Thomas S, Qazilbash MH, Parmar S, Shah N, Bashir Q, Popat U, Weber D. Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma. Blood 52nd ASH Annual Meeting 116(21):1948, 2010. e-Pub 2010.
490. Okoroji GJ, Silva LD, Saliba RM, Korbling M, McLaughlin P, Hosing C, Anderlini P, Alousi A, de Lima M, Kebriaei P, Popat U, Qazilbash M, Fayad L, Samaniego F, Fowler N, Champlin R, Hagemeister F, Khouri IF. Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy. Blood 52nd ASH Annual Meeting 116(21):3510, 2010. e-Pub 2010.
491. Champlin R, Lee DA, Fernandez-Vina M, Rondon G, McAdams P, Chen J, Qazilbash MH, Kebriaei P, Parmar S, Shpall EJ, Popat U, Alousi A, Ciurea SO, Cooper L, Thall P, McMannis J. Alloreactive Nk Cells to Augment Antileukemia Cytotoxicity with Allogeneic Stem Cell Transplantation for Aml/Mds: A Phase I Study. Blood 52nd ASH Annual Meeting 116(21):489, 2010. e-Pub 2010.
492. Alousi AM, Andersson BS, Saliba RM, Botnick W, Rondon G, Shpall EJ, de Lima M, Popat U, Hosing C, Kebriaei P, Khouri I, Qazilbash MH, Anderlini P, Nieto Y, Ciurea S, Jones R, Champlin R. Reduced Intensity Conditioning Combined with Post-Transplant Cyclophosphamide for Graft Vs. Host Disease Prophylaxis In Older-Aged or Medically Frail Patients with Advanced Hematological Malignancies. Blood 52nd ASH Annual Meeting 116(21):2341, 2010. e-Pub 2010.
493. Chiattone A, Saliba RM, Andersson BS, Giralt S, Sharma MR, Rondon G, Kebriaei P, Hosing C, Popat U, Parmar S, Alatrash G, Bashir Q, Chen JJ, Yuen CH, Chiattone VC, Champlin RE, de Lima M. Treatment of AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Low-Dose Azacitidine (AZA). Blood 52nd ASH Annual Meeting 116(21):3445, 2010. e-Pub 2010.
494. Akpek G, Pasquini MC, Agovi MA, Logan B, Cooke KR, Maziarz RT, Gupta V, Lazarus HM, Hale GA, Marks DI, Maharaj D, Popat U, Carabasi M, Bornhaeuser M, Bolwell BJ, Ringden O, Ballen KK, Rizzo JD, McCarthy PL, Ho VT. Spleen Status and Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation (HCT). Blood 52nd ASH Annual Meeting 116(21):3486, 2010. e-Pub 2010.
495. Konopleva M, Zhihong Z, Wang R, Thall PF, McCormick G, Lu H, Chen JL, Shpall EJ, Ciurea SO, Kebriaei P, Alousi AM, Popat U, Anderlini P, Nieto Y, Parmar S, McMullin B, Rondon G, Schober WD, Gulbis A, Cool R, Lin E, Andreeff M, Champlin R. A Phase I/II Trial of Plerixafor/G-CSF Combined with IV Bu/Flu Conditioning Regimen In AML/MDS Patients Undergoing Allogenic Stem Cell Transplantation. Blood 52nd ASH Annual Meeting 116(21):2358, 2010. e-Pub 2010.
496. de Lima M, Robinson S, McMannis J, Alousi AM, Saliba RM, Munsell M, Kebriaei P, Hosing C, Parmar S, Cooper L, Shah N, Staba Kelly S, Rondon G, Fernandez-Vina M, Maewall I, Bosque D, Bollard CM, Chen JJ, McNiece IK, Komanduri KV, Nieto Y, Jones R, Andersson BS, Popat U, Champlin RE, Simmons PJ, Shpall EJ. Mesenchymal Stem Cell (MSC) Based Cord Blood (CB) Expansion (Exp) Leads to Rapid Engraftment of Platelets and Neutrophils. Blood 52nd ASH Annual Meeting 116(21):362, 2010. e-Pub 2010.
497. Vigil KJ, Adachi JA, Jiang Y, Popat UR, Mahani MG, Granwehr B, Malik I, Gaeta S, Champlin RE, Raad I, Chemaly R. Novel Influenza A (2009/H1N1) Infection in Cancer Patients During the Ongoing Pandemic: Early Therapy Improves Outcome. 2010 IDSA Annual Meeting, 2010. e-Pub 2010.
498. Yuen CH, Saliba RM, Andersson BS, Shpall E, Popat UR, Qazilbash MH, Hosing C, de Lima MJ, Giralt SA, Champlin RE, Kebriaei P. Faster Lymphocyte Recovery After Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts For Decreased Non-Relapse Mortality (NRM) In Adults With Acute Lymphoblastic Leukemia (ALL). Biol Blood Marrow Transplant 2010 BMT Tandem Meetings 16(2, Supplement):S283, 2010. e-Pub 2010.
499. Andersson BS, de Lima M, Valdez BC, Thall PF, Worth LL, Popat U, Jones RB, Shpall EJ, Madden T, McAdams PL, Alousi AM, Rondon G, Kebriaei P, Champlin RE. Clofarabine±Fludarabine With IV Busulfan And Allogeneic Stem Cell Transplantation For Relapsed, Refractory Myeloid Leukemia (ML) And MDS. Biol Blood Marrow Transplant 2010 BMT Tandem Meetings 16(2, Supplement 2):S271-S272, 2010. e-Pub 2010.
500. Anderlini P, Acholonu S, Okoroji G, Popat U, Giralt SA, Shpall EJ, Qazilbash M, de Lima M, Worth L, Champlin RE. Fludarabine, Cyclophosphamide And Antithymocyte Globulin (ATG) As Conditioning Regimen In Matched Related And Unrelated Allogeneic Stem Cell Transplantation For Severe Aplastic Anemia (SAA): The M.D. Anderson Cancer Center Ten-Year Experience. Biol Blood Marrow Transplant 2010 BMT Tandem Meetings 16(2, Supplement 2):S217, 2010. e-Pub 2010.
501. Sharma M, Qazilbash MH, Hosing CM, Thall PF, Mendoza FL, Han E, Wang M, Shah J, Alousi AM, Anderlini P, Kebriaei P, Khouri IF, Popat UR, de Lima M, Champlin RE, Giralt SA. Addition Of Bortezemib To High Dose Melphalan Does Not Improve Response Rate Or Progression-Free Survival. Biol Blood Marrow Transplant 2010 BMT Tandem Meetings 16(2, Supplement 2):S200-S201, 2010. e-Pub 2010.
502. Sharma M, Thall P, Wang X, Hosing C, Mendoza FL, Han E, Wang M, Weber D, Shah J, Alousi A, Anderlini P, Kebriaei P, Khouri IF, Popat U, de Lima M, Champlin RE, Giralt S, and Qazilbash M. A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma. Blood 51st ASH Annual Meeting 114(22):2309, 2009. e-Pub 2009.
503. Popat U, Hosing C, Fanale M, Medeiros LJ, Alousi AM, Giralt SA, de Lima MJ, Qazilbash MH, Kebriaei P, Younes A, Khouri I, Andersson B, Champlin R, and Anderlini P. Autologous Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). Blood 51st ASH Annual Meeting 114(22):912, 2009. e-Pub 2009.
504. Bashir Q, Thall P, Hosing C, Mendoza F, Han E, Wang M, Shah J, Alousi A, Anderlini P, Kebriaei P, Khouri IF, Popat U, de Lima M, Champlin R, Giralt SA, and Qazilbash MH. Salvage Autologous or Allogeneic Stem Cell Transplantation After the Failure of First Autograft in Patients with Multiple Myeloma. Blood 51st ASH Annual Meeting 114(22):1186, 2009. e-Pub 2009.
505. Khouri IF, Harrell R, Valverde R, Korbling M, Manshouri T, Samuels B, Maadani F, Okoroji GJ, Bassett RL, Jr, Amin A, Anderlini P, de Lima M, Giralt S, Hosing C, Kebriaei P, Popat U, Qazilbash M, Ueno N, Stachowiak AM, Erwin B, Fayad L, Pro B, Fowler N, McLaughlin P, Neelapu S, Younes A, Champlin R, and Podoloff F. Stem Cell Transplantation with 90yttrium Ibritumomab Tiuxetan(90YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies. Blood 51st ASH Annual Meeting 114(22):868, 2009. e-Pub 2009.
506. Popat U, Rondon G, Alousi A, Anderlini P, Andersson B, Hosing C, de Lima M, Ciurea S, Giralt S, Kebriaei P, Nieto Y, Khouri I, Qazilbash MH, Jones R, and Champlin R. Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis. Blood 51st ASH Annual Meeting 114(22):900, 2009. e-Pub 2009.
507. Kebriaei P, Madden T, Kazerooni R, Shpall E, Wang X, Thall P, Hosing C, Qazilbash M, Popat U, Ledesma C, Khouri I, Champlin R, Jones R, and Andersson BS. Intravenous Busulfan Plus Melphalan Is a Highly Effective, Non-Toxic Preparative Regimen for Autologous Stem Cell Transplantation (ASCT) in Patients with Advanced Lymphoid Malignancies. Blood 51st ASH Annual Meeting 114(22):3415, 2009. e-Pub 2009.
508. Shah N, Ahmed KF, Qureshi S, Shah J, Orlowsk RZ, Weber DM, Hosing C, Popat U, Alousi A, Champlin RE, Giralt S, and Qazilbash M. Durable Remission with Salvage Autotransplants in Patients with Multiple Myeloma. Blood 51st ASH Annual Meeting 114(22):1227, 2009. e-Pub 2009.
509. Leandro DS, Saliba R, McCormick D, Okoroji GJ, Alousi A, Anderlini P, Ciurea S, Hosing C, Kebriaei P, Popat U, Qazilbash M, Ueno N, McMannis J, Champlin R, Pro B, and Khouri IF. Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL). Blood 51st ASH Annual Meeting 114(22):3213, 2009. e-Pub 2009.
510. Alousi AM, Rondon G, Okoroji GJ, Popat U, Silva LD, Hymes S, Neumann J, Brunelle NM, Kebriaei P, Hosing C, Khouri IF, Shpall EJ, Qazilbash MH, Giralt S, Champlin R, Saliba RM. Co-Morbidity Score at the Time of Transplant Determines Prognosis in Older Patients Who Develop Acute Graft-Vs.-Host Disease (GVHD). Blood 51st ASH Annual Meeting 114(22):2244, 2009. e-Pub 2009.
511. Qureshi S, Sharma M, Hosing C, Mendoza FL, Shah J, Alousi A, Anderlini P, Kebriaei P, Khouri IF, Popat U, de Lima M, Champlin RE, Giralt S, and Qazilbash MH. Outcome of IgD Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Blood 51st ASH Annual Meeting 114(22):4354, 2009. e-Pub 2009.
512. Popat UR, Saliba R, Hosing C, Khouri I, Alousi AM, Giralt SA, de Lima MJ, Qazilbash MH, Champlin R, Anderlini P. Age at diagnosis does not adversely affect outcome in patients with Hodgkin's Disease (HD) after autologous transplantation. J Clin Oncol 2009 ASCO Annual Meeting 27(15_suppl):e19507, 2009. e-Pub 2009.
513. Sola CB, Silva L, Saliba R, De Lima M, Giralt S, Qazilbash M, Champlin R, Khouri I, Popat U, Hosing C. Outcomes of autologous bone marrow transplantation in non-Hodgkin's lymphoma patients who failed peripheral blood stem cell mobilization. J Clin Oncol 2009 ASCO Annual Meeting 27(15_suppl):7040, 2009. e-Pub 2009.
514. Wundes A, Bowen JD, Kraft GH, Hutton GJ, Openshaw H, Forman SJ, Frohman EM, Griffith LM, Muraro PA, Racke MK, Sayre P, MD, Stuve O, Popat U, Nash RA. HALT MS - Phase II Clinical Trial of High Dose Immunosuppressive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Active Relapsing-Remitting Multiple Sclerosis. Neurology AAN 61st Annual Meeting:P07.133, 2009. e-Pub 2009.
515. Kazmi SMA, Parikh GC, Lahoti A, Mendoza F, Hosing C, Popat U, Alousi AM, Weber DM, Wang M, Champlin RE, Giralt SA, Qazilbash MH. Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients With Multiple Myeloma. Biol Blood Marrow Transplant 2009 BMT Tandem Meetings 15(2, Supplement):41, 2009. e-Pub 2009.
516. Andersson BS, de Lima M, Popat U, Jones RB, Shpall EJ, Hosing C, McAdams PL, Alousi AM, Kebriaei P, Champlin RE, Worth LL, Madden TL, Kazerooni R. Allogeneic Stem Cell Transplantation (Allo-SCT) For Relapsed, Refractory Myeloid Leukemia and Mds Using Clofarabine (Clo) ± Fludarabine (Flu) with IV Busulfan (Bu) As Conditioning Therapy. Biol Blood Marrow Transplant 2009 BMT Tandem Meetings 15(2, Supplement):86-87, 2009. e-Pub 2009.
517. Brunelle NM, Giralt SA, Nash VL, Neumann JL, Nieto Y, Popat UR, Qazilbash MH, Champlin RE. Evaluating Efficiacy And Cost Of Standard Antiemetic Adminstration Route In the Outpatient Autologous Stem Cell Transplant. Biol Blood Marrow Transplant 2009 BMT Tandem Meetings 15(2, Supplement):148-149, 2009. e-Pub 2009.
518. Stolar KR, Neumann J, Popat UR, Alousi AM. Identifying And Addressing the Long Term Needs Of the Adult Allogeneic Stem Cell Transplant (SCT) Recipient Through A Survivorship Clinical Program. Biol Blood Marrow Transplant 2009 BMT Tandem Meetings 15(2, Supplement):144-145, 2009. e-Pub 2009.
519. Anderson JE, Gulbis AM, Cool RM, Westmoreland MD, de Lima M, Giralt S, Hosing C, Popat U, Qazilbash MH, Shpall E, Khouri IF, Champlin R, Kebriaei P. Use of Palifermin in Allogeneic Stem Cell Transplantation (SCT) for Patients with Acute Lymphoblastic Leukemia (ALL). Biol Blood Marrow Transplant 2009 BMT Tandem Meetings 15(2, Supplement):113, 2009. e-Pub 2009.
520. de Lima M, McNiece I, McMannis J, Hosing C, Kebraei P, Komanduri K, Worth L, Staba S, Cooper L, Petropolous D, Lee D, Jones R, Nieto Y, Andersson B, Korbling M, Alousi A, Qazilbash M, Popat U, Khouri I, Bollard C, Leen A, Rondon G, Molldrem J, Champlin R, Simmons P, Shpall E. Double Cord Blood Transplantation (CBT) With Ex-Vivo Expansion (EXP) of One Unit Utilizing A Mesenchymal Stromal Cell (MSC) Platform. Biol Blood Marrow Transplant 2009 BMT Tandem Meetings 15(2, Supplement):47-48, 2009. e-Pub 2009.
521. Pelosini M, Mendoza F, Hosing C, Popat UR, Anderlini P, Alousi AM, Kebriaei P, Weber DM, Wang M, Champlin RE, Giralt SA, Qazilbash MH. Improved Outcome for Allogeneic Transplantation Performed After January 2000. Biol Blood Marrow Transplant 2009 BMT Tandem Meetings 15(2, Supplement):68-69, 2009. e-Pub 2009.
522. Walters KH, Hosing C, Smith VR, Rhodes BA, Thompson RC, Qazilbash MH, McMannis JD, Alousi A, De Lima M, Kebriaei P, Giralt S, Khouri I, Champlin RE, Popat UR. An Analysis of the Charges Associated With Peripheral Blood Hematopoietic Progenitor Cell (HPC) Mobilization, Collection and Cryopreservation In Patients With Lymphomas Undergoing Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant 2009 BMT Tandem Meetings 15(2, Supplement):71-72, 2009. e-Pub 2009.
523. Silva LD, Saliba R, Giralt S, Hosing C, Khouri I, Popat U, Qazilbash M, Shpall E, Thomas D, Kantarjian H, Champlin R, Kebriaei P. Reduced Intensity Conditioning (RIC) Regimen Followed By Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adult Patients (PTS) With Acute Lymphoblastic Leukemia (ALL). Biol Blood Marrow Transplant 2009 BMT Tandem Meetings 15(2, Supplement):63, 2009. e-Pub 2009.
524. Koca E, Saliba RM, de Lima M, Popat U, Kebriaei P, Rondon G, Zhang W, Giralt S, Andersson BA, Champlin R. Impact of Cytogenetics and Marrow Remission Status on Disease Progression in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 2009 BMT Tandem Meetings 15(2, Supplement):99-100, 2009. e-Pub 2009.
525. Saliba RM, Komanduri KV, Koca E, Alousi AM, Giralt S, Andersson BS, Zhang W, Rondon G, Neumann J, Popat UR, Kebriaei P, de Lima M, Champlin RE. High Rate Of De Novo Chronic Graft-Versus-Host (cGVHD) Following Busulfan-Fludarabine Conditioning And Allogeneic Stem Cell Transplantation From A Matched-Sibling Donor (MSD) For AML/MDS. Biol Blood Marrow Transplant 2009 BMT Tandem Meetings 15(2, Supplement):122, 2009. e-Pub 2009.
526. Smith VR, Hosing C, Popat U, Schindler J. New Mobilization Strategies for Collection of Peripheral Blood Progenitor Cells for Lymphoma and Myeloma Patients. Biol Blood Marrow Transplant 2009 BMT Tandem Meetings 15(2, Supplement):29, 2009. e-Pub 2009.
527. Efebera Y, Saliba RM, Thandi RS, Popat U, De Lima M, Alousi A, Hosing C, Ledford M, Champlin R, Giralt S. Impact of Pre-stem Cell Transplant Ferritin Levels on Late Transplant Complications. A Landmark Analysis to Determine Potential Role of Iron Chelation in Improving Transplant Outcomes. Biol Blood Marrow Transplant 2009 BMT Tandem Meetings 15(2, Supplement):92-93, 2009. e-Pub 2009.
528. Kebriaei P, Munsell M, Gutierrez K, de Lima M, Giralt S, Hosing C, Popat U, Qazilbash MH, Thomas D, Kantarjian H, Khouri IF, Champlin RE. Inferior Outcome With Addition Of Rituximab For Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Acute Lymphoblastic Leukemia (ALL). Biol Blood Marrow Transplant 2009 BMT Tandem Meetings 15(2, Supplement):117, 2009. e-Pub 2009.
529. Ciurea SO, de Lima M, Giralt S, Alousi A, Kebriaei P, Khouri IF, Anderlini P, Andersson BS, Hosing CM, Champlin RE, Popat U. Outcomes Of Allogeneic Stem Cell Transplantation for Patients With Acute Leukemia Transformed from Myelofibrosis. Biol Blood Marrow Transplant 2009 BMT Tandem Meetings 15(2, Supplement):62, 2009. e-Pub 2009.
530. de Padua Silva L, Saliba RM, Giralt S, De Lima M, Hosing C, Khouri IF, Popat U, Qazilbash M, Shpall E, Thomas DA, Kantarjian H, Champlin R, Kebriaei P. Reduced Intensity Conditioning (RIC) Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Adult Patients with Acute Lymphoblastic Leukemia (ALL). Blood 50th ASH Annual Meeting 112(11):4326, 2008. e-Pub 2008.
531. Khan ZU, Saliba RM, Qureshi S, Hosing C, Giralt SA, De Lima MJ, Yusuf SW, Popat U. Outcome of Allogeneic Stem Cell Transplantation in Patients with Low Ventricular Ejection Fraction. Blood 50th ASH Annual Meeting 112(11):3306, 2008. e-Pub 2008.
532. Tam CS, Bassett R, Ledesma C, Korbling M, Okoroji GJ, Harrell R, Hsu Y, Silva LD, Alousi AM, Hosing CM, Kebriaei P, Rondon G, Giralt S, De Lima M, Anderlini P, Popat U, Qazilbash MH, Samuels B, Champlin RE, and Khouri IF. Rituximab Containing Autologous Stem Cell Transplantation May Be Curative in Mantle Cell Lymphoma for Patients in First Remission, but Not for Patients with Recurrent Disease. Blood 50th ASH Annual Meeting 112(11):1142, 2008. e-Pub 2008.
533. Khouri IF, Lopez A, Okoroji GJ, Korbling M, McCormick G, Hsu Y, de Padua L, Alousi AM, Hosing CM, Kebriaei P, Rondon G, Giralt SA, de Lima MJ, Anderlini P, Popat UR, Qazilbash MH, Champlin RE, and Pro B. Myeloablative Chemotherapy for T-Cell Lymphoma: a Case for Autologous Stem Cell Transplantatin (Auto) in First Remission. Blood 50th ASH Annual Meeting 112(11):1141, 2008. e-Pub 2008.
534. Khouri IF, Bassett R, Samuels B, Maadani F, Okoroji GJ, Harrell R, Korbling M, Silva LD, Alousi A, Hosing C, Giralt S, de Lima M, Anderlini P, Popat U, Valverde R, Hsu Y, Hagemeister F, McLaughlin P, and Medeiros LJ. Addition of Rituximab to Mobilization and Conditioning Overcomes the Predictive Value of Follicular Lymphoma International Prognostic Index (FLIPI) Score in Patients with Relapsed FL Undergoing Autologous Stem Cell Transplantation (AUTO). Blood 50th ASH Annual Meeting 112(11):1140, 2008. e-Pub 2008.
535. De Lima M, Silva LD, Giralt S, Komanduri K, Andersson BS, Hosing C, Qazilbash M, Shpall E, Thall P, Zhang W, McCormick G, Wang X, Popat U, Soriano A, Alousi A, Champlin R, and Garcia-Manero G. Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study. Blood 50th ASH Annual Meeting 112(11), 2008. e-Pub 2008.
536. Popat U, de Lima MJ, Ativitavas T, Rondon G, Silva LD, Koca E, Zhang W, Alousi A, Anderlini P, Giralt SA, Hosing CM, Jones R, Kebriaei P, Khouri I, Nieto Y, Qazilbash MH, Andersson BS, and Champlin R. Allogeneic Transplantation (HCT) for Myelodysplastic Syndrome:Recent MDACC Experience. Blood 50th ASH Annual Meeting 112(11), 2008. e-Pub 2008.
537. Khouri I, Bassett RL, Hsu Y, Dickason T, Acholonu S, Harrell R, Okoroji GJ, Silva LD, Korbling MJ, Alousi AM, Hosing C, Popat U, Giralt SA, Kebriaei P, Qazilbash MH, Ledesma C, Keating MJ, Champlin RE, and Bueso-Ramos C. Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival. Blood 50th ASH Annual Meeting 112(11), 2008. e-Pub 2008.
538. Hosing C, Smith VR, Rhodes BA, Walters KH, Qazilbash MH, McMannis JD, Alousi AM, de Lima M, Kebriaei P, Giralt S, Khouri I, Champlin R, and Popat U. An Analysis of the Costs Associated with Peripheral Blood Hematopoietic Progenitor Cell Mobilization, Collection and Cryopreservation in Patients with Lymphomas Undergoing Autologous Stem Cell Transplantation. Blood 50th ASH Annual Meeting 112(11):2377, 2008. e-Pub 2008.
539. Saliba RM, Komanduri KV, Koca E, Alousi AM, Giralt SA, Andersson BS, Zhang W, Rondon G, Popat UR, Kebriaei P, de Lima M, and Champlin RE. Donor Type Impacts the Incidence of Severe Acute but Not Chronic Graft- Versus-Host Disease (GVHD) after Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplantation (ASCT) for Treatment of AML/MDS. Blood 50th ASH Annual Meeting 112(11):2227, 2008. e-Pub 2008.
540. Giralt S, Saliba RM, Rondon G, Silva LD, Alousi M, Popat U, De Lima M, Andersson B, Kebriaei P, Anderlini P, Hosing C, Jones R, Shpall EJ, Champlin RE, and Khouri IF. Outcomes of Allogeneic Stem Cell Transplant in Patients with Myeloid Leukemias Over 65 Years of Age. Rationale for Aggressive Therapy with Curative Intent. Blood 50th ASH Annual Meeting 112(11):2153, 2008. e-Pub 2008.
541. Joseph RW, Jr, Komanduri KV, Saliba RM, Alousi A, Giralt S, Rondon G, Neumann J, Trevino C, Couriel DR, Champlin R, and Popat U. High Prevalence of Vitamin D Deficiency in Allogeneic Stem Cell Transplant Recipients. Blood 50th ASH Annual Meeting 112(11):2138, 2008. e-Pub 2008.
542. Popat U, Saliba R, Silva LD, Andersson BS, Alousi AM, Anderlini P, de Lima M, Okoroji GJ, Hosing CM, Jones RB, Kebriaei P, Khouri I, Nieto Y, Qazilbash MH, Champlin R, and Giralt SA. Busulfan and Fludarabine Conditioning Regimen Negates the Impact of Comorbidity Score on Nonrelapse Mortality in Patients with AML/MDS. Blood 50th ASH Annual Meeting 112(11):799, 2008. e-Pub 2008.
543. Qazilbash MH, Saliba RM, Pelosini M, Hosing CM, Mendoza FL, Han E, Wang M, Weber DM, Alousi AM, Anderlini P, Kebriaei P, Khouri IF, Popat UR, De Lima M, Orlowski RZ, Champlin RE, and Giralt SA. A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma. Blood 50th ASH Annual Meeting 112(11):3320, 2008. e-Pub 2008.
544. Cole SM, Saliba R, Pelosini M, Mendoza FL, Weber D, Wang M, Thomas S, Orlowski RZ, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, and Qazilbash MH. Reduced-Intensity Regimens for Allogeneic Stem Cell Transplantation Improve the Outcome in Advanced Multiple Myeloma. Blood 50th ASH Annual Meeting 112(11):3298, 2008. e-Pub 2008.
545. Kebriaei P, Giralt S, Jones D, Gutierrez K, De Lima M, Korbling M, Khouri IF, Popat U, Qazilbash MH, Alousi A, Ciurea SO, Cooper L, Shpall E, and Champlin R. Addition of Umbilical Cord Blood (UCB) Unit to Reduced Intensity Conditioning (RIC) Regimen to Augment Graft Versus Tumor (GVT) in Patients (pts) with Advanced Hematologic Malignancies. Blood 50th ASH Annual Meeting 112(11):3297, 2008. e-Pub 2008.
546. Ciurea SO, De Lima M, Giralt S, Qazilbash MH, Alousi A, Kebriaei P, Khouri IF, Anderlini P, Andersson B, Hosing C, Verstovsek S, Kantarjian H, Champlin R, and Popat U. Allogeneic Stem Cell Transplantation for Patients with Acute Leukemia Transformed from Myelofibrosis. Blood 50th ASH Annual Meeting 112(11):3293, 2008. e-Pub 2008.
547. De Lima M, McMannis JD, Saliba R, Worth L, Kebriaei P, Popat U, Qazilbash M, Jones R, Giralt S, Silva LD, Cooper L, Petropoulos D, Lee D, Kelly S, Thall P, Robinson S, Khouri I, Hosing C, Korbling M, Alousi A, Rondon G, Andersson BS, Nieto Y, Ciurea S, Komanduri K, Champlin RE, and Shpall E. Double Cord Blood Transplantation (CBT) with and without Ex-Vivo Expansion (EXP): A Randomized, Controlled Study. Blood 50th ASH Annual Meeting 112(11):154, 2008. e-Pub 2008.
548. Andersson BS, de Lima M, Worth LL, Popat U, Jones RB, Shpall EJ, Hosing C, Madden T, Kazerooni R, McAdams P, Alousi A, Kebriaei P, and Champlin RE. Clofarabine (Clo) +/– Fludarabine (Flu) with IV Busulfan (Bu) and Allogeneic Stem Cell Transplantation (Allo-SCT) for Relapsed, Refractory Myeloid Leukemia (ML) and MDS. Blood 50th ASH Annual Meeting 112(11):4390, 2008. e-Pub 2008.
549. Jabbour E, Cortes J, de Padua Silva L, De Lima M, Jones D, O'Brien S, Rondon G, Popat U, Giralt S, Kantarjian H, Champlin R. Results of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Advanced Chronic Myeloid Leukemia (CML) Patients (pts) Who Failed Tyrosine Kinase Inhibitors (TKIs) after Developing BCR-ABL Kinase Domain (KD) Mutations. Blood 50th ASH Annual Meeting 112(11):973, 2008. e-Pub 2008.
550. Samuelson SJ, Sandmaier BM, Heslop HE, Popat U, Boyer M, Hickman K, Prchal JT, Deeg HJ. Allogeneic Hematopoietic Cell Transplants in Patients with Myelofibrosis Age 60 and Older. Blood 50th ASH Annual Meeting 112(11):2138, 2008. e-Pub 2008.
551. Joseph RW, Kim TK, St John L, Khalili J, Popat UR, Champlin RE, Molldrem JJ, Wieder E, Komanduri K. Demonstration of a Direct Immunomodulatory Role for Vitamin D in Human T Cells Using Flow Cytometry. Blood 50th ASH Annual Meeting 112(11):2577, 2008. e-Pub 2008.
552. de Padua Silva L, Andersson BS, Popat U, Griffin L, Alvarez M, Patah P, Parmar S, Giralt S, Rondon G, Fernandez-Vina M, Cano P, Champlin RE, De Lima M. Treatment of AML in First Remission (CR1) with Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Unrelated Donors (UD). Blood 50th ASH Annual Meeting 112(11):976, 2008. e-Pub 2008.
553. Koca E, Saliba RM, De Lima M, Popat U, Kebriaei P, Rondon G, Giralt S, Andersson BS, Champlin RE. Impact of Pretransplant Cytogenetics and Marrow Remission Status on Outcome of Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Stem Cell Transplantation Conditioned with Busulfan and Fludarabine. Blood 50th ASH Annual Meeting 112(11):341, 2008. e-Pub 2008.
554. Thomas SK, Hosing C, Delasalle KB, Gavino M, Popat UR, Qazilbash MH, Giralt S, Weber DM. Success rates of autologous stem cell collection in patients with Waldenstrom's Macroglobulinemia. 5th International Workshop on Waldenström’s Macroglobulinemia, 2008. e-Pub 2008.
555. Borthakaur G, Beran M, Liu J, Verma D, Dong XQ, Rondon G, Champlin RE, Kantarjian H, and Popat UR. Outcomes in Patients with Chronic Myelomonocytic Leukemia: Analysis of 279 Patients. Blood 50th ASH Annual Meeting 112(11):3235, 2008. e-Pub 2008.
556. Popat U, Saliba R, Ahlawat S, Okoroji GJ, Alousi A, Anderlini P, Andersson B, de Lima M, Jones R, Kebriaei P, Korbling M, Nieto Y, Qazilbash M, Shpall EJ, Khouri I, Giralt S, Champlin R, Hosing C. Incidence and Factors Influencing Stem Cell Mobilization in Patients with Non-Hodgkin's Lymphoma (NHL) and Hodgkin's Disease (HD). Biol Blood Marrow Transplant 2008 BMT Tandem Meetings 14(2, Supplement):37-38, 2008. e-Pub 2008.
557. Petropoulos D, Giralt SA, Andersson BS, Chan KW, Rondon G, Popat UR, Hosing C, Alousi AM, Champlin RE, de Lima MJ. Central Nervous System (CNS) Involvement at Diagnosis does not Adversely Affect the Outcome of High-Dose Chemotherapy and Transplant for Patients with Acute Myeloid Leukemia (AML). Biol Blood Marrow Transplant 2008 BMT Tandem Meetings 14(2, Supplement):61-62, 2008. e-Pub 2008.
558. Silva L, Patah P, Szewczyk N, Saliba RM, Gilman L, Gulbis A, Neumann J, Walker JA, Petropoulos D, El-Zimaity M, Anderlini P, Tarrand J, Ciurea SO, Shpall E, Popat U, Jones R, Giralt S, Champlin RE, de Lima M. A Prospective Evaluation of the Effect of Polyoma (BK) Virus Infection on the Incidence of Hemorrhagic Cystitis (HC) after Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation (UD HSCT). Biol Blood Marrow Transplant 2008 BMT Tandem Meetings 14(2, Supplement):102-103, 2008. e-Pub 2008.
559. Ramos CA, Saliba RM, Giralt S, Khorshid O, de Padua L, Andersson BS, Nieto YL, Popat UR, Qazilbash MH, Qureshi S, Zhang W, Champlin RE, de Lima M. The Impact of Resolved Hepatitis B Infection on Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies. Biol Blood Marrow Transplant 2008 BMT Tandem Meetings 14(2, Supplement):8, 2008. e-Pub 2008.
560. Chu DT, Saliba R, Qureshi S, Alousi A, Anderlini P, Bukhari F, Delima M, Giralt SA, Kebriaei P, Khouri IF, Parik G, Popat U, Shpall EJ, Yusuf WS, Champlin RE, Qazilbash MH, Hosing C. Cardiac Toxicity and Non-Relapse Mortality in Patients with Low Left Ventricular Ejection Fraction Undergoing Stem Cell Transplantation. Blood 49th ASH Annual Meeting 110(11):3002, 2007. e-Pub 2007.
561. Qazilbash MH, Saliba RM, Parikh GC, Hosing C, Mendoza F, Weber DM, Wang M, Thomas SK, Flosser TS, Kebriaei P, Popat U, Alousi AM, de Lima M, Champlin RE, Giralt SA. A Non-Myeloablative Regimen of Fludarabine and Melphalan Is Safe and Well Tolerated for Allogeneic Transplantation in Multiple Myeloma. Blood 49th ASH Annual Meeting 110(11):3032, 2007. e-Pub 2007.
562. Popat UR, Rondon G, Alousi AM, Anderlini P, Andersson BS, de Lima MJ, Giralt SA, Hosing CM, Kebriaei P, Jones R, Nieto Y, Shpall EJ, Verstovesek S, Qazilbash MH, Champlin R. Myelofibrosis and Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RISCT). Blood 49th ASH Annual Meeting 110(11):3062, 2007. e-Pub 2007.
563. de Lima M, Andersson B, Fernadez-Vina M, Giralt S, Couriel D, Shpall E, Popat U, Qazilbash M, Alousi A, Cano P, Bosque D, Hosing C, Qureshi S, de Padua L, Munsell M, Anderlini P, Jones R, Westmoreland M, Gulbis A, Champlin R. Prophylaxis of Graft-Versus-Host Disease (GVHD) with Pentostatin, Tacrolimus, and Mini-Methotrexate (MTX): A Phase I/II Controlled, Randomized Study in Unrelated Donor (UD) Transplantation. Blood 49th ASH Annual Meeting 110(11):40, 2007. e-Pub 2007.
564. Tam CS, Ledesma C, Korbling M, Fayad LE, Wang M, Alousi A, Hosing C, Kebriaei P, Rondon G, Giralt SA, Anderlini P, Popat U, Couriel D, Pro B, Samuels B, Hagemeister F, Champlin RE, Khouri IF. Non-Myeloablative Allogeneic Stem Cell Transplantation (NMT) Overcomes the Adverse Effects of Treatment Resistance and High Beta-2-Microglobulin in Patients with Mantle Cell Lymphoma (MCL): An Analysis of 123 Transplantations at the MD Anderson Cancer Center. Blood 49th ASH Annual Meeting 110(11):484, 2007. e-Pub 2007.
565. Parikh GC, Saliba RM, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi A, Champlin RE, Giralt SA, Qazilbash MH. Autotransplantation in Patients with Multiple Myeloma and Concurrent Renal Failure Is Safe and Feasible and Associated with Recovery of Renal Function in > 30% of Patients. Blood 49th ASH Annual Meeting 110(11):5126, 2007. e-Pub 2007.
566. Hosing C, Munsell M, Popat U, Körbling M, Valverde R, Maadani F, Kebriaei P, Alousi A, DeLima M, McMannis J, Shpall EJ, Qazilbash MH, Anderlini P, Giralt S, Champlin R, Khouri I. Chemotherapy with Granulocyte Colony Stimulating Factor (G-CSF) Alone Versus Granulocyte Colony Stimulating Factor (G-CSF) Plus Granulocyte-Macrophage Stimulating Factor (GM-CSF) for Hematopoietic Progenitor Cell Mobilization in Patients with Relapsed Non-Hodgkins Lymphomas (NHLs). Blood 49th ASH Annual Meeting 110(11):1900, 2007. e-Pub 2007.
567. Giralt S, Saliba RM, Mendoza F, Parikh G, Qureshi S, Zhang W, Popat U, Qazilbash M, Khouri I, Hosing C, Alousi A, Anderlini P, Andersson B, Jones R, Shpall E, Kebriaei P, Nieto Y, Ueno N, Champlin R, de Lima M. Pre Transplant Values of C Reactive Protein (CRP) and Brain Natriuretic Peptide (BNP) as Predictors of Transplant Outcomes in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndromes (AML/MDS) Undergoing Allogeneic Stem Cell Transplantation (AlloSCT). Blood 49th ASH Annual Meeting 110(11):1984, 2007. e-Pub 2007.
568. Alousi AM, Hosing C, Saliba RM, Valverde RB, Maadani F, Korbling M, Okoroji GJ, Fayad LE, Stachowiak AM, Erwin WD, Anderlini P, de Lima MJ, Giralt SA, Popat UR, Kebriaei P, Ueno NT, McLaughlin PW, Pro B, Wang M, Rodriguez A, Hagemeister FB, Macapinlac HA, Podoloff DA, Champlin RE, Khouri IF. Zevalin/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status. Blood 49th ASH Annual Meeting 110(11):620, 2007. e-Pub 2007.
569. Qazilbash MH, Saliba RM, Parikh G, Hosing C, Mendoza F, Qureshi SP, Weber DM, Wang M, Flosser T, Couriel DR, Kebriaei P, Popat U, Alousi A, de Lima M, Champlin RE, Giralt S. Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan Is Safe and Effective for Autotransplantation for Multiple Myeloma. Blood 49th ASH Annual Meeting 110(11):942, 2007. e-Pub 2007.
570. Silva LD, Saliba RM, de Lima M, Okoroji GJ, Alousi A, Andersson B, Hosing C, Sphall E, Khouri I, Qazilbash M, Anderlini P, Kebriaei P, Champlin RE, Jones R, Giralt S, Popat U. Obesity Does Not Impact Outcome in Patients with AML/MDS Undergoing Allogeneic Transplantation. Blood 49th ASH Annual Meeting 110(11):1989, 2007. e-Pub 2007.
571. de Lima M, Padua L, Giralt S, Hosing C, Komanduri K, Qazilbash M, Shpall EJ, Thall P, Qureshi S, McCormick G, Tong W, Popat U, Soriano A, Champlin R, Garcia-Manero G. A Dose and Schedule Finding Study of Maintenance Therapy with Low-Dose 5-Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for High-Risk AML or MDS. Blood 49th ASH Annual Meeting 110(11):3012, 2007. e-Pub 2007.
572. Popat UR, de Lima M, Anderlini P, Andersson B, Couriel D, Hosing C, Kebriaei P, Qazilbash M, Alousi A, Champlin R, Giralt SA. Long-term survival of patients with AML in remission after reduced intensity allogeneic hematopoietic stem cell transplantation (RISCT). J Clin Oncol 2007 ASCO Annual Meeting 25(17_suppl):7002, 2007. e-Pub 2007.
573. Qazilbash MH, Gul Z, Jindani S, Saliba R, Hosing C, Mendoza F, Qureshi SP, Weber DM, Wang M, Flosser T, Couriel DP, DeLima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA. Autologous stem cell transplantation for elderly patients with multiple myeloma. Biol Blood Marrow Transplant 2007 BMT Tandem Meetings 13(2, Supplement):10, 2007. e-Pub 2007.
574. Trevino CM, Neumann J, Couriel D, Popat U, Hsu Y. Establishment of a long-term allogeneic blood and marrow program for early detection of complication and measuring outcomes. Biol Blood Marrow Transplant 2007 BMT Tandem Meetings 13(2, Supplement):149-150, 2007. e-Pub 2007.
575. Qazilbash MH, Jindani S, Gul Z, Saliba R, Hosing C, Mendoza F, Qureshi SP, Weber DM, Wang M, Flosser T, Couriel DP, Kebriaei P, Popat U, Alousi AM, DeLima M, Champlin RE, Giralt SA. Arsenic trioxide with ascorbic acid and high-dose melphalan for autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2007 BMT Tandem Meetings 13(2, Supplement):9-10, 2007. e-Pub 2007.
576. De Souza JA, Saliba R, Patah PA, Rondon G, Qazilbash MH, Hosing C, Popat U, Champlin RE, de Lima M. Renal function impairment and outcomes of reduced-intensity allogeneic hematopoietic stem cell transplantation. Blood 48th ASH Annual Meeting 108(11):48, 2006. e-Pub 2006.
577. Qazilbash MH, Saliba R, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA. Autologous Stem Cell Transplantation for Elderly Patients with Multiple Myeloma. Blood 48th ASH Annual Meeting 108(11):5422, 2006. e-Pub 2006.
578. De Lima M, Wang X, Thall PF, Couriel D, Jones RB, Shpall EJ, Popat U, Giralt S, Korbling M Champlin R, Andersson BS. Long-term follow-up of IV busulfan (Bu) with Fludarabine (Flu) vs IV Bu with cyclophosphamide (Cy) as pre (allogeneic) transplant conditioning therapy for AML/MDS. Blood 48th ASH Annual Meeting 108(11):322, 2006. e-Pub 2006.
579. Khouri IF, Saliba RM, Hosing C, Valverde R, Erwin WD, Fayad L, Maadani F, Korbling MJ, Okoroji GJ, Stachowiak AM, Samuels, BI, Anderlini P, Couriel DR, de Lima M, Giralt S, Popat U, Kebriaei P, Ueno N, Qazilbash MH, McLaughlin PW, Hagemeister FB, Younes A, Podoloff DA, Champlin RE. Efficacy and safety of yttrium 90 (90Y) ibritumomag tiuxetan in autologous and nonmyeloablative stem cell transplantation (NST) for relapsed non-hodgkin’s lymphoma (NHL). Blood 48th ASH Annual Meeting 108(11):315, 2006. e-Pub 2006.
580. Kebriaei P, Giralt S, Madden TL, Thapar N, Shpall EJ, Hosing C, Qazilbash MH, Couriel DR, Popat U, Thall PF, Champlin RE, Jones R, Andersson BS. Toxicity and early response after intravenous (IV) busulfan (Bu) plus melphalan (Mel) conditioning for autologous stem cell transplantation (SCT) in patients (pts) with multiple myeloma (MM). Blood 48th ASH Annual Meeting 108(11):2943, 2006. e-Pub 2006.
581. Ahmed B, Saliba RM, Ashraf, Mendoza F, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH. Deletion of the short arm of chromosome 1 (del 1p) is the strongest pre Blood dictor of poor outcome in myeloma patients undergoing an autotransplant. Blood 48th ASH Annual Meeting 108(11):3101, 2006. e-Pub 2006.
582. Hosing C, Saliba RM, Okoroji GJ, Popat U, Couriel D, Kebriaei P, Ali T, de Lima M, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I. High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation (AHCT) for non-hodgkin’s lymphoma (NHL) in patients over 65 years of age. Blood 48th ASH Annual Meeting 108(11):3059, 2006. e-Pub 2006.
583. Qazilbash MH, Saliba R, Mendoza F, Roden L, Hosing C, Couriel D, Kebriaei P, Popat U, DeLima M, Champlin RE, Giralt SA. Salvage autologous transplantation in multiple myeloma. Bio Blood Marrow Transplant 2006 TCT Meetings of ASTCT and CIBMTR 12(2, Supplement 1):121-122, 2006. e-Pub 2006.
584. Neumann Hsu Y, Popat U, Champlin RE, Couriel D. Establishment of a long-term allogeneic blood and marrow follow-up program for early detection of complications and measuring outcomes. Bio Blood Marrow Transplant 2006 TCT Meetings of ASTCT and CIBMTR 12(2, Supplemental 1):164-165, 2006. e-Pub 2006.
585. Qazilbash MH, Saliba R, Mendoza F, Roden L, Hosing C, Couriel DE, Kebriaei P, Popat U, DeLima M, Champlin RE, Giralt SA. Salvage non-myeloablative allogeneic transplantation after failure of an autologous transplantation in multiple myeloma. Bio Blood Marrow Transplant 2006 TCT Meetings of ASTCT and CIBMTR 12(2, Supplement 1):117, 2006. e-Pub 2006.
586. Popat U, Liu E, Guan Y, Prchal JT. High Circulating CD34 Cells, Dacrocytes, Clonal Hematopoiesis, and JAK 2 Mutation Differentiate Secondary Myelofibrosis Associated with Pulmonary Hypertension from Myelofibrosis with Myeloid Metaplasia. Blood 47th ASH Annual Meeting 106(11):2589, 2005. e-Pub 2005.
587. Lamba R, Myers DG, Popat U, Bollard CM, Carrum G, Krance R, Heslop HE, Brenner MK. Assessing cytomegalovirus (CMV) specific immune recovery after reduced intensity conditioning allogeneic stem cell transplantation with monoclonal antibody (Alemtuzumab). J Clin Oncol 2005 ASCO Annual Meeting 23(16_suppl):6650, 2005. e-Pub 2005.
588. Popat U, Frost A, Liu E, May R, Reddy V, Durett A, Prchal J. High Peripheral Blood CD34 Count in Patients with Idiopathic Myelofibrosis (IF) Is Not Due to Fibrosis and Altered Marrow Microenvironment. Blood 46th ASH Annual Meeting 104(11):2439, 2004. e-Pub 2004.
589. Chen G, Carrum G, Popat U. Stem Cell Transplantation in Patients with Preexisting Coronary Artery Disease. Blood 46th ASH Annual Meeting 104(11):5028, 2004. e-Pub 2004.
590. Lamba R, Carrum G, Krance R, Heslop H, Brenner M, Popat U. High Incidence but Low Morbitiy of Early Cytomegalovirus (CMV) Infections Following Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation with Alemtuzumab and Ganciclovir Prophylaxis. Blood 46th ASH Annual Meeting 104(11):5098, 2004. e-Pub 2004.
591. Liu E, Frost AE, Popat UR, Prchal JT. Dysregulation of BMPR2, Arginase II and HMGA2 Expression in Idiopathic Myelofibrosis and Secondary Myelofibrosis. Blood 46th ASH Annual Meeting 104(11):792, 2004. e-Pub 2004.
592. Nishino HT, Zu Y, Rice L, Baker KR, McCarthy JJ, Zeng G, Popat UR, Carrum G, C-C C. Quantitative Analysis of Flow Cytometry Immunophenotyping Data for Aiding in the Diagnosis of Myelodysplastic Syndromes (MDS). Blood 46th ASH Annual Meeting 104(11):4735, 2004. e-Pub 2004.
593. Biagi E, Popat U, Rousseau R, Yvon E, Giampietro D, Lawrence R, Andreef M, Brenner M. Immunotherapy of Chronic Lymphocytic Leukemia Using CD40L and IL2 Expressing Autologous Tumor Cells. Blood 46th ASH Annual Meeting 104(11):768, 2004. e-Pub 2004.
594. Strader D, Oholendt MS, Popat U, Carrum G, Heslop HE. Rasburicase Improves Renal Function and Uric Acid Nephropathy in Patients Developing Acute Renal Failure after Conditioning for Hematopoietic Stem Cell Transplant (HSCT). Blood 46th ASH Annual Meeting 104(11):1142, 2004. e-Pub 2004.
595. Barrett CM, Oholendt MS, Popat U, Carrum G, Heslop HE. Evaluation of Aprepitant for Treatment of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting in Patients Undergoing Autologous Stem Cell Transplantation. Blood 46th ASH Annual Meeting 104(11):5041, 2004. e-Pub 2004.
596. Popat UR, Carrum G, Krance R, Brenner M, Heslop H. Evaluation of reduced intensity allogeneic hematopoietic stem cell transplantation (HSCT) using anti lymphocyte antibodies in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). J Clin Oncol 2004 ASCO Annual Meeting 22(14_suppl):6544, 2004. e-Pub 2004. PMID: 28016932.
597. Lamba R, Carrum G, Krance R, Heslop H, Brenner M, Popat U. Infectious complications in reduced intensity conditioning (RIC) allogeneic stem cell transplantation with antilymphocyte antibodies. J Clin Oncol 2004 ASCO Annual Meeting 22(14_suppl):6627, 2004. e-Pub 2004. PMID: 2806298.
598. Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP, Spivak JL, Hoffman R, Fruchtman S. Allogeneic hsct with reduced intensity conditioning regimens in high risk patients with myelofibrosis. Biol Blood Marrow Transplant 2004 BMT Tandem Meetings 10(Supplement 1):12, 2004. e-Pub 2004.
599. Frost E, Popat U, Liu E, Prchal J. Pulmonary arterial hypertension and the Development of Myelofibrosis. American Thoracic Society’s 100th Annual Meeting, 2004. e-Pub 2004.
600. Popat U, Carrum G, Kuehnle I, Bollard C, Gottschalk S, Heslop H, Krance R, Brenner M. Reduced intensity conditioning regimen with CD 45 monoclonal antibodies for stem cell transplantation using matched unrelated or mismatched donors. Blood 45th ASH Annual Meeting 102(11):705a, 2003. e-Pub 2003.
601. Straathof KC, Bollard CM, Popat UR, Huls MH, Zhang L, Morriss C, Gee AP, Brenner MK, Rooney CM, Heslop HE. Cytotoxic T lymphocyte therapy for Epstein Barr virus-positive nasopharyngeal carcinoma. Blood 45th ASH Annual Meeting 102(11), 2003. e-Pub 2003.
602. Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP, Spivak JL, Hoffman R, Fruchtman S. Non-Myeloablative Allogeneic HSCT in High Risk Patients with Myelofibrosis. Blood 45th ASH Annual Meeting 102(11):199a, 2003. e-Pub 2003.
603. Popat U, Frost A, Liu E, Bag R, May R, Reddy V, Durett A, Purl H, Carrum G, Prchal J. Myelofibrosis is frequently seen in patients with primary pulmonary hypertension and is associated with polyclonal hematopoiesis and normal CD34 count. Blood 45th ASH Annual Meeting 102(11):919a, 2003. e-Pub 2003.
604. Bollard CM, Straathof KC, Huls MH, Gresik MV, Carrum G, Popat U, Brenner MK, Rooney CM, Heslop HE. Cytotoxic T lymphocyte therapy for EBV positive Hodgkins disease. J Clin Oncol 2003 ASCO Annual Meeting 22, 2003. e-Pub 2003.
605. Popat UR, Straathof KC, Bollard CM, Huls MH, Gee AP, Brenner MK, Rooney CM, Heslop HE. Adoptive immunotherapy with Epstein Barr-Virus (EBV) specific cytotoxic T cells (CTLs) for EBV positive Nasopharyngeal Carcinoma (NPC). J Clin Oncol 2003 ASCO Annual Meeting 22, 2003. e-Pub 2003.
606. Carrum G, Przepiorka D, Popat U, Heslop HE, Krance R, Kuehnle I, May R, Bollard C, Gottschalk S, Brenner M. Submyeloablative conditioning regimen using CAMPATH 1-H for allogeneic stem cell transplant. Blood 44th ASH Annual Meeting 100(11):434b, 2002. e-Pub 2002.
607. Straathof KC, Bollard CM, Huls H, Popat U, Gee AP, Malcolm Brenner M, Rooney CM, Heslop H. Cytotoxic T lymphocyte therapy for Epstein Barr Virus-positive Nasopharyngeal Carcinoma. American Society of Hematology’s annual meeting. Blood 44th ASH Annual Meeting 100(11):121a, 2002. e-Pub 2002.
608. Rousseau R, Biagi E, Yvon E, Mei Z, Inman S, Rill D, Heslop H, Popat U, Gee A, Krance R, Carrum G, Alcoser P, Rodgers S, Kuehnle I, Margolin J, Brenner M. Treatment of high-risk acute leukemia with an autologous vaccine expressing transgenic IL-2 and CD40L. Blood 44th ASH Annual Meeting 100(11):867a, 2002. e-Pub 2002.
609. Carrum G, Przepiorka D, Popat U, Heslop HE, Krance R, Khan S, Kuehnle I, May R, Bates P, Gee AP, Brenner MK. Submyeloablative Conditioning Regimens Using Anti-Lymphocyte Antibodies for Allogeneic Stem Cell Transplantation. Blood 43rd ASH Annual Meeting 98, 2001. e-Pub 2001.
610. Krance R, Rill D, Khan S, Kuehnle I, Heslop HE, Przepiorka D, Carrum G, Popat U, Brenner MK. Anti-Human CD45 (AHCD45) Antibody Therapy Preceding Allogeneic Stem Cell Transplantation (alloSCT)for High Risk Hematologic Malignancies. Blood 43rd ASH Annual Meeting 98, 2001. e-Pub 2001.
611. Popat UR, Bassett Jr RL, Thall PF, Alousi AM, Alatrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Marin D, Mehta RS, Nieto Y, Olson AL, Oran B, Valdez B, Qazilbash MH, Champlin RE, Shpall EJ, Andersson BS. Myeloablative fractionated busulfan conditioning regimen with sorafenib for allogeneic stem cell transplant in AML: Results of a phase 1/2 study. 2025 ASCO Annual Meeting.

Book Chapters

1. Srour SA, Popat UA. Allogeneic Cell Transplantation for Myeloproliferative Neoplasms. In: Manual of Hematopoietic Cell Transplantation and Cellular Therapies. Elsevier Inc, 279-286, 2024.
2. Srour, S, Popat, UR. Allogeneic Cell Transplantation for Myeloproliferative Neoplasms, 279-286, 2023.
3. Fanale M, Dabaja B, Popat U, Anderlini P, Younes A. Hodgkin Lymphoma. In: 60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. Springer Science, 225-239, 2012.
4. Popat U, Giralt S. Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia. In: Contemporary Hematology, Stem Cell Transplantation for Hematoligic and other Disorders. Humana Press, 2008.
5. Rice L, Popat U. Non-Hodgkin's Lymphoma. In: Conn's Current Therapy 2008. Saunders-Elsevier, 458-461, 2008.
6. Popat U, Giralt S. Hematopoietic cell transplantation for chronic myeloid leukemia and myelofibrosis. In: Chronic Myeloproliferative Disorders. Informa Press, 2008.
7. Rice L, Popat U. Lymphomas. In: Conn’s current therapeutics, 2005.
8. Rice L, Popat U. Hemolytic Anemias. In: PIER American college of physician’s online textbook, 2004.
9. Hutton G, Oyama Y, Burt RK, Popat UR. Hematopoietic stem cell transplantation in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy. In: Stem Cell Therapy for Autoimmune Diseases. Landes Bioscience, 419-428, 2004.

Books (edited and written)

1. Ustun C, Popat U. Chronic Myeloid Leukemia: From Daily Management to Complicated Issues. Nova Science Publishers, Inc, 2014.
2. Guest Editor - Popat U. Leukemia in Emerging Cancer Therapeutics Series. Demos Medical Publishing, LLC, 2011.

Letters to the Editor

1. Marvin-Peek J, Kantarjian H, Jen WY, Daver N, Short N, Borthakur G, Bazinet A, Maiti A, Abbas H, Yilmaz M, Issa G, Macfarland M, Alvarado Y, Garcia-Manero G, Alousi A, Popat U, Shpall E, Ravandi F, DiNardo C, Kadia TM. Evaluating the Impact of Fewer Frontline Intensive Chemotherapy Plus Venetoclax Consolidation Cycles on Outcomes in AML. Am J Hematol, 2026.
2. Chiusolo P, Bacigalupo A, Salit R, Schroeder T, Finazzi MC, Gurnari C, Pagliuca S, Metzdorf J, Rautenberg C, Robin M, Rubio MT, Maciejewski J, Popat U, Rambaldi A, Reinhardt HC, Scott B, Kroger N, Gagelmann N. PTCy or ATG for Matched Transplantation in Myelofibrosis. Am J Hematol, 2026.
3. Senapati J, Garcia-Manero G, DiNardo CD, Deshmukh I, Borthakur G, Kadia TM, Jabbour E, Short NJ, Abbas HA, Pemmaraju N, Jain N, Haddad FG, Issa GC, Maiti A, Shpall E, Popat U, Loghavi S, Tang G, Yilmaz M, Alvarado Y, Montalban-Bravo G, Ravandi F, Kantarjian HM, Daver NG. Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia. Bone Marrow Transplant 60: 910-913, 2025.
4. Smallbone, PI, Sekhar, M, Srour, S, Ramdial, JL, Carmicheal Kusy, CL, Shpall, E, Popat, UR. Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis and Splanchnic Vein Thrombosis. American journal of hematology 100: 305-309, 2025.
5. Rafaeli N, Costa DM, Ledesma C, Jain N, Tewari P, Khouri I, Alatrash G, Short N, Jabbour E, Rezvani K, Alousi A, Popat U, Champlin R, Shpall E, Kebriaei P. Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 25: e374-e377, 2025.
6. Smallbone P, Sekhar M, Srour SA, Ramdial JL, Carmicheal Kusy CL, Shpall EJ, Popat UR. Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis and Splanchnic Vein Thrombosis: A Case Series. Am J Hematol, 2024.
7. Pasvolsky O, Saliba RM, Ledesma C, Popat UR, Alousi A, Olson A, Oran B, Hosing C, Bashir Q, Qazilbash MH, Short NJ, Ravandi F, Champlin R, Shpall EJ, Kebriaei P. Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission. Am J Hematol 98: E35-E37, 2023.
8. Short NJ, Macaron W, Kadia T, Dinardo C, Issa GC, Daver N, Wang S, Jorgensen J, Nguyen D, Bidikian A, Patel KP, Loghavi S, Konopleva M, Yilmaz M, Jabbour E, Maiti A, Abbas HA, Shpall E, Popat U, Al-Atrash G, Pierce S, Kantarjian HM, Ravandi F. Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission. Am J Hematol 97: E408-E411, 2022.
9. Popat UR, Andersson BS, Bassett R, Kawedia J, Valdez BC, Alousi AM, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Marin D, Nieto Y, Oran B, Olson A, Qazilbash MH, Srour SA, Shpall EJ, Champlin RE, Mehta RS. Myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA matched and haploidentical transplantation: results of a phase II study. Haematologica 107: 2496-2500, 2022.
10. Patel R, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Daher M, Mehta R, Srour S, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Shpall ES, Champlin RE, Saini N, Qazilbash MH. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. Am J Hematol 96: E455-E457, 2021.
11. Srour SA, Milton DR, Bashir Q, Nieto Y, Saini N, Daher M, Ramdial J, Im J, Hosing C, Delgado R, Manasanch E, Lee HC, Thomas S, Kaufman G, Patel K, Popat U, Weber D, Orlowski R, Shpall E, Champlin RE, Qazilbash MH. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica 106: 3211-3214, 2021.
12. Yilmaz M, Daver N, Borthakur G, Kadia T, DiNardo C, Kanagal-Shamanna R, Loghavi S, Oran B, Popat UR, Pierce S, Jabbour E, Short NJ, Issa G, Ohanian M, Konopleva M, Patel K, Kantarjian H, Ravandi F. FLT3 inhibitor based induction and allogeneic stem cell transplant in CR1 improves outcomes in patients with newly diagnosed AML with very low FLT3 allelic burden. Am J Hematol 96: E275-E279, 2021.
13. Koller P, Saliba RM, Ledesma C, Rondon G, Popat U, Alousi A, Mehta R, Oran B, Olson A, Hosing C, Qazilbash M, Khouri I, Ciurea S, Shpall E, Jorgensen J, Wang S, Jain N, Jabbour E, Kantarjian H, Champlin R, Konopleva M, Kebriaei P. Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 56: 1746-1749, 2021.
14. Shah MV, Saliba RM, Varma A, Ciurea SO, Oran B, Olson A, Bose P, Bashir Q, Masarova L, Alousi AM, Srour S, Mehta RS, Daver N, Pemmaraju N, Verstovsek S, Champlin RE, Popat UR. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol 193: 1004-1008, 2021.
15. Wilson NR, Fang H, Loghavi S, Wang W, Tang G, Haltom RO, Rausch CR, McClain KL, Rao KV, Popat UR, Fayad LE, Champa N, Calvo KR, Allen CE, Kadia TM, Pemmaraju N. Treating Rosai-Dorfman disease and RAS-associated autoimmune leucoproliferative disorder with malignant transformation. Br J Haematol 192: 667-671, 2021.
16. Saliba RM, Veltri L, Rondon G, Chen J, Al-Atrash G, Alousi A, Martinez C, Augustine L, Hosing CM, Oran B, Rezvani K, Shpall EJ, Kebriaei P, Khouri IF, Popat U, Champlin RE, Ciurea SO. Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation. Haematologica 106: 269-274, 2021.
17. Ciurea SO, Kongtim P, Srour S, Saini N, Im J, Ramdial J, Khouri I, Anderlini P, Popat U, Hosing C, Champlin RE, Lee HJ, Fayad LE, Hagemeister FB, Bica AM, Lipan L, Craciun O, Jercan CG, Tanase A, Colita A. Can we cure refractory Hodgkin's lymphoma with transplantation?. Bone Marrow Transplant 56: 278-281, 2021.